Detailed Information

Research Field/Keywords for Research Field

• Cardiovascular Medicine

Education

• 1997/03, Doctor Course, Completed

Employment Experience

• 1997/04 - 1999/09 Researcher
• 2002/11 -  *  Professor, Department of Cardiovascular Medicine, Saga University
• 2008/04 - 2010/03 University Hospital, Faculty of Medicine, Saga University
• 2008/04 - 2010/03 University Hospital, Faculty of Medicine, Saga University
• 2014/04 - 2017/03 Professor, Faculty of Medicine, Saga University
• 2014/04 - 2017/03 University Hospital, Faculty of Medicine, Saga University
• 2016/04 -  *  Professor, Saga University
• 2017/04 - 2019/01 Professor, Saga University
• 2019/09 - 2020/03 Professor, Saga University

Field of Specialization

• Cardiovascular medicine

Membership in Academic Societies

• Japanese College of Angiology, The Japan Endocrine Society, The Japanese SOciety of Clinical Pharmacology and Therapeutics, The Japanese Society of Cardiovascular Endocrinology and Metabolism, Japanese Circulation Society, The Japan Geriatrics Society, Japanese Society for Medical and Biological Engineering , Japan Section for International Society of Cardiovascular Pharmacotherapy, American Heart Association, American College of Cardiology, The Japanese College of Cardiology, The Japanese Coronary Association, The Japanese Heart Failure Society, Japanese Society of Clinical Physiology (JSCP), The Japanese Society of Internal Medicine, The Japanese Society of Nuclear Cardiology, The Japanese Society of Hypertension, Japan Atherosclerosis Society, The Japan Society of Adult Disease, The Japanese Society of Nephrology, European Society of Cardiology, International Society of Heart Research (ISHR), Japan Diabetes Society, Nitric Oxide Society of Japan

Research Topics and Results

• Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients With Cancer  2023/02
• Body fluid regulation via chronic inhibition of sodium-glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial  2023/01
• Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan  2022/12
• Glycemic status and the association of change in blood pressure with incident cardiovascular disease  2022/12
• Association of Life's Simple 7 with incident cardiovascular disease in 52,956 patients with cancer  2022/12
• Dose-dependent relationship of blood pressure and glycemic status with risk of aortic dissection and aneurysm  2022/12
• Threshold of Body Mass Index for the Development of Hypertension Among Japanese Adults 2022/11
• Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors 2022/11
• Sex Difference in the Association between Lipid Profile and Incident Cardiovascular Disease among Young Adults 2022/10
• Association of Cardiovascular Health Metrics with Risk of Transition to Hypertension in Non-Hypertensive Young Adults  2022/10
• So-far overlooked HFpEF patients with normal natriuretic peptide level need more evidence  2022/10
• Potential negative effect of total parenteral nutrition on the human circadian clock  2022/10
• Multimodality Imaging Approach for a Left Ventricular Aneurysm in a Patient With Myocardial Infarction and Non-Obstructive Coronary Arteries  2022/09
• Antihypertensive drugs and cancer risk  2022/09
• Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists  2022/09
• Medication Naïve Blood Pressure and Incident Cancers: Analysis of Two Nationwide Population-Based Databases 2022/08
• Need for more evidence of safety in the pharmacological therapy of anemia in chronic kidney disease: a cardiovascular perspective  2022/08
• Age-Specific Relation of Cardiovascular Health Metrics With Incident Cardiovascular Disease 2022/08
• Assessment of thromboembolism risk in COVID-19 patients with cardiovascular disease risk factors: Analysis of a Japanese Nationwide Registry 2022/08
• Update on Hypertension Research in 2021 2022/08
• Semiquantitative assessed proteinuria and risk of heart failure: analysis of a nationwide epidemiological database  2022/08
• Prevalence of hypertensive diseases and treated hypertensive patients in Japan: A nationwide administrative claims database study 2022/07
• New-Onset Atrial Fibrillation in Patients With Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease - Insights From the CLAVIS-COVID Registry  2022/07
• Hospitalizations for Cardiovascular Diseases During the Early Stage of the COVID-19 Pandemic in Japan 2022/07
• Prediabetes in Young Adults and Its Association with Cardiovascular Health Metrics in the Progression to Diabetes  2022/06
• Development of a Laboratory Risk-Score Model to Predict One-Year Mortality in Acute Myocardial Infarction Survivors  2022/06
• Healthcare resource utilization in patients treated with empagliflozin in East Asia  2022/05
• Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus  2022/05
• Collective Knowledge Used to Unveil Cardiovascular Injury Emerged during COVID-19  2022/05
• Revisited Metformin Therapy in Heart Failure With Preserved Ejection Fraction 2022/05
• Age-Dependent Relationship of Hypertension Subtypes With Incident Heart Failure 2022/05
• Efficacy of Cardiac Computed Tomography for Diagnostic and Therapeutic Evaluation of Bioprosthetic Valve Thrombosis 2022/05
• Author Correction: A novel soluble epoxide hydrolase vaccine protects murine cardiac muscle against myocardial infarction  2022/05
• Mediators of the effects of canagliflozin on N-terminal pro-brain natriuretic peptide concentration: An exploratory mediation analysis of the randomized CANDLE trial  2022/05
• Association of retinal atherosclerosis assessed using Keith-Wagener-Barker system with incident heart failure and other atherosclerotic cardiovascular disease: Analysis of 319,501 individuals from the general population 2022/05
• Impact of body mass index on the outcome of Japanese patients with cardiovascular diseases and/or risk factors hospitalized with COVID-19 infection 2022/04
• Cardiac acoustic biomarkers as surrogate markers to diagnose the phenotypes of pulmonary hypertension: an exploratory study  2022/04
• Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives  2022/04
• A novel soluble epoxide hydrolase vaccine protects murine cardiac muscle against myocardial infarction 2022/04
• The role of cell-autonomous circadian oscillation of Cry transcription in circadian rhythm generation  2022/04
• Association between proteinuria and incident colorectal cancer: analysis of a nationwide population-based database  2022/04
• Impact of serum lactate dehydrogenase on the short-term prognosis of COVID-19 with pre-existing cardiovascular diseases  2022/04
• Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study  2022/04
• Differential effect of a xanthine oxidase inhibitor on arterial stiffness and carotid atherosclerosis: a subanalysis of the PRIZE study  2022/04
• Risk for Proteinuria in Newly Defined Hypertensive People Based on the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline 2022/04
• Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial  2022/04
• Women with type 2 diabetes and coronary artery disease have a higher risk of heart failure than men, with a significant gender interaction between heart failure risk and risk factor management: a retrospective registry study  2022/04
• Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19)  2022/03
• Atrial Structural Remodeling in Patients With Atrial Fibrillation Is a Diffuse Fibrotic Process: Evidence From High-Density Voltage Mapping and Atrial Biopsy  2022/03
• Better vascular function tests in cardiovascular care: learning from evidence and providing improved diagnostics to the patient  2022/03
• Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial 2022/03
• Impact of Tweeting Summaries by the Japanese Circulation Society Official Account on Article Viewership - Pilot Trial 2022/03
• Clinical roles of vascular function assessment in cancer care  2022/02
• Serum Albumin and Bleeding Events After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction (from the HAGAKURE-ACS Registry)  2022/02
• Simple risk-score model for in-hospital major bleeding based on multiple blood variables in patients with acute myocardial infarction  2022/01
• Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study  2022/01
• Annual reports on hypertension research 2020  2022/01
• Statement of the Asian Hypertension Society Network: the Okinawa Declaration on the unity of hypertension societies in Asian countries and regions to overcome hypertension and hypertension-related diseases  2022/01
• Age Modified Relationship Between Modifiable Risk Factors and the Risk of Atrial Fibrillation  2022/01
• Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy  2022/01
• Impact of Glucose Tolerance and Its Change on Incident Proteinuria: Analysis of a Nationwide Population-Based Dataset 2022
• Change in Cardiovascular Health Metrics and Risk for Proteinuria Development: Analysis of a Nationwide Population-Based Database  2022
• Spatiotemporal dynamics of SETD5-containing NCoR-HDAC3 complex determines enhancer activation for adipogenesis  2021/12
• Natriuretic Peptide-Based Risk Prediction and Assessment of Treatment Effect: Revisited in This Era  2021/12
• JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure  2021/12
• Prognostic impact of follow-up serum albumin after acute myocardial infarction  2021/12
• Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline  2021/12
• JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure 2021/12
• A novel prediction model of acute kidney injury based on combined blood variables in STEMI 2021/12
• Relation of the Metabolic Syndrome to Incident Colorectal Cancer in Young Adults Aged 20 to 49 Years  2021/11
• New Vision, Mission, and Values of the Japanese Circulation Society  2021/11
• JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure  2021/11
• Untreated Hypertension and Subsequent Incidence of Colorectal Cancer: Analysis of a Nationwide Epidemiological Database  2021/11
• Lifestyle- and comorbidity-related factors for the prescription of proton pump inhibitors after Helicobacter pylori eradication in Japan 2021/11
• A Novel Soluble Epoxide Hydrolase Peptide Vaccine Attenuates Cardiac Remodeling After Myocardial Infarction Through Angiogenesis 2021/11
• The Long Non-Coding Rna Caren Improves Cardiac Dysfunction in Aged Mice 2021/11
• Association Between Blood Pressure Classification Using the 2017 ACC/AHA Blood Pressure Guideline and Retinal Atherosclerosis  2021/10
• WBC count predicts heart failure in diabetes and coronary artery disease patients: a retrospective cohort study  2021/10
• What Is Behind the HbA1c Value? 2021/10
• Multiple Cardiovascular Diseases or Risk Factors Increase the Severity of Coronavirus Disease 2019  2021/10
• Advance care planning from the penultimate hospitalization in patients with end-stage heart failure: a single-center, 10-year experience  2021/09
• Proximal Optimization Technique Facilitates Wire Entry Into Stumpless Chronic Total Occlusion of Side Branch  2021/09
• Semiquantitative assessed proteinuria and risk of heart failure: Analysis of a nationwide epidemiological database  2021/09
• Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents  2021/09
• Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial  2021/09
• External validation of the 4C Mortality Score for patients with COVID-19 and pre-existing cardiovascular diseases/risk factors 2021/09
• Comparison Of The Clinical Effect Of Empagliflozin On Glycemic And Non-glycemic Parameters In Japanese Patients With Type 2 Diabetes And Cardiovascular Disease Treated With Or Without Baseline Metformin 2021/09
• Hypertension in diabetes care: emerging roles of recent hypoglycemic agents  2021/08
• Relation of Serum Uric Acid and Cardiovascular Events in Adults Aged 20-49 Years  2021/08
• Clinical impact of CREDO-kyoto risk score on in-hospital bleeding in patients with acute coronary syndrome 2021/08
• Empagliflozin improves prognosis and energetic properties through modulating mitochondrial function in failing murine hearts 2021/08
• Prognostic impact of follow-up serum albumin after acute myocardial infarction 2021/08
• Long-year follow-up of Acute Myocardial Infarction with Preserved Initial LVEF: Prognostic Impact of Progressively Reduced LVEF 2021/08
• Prognostic impact of initial serum albumin for newly developing heart failure after acute myocardial infarction 2021/08
• Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE) 2021/08
• Incidence of progressively reduced LVEF during long-year follow-up after myocardial infarction : impact for mid-term outcomes 2021/08
• Gender difference in Low-BMI patients with acute myocardial infarction makes an impact on mid-term outcomes 2021/08
• Uric acid and cardiovascular disease: A clinical review  2021/07
• Association of Body Mass Index with Ischemic and Hemorrhagic Stroke  2021/07
• Call for Fine Remote Monitoring of Prognostic Signs and Symptoms in Heart Failure  2021/07
• Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin  2021/07
• Clinical efficacy of intracoronary papaverine after nicorandil administration for safe and optimal fractional flow reserve measurement 2021/07
• Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation  2021/06
• Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial  2021/06
• In-hospital therapy for worsening heart failure: black box or sweet spot?  2021/06
• Relationship Between Official Twitter Ambassadors and the Number of Retweets in the Annual Congress - "Tweet the Meeting" 2021/06
• Intensive Care Unit Admission for Moderate-to-Severe COVID-19 Patients With Known Cardiovascular Diseases or Their Risk Factors - Insights From a Nationwide Japanese Cohort Study  2021/06
• Fasting Plasma Glucose and Incident Colorectal Cancer: Analysis of a Nationwide Epidemiological Database 2021/06
• Reduction of estimated fluid volume parameters following initiation of empagliflozin in patients with type 2 diabetes and established cardiovascular disease 2021/06
• Fluid volume regulation in patients with heart failure  2021/05
• Clinical and Biomarker Profiles and Prognosis of Elderly Patients With Coronavirus Disease 2019 (COVID-19) With Cardiovascular Diseases and/or Risk Factors  2021/05
• Outcomes of Drug-Eluting Stent Thrombosis After Treatment for Acute Versus Chronic Coronary Syndrome  2021/05
• Nationwide Survey of Japanese Cardiac Rehabilitation Training Facilities During the Coronavirus Disease 2019 Outbreak  2021/05
• The lncRNA Caren antagonizes heart failure by inactivating DNA damage response and activating mitochondrial biogenesis  2021/05
• Is It Time to Shift the Monotherapy After Percutaneous Coronary Intervention From Aspirin to P2Y 12 Inhibitors? - New Normal in the New-Generation Era  2021/05
• Low HbA(1c) Level and High Mortality: A Reversal of Cause and Effect? 2021/05
• Association Between Statin Use Prior to Admission and Lower Coronavirus Disease 2019 (COVID-19) Severity in Patients With Cardiovascular Disease or Risk Factors  2021/05
• A NOVEL RISK-SCORE MODEL OF IN-HOSPITAL ACUTE KIDNEY INJURY BASED ON COMBINED BLOOD VARIABLES IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION 2021/05
• The Japanese Medical Science Federation COVID-19 Expert Opinion English Version  2021/04
• JCS 2018 Guideline on Diagnosis of Chronic Coronary Heart Diseases  2021/03
• Cardiology Department Practices in the First Wave of the Coronavirus Disease Pandemic - A Nationwide Survey in Japan by the Japanese Circulation Society  2021/02
• Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors  2021/02
• New Strategy to Prevent Acute Myocardial Infarction by Public Education - A Position Statement of the Committee on Public Education About Emergency Medical Care of the Japanese Circulation Society  2021/02
• Vascular functional tests and preemptive medicine  2021/01
• Decline incidence in upper gastrointestinal bleeding in several recent years: data of the Japan claims database of 13 million accumulated patients 2021/01
• Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure  2021/01
• Letter by Tanaka and Node Regarding Article, "Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases: A Nationwide Study"  2021/01
• Cardiology Department Policy in Japan After Coronavirus Disease-2019 (COVID-19) - Descriptive Summary of 2nd Nationwide Survey by the Japanese Circulation Society  2021/01
• Lifestyle- and Comorbidity-Related Risk Factors Associated with Prescription of Gastric Acid Secretion Inhibitors to Japanese Patients Who Were Helicobacter pylori Negative and Had No Upper Gastrointestinal Lesions  2021
• Effects of febuxostat on carotid intima-media thickness in asymptomatic hyperuricemia: a randomized clinical trial (PRIZE) 2021
• Prognostic impact of follow-up serum albumin after acute myocardial infarction 2021
• Low Serum Albumin and Bleeding Events After Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: From the HAGAKUREACS Registry 2021
• Right Ventricular Branch Compromise after Percutaneous Coronary Intervention and Baseline Chronic Kidney Disease: A High-Risk Combination Associated with Long-Term Prognoses in Acute Inferior Myocardial Infarction 2021
• Systemic endothelial dysfunction: a key pathophysiological explanation of fatal outcome in COVID-19? 2021
• A detection method for latent circadian rhythm sleep-wake disorder 2020/12
• Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes - A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society  2020/12
• When and for Whom Should We Use SGLT2 Inhibitors in HFrEF?  2020/12
• How should we monitor the cardiovascular benefit of sodium-glucose cotransporter 2 inhibition? 2020/12
• Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial 2020/12
• The effect of switching from statin-monotherapy to statin/ezetimibe combination therapy on lipid profiles in patients with type 2 diabetes and dyslipidemia: a multicenter open-label study (EUCLID) 2020/12
• Usefulness of the SAGE score to predict elevated values of brachial-ankle pulse wave velocity in Japanese subjects with hypertension  2020/11
• Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design  2020/11
• Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society 2020/11
• Crosstalk between the liver and heart: revisited for prevention and treatment  2020/10
• Recommendations for Maintaining the Cardiovascular Care System Under the Conditions of the COVID-19 Pandemic - 1st Edition, April 2020  2020/10
• Reduction in hsCRP levels is associated with decreased incidence of cardiovascular events in Japanese hypertensive women but not in men  2020/10
• Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care  2020/09
• Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus 2020/09
• Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study 2020/09
• Two-Year Experience in "Tweeting the Meeting" During the Scientific Sessions - Rapid Report From the Japanese Circulation Society 2020/09
• Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)  2020/08
• Increased arterial stiffness and cardiovascular risk prediction in controlled hypertensive patients with coronary artery disease: post hoc analysis of FMD-J (Flow-mediated Dilation Japan) Study A  2020/08
• Suspected Borderline Aldosteronism in Hypertension: The Next Target?  2020/08
• Prognostic Impact of Serum Albumin for Developing Heart Failure Remotely after Acute Myocardial Infarction  2020/08
• Does cilnidipine, a dual L- and N-type Ca 2+ blocker, shows promise in drug repositioning approaches?  2020/07
• NT-proBNP in Heart Failure With Preserved Ejection Fraction: Quest for a Marker Reflecting the Truth  2020/07
• Impact of Renal Dysfunction on Left Atrial Structural Remodeling and Recurrence After Catheter Ablation for Atrial Fibrillation - A Propensity Score Matching Analysis  2020/07
• First report of lotus root-like appearance at the site of coronary spasm in a patient with acute coronary syndrome  2020/07
• Management of anticoagulant therapy using a portable point-of-care international normalized ratio device and social networking service in a patient with a left ventricular assist device  2020/07
• Effect of rivaroxaban on urinary albumin excretion in patients with atrial fibrillation and chronic kidney disease: a randomized trial (X-NOAC)  2020/06
• Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized trial  2020/06
• Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy  2020/06
• Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial  2020/06
• Promising roles of sodium-glucose cotransporter 2 inhibitors in heart failure prevention and treatment 2020/06
• Ex vivo Culture Assay Using Human Hair Follicles to Study Circadian Characteristics 2020/06
• Secondary Analyses to Assess the Profound Effect of Empagliflozin on Endothelial Function in Patients with Type 2 Diabetes and Established Cardiovascular Diseases: The Placebo-Controlled Double-Blind Randomized EMBLEM Trial 2020/06
• Coronavirus Disease 2019 (COVID-19) Information for Cardiologists - Systematic Literature Review and Additional Analysis  2020/05
• In-stent restenosis following third-generation sirolimus-eluting stent implantation: first report analysed from imaging modalities and histopathological findings  2020/05
• Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia  2020/05
• Bright light improves sleep in patients with Parkinson's disease: possible role of circadian restoration  2020/05
• Joint Declaration on COVID-19 by the Japan Stroke and Japanese Circulation Societies 2020/05
• Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial  2020/04
• A Novel Predictive Model for In-Hospital Mortality Based on a Combination of Multiple Blood Variables in Patients with ST-Segment-Elevation Myocardial Infarction  2020/03
• Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure  2020/02
• Current status of long-term prognosis among all subtypes of pulmonary hypertension in Japan  2020/02
• Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial  2020/02
• Diagnostic Criteria of Flow-Mediated Vasodilation for Normal Endothelial Function and Nitroglycerin-Induced Vasodilation for Normal Vascular Smooth Muscle Function of the Brachial Artery  2020/01
• Risk Factors for Post-Endoscopic Retrograde Pancreatography Pancreatitis: A Retrospective Chart Review in a Regional Hospital in Japan  2020/01
• Systemic hemodynamic atherothrombotic syndrome (SHATS) - Coupling vascular disease and blood pressure variability: Proposed concept from pulse of Asia  2020
• Long-year follow-up of Acute Myocardial Infarction with Preserved Initial LVEF: Prognostic Impact of Progressively Reduced LVEF 2020
• Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized clinical trial (CANDLE)  2020
• Brachial-Ankle Pulse Wave Velocity Versus Its Stiffness Index β-Transformed Value as Risk Marker for Cardiovascular Disease.  2019/12
• Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial.  2019/12
• Systemic hemodynamic atherothrombotic syndrome (SHATS) - Coupling vascular disease and blood pressure variability: Proposed concept from pulse of Asia.  2019/12
• GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy.  2019/11
• Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial. 2019/11
• Effect of Lubiprostone on Urinary Protein Excretion: A Report of Two IgA Nephropathy Patients with Chronic Constipation. 2019/11
• Total adiponectin is associated with incident cardiovascular and renal events in treated hypertensive patients: subanalysis of the ATTEMPT-CVD randomized trial. 2019/11
• Full-metal jacket technique using second-generation drug-eluting stent: clinical and angiographic follow-up in 2 years.  2019/10
• Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial.  2019/10
• JSH Statement: Asahikawa declaration in promotion of diversity by the Japanese society of hypertension-the JSH Asahikawa declaration.  2019/10
• JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure　- Digest Version.  2019/09
• The effect of continuous positive airway pressure (CPAP) treatment on serum levels of proBDNF and mature BDNF in patients with obstructive sleep apnea.  2019/09
• Influence of preoperative serum creatinine level and intraoperative volume of contrast medium on the risk of acute kidney injury after transfemoral transcatheter aortic valve implantation: a retrospective observational study. 2019/08
• 2-Cl-C.OXT-A stimulates contraction through the suppression of phosphodiesterase activity in human induced pluripotent stem cell-derived cardiac organoids.  2019/07
• In vivo evaluation of the effect of lithium on peripheral circadian clocks by real-time monitoring of clock gene expression in near-freely moving mice. 2019/07
• JSH Statement: Kyoto declaration on hypertension research in Asia.  2019/06
• Anemia is an independent risk factor for cardiovascular and renal events in hypertensive outpatients with well-controlled blood pressure: a subgroup analysis of the ATTEMPT-CVD randomized trial. 2019/06
• Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial. 2019/06
• Microvascular and macrovascular endothelial function in two different types of primary aldosteronism.  2019/05
• Rheumatoid Arthritis and Vascular Failure - Rheumatoid Arthritis Is a Risk Factor for Cardiovascular Disease.  2019/05
• Development of an immunodeficient pig model allowing long-term accommodation of artificial human vascular tubes.  2019/05
• Target of Triglycerides as Residual Risk for Cardiovascular Events in Patients With Coronary Artery Disease　- Post Hoc Analysis of the FMD-J Study A.  2019/04
• Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials. 2019/02
• Differential effect of concomitant antidiabetic agents on carotid atherosclerosis: a subgroup analysis of the PROLOGUE study.  2019/02
• A reduction of BMI predicts the risk of rehospitalization and cardiac death in non-obese patients with heart failure. 2019/02
• Bipolar Voltage Mapping for the Evaluation of Atrial Substrate: Can We Overcome the Challenge of Directionality?  2019/02
• COA-Cl (2-Cl-C.OXT-A) can promote coronary collateral development following acute myocardial infarction in mice.  2019/02
• Loss of Endogenous HMGB2 Promotes Cardiac Dysfunction and Pressure Overload-Induced Heart Failure in Mice. 2019/01
• Gut microbiota and hypertension.  2019/01
• Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.  2019/01
• Inflammation in pulmonary artery hypertension.  2019
• Comparison of Left Atrial Voltage Maps ? Does Mapping Catheter Configuration Pattern Matter? 2019
• Short-term effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular diseases: a placebo-controlled randomized trial (EMBLEM)  2019
• Spontaneous Internal Mammalian Artery Graft Dissection Triggered by Emotional Stress 2019
• The Visualization of BVS Using Angiography  2019
• OCT guided LM intervention with jailed balloon 2019
• DK vs. Culotte -chapter 2- 2019
• Association between local slow conduction and bipolar voltage - an analysis using HD grid mapping catheter in atrial fibrillation patients 2019
• Does low voltage zone represent localized fibrosis? -an analysis using HD grid mapping catheter in atrial fibrillation patients  2019
• Effects of Canagliflozin in Patients With Type 2 Diabetes and Chronic Heart Failure: A Randomized Clinical Trial (CANDLE) 2019
• Gender Differences in Cardiovascular Outcomes and Their Association With Risk Factors in Type 2 Diabetic Patients With Established Coronary Artery Disease 2019
• Dk-Crush Stenting Increases the Risk of Incomplete Stent Apposition Compared With Culotte Stenting for the Treatment of Left Main Coronary Bifurcation Lesion: Analysis From Micro CT 2019
• Cardiac Dysfunction Induced by Incretin-Related Drugs Due to Energetic Starvation in Non-Diabetic Failing Heart 2019
• Brachial artery diameter as a marker for cardiovascular risk assessment: FMD-J study.  2018
• The non-biphenyl-tetrazole angiotensin AT1 receptor antagonist eprosartan is a unique and robust inverse agonist of the active state of the AT1 receptor. 2018
• Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure.  2018
• Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials. 2018
• Effect of anagliptin and sitagliptin on low-density lipoprotein cholesterol in type 2 diabetic patients with dyslipidemia and cardiovascular risk: rationale and study design of the REASON trial.  2018
• Role of tissue factor in vascular failure. 2018
• N-Terminal Pro-B-Type natriuretic peptide is not a significant predictor of stroke incidence after 5 years　- The Ohasama Study.  2018
• Intensive treat-to-target statin therapy in high-risk Japanese patients with hypercholesterolemia and diabetic retinopathy: report of a randomized study.  2018
• Potential role of the pancreatic hormone insulin in resetting human peripheral clocks. 2018
• Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus. 2018
• The first multicenter, randomized, controlled trial of home telemonitoring for Japanese patients with heart failure: home telemonitoring study for patients with heart failure (HOMES-HF) 2018
• Comparison of the effects of linagliptin and voglibose on endothelial function in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, pilot study (EFFORT). 2018
• Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial. 2018
• Effects of uric acid on vascular endothelial function from bedside to bench. 2018
• The Japanese Society of Hypertension-Digest of plan for the future. 2018
• Pleiotropic effects of calcium channel blockers. 2018
• Is GRK2 a new target for cardiovascular disease? 2018
• Physiological diagnostic criteria for vascular failure. 2018
• Mobilization of progenitor cells and assessment of vessel healing after second generation drug-eluting stenting by optical coherence tomography. 2018
• Longitudinal association among endothelial function, arterial stiffness and subclinical organ damage in hypertension. 2018
• Sitagliptin on carotid intima-media thickness in type 2 diabetes patients receiving primary or secondary prevention of cardiovascular disease: A subgroup analysis of the PROLOGUE study. 2018
• Cross-sectional and longitudinal associations between serum uric acid and endothelial function in subjects with treated hypertension.  2018
• Endothelial dysfunction, increased arterial stiffness, and cardiovascular risk prediction in patients with coronary artery disease: FMD-J (Flow-Mediated Dilation Japan) study A. 2018
• Prediction of stroke after cardiac catheterization: no reason, no stroke. 2018
• Azelnidipine Inhibits the Differentiation and Activation of THP-1 Macrophages through the L-Type Calcium Channel. 2018
• Incidence of aspiration pneumonia during hospitalization in Japanese hospitalized cases did not increase whereas concern factors were exacerbated in a time-dependent manner: analysis of Diagnosis Procedure Combination (DPC) data. 2018
• Obesity Is a Culprit in Heart Failure: Do NOT Miss HFpEF, Especially in Obese Women. 2018
• Cardiovascular and renal protective role of angiotensin blockade in hypertension with advanced CKD: a subgroup analysis of ATTEMPT-CVD randomized trial.  2018
• The addition of human iPS cell-derived neural progenitors changes the contraction of human iPS cell-derived cardiac spheroids.  2018
• Acute mitral regurgitation of unknown etiology associated with disseminated intravascular coagulation eventually diagnosed as enterococcus faecalis infective endocarditis by mitral valve surgery. 2018
• Multiple potency of ezetimibe in a patient with macroproteinuric chronic kidney disease and statin-intolerant dyslipidemia.  2018
• Clinical impact of endothelial dysfunction and atherosclerosis continuum  2018
• Asian epidemic of cardiometabolic syndrome 2018
• Pathophysiological association between serum uric acid and vascular damages in subjects with hypertension 2018
• Losing body weight is a strong independent predictor of rehospitalization and prognosis in patients with heart failure. 2018
• Mid-term outcomes of second-generation drug-eluting-stent implantation for left main coronary artery disease compare with first-generationdrug-eluting-stent. 2018
• Switching from an angiotensin II receptor blocker to azilsartan improved health-related QOL scores beyond sufficient blood pressure-lowering in patients with uncontrolled hypertension  2018
• EGCG attenuate cardiac hypertrophy in the hypertensive Dahl rats. 2018
• Gender differences in structural remodeling and clinical outcomes among patients undergoing atrial fibrillation ablation. 2018
• Increased amputation risk with canagliflozin treatment:behind the large cardiovascular benefit?  2017
• Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. 2017
• Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study. 2017
• α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study. 2017
• Reduction in incomplete stent apposition area caused by jailed struts after single stenting at left main bifurcation lesions: micro-CT analysis using a three-dimensional elastic bifurcated coronary artery model. 2017
• Association Between Waist-to-Height Ratio and Endothelial Dysfunction in Patients With Morbidity　- A Report From the FMD-J Study.  2017
• Hypercholesterolemia Causes Circadian Dysfunction: A Potential Risk Factor for Cardiovascular Disease.  2017
• Effect of different light-dark schedules on estrous cycle in mice, and implications for mitigating the adverse impact of night work.  2017
• Prevalence of prehypertension and left ventricular hypertrophy. Hypertens Res.  2017
• Amelioration of arterial pressure lability: an unmissable target for diabetes management. 2017
• Endothelial Function Is Impaired in Patients Receiving Antihypertensive Drug Treatment Regardless of Blood Pressure Level: FMD-J Study (Flow-Mediated Dilation Japan). 2017
• APEQ Study Investigators. Association Between Blood Pressure Lowering and Quality of Life by reatment of Azilsartan.  2017
• Protective effects of bisoprolol against myocardial injury and pulmonary dysfunction in patients with chronic heart failure.  2017
• Myeloid-related protein-8/14 in acute coronary syndrome. 2017
• EGCG, a green tea catechin, attenuates the progression of heart failure induced by the heart/muscle-specific deletion of MnSOD in mice.  2017
• Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology.  2017
• Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial. 2017
• Who Will Be Rehospitalized Next?: Targeting Heart Failure Patients With Brittle?Dimensions.  2017
• Validity and Reliability of Three-chamber-View Three-directional Encoded Phase-contrast Magnetic Resonance Velocity-Vector Mapping for Transmitral Velocity Measurements: Comparison with Doppler Echocardiography and Intra- and Inter-observer Variability.  2017
• Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased　agonism. 2017
• N-terminal pro-brain natriuretic peptide and associated factors in the general working population: a baseline survey of the Uranosaki cohort study. 2017
• A simple method using ex vivo culture of hair follicle tissue to investigate intrinsic circadian characteristics in humans.  2017
• Effect of particulate matters on cardiovascular disease 2017
• Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome. 2017
• Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report.  2017
• Therapeutic potential of tofogliflozin on nephrotic syndrome secondary to diabetic nephropathy 2017
• N-Termainal Pro-Brain Natriuretic Peptide and Associated Clincial Variables in the General Working Population: a Vaseline Survey of the Uranosaki Cohort Study.  2017
• Clinical association between serum uric acid level and vascular endothelial function: a sub-analysis from multicenter prospective observational study, FMD-J  2017
• Treatment with novels agents (SGLT2i) 2017
• The coronary collateral development by angiogenesis of COA-Cl (2-Cl-C.OXT-A) in myocardial infarction  2017
• High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial.  2016
• The relationship between neutrophil to lymphocyte　ratio, endothelial function, and severity in patients with obstructive sleep　apnea. 2016
• Impact of Obstructive Sleep Apnoea on Heart Failure　with Preserved Ejection Fraction. 2016
• Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study. 2016
• Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study. 2016
• Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. 2016
• Novel insights into renovascular hypertension and cardio-renal protection by iron restriction. 2016
• The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial. 2016
• Estimation methods for human circadian phase by use of peripheral tissues. 2016
• Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study. 2016
• Deletion of Apoptosis Inhibitor of Macrophage (AIM)/CD5L Attenuates the Inflammatory Response and Infarct Size in Acute Myocardial Infarction. 2016
• Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. 2016
• Aquaporin-2 is a potential biomarker for tolvaptan efficacy in decompensated heart failure complicated by diabetic nephrotic syndrome. 2016
• Long-term effects of AST-120 on the progression and prognosis of pre-dialysis chronic kidney disease: a 5-year retrospective study. 2016
• Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial). 2016
• Development of a three-dimensional pre-vascularized scaffold-free contractile cardiac patch for treating heart disease. 2016
• A trial of telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD): Biomarker study. 2016
• Coexistence of atypical hemolytic uremic syndrome and crescentic IgA nephropathy treated with eculizumab: a case report 2016
• Progressive idiopathic nodular glomerulosclerosis mimicking diabetic nephropathy without abnormal glycemic metabolism. 2016
• Impact of low-density lipoprotein apheresis for nephrotic syndrome in a patient with immunoglobulin M nephropathy.  2016
• Aquaporin-2 is a potential biomarker for tolvaptan efficacy in decompensated heart failure complicated by diabetic nephrotic syndrome.  2016
• Continuous positive airway pressure therapy improves endothelial function and neutrophil-lymphocyte ratio in patients with obstructive sleep apnea syndrome 2016
• Common clinical issues in cardiology ? Introduction to the session. 2016
• Lack of association between HbA1c and cardiovascular outcome in Japanese type 2 diabetic patients with coronary artery disease.  2016
• 「The effects of the vildagliptin for cardiac dysfunction after the acute myocardial infarction」 「Apoptosis inhibitor of macrophage activates inflammatory response after acute myocardial infarction」 「EGCG, a green tea catechin, attenuates the progression of heart failure induced by the heart/muscle-specific deletion of MnSOD in mice」  2016
• The Ratio of the Bilateral-filling Pressure (RAP/PCWP) is an Important Prognostic Factor in Congestive Heart Fialure 2016
• 2-year Follow-up Angiograpy of Second-generation Drug-eluting Stent Implantationof Chronic Total Occlusion 2016
• ”Full-metal Jacket” Stenting of Drug Eluting Stent in 2-year-Follow-up 2016
• Development of a Heart Failure Home Management System to Improve Cooperation between Medical and Nursing Care Providers 2016
• Home Telemonitoring Study for Japanese Patients with Heart Failure (HOMES-HF) 2016
• Choice of Anti-hypertensive Combination Therapy Based on Daily Salt Intake 2016
• Future Clinical Research in Patients with Cardiovascular Diseases: Perspectives 2016
• Blocking the Adaptor Protein CARD9 for NF-κB Signaling Inhibits Dendritic Cell-mediated Atherosclerosis 2016
• Decreasing of Body Mass Indes is Associated wit Repeated Hospitalizations of Patients with Heart Failure 2016
• Sex Difference in 1-year Cardiac Events Following Acute Myocardial Infraction  2016
• Visualization of Unobservable Bioresorbable Scaffolds Using Angiography 2016
• Varenicline-assisted smoking cessation improves vascular endothelial function associated with a reduction in oxidative stress」  2016
• NO and cardiovascular medicine  2016
• Endothelia dysfunction in the obstructive sleep apnea syndorome and effectiveness of continuous positive airway pressue therapy 2016
• A Case Elderly Heart Failure Patient with Cardiac Cachexia; How should We Improve Malnutrition? 2016
• Are there vascular protective effects in newer anti-daiabetic agents? 2016
• Influence of diabetes in patients with ischemic heart disease 2016
• A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients.  2016
• 2型糖尿病高齢者におけるシタグリプチンの有効性と安全性 2015
• SETDYによる脂肪細胞および骨芽細胞分化制御機構の解明 2015
• Ⅳ特殊な冠動脈病変に対するPCI治療の考え方 病変部位 左冠動脈主幹部遠位部病変 2015
• Chapter 5 Practice ～種々の疾患リスクとしての高尿酸血症 １.循環器疾患と尿酸代謝の関わり ②動脈硬化（尿酸と血管リモデリング）の形成と進展 1)血管内皮機能 2015
• 5章 拡張不全の治療 50●拡張不全診療における米国のガイドラインに関して解説してください 2015
• II.心不全診療Q&A 1.心不全の疫学 2.日本人の心不全の原因疾患について教えてください 2015
• IV.高血圧・肺高血圧・脂質異常症 A.高血圧 5.高血圧診療における最適な血管障害指標は何か？ 2015
• 文献792-496 2015
• Correction: Scaffold-Free Tubular Tissues Created by a Bio-3D Printer Undergo Remodeling and Endothelialization when Implanted in Rat Aortae. 2015
• Reliability of measurement of endothelial function across multiple institutions and establishment of reference values in Japanese.  2015
• Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells.  2015
• Choice of Antihypertensive Combination Therapy Based on Daily Salt Intake.  2015
• Rationale and design of the efficacy of rivaroxaban on renal function in patients with non-valvular atrial fibrillation and chronic kidney disease: The X-NOAC study.  2015
• A novel cardioprotective mechanism of exogenous nitric oxide: inhibition of Rho-associated kinase activity.  2015
• Structure-Function Basis of Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for Active-State Angiotensin II Type 1 Receptor.  2015
• The effects and safety of vildagliptin on cardiac function after acute myocardial infarction. 2015
• Glycemic variability and cardiac remodeling in patients with acute myocardial infarction.  2015
• Docosahexaenoic Acid with a statin and endothelial function in patients with coronary artery disease.  2015
• Association between N-terminal pro B-type natriuretic peptide and day-to-day blood pressure and heart rate variability in a general population: the Ohasama study. 2015
• A trial of telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD): Biomarker study.  2015
• Development of a three-dimensional pre-vascularized scaffold-free　contractile cardiac patch for treating heart disease. 2015
• Molecular analysis of ATP-sensitive K(+) channel subunits expressed in mouse portal vein. 2015
• Long-term effects of AST-120 on the progression and prognosis of pre-dialysis chronic kidney disease: a 5-year retrospective study.  2015
• Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial). 2015
• Effect of a Low-Intensity Pulsed Ultrasound Device, SX-1001, on Clinical Symptoms in Buerger Disease With Limb Ischemia. 2015
• 脳心血管合併症予防と患者QOLの向上を見据えた２型糖尿病治療 2015
• 心血管疾患イベントを減少させる糖尿病治療の最前線と明日への希望 2015
• 患者特異的iPS細胞を用いた肥大型心筋症の基礎的病態解明 2015
• サーカディアンリズムと心血管病 -心血管病発症における日内変動 2015
• 概日時計とそのしくみ 2015
• SGLT2阻害薬の多面的臓器保護効果 (特集 SGLT2阻害薬のインパクト) 2015
• バイオ3Dプリンターで立体造形したScaffold Freeの血管組織構築 (特集 心筋再生の現状と展望) 2015
• 2.診療ツールとしてのバイオマーカーを識る c.慢性冠動脈疾患 -冠動脈プラークの把握におけるPTX3の測定意義- 2015
• 日内変動パラメーターと動脈硬化 9)時計遺伝子と動脈硬化 2015
• 忙しい人のための抄読会 第3回 ミトコンドリアプロトノフォアの徐放製剤はラットの2型糖尿病および脂肪性肝炎の病態を改善する 2015
• 忙しい人のための抄読会 第2回 食物中の乳化剤はマウスの腸内細菌叢に影響を与え大腸炎とメタボリックシンドロームを促進する 2015
• 特集■血糖・尿酸と循環器の連関 キサンチンオキシダーゼ（XO）阻害薬の心血管作用 2015
• Meet the Expert　 2015
• (1366) 心拍変動と心拍数 2015
• ［医窓通信］ 2015
• ●解説 左室駆出率が保たれた心不全(HFPEF) 2015
• 52.INTERVIEW 心血管イベント発症の”残されたリスクファクター”高尿酸血症の関与を考察する 2015
• 中等量以下の飲酒者でも節酒は心血管系の健康に有益：解説「遺伝子を飲酒量のマーカーに使い、先行研究への疑問を示す」 2015
• インクレチン関連薬とRAS 2015
• 座談会 糖尿病患者の心腎連関をどのように考えるか (糖尿病性大血管障害Controversy 糖尿病患者の心腎連関をどのように考えるか) 2015
• 体内時計と循環器病の連関の解明 2015
• XO阻害薬と心血管障害 2015
• 『尿酸と血糖』これからの研究の道しるべ　 2015
• 心不全における性差医療 2015
• ●第3章 循環器疾患 4.肥大型心筋症（HCM） 2015
• 血管不全 2015
• 9.分岐部ステントにおけるステント選択および留置方法選択の重要性について 2015
• Bedside Teaching SGLT2阻害薬と心血管疾患 2015
• サーカディアンリズムと循環器疾患 はじめに 2015
• CKD合併心血管不全の治療戦略 2015
• 特集 血糖・尿酸と循環器の連関 序 2015
• Continuous positive airway pressure therapy improves endothelial function and neutrophil-lymphocyte ratio in patients with obstructive sleep apnea syndrome. 2015
• Common clinical issues in cardiology – Introduction to the session. 2015
• Lack of association between HbA1c and cardiovascular outcome in Japanese type 2 diabetic patients with coronary artery disease. 2015
• Apoptosis Inhibitor of Macrophage Activates Inflammatory Response After Acute Myocardial Infarction 2015
• 感染性大動脈瘤のステントグラフト術後に炎症性大動脈瘤を発症したと考えられる一例 2015
• 重症大動脈弁狭窄症に対するTAVI前後における心エコー図の変化と合併症の検討について 2015
• 巨大冠動脈瘤を合併した左冠動脈冠静脈洞瘻の診断に心エコーが有用であった１例 2015
• 正常心に生ずる僧帽弁の加齢変化についての検討 2015
• 僧帽弁逸脱症における経胸壁心エコー図所見と手術所見の比較検討 2015
• 心血管疾患予防に向けた糖尿病治療 2015
• Pentraxin3 regulates activity of macrophages. 2015
• High-dose statin therapy by rosuvastatin reduced small-dense LDL and MDA-LDL:The high-dose Statin therApy with Rosuvastatin for lipiD- lowing (SARD) trial 2015
• The Study of Evaluate the Effets of DPP-4 hinhibitor on Atherosclerosis in Patients with Diabetes Mellitus: PROLOGUE Study  2015
• 心血管不全予防のための糖尿病治療 2015
• Hypercholesterolemia causes circadian dysfnction, a potential risk factor for cardiovascular disease. 2015
• 高血圧診療に無侵襲診断がどこまで必要か？ 2015
• Recent progress in pathophysiology of hypertrophic cardiomyopathy using iPS cells. 2015
• PIT catheter　PITカテーテルによる選択的冠動脈血栓溶解療法の有効性について 2015
• 子宮頚部腫瘍に伴う肺塞栓症に対して血栓吸引療法により腫瘍塞栓を診断しえた1例 2015
• 動脈硬化症を予防する戦略 2015
• 新規糖尿病治療薬の心血管不全に対する効果 2015
• 冠動静脈瘻を伴う巨大冠動脈瘤2症例に対する治療の比較 2015
• 救急夜勤中の研修医の心拍変動異常についての検討 2015
• 巨細胞性心筋炎による重症心不全にHeart Mate Ⅱ植込み後、左室流出路にマイクロバブルを認めた一例 2015
• post capillary PH患者において両室充満圧の比（RAP/PCWP）は右室の仕事量と相関し、予後を予測する 2015
• スタチンの心不全予防結果-PEARL研究から- 2015
• GLP-1受容体アナログの非糖尿病性心不全における作用 2015
• SGLT阻害薬と血圧に関する考察 2015
• 高血圧と糖尿病治療 2015
• 日本高血圧学会・男女共同参画委員会からの報告 2015
• 脂質低下療法における高用量スタチンと標準量スタチンの比較試験(SARD trial) 2015
• 心筋梗塞後の心機能障害に対するビルダグリプチンの効果 2015
• Recent clinical trials of newer anti-diabetic drugs: What do biomarkers tell us? 2015
• 高度頸動脈病変を有する重症AS患者に対し、頸動脈ステント留置術施行後にTAVIを行った一例 2015
• 心臓３D-CTによる評価が有用であった巨大冠静脈洞憩室頸部副伝導路による房室回帰性頻拍の１例 2015
• F-FDG-PETが診断および病勢の評価に有用であった心サルコイドーシスの2例 2015
• 深部静脈のみならず動脈内にも多量の血栓を認めたType1プロテインC欠病症の1例 2015
• 動脈硬化の診断と治療 2015
• インクレチン関連薬の不全心に与える作用 2015
• 冠動脈CTによる血管壁の評価が有用であった左冠動脈主幹部狭窄を伴う労作性狭心症の1例 2015
• Ⅴ.治療 F.降圧薬の特徴と薬理・副作用　5.β遮断薬（含αβ遮断薬）、α遮断薬 2014
• Lecture 8　専門医はこう考える　一問一答　Q14.観血的治療（外科・歯科など）をおこなう際の血圧管理はどうしていますか？ 2014
• Ⅴ.バルーンのピンチも乗り越える！ バルーン通過困難時 041分岐部病変の側枝にバルーンが通過せず、KBTもできないとき 2014
• PART6 2型糖尿病治療におけるSGLT2阻害薬の位置づけを探る 3.SGLT2阻害薬のベネフィットを展望する 2014
• 高血圧治療薬　α遮断薬 2014
• 高血圧治療薬　β遮断薬（含αβ遮断薬） 2014
• Ⅲ循環器診療における医療安全 2014
• 末梢動脈疾患(PAD)患者の下肢病変　治療(①薬物療法)　 2014
• 末梢動脈疾患(PAD)患者の下肢病変　治療(②血管内治療)　　 2014
• IV薬物療法関連のエビデンス 29.Alogliptin 2014
• Takotsubo cardiomyopathy in the presence of right ventricular apical pacing: A case report. 2014
• Successful treatment of primary cardiac lymphoma causing ST-elevation myocardial infarction by percutaneous coronary intervention combined with chemotherapy.  2014
• Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes. 2014
• Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). 2014
• The mammalian circadian clock protein period counteracts cryptochrome in phosphorylation dynamics of circadian locomotor output cycles kaput (CLOCK).  2014
• Sympathetic nerve activity and endothelial function. 2014
• Therapeutic potential of α-glucosidase inhibitors to prevent postprandial endothelial dysfunction.  2014
• The role of the endocrine system in feeding-induced tissue-specific circadian entrainment.  2014
• A positive role for PERIOD in mammalian circadian gene expression.  2014
• Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study.  2014
• The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). 2014
• Risk markers for coronary plaque progression and destabilization beyond LDL-cholesterol in acute coronary syndrome.  2014
• Varenicline-assisted smoking cessation decreases oxidative stress and restores endothelial function. 2014
• Incretin therapy and heart failure. 2014
• Compensation for intracellular environment in expression levels of mammalian circadian clock genes. 2014
• Do incretins improve endothelial function?  2014
• Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report.  2014
• High-intensity signals in coronary plaques on noncontrast T1-weighted magnetic resonance imaging as a novel determinant of coronary events.  2014
• Clinical significance of non-slip element balloon angioplasty for patients of coronary artery disease: a preliminary report. 2014
• Guidelines for Diagnosis and Treatment of Patients With Vasospastic Angina (Coronary Spastic Angina) (JCS 2013): Digest Version 2014
• The late-phase inflammatory response after drug-eluting stent implantation.  2014
• インクレチン関連薬と心血管病 2014
• 高TG血症・低HDL-C血症と冠動脈疾患発症との関係 2014
• 心血管不全予防の為の血糖管理 2014
• ２型糖尿病患者の血管内皮機能障害における血糖コントロールと血圧のモーニングサージの関連 2014
• 抗血栓療法 2014
• 時計からみた高齢者循環器疾患 2014
• JSH2014におけるβ遮断薬の位置づけ 2014
• 糖尿病性大血管障害Controversy 高齢者糖尿病の治療目標 2014
• 7.RAAS阻害薬の副作用としての電解質異常 2014
• 尿酸と血糖のかかわりー本誌創刊の意義ー 高尿酸血症と高血糖は血管にどのような影響を与えるのか？ 2014
• 特集：『超高齢社会におけるアンチエイジングとRAS』 心不全におけるQOLとRAS 2014
• 急性冠症候群　 2014
• 動脈硬化治療の最前線　 2014
• 高血圧発症にかかわる時計遺伝子の役割 2014
• Discussion―座談会 2型糖尿病治療におけるSGLT2阻害薬の可能性 2014
• 生体リズムと生活習慣病 生体リズム改善による疾患治療 2014
• 糖尿病患者の血圧管理はどうするのか　JSH 2014をふまえて 2014
• 循環器疾患治療薬のpleiotropic effect 2014
• 特発性心筋症に関する調査研究  2014
• 高血圧の最新知見と薬物治療のさらなる可能性 2014
• 管理する医療から自ら治そうと思える医療へ 2014
• Meet the Expert - 対談 2014
• DPP-4阻害薬と心血管イベント 2014
• インクレチン製剤の心血管への作用とその機序 2014
• 第34回日本臨床薬理学会学術総会 学会トピックス インクレチン関連薬と心血管病 2014
• 12)糖尿病を合併する心不全はどのように治療するか？ 2014
• メタボリックシンドローム 特集/高血圧診療のup to date 他疾患を合併する高血圧  2014
• 特集　長寿社会に求められる弁膜症治療 治す14）ハートチームによる高齢者へのアプローチ 2014
• HEM-9000AIのAI・中心血圧　formのPWV/ABIに関するQ&A  2014
• 腎臓と高血圧の病態と治療　腎血管性高血圧の診断と治療 2014
• 糖尿病と大血管障害 2014
• 末梢血管抵抗と心拍出量 2014
• 血管機能の非侵襲的評価法に関するガイドライン ダイジェスト版 2014
• 血管機能の非侵襲的評価法に関するガイドライン 2014
• Special Report Resolute Integrityの特徴と可能性 2014
• 体内時計と心血管疾患 2014
• 糖尿病患者の血圧管理はどうするのか－JSH2014をふまえて－ 2014
• 日本の中高年一般住民において、血中のN末端プロ脳性ナトリウム利尿ペプチド濃度（NT-proBNP）は脳卒中発症の予測指標となるか？ 2014
• 今月号のトピック 対談：変革期を迎える日本の糖尿病治療 2014
• ヒストン脱アセチル化酵素は心筋細胞のオートファジーを誘導することにより虚血再灌流障害を減少させる 2014
• Endothelin-1 induces contraction variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes 2014
• The ratio of the bilateral-filling pressure is superior to the right atrial pressure alone for predicting right ventricular dysfunction in patiets with post-capillary pulmonary hypertension. 2014
• What are Key Factors to Achieve Better Stent Apposition at Left Main Bifurcation by Culottes Stenting Technique? Micro-CT Analysis Using Bifurcated Elastic Coronary Artery Models  2014
• 細胞のみで立体的心臓血管臓器を構築し移植する技術の開発 2014
• 内皮細胞から見える循環器疾患治療の方向性 2014
• 内皮機能検査 2014
• 高齢者心疾患患者の疾患管理のポイント 2014
• 経胸壁心エコーで緊急手術の適応を判断した左室内の有茎性可動性球状血栓の一例 2014
• 睡眠時無呼吸症候群患者における血管内皮機能に対する持続陽圧呼吸療法の効果について 2014
• 細胞のみで構築する3次元血管組織型パッチの開発 2014
• 新規組織工学技術による次世代型小口径人工血管の開発 2014
• Vascular Statinの特徴とさらなる可能性 2014
• 心臓病と睡眠の関係 2014
• 高齢者の心不全 2014
• 生活習慣病における時間生物学 2014
• 患者特異的iPS細胞を用いた肥大型心筋症の疾患モデリングと新規発症メカニズムの解明 2014
• 心拍変動解析を用いた研修医の自律神経機能評価と蓄積的疲労(第1報)　夜間救急研修中の研修医の1例 2014
• デリバリーバルーン3回拡張で留置したバイオリムスエリューティングステント 2014
• 脳・心血管イベント抑制を考慮した血圧治療管理とは 2014
• 糖尿病合併冠動脈疾患例への薬物治療 2014
• 肥満と循環器疾患 2014
• 血管内皮機能検査：FMD 2014
• 心不全における性差医療 2014
• 睡眠時無呼吸症候群における血管不全 2014
• 心血管不全治療の為の血糖管理 2014
• 心不全予防の為の血糖管理 2014
• Mismatch of bilateral filling pressure is effective for evaluation of right vetricular dysfunction 2014
• An assessment f the current status on the palliative care in patients with endo-of-life stage heart failure 2014
• 男女共同参画アンケート報告 2014
• 他の医療系学会における男女共同参画に対する取り組みについて　 2014
• 糖尿病合併冠動脈疾患　血圧コントロールとアウトカムに関するコホート研究 2014
• 心疾患合併高血圧の治療戦略 2014
• Physiological role of insulin in feeding-induced circadian entrainment 2014
• Disrupted diurnal rhythm exacerbates albuminuria in diabetic nephyropathy 2014
• Disease modeling of hypertroppic cardiomyopathy by using patient-specific iPS 2014
• Immunoregulatory cytokine-mediated inhibition of vascular inflammation 2014
• Time is Lifeー体内時計制御でアンチエイジングー 2014
• SETDYは脂肪細胞分化と骨芽細胞分化を制御する 2014
• Endothelin-1 induces contraction variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes 2014
• Endothelin-1 induces contraction variability in hypertrophic cardiomyopathy-iPS cell-derived cardiomyocytes 2014
• Endothelin-1 induces contraction variability in hypertrophic cardiomyopathy-iPS cell-derived cardiomyocytes 2014
• 冠動脈疾患の診断と予防 2014
• 「Vascular statinの特徴とさらなる可能性 2014
• バーロキサバン内服中に間質性肺炎を発症した心房細動の３症例 2014
• 冠静脈洞内からのペーシング時のみ順行性伝道が顕在化した間欠性WPW症候群の一例 2014
• 感染性大動脈瘤のステントグラフト術後に炎症性大動脈瘤を発症したと考えられる一例 2014
• バルーン大動脈弁形成術を先行させ、経カテーテル大動脈弁留置術を行った1症例 2014
• 佐賀大学におけるTAVIの初期成績 2014
• 急速に増大する心室瘤の診断に心エコー図検査が有用であった一例 2014
• 広範型急性肺血栓塞栓症に対してカテーテル治療を行い救命し得た一例 2014
• Clarifying function of SETDY in adipogenesis and osteogenesis 2014
• テルミサルタン製剤に期待される強力かつ持続的な高圧効果と多面的作用 2013/06
• 7.β遮断薬はなぜ冠動脈疾患に有効か？ 2013
• 17 スタチン 2013
• 第7章 虚血性心疾患 急性冠症候群とその治療 2013
• 第4章 治療薬総論 その他の抗動脈硬化薬 2013
• IV.ひと工夫した降圧薬の使い方 1)時間降圧療法～夜間投与への有用性～ 2013
• 血流依存性血管拡張反応(FMD) 2013
• Endothelium-derived hyperpolarizing factor and hypertension. 2013
• Interleukin 27 inhibits atherosclerosis via immunoregulation of macrophages in mice. 2013
• Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version: JSN, JRS, and JCS Joint Working Group. 2013
• A molecular clock regulates angiopoietin-like 1 protein 2 expression. 2013
• Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study. 2013
• Home telemonitoring study for Japanese patients with heart failure (HOMES-HF): protocol for a multicentre randomised controlled trial. 2013
• Predictive value of high-molecular weight adiponectin in subjects with a higher risk of the development of metabolic syndrome: From a population based 5-year follow-up data. 2013
• Nuclear receptor-mediated cell-autonomous oscillatory expression of the circadian transcription factor, neuronal PAS domain protein 2 (NPAS2). 2013
• 併用療法からエックスフォージ切り替えにおける費用対効果とアドヒアランスに関する検討 2013
• Detection of early stage atherosclerotic plaques using PET and CT fusion imaging targeting P-selectin in low density lipoprotein receptor-deficient mice. 2013
• High-intensity signals in coronary plaques on non-contrast T1-weighted magnetic resonance imaging as a novel determinant of coronary events. 2013
• Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version : JSN, JRS, and JCS Joint Working Group. 2013
• An out-of-lab trial: a case example for the effect of intensive exercise on rhythms of human clock gene expression. 2013
• Effects of sitagliptin beyond glycemic contol: Focus on quality of life. 2013
• シルニジピンとアムロジピンの降圧および腎保護効果に関する比較研究 2013
• Is direct renin inhibition superior to angiotensin receptor blocade in the effects beyond blood pressure lowering? 2013
• Evaluation of serial changes in tissue characteristics during statin-induced plaque regression by virtual histology intravascular ultrasound. 2013
• Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension. 2013
• Prognostic stratification of patients with vasospastic angina: a comprehensive clinical risk score developed by the Japanese coronary spasm association. 2013
• Effects of pitavastatin in Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study). 2013
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes. 2013
• Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF) 2013
• Increased oxidative stress impairs adipose tissue function in sphingomyelin synthase 1 null mice. 2013
• PM2.5の循環器疾患への影響 2013
• スタチンの抗炎症作用 (特集 "抗炎症"への新しいアプローチを考える) -- (非抗炎症性薬剤における抗炎症作用) 2013
• コントロール不良な高血圧 2013
• 生体リズム 2013
• 変遷する糖尿病治療と今後の展望 2013
• Total Vascular Control を考える 2013
• 大血管障害抑制を見据えた糖尿病の治療戦略 2013
• 血糖変動性と循環器疾患 2013
• 糖尿病と虚血性心疾患のリスク評価のここがわからない!? 2013
• I型糖尿病患者への集中的な糖尿病治療に伴う体重増加の心血管リスク因子とアテローム性動脈硬化症に対する効果―DCCT/EDIC Studyからの報告― 2013
• 心電図リテラシーQ& A　完全右脚ブロックに軸偏位を伴った場合、どのような病態を考えますか? 2013
• インクレチンは心血管事故の予防に有効か？ 2013
• 代謝異常を伴う高血圧患者に対する治療戦略 2013
• 代謝異常を伴う高血圧患者に有用な強力かつ持続的な高圧効果を有するテルミサルタン製剤 2013
• Scaffold freeの心臓・血管組織の構築 2013
• 降圧薬の抗炎症・免疫効果 2013
• 高血圧性臓器障害-どこまで評価するか? 血流依存性血管拡張反応(FMD) 2013
• インスリン抵抗性改善薬の心血管イベント抑制効果 2013
• スタチンのプラーク安定化作用 2013
• 時間降圧療法の有効性 2013
• DPP-4阻害薬の安全性 2013
• 「特集にあたって」糖尿病における心腎連関 2013
• インターネット回線を通じた慢性心不全の在宅管理 2013
• 心筋梗塞の治療 2013
• 心疾患から全身の血管病へと変わる概念 予防に欠かせない包括的リスク管理の視点 2013
• メタボ体質とホルモン関連 佐賀大附属病院 鹿島市民を追跡調査 2013
• 糖尿病薬で不眠改善 佐大医学部野出教授ら 国際学誌に発表 2013
• 「患者の生活の質向上」野出教授ら研究成果発表 2013
• 性差から試みる高齢者の生活習慣病アプローチ 2013
• 生体リズムに合わせて服薬 2013
• 心リハや遠隔モニタリング導入 患者自身の取り組みで予後の改善を 2013
• 高血圧研究におけるシステム医学の重要性 2013
• 糖尿病治療薬に期待されること 2013
• 心血管イベント抑制のための食後高血糖の管理 2013
• 生活習慣病の是正による血管不全改善効果 2013
• 更年期障害 2013
• 実践！女性のミカタ～かかりつけ医として、女性の健康寿命の延伸を目指す～ 2013
• アートとサイエンスの心臓血管病医療を目指す 2013
• 代謝異常を伴う高血圧患者に対するテルミサルタン製剤の新たな可能性 2013
• 不安定プラークをバイオマーカーからとらえる 2013
• CKD、透析患者のCVDリスクと管理 2013
• 糖尿病患者の冠動脈多枝病変に対する結構再建ストラテジー 2013
• 心三腔像MR速度ベクトルマップによる左室拡張期血流パラメータ測定の検討 2013
• 大動脈・末梢血管の画像診断 大動脈・末梢血管で使用するモダリティ MRI 2013
• スタチン 2013
• 高血糖が及ぼす影響　高血糖が脳・心臓に与える影響 2013
• 血管不全を治す 2013
• ARBの抗動脈硬化作用 2013
• High-sensitivity assay of plasma cardiac troponin T predicts the effects of pitavastatin I patients with chronic heart failure: a sub-group analysis from the pitavastatin heart failure study (PEARL). 2013
• Effects of pitavastatin on Japanese patients with chronic heart failure: a subanalysis of the PEARL. 2013
• Effectiveness of therapy with pitavastatin is associated with plasma interleukin-8 levels and improved cardiovascular outcomes in patients with chronic heart failure. 2013
• 糖尿病患者の大血管症Update 2013
• 悪性リンパ腫による心臓腫瘍のため、ST上昇型急性心筋梗塞を発症した1例 2013
• 高分子アディポネクチンはハイリスク男性においてメタボリック症候群発症を予測する 2013
• The Supporting Project "SAGA JOY" in Saga Prefecture and Saga University Hospital - Challenge to Reduce the Risk of Quitting 2013
• Effect of Diabetic Agent on Cardiovasuclar Failure in Japanese Patients 2013
• Effects of Pitavastatin on Japanese Patients With Chronic Heart Failure -The Pitavastatin Heart Failure Study (PEARL Study)- 2013
• Stenting Technique for Left Main Coronary Artery Stenosis can be Improved. Suggestion Raised from Bench Test Evaluation 2013
• Endothelin-1 Has a Pivotal Role in Contraction Variability in Hypertrophic Cardiomyopathy-Induced Pluripotent Stem Cell-Derived Cardiomyocytes 2013
• Spheroid Based Cardiovascular Regeneration Using Robotics Engineering 2013
• Sulfatides are Associated with Neointimal Thickning After Vascular Injury 2013
• Clinical and Angiographic Progression of Non-target Lesion after Percutaneous Coronary Intervention: Retrospective Analysis 2013
• Assesment by SYNTAX Score and EURO Score of Left Main Trunk (LMT) Disease 2013
• Five Years Consecutive Complete Follow-up Result of Silorims Eluting Stent (SES) Implanted Lesion 2013
• 新しい組織工学を用いた自己細胞のみで形成される3次元組織構築法の開発 2013
• 心不全のICTを用いた遠隔モニタリング(HOMES-HF) 2013
• 体内時計と生活習慣病治療 2013
• 糖尿病における心腎連関 2013
• CETP阻害薬の開発の現状 2013
• 血管年齢を正確に知ってアンチエイジング！酸化ストレスと血管機能 2013
• Atherosclerosis and Diabetes 2013
• 糖尿病患者の心疾患治療のevidence糖尿病合併冠動脈疾患患者レジストリに基づいたコホート研究とランダム化比較試験　積極的脂質低下降圧と標準的治療の比較 2013
• 高齢者の慢性心不全在宅管理における遠隔モニタリングの可能性(HOMES-HF) 2013
• 冠動脈疾患の至適血糖管理 2013
• 体内時計と循環器疾患 2013
• 慢性心不全における血中多価不飽和脂肪酸分画に対するピタバスタチンの影響 2013
• 左主幹部病変に対するステント留置術の抱える問題点とその改善策 2013
• アゼルニジピンにおけるマクロファージ活性化抑制の作用機序 2013
• 外来での心房細動患者における抗凝固療法の実態について 2013
• 慢性心不全の在宅管理における遠隔モニタリングデバイスの長期的有効性について 2013
• 心血管不全予防の為の糖尿病治療戦略 2013
• Scaffold Freeな機能的心臓・血管組織構築法の開発 2013
• 血管機能を高血圧診療に活かす 2013
• ワークライフバランスの実現に向けて、今を見つめなおす 2013
• フェブキソスタット錠の糸球体濾過量(eGFR)と血圧に及ぼす影響 2013
• 睡眠と生活リズムで心臓病を予防する 2013
• 心血管リスクを考慮した糖尿病の治療戦略 2013
• Home Telemonitoring for Japanese Patients with Chronic Heart Fiilure. 2013
• インクレチン関連薬と心血管病 2013
• 心臓MRAによる冠動脈疾患のスクリーニングとその有用性 2013
• 糖尿病性腎症を合併した閉塞性動脈硬化症の経皮的動脈形成術にCO2造影が有用であった一例 2013
• 新規組織工学を用いた自己細胞由来小口径血管の開発 2013
• 持続性心室頻拍を頻発し急激な経過をたどった心筋膿瘍の1例 2013
• 消化管出血後のショックを伴う心筋梗塞患者の治療に苦慮した症例 2013
• 心エコー検査で急速な左室肥大の進行を認めたクッシング症候群の一例 2013
• Repetitive hyperthermia attenuates progression of left ventricular hypertrophy and increases telomerase activity in hypertensive rats. 2012/05
• The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. 2012/04
• Continuous positive airway pressure therapy improves vascular dysfunction and decreases oxidative stress in patients with the metabolic syndrome and obstructive sleep apnea syndrome. 2012/04
• Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure: the pitavastatin heart failure study (PEARL study). 2012/04
• Endothelial dysfunction as a cellular mechanism for vascular failure. 2012/02
• Hyperthermia by bathing in a hot spring improves cardiovascular functions and reduces the production of inflammatory cytokines in patients with chronic heart failure. 2012/01
• Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model. 2012/01
• 時計遺伝子 2012
• 日本人では心不全の発症予防になにを指導すればよいですか？ 2012
• 日本人の心不全は欧米人と差がありますか 2012
• 日本人の心不全の原因疾患について教えてください 2012
• 糖尿病患者では心不全のリスクが高くなるのですか？ 2012
• 積極的降圧治療の有効性と安全性およびQOLに関する研究 -ロサルタンサブ解析- 2012
• A multicenter study design to assess the clinical usefulness of semi-automatic measurement of flow-mediated vasodilatation of the brachial artery. 2012
• Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. 2012
• Endothelial dysfunction as a cellular mechanism for vascular failure. 2012
• 現代の日本人の病態から生活習慣病の予防と治療を考える 2012
• 脂質異常症薬(脂質異常症薬+Ca拮抗薬を含む) 2012
• 脂肪代謝と動脈硬化 RAS 2012
• 糖尿病薬のアンチエイジング作用 2012
• 心血管系の慢性炎症におけるスタチンの効果 2012
• 動脈硬化、プラーク破綻におけるバイオマーカーの意義と展望 2012
• 脂質異常症 2012
• 透析導入前の慢性腎臓病 (CKD) 患者における24時間血圧測定による予後評価 2012
• 合剤は動脈硬化性疾患のアウトカムを変え得るか -功罪について- 2012
• これからの高血圧治療 -残された課題への挑戦 -バイオマーカー- 2012
• 動脈硬化における性差 臨床にどう活かすか 2012
• 体内リズムと循環器病 2012
• 概日時計の振動原理 2012
• 循環器病のバイオマーカー AIM 2012
• 脂質代謝とPPARγ 2012
• 慢性腎臓病における貧血と心疾患 2012
• 慢性透析症例での心血管疾患をいかに治療するか？ 2012
• メタボリックシンドロームのリスクファクターを有する高血圧治療戦略 2012
• LEMの結果をどのように臨床に生かすか-LEMサブ解析からの知見- 2012
• 血圧・脂質の同時治療の意義 2012
• PADの最適な治療 -リスク管理の重要性と内科医の役割- 2012
• 心血管リスクを見据えた糖尿病腎症の管理 2012
• トリグリセライド(中性脂肪) 2012
• 腎臓を守ることは心臓を守ること 2012
• 糖尿病における心血管病の特徴と対策 2012
• 病態に応じた積極的降圧療法 2012
• インクレチンの心臓に対する作用 2012
• 炎症マーカーと慢性心不全 2012
• 現代型不眠と生活習慣病 2012
• 心血管病に対するインクレチン製剤の心保護作用について 2012
• 心不全に対する GLP-1 の効果 2012
• 慢性心不全の ICT による遠隔モニタリング(HOMES-HF) 2012
• 生活習慣病における時計遺伝子解析 2012
• 時計遺伝子と高血圧 2012
• メタボリックシンドロームやそのリスクファクターを有する高血圧の治療戦略と新たなアプローチ 2012
• 不整脈発生予防に対する運動・日常身体活動の役割 2012
• 人工臓器　最近の進歩　再生医療による人工臓器研究の最近の進歩　scaffold freeの心臓・血管組織の構築 2012
• Repetitive hyperthermia attenuates progression of left ventricular hypertrophy and increases telomerase activity in hypertensive rats. 2012
• Endothelin-1 Has a Pivotal Role in Contraction Variability in Hypertrophic Cardiomyopathy-Induced Pluripotent Stent Cell-Derived Cardiomyocytes. 2012
• Epigallocatechin gallate attenuates the progression of heart failure induced by heart/muscle-specific deletion of Mn-SOD in mice through scavenging free radicals and improving the cardiac chronic inflammation. 2012
• The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. 2012
• これからの心血管保護戦略 2012
• Bio Rapid Prototyping Project for Cardiovascular Regeneration: A Simple Method to Build Scaffold Free Living 3D Micro Patterned Cell Construct. 2012
• Intensive Lipid and Blood Pressure Lowering in Japanese CAD Patients with Diabetes: Design and Rationale of RCT on Registry. 2012
• Possible Protective Role of Incretin Hormones in Cardiovascular Diseases. 2012
• Immunoregulatory Cytokine-mediated Inhibition of Vascular Inflammation in Atherosclerosis. 2012
• Web Linked Home Telemonitoring System for Japanese Patients with Heart Failure. 2012
• Recent Advances in Coronary Vessel Wall Imaging with Cardiac MRI. 2012
• MRP8/14 is a Novel Biomarker for Atherothrombosis. 2012
• Molecular Basis Where by Activated AT1 Receptor Conformation Attenuate Inverse Agonist Efficacy. 2012
• 4-Year Consecutive Complete Follow-up Result of Silorims Eluting Stent (SES) Implanted Lesion. 2012
• Comparison of CABG and PCI with Drug-eluting Stent (DES) for the Teatment of LMT Disease . 2012
• Comparison of CABG and PCI with Drug-Eluting Stent (DES) for the Treatment of 3-Vessel Disease by SYNTAX Score. 2012
• Matrix Metalloproteinase-9 Might Contribute to Mobilization of Bone Marrow-Derived Cells After Coronary Stent Implantation. 2012
• 高血圧と時計遺伝子 2012
• 糖尿病と心不全 2012
• 2型糖尿病患者におけるGLP-1アナログ製剤の睡眠障害に及ぼす影響　アクチグラフによる検討 2012
• 慢性心不全のＩＣＴによる遠隔モニタリング(HOMES-HF) 2012
• 心血管不全と体内時計 2012
• 光陰矢のごとし　体内時計からアンチエイジングを考える 心血管不全と体内時計 2012
• Evaluation of Vascular Fialure and the association with oxidative stress and NO. 2012
• 心筋梗塞の二次予防 2012
• The Glucagon-like Peptide 1 Analog Liraglutide Reduces TNF-α- induced Oxidative Stress and Inflammation in Endothelial Cells. 2012
• Audience Response System(ARS)は循環器学の臨床前教育を魅力的にするツールである 2012
• 心臓MRAによる冠動脈疾患のスクリーニングとその有用性 2012
• 心血管不全の診断と治療 2012
• 治療経過中のLDL-Cレベルではなく、スタチンの使用が糖尿病合併安定肝動脈疾患患者のイベント発症に関連する 2012
• Audience Response System (ARS)を用いた心電図教育法 2012
• 最近の話題：血管・危険因子 2012
• 積極的降圧治療の有効性とQOLに関する調査S-CATS: Saga Challenge Antihypertensive Study　ロサルタンサブ解析 2012
• 糖尿病と抗血栓療法 2012
• 血管不全を標的とした臨床試験 2012
• Effect of Eicosapentaic Acid and HMG-CoA Reductase Inhibitor on Chronic Heart Failure. 2012
• 体内時計と心血管疾患―メカニズムから薬物療法を考える― 2012
• MRP-8/14 はアテローム性動脈硬化プラークの不安定化を予測するバイオマーカーになりうるか？ 2012
• 慢性心不全における在宅モニタリングの試み 2012
• 血糖管理による心血管不全治療―インクレチン製剤への期待― 2012
• 冠静脈洞の著明な拡大を認めた一例 2012
• ステント留置時にステントのshorteningを認め、IVUSカテーテルが抜去困難となった症例　 2012
• MRP8/14は不安定プラークのバイオマーカーになりうるか? 2012
• たこつぼ心筋症を発症した2:1房室ブロックに対するペースメーカー植え込み術後の1例 2012
• 中枢性無呼吸と洞停止を合併したPerry 症候群の1 例 2012
• インクレチンはアンチエイジングホルモンになりえるか？ 2012
• Prospective cohort study of　gastrointestinal complications and vascular diseases in patients taking aspirin: 　rationale and design of the MAGIC Study. 2011/12
• Antihypertensive treatment using an angiotensin receptor blocker　and a thiazide diuretic improves patients' quality of life: the Saga Challenge　Antihypertensive Study (S-CATS). 2011/12
• New Paradigm of Cardiovascular Failure Therapy. 心血管不全治療の新展開 2011/12
• 生活習慣病薬開発・臨床試験の最前線 糖尿病薬の臨床研究 2011/12
• 大動脈弁に付着した巨大疣腫を3D経食道心エコーで観察し得た感染性心内膜炎の一例 2011/12
• 循環器専門医から見た糖尿病治療～DPP-4阻害薬の期待 2011/12
• 糖尿病と心血管不全. 2011/12
• IL-27 inhibits hyperglycemia and pancreatic islet inflammation induced by streptozotocin in mice. 2011/11
• Matrix Metalloproteinase-9 Might Contribute to Mobilization of Bone Marrow-Derived Cells After Coronary Stent Implantation. 2011/11
• Molecular Mechanism Whereby Activated State of the Angiotensin II Type 1 Receptor Attenuate Inverse Agonist Efficacy. 2011/11
• 新規発症2型糖尿病患者の食後血管内皮機能不全に対するアカルボースとナテグリニドの効果の比較検討 2011/11
• 肥満と塩分摂取量に関する検討 2011/11
• 閉経後女性と循環器疾患　スタチン治療を中心に 2011/11
• Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. 2011/10
• 新規糖尿病治療薬GLP-1アナログ・リラグルチドの血管内皮細胞における抗酸化作用と抗炎症作用 2011/10
• インクレチンと心血管病. 2011/10
• 心不全における遠隔治療―ITによる在宅管理（HOMES-CHF） 2011/10
• 心不全に対するスタチンの可能性. 2011/10
• 脳・心・腎保護を目指した治療戦略　降圧療法 2011/10
• 高血圧の成因、病態、治療に関するパラダイムシフト 時計遺伝子とバイオリズム・高血圧 2011/10
• 慢性腎臓病におけるスタチンの腎保護作用について 2011/10
• ２型糖尿病患者におけるGLP-1アナログ製剤の睡眠障害に及ぼす影響：アクチグラフによる検討 2011/10
• 心不全にならないためにはどうしたらよいか 2011/10
• Renovascular protective effects of erythropoietin in patients with chronic kidney disease. 2011/09
• Apixaban versus warfarin in patients with atrial fibrillation. 2011/09
• 心臓MRAによる冠動脈疾患のスクリーニングとその有用性 2011/09
• New Insights of Statin Treatment for Vascular Failure～心血管不全に対するスタチンの新たな可能性～. 2011/09
• 体内リズムと高血圧治療. 2011/09
• 循環器診療におけるインクレチンの役割 2011/09
• 慢性腎臓病における貧血と心疾患 2011/09
• 地域医療体制を維持するために真に必要とされる循環器専門医とは 2011/09
• Molecular Mechanism of Circadian Clock Gene Regulation. 2011/08
• Treatment of CKD with Chronic Heart Failure. 2011/08
• Estrogen and Cardiovascular Failure and Aging. 2011/08
• The Role of GLP-1 Analog and DPP-4 Inhibitor in Cardiovascular System. 2011/08
• Prediction of Acute Coronary Syndrome by Using Multislice Computed Tomography. 2011/07
• Relationships among hyperuricemia, metabolic syndrome, and endothelial function. 2011/07
• Interleukin 27 Inhibits Hyperglycemia and Pancreatic Islet inflammation Induce d by Streptozotocin in Mice 2011/07
• Angiotensin II induces microtubule reorganization mediated by a deacetylase SIRT2 in endothelial cells. 2011/06
• Design and Rationale of Japanese Evaluation Between Formula of Azelnidipine and Amlodipine Add on Olmesartan to Get Antialbuminuric Effect Study (J-FLAG) : Evaluation of the Antialbuminuric Effects between Calcium Channel Blocker with Sympatholytic Action in Hypertensive Patients with Diabetes and Albuminuria. 2011/06
• ARBとスタチンの併用 2011/06
• 特別講演「慢性心不全治療 up-to-date」 2011/06
• 特別講演「器質的心疾患を伴う頻脈性不整脈に対する治療戦略」 2011/06
• 特別講演「将来の脳・心血管イベント予防のために今できる治療」 2011/06
• 特別講演「心血管病予防の為の血糖管理」 2011/06
• 講演「心を護る」 2011/06
• 特別講演「新臨床研修医制度によって何がどう変化したか？各大学がいかに取り組んでいるのか？」 2011/06
• 特別講演「慢性心不全の遠隔医療」 2011/06
• Clinical characteristics and long-term prognosis of vasospastic angina patients who survived out-of-hospital cardiac arrest: multicenter registry study of the Japanese Coronary Spasm Association. 2011/06
• 非糖尿病性早期CKDにおけるスタチンのAGE/RAGE系への影響 2011/06
• ステント留置後のLate luminal loss-シロリムス溶出性ステントとパクリタキセル溶出性ステントとの比較 2011/06
• 心不全と電解質異常 2011/05
• 「特集にあたって」食後高血糖と動脈硬化 2011/05
• 食後高血糖に対するARBの効果 2011/05
• 食後高血糖に対する運動療法 2011/05
• 食後高血糖を予防する食事療法 2011/05
• [Effects of incretin on cardiovascular isease and risk factors] 2011/05
• 講演「メタボサルタンの生活習慣病への期待」 2011/05
• 特別講演「高血圧治療 up to date」 2011/05
• インスリン使用中2型糖尿病患者の心血管系リスクに関する研究(CREDIT Study)からみたレジメン維持例とインスリン離脱例の特徴 2011/05
• インスリン使用中の2型糖尿病患者を対象とした心血管系リスクに関する研究(CREDIT Study)からみた日本のインスリン導入の実態 2011/05
• 病態モデル動物のライブイメージング 64Cu標識P-セレクチン抗体を用いたLDLレセプター欠損マウスの動脈硬化病変の検出 2011/05
• A promising culture model for analyzing the interaction between adipose tissue and cardiomyocytes. 2011/04
• 特別講演「心血管イベント抑制から見た食後高越冬地量の重要性」 2011/04
• Febrication of tissue engineered pulsatile 3-Dimensional scaffold-free cardiac tissue from embryonic stem cells. 2011/04
• 新しい組織工学技術を用いた自己細胞由来人工血管の作成の可能性 2011/04
• 虚血性心疾患の診断と治療UPDATE 2011/04
• バイオリズムと生活習慣病 2011/03
• 「バイオリズムと生活習慣病」 2011/03
• 特別講演「メタボサルタンの生活習慣病への期待」 2011/03
• 特別講演「インクレチンの動脈硬化薬としての可能性」 2011/03
• 「糖尿病治療の新展開～ヒトGLP-アナログ製剤の可能性」 2011/03
• Pleiotropic effects of ARB on dyslipidemia. 2011/03
• 副作用緩和のための新しい薬理学的アプローチ 体内時計遺伝子の調節と循環器治療 2011/03
• 講演「糖尿病患者の心血管イベントを抑制するために」 2011/02
• 特別講演「高血圧の治療 up date」 2011/02
• 「体内リズムと生活習慣病」 2011/02
• 特別講演「CKDと心血管不全」 2011/02
• Inhibition of intestinal cholesterol absorption might explain cholesterol-lowering effect of telmisartan. 2011/02
• Mitochondrial dysfunction and increased reactive oxygen species impair insulin secretion in sphingomyelin synthase 1-null mice. 2011/02
• 新しい心筋細胞立体構造体形成技術による心筋再生療法 2011/02
• 体内時計の分子機構 2011/02
• スタチンの新しい展開～心・腎連関を踏まえて 2011/02
• The role of vascular failure in coronary artery spasm. 2011/01
• 血管と細胞骨格（RASとの関連） 2011/01
• Research Report Presentation Part 2「Interleukin 27 Inhibits Hyperglycemia and Pancreatic Islet inflammation Induced by Streptozotocin in Mice」 2011/01
• 特別講演「糖尿病の血管不全」 2011/01
• 特別講演「インクレチンの心血管作用」 2011/01
• 「高血圧治療 Up to Date-体内リズムと生活習慣病-」 2011/01
• 特別講演「不眠と循環器病」 2011/01
• Rab5a-mediated localization of claudin-1 is regulated by proteasomes in endothelial cells. 2011/01
• [Anti-atherosclerotic effect of fibrates and eicosapentaenoic acid]. 2011/01
• 座談会　心血管疾患における耐糖能障害・CKDの関与 2011
• 大血管症リスクとしての食後高血糖と低血糖 2011
• 特集にあたって　血圧・血糖・脂質マネジメント 2011
• 特集にあったって　特集：糖尿病と循環器疾患 2011
• インクレチンと心血管病 2011
• 分岐部病変：two-stent vs one-stent technique 2011
• 虚血性腎症を探る〈企画にあたって〉 2011
• 第83回米国心臓協会・学術集会（AHA） 2011
• 中高年女性における不眠症治療 2011
• インクレチンノ心血管リスク抑制作用 2011
• CKDと心血管不全 2011
• 血管糖尿病2011 2011
• 血管糖尿病コンセプトレビュー Vascular Diabetes創生―Keynote remarksとして 2011
• 食後高血糖と血管不全 2011
• 私が推す2010年のこの一報 2011
• 脂質異常症治療が心血管イベントに及ぼす効果 2011
• 【総説】冠動脈プラークイメージング－VH-IVUSとMDCT－ 2011
• 【オープニングリマークス】冠動脈のプラークイメージング 2011
• 慢性腎不全患者に対する虚血性心疾患の予防と治療について教えてください 2011
• 高齢者虚血性心疾患の特徴 2011
• メタボリックシンドロームと心疾患 2011
• 【新聞記事】LMT分岐部病変PCI治療戦略の最新知見を報告(座談会・新聞記事など) 2011
• 【対談記事】テルミサルタンの強力な降圧効果とPPAR-ｒ活性化への期待(座談会・新聞記事など) 2011
• 日内リズムと時計遺伝子(座談会・新聞記事など) 2011
• CKD合併の高血圧治療(座談会・新聞記事など) 2011
• Potential Benefit of Statin Therapy for Dyslipidemia with Chronic Kidney Disease: Fluvastatin Renal Evaluation Trial (FRET). 2011
• Effects of aerobic exercise on lipid profiles and high molecular weight adiponectin in Japanese workers. 2011
• Prediction of acute coronary syndrome by using　multislice computed tomography. -Can we predict the onset of acute coronary　syndrome? (Pro)-. 2011
• Risk stratification based on metabolic syndrome as well as non- metabolic risk factors in the assessment of carotid atherosclerosis. 2011
• 拡張不全の治療はどのようにしたらよいでしょうか？　 2011
• 血圧・体重の遠隔モニタリングによる慢性心不全の管理を検証 2011
• 慢性心不全在宅管理における遠隔モニタリングの有用性 2011
• 左室補助装置送血管内疣腫および送血側人工弁心内膜症により、LVAD不全を呈した重症心不全の一例 2011
• 拡張型心筋症、僧帽弁閉鎖不全症の周術期に心臓再同期療法を併用し有効であった1 例 2011
• 経皮的冠動脈ステント留置術が下肢閉塞性動脈硬化症、糖尿病性壊疽の創治癒に好影響を 及ぼした一例 2011
• 左冠動脈主幹部におけるKBTステント留置後の一剖検症例 "micro focus CTによるKBT後のstent strut評価" 2011
• 第83回米国心臓協会・学術集会（AHA） 2011
• 糖尿病と抗血栓療法 2011
• 心不全診断で重要な心電図変化を教えてください 2011
• ジギタリスの使い方のポイントを教えてください 2011
• 心不全のくすり 2011
• 序 2011
• 検査・診断 2011
• Glucose Lowering: Is it Safe for the Heart? 2011
• 高血圧における血管不全の診断と降圧薬の選び方 2011
• 心房性不整脈合併例の治療方法について教えてください. 2011
• 心室性不整脈合併例の治療方法について教えてください 2011
• 負荷心電図 2011
• DESの可能性と限界について　ベンチテストからの考察 2011
• 運動負荷試験による血圧変化と心・血管病との関連 2011
• 動脈硬化と概日時計 2011
• 生化学・分子生物学　ヒト体内時刻の新測定法 2011
• 体内時計と生活習慣病 2011
• 【座談会】心血管病予防へのアプローチ 2011
• 冠動脈疾患における治療学の進歩　冠動脈インターベンション(PCI)　薬剤溶出性ステント(DES)　薬剤溶出性ステントの基本構造 2011
• 循環器疾患の薬剤知識とγ計算が得意になるコツ　循環器疾患の薬剤知識とγ計算が得意になるコツ　ガンマで投与する理由と2つの式　ガンマ投与指示量から点滴速度を求める式、体重掛ける6の式 2011
• 動脈硬化における慢性炎症 2011
• 冠循環の病理・病態　冠動脈プラークの病理・病態　冠動脈プラークと血管内皮機能 2011
• 【座談会】関連学会から女性医学学会に期待すること」＜日本女性医学学会　将来への展望2011＞ 2011
• 【座談会】 T/L型Ca拮抗薬の腎・血管保護作用を考える 2011
• 心年齢に対するアンチエイジング 2011
• 【座談会】腎保護を考慮した糖尿病合併高血圧の治療 2011
• 心不全患者の総死亡率におけるカンデサルタンとロサルタンの比較 2011
• 心不全に対するβ遮断薬の使い方 2011
• 誌上ディベート　スタチンを飲む?飲まない?　スタチンを「飲む」 2011
• インクレチンの基礎・臨床研究の進歩　インクレチンの膵外作用とその臨床応用　インクレチンの心血管リスク抑制作用 2011
• 【座談会】メタボリックシンドローム合併　高血圧治療における”メタボサルタン”への期待 2011
• 日内リズムとアンチエイジング(第2回)　日内リズムと高血圧 2011
• ARB+CCBにおけるCCBの違いによる差異 2011
• 【座談会】循環器疾患をアンチエイジングから考える 2011
• 心不全治療における最近の大規模研究　Large-scale clinical trials in heat failure 2011
• エストロゲンの心筋への作用 2011
• 体内リズムと循環器病－時計遺伝子の関与－ 2011
• BNP「検査値を読む」 2011
• 糖尿病患者の心血管イベントを抑制するために 2011
• 【座談会】】血圧とLDLコレステロールを１錠で同時にコントロールできるメリットとは 2011
• 【座談会】CKD合併症例における脂質治療戦略について 2011
• 大血管疾患予防を目指した糖尿病治療を考える 2011
• 睡眠時無呼吸と高血圧 2011
• インクレチン製剤の効果 2011
• 薬物療法　フィブラート・EPA 2011
• 【対談】心血管疾患とCKD 2011
• 循環器疾患の薬剤知識とγ計算が得意になるコツ　不整脈の知識と薬剤の作用、効果の見極め、持続、配合の禁忌 2011
• メタボリックシンドローム発症にかかわる血管内皮細胞機能異常 2011
• 高血圧－閉経後女性の降圧療法－ 2011
• 【座談会】糖尿病と循環器疾患 2011
• 【座談会】心血管病予防へのアプローチ　次世代の治療とは 2011
• 【座談会】厳格な降圧療法と尿酸管理　ARB/HCTZ配合剤とARB/CCB配合剤の使い分け 2011
• 【座談会】これからの心臓病治療 2011
• Marked cerebral atrophy is correlated with kidney dysfunction in nondisabled adults. 2010/12
• PCI using a 4-Fr "child" guide catheter in a "mother" guide catheter: Kyushu KIWAMI� ST registry. 2010/12
• 特別講演「血管不全の病態と治療」 2010/12
• 「体内時計からみた生活習慣病」 2010/12
• On behalf of the PEARL Study Investigators. Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure The pitavastatin heart failure study (PEARL study). 2010/11
• Low serum albumin level is risk factor for patients with percutaneous endoscopic gastrostomy. 2010/11
• 特別講演「インクレチンの動脈硬化予防薬としての可能性」 2010/11
• Special Lecture「脂質異常をともなう高血圧の最新治療戦略」 2010/11
• 特別講演「血管病としてとらえるべき狭心症」 2010/11
• Lecure「高血圧治療の New Wave」 2010/11
• 大動脈弁狭窄症 2010/10
• 酸化ストレスによる心血管障害とスタチン 2010/10
• 特集にあたって　特集：ライフスタイルと不整脈のかかわりを探る 2010/10
• メタボリックシンドロームと時計遺伝子 2010/10
• 老化と酸化ストレス 2010/10
• 酸化ストレスによる心血管障害とスタチン 2010/10
• 喫煙と不整脈　喫煙はどのようにして不整脈を引き起こすのか? 2010/10
• 不整脈発症を予防するための食事療法はどのようにすすめればよいか? 2010/10
• ランチョンセミナー LS-2「閉経女性と冠動脈疾患－女性ホルモンを中心に―」 2010/10
• 一般演題（口演）頸部リンパ説腫脹を伴ったIgG4関連間質性腎炎の一例 2010/10
• 一般演題（ポスター）アルガトロバン接続点滴が著効を示した、多発血栓症を併発したヘパリン起因性血小板減少症の一例 2010/10
• 一般演題（ポスター）腎疾患治療中に発症した肺ノカルジアの３例 2010/10
• 一般演題（口演発表）02-01「高齢の慢性心不全患者に対する自己管理支援の現状と課題」 2010/10
• 一般ポスター 46:〈臨床〉高血圧性臓器障害―腎臓３ P46-220「糖尿病性腎症患者におけるCa拮抗剤のAGE/RAGE系、アルブミン尿、尿中L-FABPへの作用」 2010/10
• 一般ポスター54：〈臨床〉治療―併用療法４　P54-260「ARBと利尿剤合剤によるQuality of Lifeに与える影響(S-CATS: Saga Challenge Antihypertensive Study)」 2010/10
• 一般ポスター5５：〈臨床〉治療―併用療法 ５ P55-266「ARBと利尿剤合剤による降圧効果に与える影響(S-CATS: Saga Challenge Antihypertensive Study)」 2010/10
• ランチョンセミナー4「CKDと心血管不全」 2010/10
• 特別講演「将来の脳・心血管イベント予防のために今できる治療～医師と患者のCardiovascular Duetに向けて～」 2010/10
• 特別講演「大血管障害を見据えた糖尿病治療の新しい流れ」 2010/10
• 特別講演「大血管障害進展を見据えた糖尿病治療の新しい流れ」 2010/10
• 「将来の脳・心血管イベント予防のために今できる治療～医師と患者のCardiovasucular Duetに向けて～」 2010/10
• 特別講演「動脈硬化の治療戦略」 2010/10
• 特別講演「高血圧の診断と治療－血管不全の観点からのアプローチ―」 2010/10
• 講演「将来の脳・心血管イベント予防のために今できる治療～医師と患者のCardiovascular Duetに向けて～」 2010/10
• Japan Arteriosclerosis Longitudinal Study (JALS) group. Body mass index and risk of stroke and myocardial infarction in a relatively lean population: meta-analysis of 16 Japanese cohorts using individual data. 2010/09
• Guidelines for Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease (JCS 2008) 2010/09
• 日本の積極的脂質低下療法　脈動の10年 2010/09
• 脂質コントロール 2010/09
• 2型糖尿病の血管不全～心血管イベントに対するGLP-1の影響～ 2010/09
• 【新聞記事】「体内時計」簡便診断(座談会・新聞記事など) 2010/09
• 冠動脈インターベンションの最前線「DESの可能性と限界について　ベンチテストからの考察」 2010/09
• パネルディスカッション３　バイオマーカーは循環器病診療にどこまで生かされているか PD-3-4「新規バイオマーカーPDMPの循環器病診療における有用性」 2010/09
• LMT病変 PCI vs. CABG「LMT病変に対するPCIの可能性と限界」 2010/09
• DES留置後の抗血小板治療はいつまで続けるべきか？「障害血管の修復機転からみたDES留置後の抗血小板療法」 2010/09
• ポスター　インターベンション 1 DESの慢性期成績 P093「三枝病変冠動脈疾患に対するCABGとDESを用いたPCIとの治療成績の比較」 2010/09
• 特別講演「体内時計から見た高血圧治療」 2010/09
• 特別講演「GLP-1アナログ製剤ビクトーザの循環器領域における可能性」 2010/09
• 講演1「高血圧治療のNew Wave」 2010/09
• 「将来の脳・心血管イベント予防のために今できる治療」 2010/09
• 特別講演「将来の脳・心血管イベント予防のために今できる治療」～医師と患者のCardiovascular Duetに向けて～ 2010/09
• 特別講演「心血管イベント抑制の為の降圧療法」 2010/09
• Activation of matrix metalloproteinase-9 is associated with mobilization of bone marrow-derived cells after coronary stent implantation. 2010/08
• Noninvasive method for assessing the human circadian clock using hair follicle cells. 2010/08
• Guidelines for diagnosis and treatment of patients with vasospastic angina(coronary spastic angina) (JCS 2008): digest version. 2010/08
• 「特集にあたって」糖尿病と大血管障害 2010/08
• 高血糖と炎症マーカー 2010/08
• エストロゲンと心肥大 2010/08
• 座談会 今後の降圧治療におけるＡＲＢ/Ｃａ拮抗薬配合剤への期待 望まれる組み合わせとは（前篇）(座談会・新聞記事など) 2010/08
• フォーカスセッション１「虚血性疾患2次予防のためのOptimal Medical Treatment:その指標と実際は？」 2010/08
• 腹部大動脈瘤人工血管置き換え術後に吻合部仮性動脈瘤が十二指腸に穿孔した一例 2010/08
• 抗ミトコンドリアM2抗体の関与が疑われた繰り返す急性心筋炎の１症例 2010/08
• 迅速な血液透析療法が有効であったグリホサート中毒の一例 2010/08
• 特別講演「心血管病予防の今後」 2010/08
• 特別講演「心・腎保護を考慮した高血圧治療」～併用療法の新たな可能性を探る～ 2010/08
• Sulfatides are associated with neointimal thickening after vascular injury. 2010/07
• 動脈硬化の病態基盤としての血管炎症 2010/07
• 心血管病と体内時計 2010/07
• 一般演題　M42 MT Ostiumに留置したBare Metal Stent (BMS)の脱落症状 2010/07
• 最新治療戦略「高血圧治療のNew Wave」 2010/07
• 特別講演「体内時計から見た生活習慣病」 2010/07
• 特別講演「高血圧診療のNew Wave」 2010/07
• 講演「体内時計から見た生活習慣病」 2010/07
• 特別講演「血管不全からみた高血圧の診断と治療」 2010/07
• 特別講演「心・腎保護を考慮した高血圧治療」 2010/07
• Expert Lecture「体内時計から見た高血圧治療」 2010/07
• 基調講演「大血管障害進展を見据えた糖尿病治療の新しい流れ」 2010/07
• 講演「体内時計から見た高血圧治療」 2010/07
• 特別講演II「心・腎保護を考慮した高血圧治療」 2010/07
• Ultrasonographic detection of thyroid nodules in hemodialysis patients in Japan. 2010/06
• 血管評価 2010/06
• 心臓性急死 2010/06
• 動脈血・静脈血酸素飽和度測定を役立てる 2010/06
• シンポジウム講演1「Role of Calcium Antagonists in Coronary Artery Disease –In view of their vasoprotective action-」 2010/06
• Evening Semiar 2 Lecture1「The regulatory effect of statin on the coronary plaque from the view point of molecular mechanism」 2010/06
• Meet the Expert II　高齢者診療のポイント 14.「高齢者虚血性心疾患の特徴」 2010/06
• YIAセッション）YIA４　Pentraxin3 (PTX3)は慢性心不全の予後を予測する 2010/06
• Case Report Award)CRA1 川崎病の既往を有する重症若年発症心筋梗塞の一例 2010/06
• 研修医セッション）R3 ベーチェット病に合併し、治療に苦慮した深部静脈血症症の１例 2010/06
• 虚血性心疾患１）15.　右冠動脈入口部に留置したシロリムス溶出性ステント(SES)が破砕し、その断端を下肢動脈にて認めた症例 2010/06
• SP-07 Role of Carcium Antagonists in Coronary Artery Disease-In view of their vasoprotective action- 2010/06
• ES-02 The regulatory effect of statin on the coronary plaque from the view point of molecular mechanism 2010/06
• Plenary Session 6「Erectile Dysfunction and Endothelium Dysfunction」 2010/06
• 演題2「大血管障害進展を見据えた糖尿病治療の新しい流れ」 2010/06
• 特別講演「体内リズムからみた生活習慣病治療」 2010/06
• 特別講演「糖尿病血管合併症の病態と治療」 2010/06
• 特別講演「心・腎保護を考慮した高血圧治療～併用療法の新たな可能性を探る～」 2010/06
• 特別講演「高血圧の診断と治療～時計遺伝子の関与も含めて～」 2010/06
• 特別講演「体内リズムと生活習慣病」 2010/06
• 特別講演「腎血管保護を考慮した高血圧治療」 2010/06
• 循環器領域におけるスタチンの位置づけ 2010/05
• P-1-9-3 Interleukin 27 inhibits isoproterenol-induced cardiac hypertrophy 2010/05
• P-1-34-3 Interleukin 27 signaling inhibits hyperglycemia and pancreatic islet inflammation induced by streptozotocin in mice 2010/05
• P-1-34-5 Identification of molecular switches responsible for inverse agonist action by angiotensin II type 1 receptor blockers 2010/05
• P-1-41-4 Rab5a-mediated localization at cell-cell contacts of a tight junction protein claudin-1 is regulated by proteasome in endothelial cells. 2010/05
• P-2-15-1 Adipose tissue promotes lipid accumulation and apopotosis of cardiomyocytes, attenuating their growth and differentiation 2010/05
• P-2-21-4 Antiotensin II stimulates microtubule reorganization mediated by SIRT2 in endothelial cells. 2010/05
• P-2-40-6 Interleukin 27 inhibits neovascularization in hindlimb ischemia in mice 2010/05
• Debate Session 8-2 Cons:　虚血性心疾患合併糖尿病における運動療法の是非 2010/05
• Oral III-12-36 運動療法による耐糖能異常ならびに２型糖尿病患者の糸球体濾過率の改善効果 2010/05
• ランチョンセミナー42　演題１「動脈硬化治療の為の糖尿病治療」 2010/05
• Statin as a potential drug for treatment of heart failure. 2010/05
• Luncheon Simnar 14　血管不全と心腎連関 2010/05
• Session III「高血圧の診断と治療～レザルタスの可能性を探る～」 2010/05
• 特別講演「高血圧の診断と治療～生活習慣病と時計遺伝子の関与も含めて～」 2010/05
• 特別講演「心疾患を合併した糖尿病患者の薬物療法とマネージメント」 2010/05
• 特別講演「高血圧症の診断と治療」 2010/05
• 講演II「臓器保護を考えたCCBの選択」 2010/05
• 特別講演「高血圧の病態と治療～併用療法の新たな可能性を探る～」 2010/05
• 特別講演「冠動脈疾患の病態と治療」 2010/05
• 講演２「血管病としてとらえるべき狭心症」 2010/05
• 講演II「動脈硬化予防の為の糖尿病治療」 2010/05
• 喫煙は血管内皮機能にどのように障害を与えるか？ 2010/04
• 特別講演「高血圧の診断と治療～QOLの向上をめざして～」 2010/04
• 特別講演「これからの心血管保護戦略」 2010/04
• 特別講演「高血圧の診断と治療」 2010/04
• 特別講演「糖尿病治療の現況と今後の展開」 2010/04
• 特別講演「高血圧の診断と治療～レザルタスの可能性を探る～」 2010/04
• 講演１．「プライマリーケアにおける抗血小板療法の有用性」 2010/04
• 特別講演「高血圧の診断と治療～レザルタスの可能性を探る」 2010/04
• 特別講演「将来の脳・心血管予防のために今できる治療」 2010/04
• Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. 2010/03
• Medical agents acting on the renin-angiotensin-aldosterone axis for the treatment of heart failure. 2010/03
• プラバスタチン 2010/03
• 疫学と病態２　ＣＫＤと心血管疾患 2010/03
• 抗酸化治療の課題と展望 2010/03
• Effect of exercise therapy on monocyte and neutrophil counts in overweight women. 2010/02
• Effects of PPARgamma agonist on dyslipidemia and atherosclerosis. 2010/02
• Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker. 2010/01
• 慢性心不全　ネットで健康管理(座談会・新聞記事など) 2010/01
• 透析導入後に初めて診断され、酵素補充療法が著効したFabry病の1例 2010
• 特集　PPARｒアゴニスト 2010
• Raynaud現象 2010
• 心不全における血漿pentraxin3測定の有用性 2010
• 新たな心血管危機因子としてのCKD 2010
• 血管不全に対するカンデサルタンの効果 2010
• 酸化ストレス・炎症と動脈硬化 2010
• 炎症と動脈硬化　司会者のことば　（総説） 2010
• 血糖降下作用と心血管リスクに対するGLP-1の効果 2010
• 心・腎保護を考慮した高血圧治療～併用療法の新たな可能性を探る～ 2010
• 糖尿病における心血管リスク 2010
• 脂質異常症治療　スタチン 2010
• ステントを用いた左主幹部病変治療の可能性と限界： in vitroからの知見 2010
• DESの基本構造　Basic Efficiently of Drug-eluting Stent 2010
• 拡張期高血圧とは？下の血圧が高い人の特徴について教えてください 2010
• 糖尿病と急性冠症候群 2010
• 慢性腎不全と慢性心不全でアディポネクチンは低下しているか 2010
• 自験例をまじえた慢性腎不全と慢性心不全患者のアディポネクチン濃度の検討 2010
• フィブラート・EPA 2010
• 臨床研修における循環器研修のあり方-General Trainigが医師不足を救う- 2010
• 心不全の知識と薬剤の作用、効果の見極め、持続、配合の禁忌 2010
• 心血管障害 Cardiovascular Disease in Patients with Diabetes 2010
• FMDによる血管内皮機能検査と標準化 2010
• ARB/Ca拮抗薬の併用療法の位置づけ 2010
• 循環器領域における性差医療に関するガイドライン Guidelines for Gender-Specific Cardiovascular Disease 2010
• 座談会　今、なぜCKDが注目されているのか？（座談会・新聞記事など） 2010
• 座談会　循環器疾患における血糖コントロールを考える―循環器専門医と糖尿病専門医のクロストーク―(座談会・新聞記事など) 2010
• 座談会　降圧木尿達成のために、選択すべき降圧薬とは？(座談会・新聞記事など) 2010
• 座談会　今後の降圧治療におけるARB/Ca拮抗薬配合剤への期待 ミカムロ配合錠が果たす役割(後篇)(座談会・新聞記事など) 2010
• 今後の降圧治療におけるＡＲＢ/Ｃａ拮抗薬配合剤への期待～ミカムロ配合錠ＡＰが果たす役割～(座談会・新聞記事など) 2010
• 2型糖尿病の血管不全～心血管イベントに対するGLP-1の影響～(座談会・新聞記事など) 2010
• 【座談会】厳格な降圧とPPAR-ｙ活性化～メタボサルタンが担う臓器保護の可能性～ 2010
• 座談会　RAS研究の潮流と今後の展望(座談会・新聞記事など) 2010
• 対談　臓器障害とプロレニン,（プロ）レニン受容体(座談会・新聞記事など) 2010
• 【座談会】厳格な降圧とPPAR-γ活性化～メタボサルタンが担う臓器保護の可能性～後篇(座談会・新聞記事など) 2010
• 【座談会】血管保護を考慮した配合剤の選択(座談会・新聞記事など) 2010
• 指定講演「体内時計の分子機構」 2010
• 座談会　心血管イベント抑制をめざした降圧治療の新たなストラテジー-Direct Renin Inhibitor (DRI)の可能性-(座談会・新聞記事など) 2010
• Body mass index and risk of stroke and myocardial infarction in a relatively lean population: meta-analysis of 16 Japanese cohorts using individual data. 2010
• 血管炎症と内皮細胞 2009/10
• 心血管CT、MRI、冠動脈CT 2009/09
• 心血管系のアンチエイジングとRASの関連を探る　 2009/07
• Involvement of the protein kinase CK2 in the regulation of mammalian circadian rhythms. 2009/06
• 洞不全症候群と心不全を発症した筋緊張性ジストロフィーの1例 2009/06
• Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease 2009/05
• Reversal of Atherosclerosis with Aggressive Lipid Lowering 2009/05
• 不安定プラークの診断は可能だったか 2009/05
• 脂質異常症・動脈硬化を伴った高血圧とβ遮断薬 2009/04
• 虚血性心疾患 2009/04
• Molecular basis of restenosis and novel issues of drug-eluting stents. 2009/04
• 狭心症をいかに予防するか 2009/03
• Increased interleukin-13 levels in patients with chronic heart failure. 2009/01
• The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). 2009/01
• Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease 2009
• Reversal of Atherosclerosis with Aggressive Lipid Lowering 2009
• 心血管CT,MRI,冠動脈CT 2009
• Eicosapentaenoic acid increases cytochrome P-450 2J2 gene expression and epoxyeicosatrienoic acid production via peroxisome proliferator-activated receptor gamma in endothelial cells. 2009
• Association between high molecular weight adiponectin levels and metabolic parameters. 2009
• Benefits and risks of combination therapy in hypertension. 2009
• Postprandial hyperglycemia as an etiological factor in vascular failure. 2009
• Ebstein anomaly by cardiac magnetic resonance imaging. 2009
• Benefits and limitations of cypher stent-based bifurcation approaches: in vitro evaluation using micro-focus CT scan. 2009
• Estimated glomerular filtration rate as a predictor of secondary outcomes in Japanese patients with coronary artery disease. 2009
• Molecular basis of restenosis and novel issues of drug-eluting stents. 2009
• Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment. 2009
• Identification of four novel mutations in F5 associated with congenital factor V deficiency. 2009
• Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance. 2009
• 頻用される循環器薬の使い方　ＡＣＥ－I／ＡＲＢ 2009
• ＜心筋症治療の現況、新しい試み＞心筋症薬物療法の進歩 2009
• ロスバスタチンは慢性心不全に有効か？ 2009
• RAAS研究の進歩　アンジオテンシンIIをめぐる基礎研究　血管内皮機能障害　 2009
• 話題の論文　ロスバスタチンは症候性慢性心不全患者の臨床予後を改善しない：GISSI-HF試験 2009
• 腎機能障害のバイオマーカー心血管障害を予防する 2009
• 血小板由来マイクロパーティクルとatherothrombosis 2009
• 虚血性心疾患の再発予防―糖代謝改善薬のエビデンス 動脈硬化予防 2009
• 睡眠と生活習慣病のかかわりを探る 2009
• 体内時計の分子機構にせまる 2009
• プラーク形成・不安定化のバイオメーカー 2009
• 体内時計と血管機能 2009
• 薬物療法と電解質異常 2009
• 特集　生体リズムから心血管病を探る　特集にあたって 2009
• 高血圧治療ガイドラインにおける降圧目標の設定根拠 2009
• 虚血性心疾患・心不全の病態解明と治療法の開発 2009
• 【高齢者×高血圧　降圧療法マネジメントの重要性】 高血圧治療ガイドラインにおける降圧目標の設定根拠 2009
• 【心血管病の診断と治療におけるバイオマーカーの有用性】 L-FABP 2009
• 【Drug-eluting Stent　PCI最新動向】 薬剤溶出性ステント(DES)を理解するための基礎知識　DESの基本構造 2009
• 急性血液浄化治療の標準化　ガイドライン策定にむけて　現場からの意見 2009
• 【炎症と動脈硬化】 血管炎症によるプラークの形成　破綻と急性冠症候群 2009
• 【高血圧(第4版)　日本における最新の研究動向】　基礎編 循環生理活性物質の最新知見　受容体・シグナル伝達の最新知見　PPARγ 2009
• 【生体リズムから心血管病を探る】 時計遺伝子の分子構造を知る 2009
• 【心血管疾患における電解質異常】 治す　薬物療法と電解質異常 2009
• 【血管のアンチエイジング】 体内時計と血管機能 2009
• 【心筋梗塞・狭心症の再発予防】 虚血性心疾患の再発予防　糖代謝改善薬のエビデンス 2009
• 生活習慣病における医学、薬学の萠芽的研究 高分子量アディポネクチンの循環器疾患における意義の解明 2009
• 【睡眠と生活習慣病のかかわりを探る】 体内時計の分子機構にせまる 2009
• 【CRAS　心・腎・貧血の悪循環】 CRASとバイオマーカー 2009
• 【プラークバイオロジーの新展開　イメージング診断から治療まで】 プラーク形成・不安定化のバイオマーカー 2009
• 日常診療に役立つ最新!血管疾患の生理と病理　血管内皮機能の意義 2009
• PPARγ 2009
• 心臓神経症 Cardiac Neurosis 2009
• PPAR標的薬によるがん治療、アンチエイジング 2009
• 済生会熊本病院での急性大動脈解離内科治療 2009
• 連日透析後１回の心嚢穿刺で劇的な軽快を得た、尿毒症性心外膜炎による心タンポナーデの1例 2009
• Keynote Lecture: New Target of Atherosclerosis Treatment 2009
• Effect of Statin on Chronic Heart Failure 2009
• Ebastein Anomaly by Cardiac Magnetic Resonance Imaging. 2009
• 慢性心不全の診断と治療 2009
• Flow-mediated vasodilation as a diagnostic modality for vascular failure. Hypertens 2009
• Vascular Failure Workshop Group. Flow-mediated vasodilation as a diagnostic modality for vascular failure. 2008/12
• Associations of monocytes, neutrophil count, and C-reactive protein with maximal oxygen uptake in overweight women. 2008/12
• A polymorphism regulates CYP4A11 transcriptional activity and is associated with hypertension in a Japanese population. 2008/12
• Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease. 2008/12
• Flow-mediated vasodilation as a diagnostic modality for vascular failure. 2008/12
• Fracture of a sirolimus-eluting stent with migration. 2008/11
• Prognostic value of pentraxin 3 in patients with chronic heart failure. 2008/10
• Renoprotective effect of telmisartan in patients with chronic kidney disease. 2008/10
• 循環器病における食事療法-運動・食事療法のエビデンス- 2008/10
• 特集II/PPARsと炎症　序 2008/10
• 特集II/PPARsと炎症　PPARsと血管炎症 2008/10
• 特集 CKDと循環器疾患　CKD合併循環器疾患の管理　虚血性心疾患 2008/10
• Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome. 2008/09
• A case report of nephrotic syndrome due to collapsing focal segmental glomerulosclerosis treated with low-density lipoprotein apheresis. 2008/08
• Endoscopic thoracic sympathectomy as a novel strategy for vasospastic angina refractory to medical treatments. 2008/08
• 時計遺伝子 2008/07
• 経皮的冠動脈形成術後のチアゾリジン誘導体の心血管保護作用の検討 2008/07
• 心不全治療の今後の展望 2008/07
• 血管内皮機能の臨床的評価法 2008/07
• Angiotensin II increases expression of IP-10 and the renin-angiotensin system in endothelial cells. 2008/06
• Telmisartan as a metabolic sartan for targeting vascular failure. 2008/06
• 高血圧管理のための薬物療法　長時間作用型カルシウム拮抗薬 2008/05
• Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor-1alpha upregulation in endothelial cells. 2008/05
• Molecular defects associated with antithrombin deficiency and dilated cardiomyopathy in a Japanese patient. 2008/05
• Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. 2008/05
• Mechanical stretch and angiotensin II increase interleukin-13 production and interleukin-13 receptor alpha2 expression in rat neonatal cardiomyocytes. 2008/04
• Mitogen-activated protein kinase is a functional component of the autonomous circadian system in the suprachiasmatic nucleus. 2008/04
• 特集/食後高血糖と動脈硬化　特集を組むにあたって-食後高血糖がみられる段階で、大血管症を防止する企てが必要- 2008/04
• 特集/ライフスタイルは心血管不全にどう関与するのか？　特集にあたって 2008/04
• 特集/ライフスタイルは心血管不全にどう関与するのか？　食事療法と心血管不全 2008/04
• はじめに 2008/04
• PPARγと動脈硬化治療 2008/04
• 先天性心膜欠損症[完全，不完全] 2008/03
• Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. 2008/03
• STAT6 mediates apoptosis of human coronary arterial endothelial cells by interleukin-13. 2008/03
• Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy. 2008/02
• Reversible primary hypothyroidism in Japanese patients undergoing maintenance hemodialysis. 2008/02
• Partial blood recirculation: a new trial for prolonging filter life during continuous hemodiafiltration. 2008/02
• ARBとスタチン 2008/01
• 特集：糖尿病に伴う血管病に迫る-各種病因と主要血管の病像まで-　食後高血糖と血管病はどのようにかかわるか？ 2008/01
• Increased circulating platelet-derived microparticles are associated with stent-induced vascular inflammation. 2008
• Alternative spliced variants in the pantetheinase family of genes expressed in human neutrophils. 2008
• IL-13 attenuates vascular tube formation via JAK2-STAT6 pathway. 2008
• IL-13 Attenuates Vascular Tube Formation Via JAK2-STAT6 Pathway. 2008
• Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. 2008
• Mechanical Stretch and Angiotensin II Increase Interleukin-13 Production and interleukin-13 Receptor alpha2 Expression in Rat Neonatal Cardiomyocytes. 2008
• STAT6 mediates apoptosis of fuman coronary arterial endothelial cells by Interleukin-13. 2008
• Simvastatin Stimulates Vascular Endothelial Growth Factor Production by Hypoxia-inducible Factor-1alpha Upregulation in Endothelial Cells. 2008
• Tropical fruit camu-camu(Myrciaria dubia) has anti-oxidative and anti-inflammatory properties. 2008
• 急性咽喉頭炎で入院した左房粘液腫の１例 2008
• 先天性左側心膜欠損症 2008
• 最新薬物治療の実際　心血管イベント抑制のための高血圧治療 2008
• 脂質異常症-メタボリックシンドロームのリスク-　特集にあたって 2008
• 動脈硬化およびその予防に対するＱ＆Ａ３　脂質代謝異常を有する高血圧に対しての第１選択薬を教えてください． 2008
• 動脈硬化およびその予防に対する薬物療法Ｑ＆Ａ５原則併用禁忌であるスタチン系薬とフィブラート系薬の同時処方をみることがありますが、どのような患者さんに併用されるのですか？また、同時処方に対して疑義照会は必須でしょうか？ 2008
• 巻頭言　ゲノム医学とシステム医学 2008
• 特集/心腎連関　序文 2008
• 特集/心腎連関　心腎連関の重要性 2008
• スタチンと心不全 2008
• 人工透析と移植について 2008
• CVDの発症阻止 2008
• Alternative spliced variants in the pantetheinase family of genes expressed in human neutrophils. 2008
• 特集…メタボリックシンドロームと特定健診　メタボリックシンドロームと虚血性心疾患 2007/12
• 特集：循環器疾患と性差医療　心肥大と性差 2007/12
• 特別シンポジウム　循環器疾患と血液レオロジー「血管機能とバイオリズム」 2007/11
• 膠原病に伴う心疾患 2007/10
• 腎疾患に伴う心疾患 2007/10
• 特集：酸化ストレスと循環器疾患　大規模臨床試験における抗酸化作用薬剤の位置づけ 2007/10
• 特集：循環器薬の使い方　チアゾリジン薬 2007/10
• 急性冠症候群の薬物治療戦略 2007/10
• ＜冠動脈疾患の薬物治療の臨床エビデンス＞糖尿病治療と冠動脈疾患の発症予防 2007/09
• メタボリックシンドロームと虚血性心疾患 2007/09
• 各種降圧薬のpleiotropic効果 2007/09
• 教育講演「体質医学からみた血管病」 2007/09
• メタボリックシンドロームと心不全～新しい心不全治療の可能性～「Lipid Disorder and Heart Failure」 2007/09
• 心房細動アップストリーム治療の考え方と実際／糖尿病を有する心房細動 2007/08
• 特集：プライマリケア医のための生活習慣病治療を考える　　特集にあたって 2007/07
• 循環器分野での原疾患の発症予防　高血圧症発症予防について考える 2007/07
• 毛根細胞を用いた遺伝子発現定量を行う際の補正手法 2007/07
• 毛包を利用した時計遺伝子発現量測定による主観的体内時刻推定技術 2007/07
• 病態生理　食後高血糖 2007/06
• 高感度CRP 2007/06
• 教育セミナー「虚血性心疾患治療の今後の展望」 2007/06
• 特集：食後高血糖・食後高脂血症―動脈硬化性疾患の源流を探る―　12.食後高血糖、食後高脂血症と炎症、血管機能 2007/05
• 慢性心不全の管理、どうしよう？ 2007/04
• スタチン 2007/04
• 心不全におけるスタチン療法の効果とは 2007/03
• 第3章　検査士が知っておきたい疾患の知識 2 各種評価法　5)血管内皮機能の評価法 2007/03
• 防げ!！心血管疾患 2007/03
• 血栓傾向データ収集方法 2007/03
• 炎症および酸化ストレスマーカー 2007/02
• 血管不全の概念と内皮機能検査 2007/01
• 糖尿病と血管障害 2007/01
• 高血圧と血管機能 2007
• Keep the Endothelial Function 糖尿病における血管内皮機能障害 2007
• メタボリックシンドロームを意識した診療　メタボリックシンドロームからみた高血圧治療 2007
• 食後高血糖、食後高脂血症と炎症、血管機能 2007
• 日本心臓病学会雑感-鹿児島で感じたこと- 2007
• 心臓血管疾患のための新規診断マーカーとしての血小板由来マイクロパーティクル 2007
• Serum sulfatides as a novel biomarker for cardiovascular disease in patients with end-stage renal failure. 2007
• Statin therapy for vascular failure. 2007
• High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. 2007
• Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus. 2007
• Clinical diagnosis of metabolic syndrome 4. Therapy for metabolic syndrome. 2007
• Beneficial effects of olmesartan and temocapril on urinary liver-type Fatty Acid-binding protein levels in normotensive patients with immunoglobin a nephropathy. 2007
• Statin Therapy for Vascular Failure. 2007
• Anti-inflammatory Effects of Simvastatin on Human Oral Cells. 2007
• 小山論文に対するEditorial Comment 2007
• PPARと疾患　はじめに Introduction 2007
• PPARγと動脈硬化治療 PPARγ and the treatment of athrosclerosis 2007
• アンジオテンシンIIの動脈硬化促進作用 2006/12
• Postprandial hyperglycemia is a possible contributor to paroxysmal atrial fibrillation: a case report. 2006/11
• 血管の観点から　糖尿病患者の心血管イベントを抑制するには！ 2006/07
• 心不全の診断方法 2006/07
• Simvastatin decreases IL-6 and IL-8 production in epithelial cells. 2006/06
• 循環器病マーカーとしてのインターロイキン１３ 2006/02
• 糖尿病＜合併症発症予防と進展抑制の視点から＞循環器からの提言 2006/01
• スタチンのプレイオトロピック効果をどう評価するか？ 2006/01
• α-Glucosidease Inhibitors:New Therapeutic Agents for Chronic Heart Failure. 2006
• 再狭窄の分子機構と薬物的予防 2005/12
• 動脈硬化症 2005/12
• グラビア「血管におけるSERMの慢性効果と急性効果」 2005/11
• 心血管系・脂質代謝 2005/11
• 糖尿病における大血管障害の特徴と早期発見の実際 2005/10
• 女性における心肥大、不整脈の特徴 2005/10
• 研究室紹介 2005/07
• NCEPを動かした介入試験　2)ハイリスクの介入試験　ＨＰＳ（特に糖尿病に関して） 2005/07
• パネルディスカッション　アドバイザー「21世紀時代のスタチンに対する期待と役割」 2005/04
• 特別講演「高血圧治療の新展開-ARBの心保護作用-」 2005/04
• 教育講演「メタボリックシンドローム病態と治療」 2005/04
• 特別講演「糖尿病と血管不全」 2005/04
• 特集心血管系とエストロゲン　エストロゲンの心筋作用 2005/03
• 薬物による心筋保護　スタチン 2005/03
• 特別講演「糖尿病と動脈硬化」 2005/03
• 特別講演「生活習慣病をどう治療するか？-スタチンの新しい作用-」 2005/03
• 特別講演「高血圧の診断と最新の治療」 2005/03
• 特別講演「メタボリックシンドロームの治療展開-スタチンの可能性-」 2005/03
• 特別講演「脳・心・腎保護をターゲットにした降圧療法-血管不全の病態-」 2005/03
• Discussion「心血管系疾患予防のための治療戦略について」 2005/03
• スタチンのPleiotropic Effects 2005/02
• 心血管系・脂質代謝 2005/02
• スタチン研究の新展開　スタチンと慢性心不全-スタチンの慢性不全に対する多面的効果 2005/02
• 虚血性心疾患に対するNOの多面的なメカニズムと効果　外因性NO供与の臨床的意義・血管弛緩因子のNOとEETの関係 2005/02
• 循環器疾患マーカーとしてのＰＤＭＰ 2005/02
• 特別講演「生活習慣病実地診療のポイント-メタボリックサルタンの可能性-」 2005/02
• 「メタボリックシンドロームと動脈硬化症」 2005/02
• セッション「糖尿病と血管不全～RASの役割～」 2005/02
• 特別講演「血管不全と腎疾患」 2005/02
• Special Lecture「メタボリックシンドロームの診断と治療」 2005/02
• スタチンと心不全 2005/01
• 強力なスタチンによるコレステロール低下作用は必要なのか-REVERSAL, PROVE ITから学ぶこと- 2005/01
• ＴＶシンポジウム「脳・心・腎保護を目指した脂質低下療法」 2005/01
• 記念講演「生活習慣病実地診療のポイント-メタボリックサルタンの可能性-」 2005/01
• セッション「疾病からのアプローチ『冠動脈疾患』」 2005/01
• 国立大学変革の中で 2005
• 心機能低下をきたす病態・基礎疾患～閉経に伴う低エストロゲン血症～ 2005
• 糖尿病患者における心血管合併症の予防と治療　食後高血糖による血管内皮機能の障害とその制御 2005
• 目で見るサルタンの臓器保護作用　血管保護作用４-血管内皮- 2005
• 感染症の関与はどこまであきらかになったか 2005
• 心不全をやっつけろ！-その鼓動をいつまでも 2005
• 経口ニコランジル前投薬は心筋虚血プレコンディショニング作用を有する 2005
• 性差から見た老化と疾病　エストロゲンの心筋保護作用 2005
• 糖尿病治療薬(α-GI,ナテグリニド,SU薬) 2004/12
• エストロゲン,ＳＥＲＭ 2004/12
• 特別講演「虚血性心疾患予防のための生活習慣病治療-血糖管理の重要性-」 2004/12
• パネルディスカッション「高脂血症治療に関するアンケート-一次予防を中心に-」 2004/12
• 講演「血管不全の診断に向けて」 2004/12
• 特別講演「血管炎症と動脈硬化」 2004/12
• 特別講演「生活習慣病治療の最新の現況-外因性ＮＯ供与の臨床的意義-」 2004/12
• 特別講演「血管不全から見た生活習慣病治療-スタチンのpleiotoropic effectをふまえて」 2004/11
• パネルディスカッション「スタチンのpleiotoropic effectについて」 2004/11
• ショートレクチャー「循環器疾患の最近の話題」 2004/10
• 特別講演「血管不全から見た生活習慣病治療-スタチンのpleiotropic effectをふまえて-」 2004/10
• 特別講演「生活習慣病実地診療のポイント～期待されるスタチンの多面的作用～」 2004/09
• 特別講演「生活習慣病診療の最近の話題-血管不全の治療-」 2004/09
• 特別講演「高脂血症治療薬の心血管保護作用」 2004/09
• 特別講演「生活習慣病実地診療のポイント-期待されるスタチンの多面的作用-」 2004/09
• 特別講演「生活習慣病診療のポイント-スタチン治療の新展開」 2004/09
• 特別講演「脳・心・腎保護をターゲットにした降圧療法～早朝高血圧を含めて～」 2004/08
• 特別講演「血管不全から見た生活習慣病治療」 2004/08
• 特別講演「脳・心・腎をターゲットにした降圧療法」 2004/08
• 特別講演「食後高血糖の心リスク」 2004/08
• 特別講演「生活習慣病実地診療のポイント～降圧薬・カクテル療法について～」 2004/08
• ショートレクチャー　「循環器疾患と最近の話題」 2004/07
• 特別講演　「血管炎症と循環器疾患」 2004/07
• 特別講演　「高血圧診療の進歩」 2004/07
• 記者セミナー　「生活習慣病のKey Factorとしての肥満」 2004/07
• ショートレクチャー　「中高年女性高血圧患者にしばしば見られる隠れ心不全について」 2004/07
• 特別講演　「脳、心、腎保護をターゲットにした降圧療法」 2004/07
• 特別講演　「脳・心・腎保護をターゲットにした降圧療法」 2004/07
• 基調講演「生活習慣病実地診療のポイント―期待されるスタチンの多面的作用―」 2004/07
• 特別講演「高血圧治療の新展開～ブロプレスの血管不全に対する有効性～」 2004/07
• 特別講演「動脈硬化と糖尿病」 2004/07
• 特別講演「生活習慣病と血管不全」 2004/07
• 特別講演「肥満と高脂血症」 2004/07
• 高血圧,心血管病の合併　病態に応じた高脂血症の薬物治療 2004/06
• 特別講演　「虚血性心臓病診療の最近の知見－HPS試験の結果を踏まえて－」 2004/06
• 特別講演　「血管不全治療におけるカンデサルタンへの期待」 2004/06
• 特別講演「血管不全から見た生活習慣病治療－メタボリックシンドロームとAIIの関わりを踏まえて」 2004/06
• 特別講演　「血管不全から見た生活習慣病治療－スタチンのpleiotropic effectをふまえて」 2004/06
• 治療への展開　抗動脈硬化薬としてのスタチンの多目的作用 2004/05
• ステント内遅発性閉塞を起こした夏期増悪型Behcet病の1例 2004/05
• 特別講演　「各種愁訴を有する中高年女性の循環器管理」 2004/05
• 特別講演　「血管不全から見た生活習慣病治療―スタチンのpleiotropic effectをふまえて」 2004/05
• 特別講演　「血管不全と炎症」 2004/05
• 特別講演　「食後高血糖による血管内皮機能障害とその抑制」 2004/05
• 特別講演　「生活習慣病診療の最近の現状－血管不全の治療－」 2004/05
• 特別講演　「高血圧診療のポイント－臓器保護の観点から－」 2004/05
• 特別講演　「生活習慣病と血管炎症」 2004/05
• 特別講演　「生活習慣病における実地診療のポイント」 2004/05
• COPERNICUS 2004/04
• 特別講演　「生活習慣病診療のポイント」 2004/04
• 特別講演　「血管不全からみた生活習慣病治療－スタチンのpleiotropic effectをふまえて」 2004/04
• 特別講演　「スタチンに関する最新の話題」 2004/04
• 特別講演　「HPS(Heart Protection Study)から明らかになったこと」 2004/04
• ショートレクチャー　「循環器疾患の最近の話題」 2004/04
• 特別講演　「虚血性心臓病の最近の話題」 2004/04
• 特別講演　「血管不全と循環器病」 2004/04
• 特別講演　「最近の循環器診療の動向―ゲノムからプロテオンノーム－」 2004/04
• 特別講演　「循環器内科医からみた食後高血糖管理の意義－DECODE/A,舟形Studyから－」 2004/03
• 特別講演　「ハートリスクマネジメントの最近の知見」 2004/03
• シンポジウム　「循環器医からみた女性と高齢者」 2004/03
• 特別講演　「心不全抑制作用」　 2004/03
• 特別講演　「循環器内科医からみた食後高血糖管理の意義－DECODE/A,舟形Study－」 2004/03
• アドバイザー　「HPS (Heart Protection Study)で得られた結果を臨床にどういかすか」 2004/03
• 特別講演　「循環器内科医からみた更年期女性の診療」 2004/03
• 特別講演　「EDHFと冠微小循環」 2004/03
• 心血管イベントとスタチン 2004/02
• 高脂血症治療－最近の現況 2004/02
• 特別講演　「生活習慣病実地診療のポイント―降圧薬・カクテル療法についてー」 2004/02
• 特別講演　「血管不全と糖尿病」 2004/02
• Sesion 「スタチンの脂質低下以外の作用を中心にから－HPS とPleiotropic Effect-」 2004/02
• 特別講演　「虚血性心疾患治療の最近の動向」 2004/02
• 特別講演　「食後高血糖と血管不全」 2004/02
• 特別講演　「生活習慣病と血管不全」 2004/02
• 特別講演　「スタチンの心不全抑制作用」 2004/02
• 特別講演　「糖尿病と動脈硬化」 2004/02
• ディスカッション　「大血管障害予防に関して各領域からみたリスクファクターの管理の意義」 2004/02
• 特別講演　「生活習慣病実地診療のポイント－期待されるスタチンの多面的作用－」 2004/02
• 代謝疾患治療薬　ＨＭＧ-ＣｏＡ還元酵素阻害薬 2004/01
• 特別講演「血管炎症と動脈硬化」　 2004/01
• 特別講演　「食後高血糖と動脈硬化」 2004/01
• Behcet disease with exacerbation in summer and late coronary stent occlusion. 2004
• 食後高血糖と大血管症 2004
• 食後高血糖と血管不全 2004
• プライマリーケアの実際　臨床研修マニュアル 2004
• ホルモン補充療法の功罪　パイオクリニカ編集委員会 2004
• 循環器医が治療する糖尿病と大血管障害 2004
• 血管不全フロンティア 2004
• 代謝疾患治療薬　HMG-CoA還元酵素阻害薬 2004
• 食後高血糖と大血管症 2004
• FMDによる血管内皮機能検査法 2004
• 高血圧、心血管病の合併 2004
• 高脂血症治療-最近の現況 2004
• 心不全を伴う高血圧症 2004
• 代謝異常へのアプローチ　D.高脂血症におけるAII受容体拮抗薬の治療戦略の根拠は何か 2004
• 特集-循環器疾患治療におけるディベート-pleiotropic effect 2004
• ホルモン補充療法の臨床；動脈硬化と心血管系 2004
• 治療の実際　高脂血症治療の最新の動向　 2004
• 積極的な脂質管理が必要な患者とは？－メタボリックシンドロームのメカニズムについてー 2004
• 血管炎症と心不全 2004
• ホルモン補充療法の功罪 2004
• IV．ＮＯ　薬理作用と生理作用－ＮＯの心保護作用－ 2004
• 糖尿病における大血管障害の管理の進歩と新展開　[２]成因/糖尿病と動脈硬化 2004
• 特集：循環器疾患における性差医学　虚血性心疾患と性差　a．一酸化窒素 2004
• 特集：循環器疾患における性差医学　心肥大と性差 2004
• 動脈硬化の性差の分子基盤とエストロゲン治療 2004
• IV糖尿病と臓器障害機序　２．心筋障害　ａ心不全：臨床 2004
• IV糖尿病と臓器障害機序　３．腎障害　 2004
• 血管内皮前駆細胞による血管内皮再生とスタチン 2004
• 腎不全 2004
• 特別講演「生活習慣病実地診療のポイント　－期待されるスタチンの多面的作用―　」 2003/12
• 基調講演「食後高血糖と循環器疾患」 2003/12
• Seminor:基礎「急性冠症候群におけるＣＲＰの意義」　　 2003/12
• 内皮由来過分極因子(EDHF) 2003/11
• 特別講演「亜硝酸剤と内皮機能の関係について」 2003/11
• 特別講演「高血圧治療の最新の知見―ARBの新たな可能性－」 2003/11
• 特別講演「生活習慣病治療の最近の話題」 2003/11
• 特別講演「生活習慣病治療の現状-血管不全とレニンアンジオテンシン系-」 2003/11
• 特別講演　「慢性心不全の病態と治療－血管保護を目的とした治療選択とスタチンの有用性－」 2003/11
• 特別講演　「生活習慣病治療の現状　–血管不全とレニンアンジオテンシン系―」 2003/11
• 特別講演「虚血性心疾患診療における今後の展望」 2003/10
• 特別講演「慢性心不全の病態と治療―スタチンの有用性」 2003/10
• 特別講演「女性と心臓病」 2003/10
• 特別講演「慢性心不全の病態と治療-血管保護を目的とした治療戦略とスタチンの有効性」 2003/10
• 特別講演「生活習慣病治療の新知見」 2003/10
• ショートレクチャー「ブロプレスメガトライアルCHARM試験の示唆するもの」 2003/10
• 特別講演「血管不全の病態と治療-糖尿病予備軍、糖尿病患者の治療戦略-」 2003/10
• 特別講演「脳、心血管イベント抑制におけるスタチンの重要性-New Insights From ASCOT- 」 2003/10
• 特別講演「高脂血症治療―最近の現状―」 2003/10
• 特別講演「生活習慣病治療の現状と今後の展望」 2003/10
• 特別講演「脳、心血管イベント抑制におけるスタチンの重要性」 2003/09
• 特別講演「慢性心不全の病態と治療－血管保護からみた治療戦略－」 2003/09
• 特別講演「生活習慣病実地診療ポイント-期待されるスタチンの多面的作用-」 2003/09
• 特別講演「生活習慣病実地診療ポイント-期待されるスタチンの多面的作用」 2003/09
• 特別講演「血管内皮機能に及ぼす食後高血糖の影響」 2003/09
• 特別講演「Multiple Syndrome の病態と治療」 2003/09
• 特別講演「高血圧治療の最新の知見-ARBの新たな可能性」 2003/09
• 特別講演「最近の高血圧治療-分子成因の解明と新しい治療の流れ-」 2003/09
• 特別講演「メタボリック症候群の病態-RA系の役割-」 2003/09
• 特別講演「Coronary Intervention と血管炎症」 2003/09
• ディスカッション「HPSで得られた結果を臨床にどういかすか」 2003/09
• 特別講演「生活習慣病診療の最新の知見」 2003/09
• 連載：日本人に適した高指血症治療を考える－フィブラートという選択－第５回　フィプラートのPleiotropic effect. 2003/08
• 女性と心血管疾患－エストロゲンと加齢の関与－　２．心臓に対する作用 2003/08
• 高血圧合併症患者には積極的なスタチン投与を－ＡＳＣＯＴ脂質低下療法試験の結果を受けて－. 2003/08
• 連載：日本人に適した高脂血症治療を考えるーフィブラートという選択―　第５回　フィブラートのPleiotropic effect 2003/08
• 女性と心血管疾患―エストロゲンと加齢の関与―２．心臓に対する作用 2003/08
• 高血圧合併症患者には積極的なスタチン投与を－ASCOT脂質低下療法試験の結果を受けて－ 2003/08
• 特別講演「心不全と糖尿病」 2003/08
• 特別講演「血管炎症と内皮機能障害-血管不全の病態-」 2003/08
• 「特発性拡張型心筋症患者におけるスタチンの有用性」 2003/08
• 指定講演　「高脂血症治療の最新の動向」 2003/08
• 特別講演　「生活習慣病治療の新知見－血管不全を治療する－」 2003/08
• 指定講演「生活習慣病実地診療のポイント」－期待されるスタチンの多面的作用－ 2003/08
• 特別講演　「脳・心血管イベント抑制におけるスタチンの重要性」 2003/08
• 特別講演　「生活習慣病実施診療のポイント」－期待されるスタチンの多面的作用― 2003/08
• 指定講演　「脳・心血管イベント抑制におけるスタチン治療の重要性－New Insight from ASCOT- 2003/08
• 指定講演「更年期障害と交感神経系」 2003/07
• 「血管不全の病態と治療」 2003/07
• 「動脈硬化性疾患診療ガイドラインのポイント」 2003/07
• 特別講演「高脂血症・動脈硬化の診療ガイドラインについて」 2003/07
• 特別講演「生活習慣病治療の現況－血管不全とレニン・アンジオテンシン系－」 2003/07
• 特別講演「血管の不全の病態と治療」 2003/07
• 指定講演「生活習慣病実地診療のポイント－期待されるスタチンの多面的作用－」 2003/07
• 特別講演「メタボリック症候群の病態と治療」 2003/07
• 特別講演「スタチンの心不全抑制効果」 2003/07
• 特別講演「生活習慣病診療の最近の知見」－血管不全の病態と治療－ 2003/07
• 座談会ASCOT(Anglo-Scandiavian Cardiac outcomes Trial-Lipid Lowering Arm)Study－その意義と臨床に与える影響－ 2003/06
• 循環器医から見た食後過血糖と血管不全 2003/06
• 指定講演「慢性心不全の病態と治療―スタチンの有用性－」 2003/06
• 特別講演「生活習慣病実地治療のポイント」－期待されるスタチンの多面的作用－ 2003/06
• 特別講演「生活習慣病実地診療のポイント－期待されるスタチンの多面的作用－」 2003/06
• 指定講演「血管不全と炎症の関わり」 2003/06
• 「高血圧の新しい治療戦略－ALLHATで得られた知見と血管不全治療の可能性－」 2003/06
• 特別講演「生活習慣病はどこまで治療できるか？　－血管不全の病態―」 2003/06
• 特別講演「生活習慣病実地治療のポイント－期待されるスタチンの多面的作用－」 2003/06
• 特別講演「糖尿病患者における循環器治療のポイント－血管不全を治療するには－」 2003/06
• 特別講演「生活習慣病はどこまで治療できるか―虚血性心臓病診療の最新知見―」 2003/05
• 講演「アラキドン酸カスケードと血管内皮シグナル」 2003/05
• 特別講演「生活習慣病実地診療のポイント」－期待されるスタチンの多面的作用－ 2003/05
• 指定講演「慢性心不全の病態と治療－スタチンの有用性―」 2003/05
• 指定講演「糖尿病と血管不全」 2003/05
• 特別講演「ハートリスクマネッジメントの最近の知見」 2003/05
• 特別講演「レニン－アンジオテンシン系と血管炎症」 2003/05
• 特別講演　「慢性心不全の病態と治療－スタチンの有用性―」 2003/05
• 「糖尿病は心血管疾患か？」 －インスリン抵抗性、グルコース・ストームのインパクト－ 2003/05
• 指定講演　「糖尿病は心血管疾患か？－インスリン抵抗性、グルコース・スパイク のインパクト－」 2003/05
• 特別講演「生活習慣病治療の状況－血管不全とレニン・アンジオテンシン系－」 2003/05
• 指定講演「血管不全の病態と治療」 2003/05
• 指定講演「生活習慣病治療における最近の動向」 2003/04
• アドバイザー「リポバスによるテーラーメイド医療の実現」 2003/03
• 特別講演「糖尿病患者での心臓病診療のポイント」 2003/03
• 指定講演「生活習慣病はどこまで治療できるかー血管不全の病態と意義―」 2003/03
• 特別講演「動脈硬化と炎症」 2003/03
• 特別講演　「糖尿病患者における循環器診療のポイント～血管不全を治療するには～」 2003/03
• β遮断薬 2003/02
• β遮断薬 2003/02
• 特別講演「血管不全と循環器疾患」 2003/02
• 指定講演「New Approach to Metabolic Syndrome」 2003/02
• 特別講演「慢性心不全の病態と治療」 2003/02
• 指定講演「循環器医からみた食後過血糖と血管不全」 2003/02
• 特別講演「女性ホルモンと心臓病」 2003/02
• 特別講演「動脈硬化における血管炎症の役割」 2003/01
• 抗血小板治療の最前線－循環器疾患領域における低容量アスピリンの使い方と可能性:第２版 2003
• 生活習慣病と血管内皮障害－スタチンとACE阻害薬の多目的効果が意味するもの:第３版 2003
• ＡＮＰの心筋炎症抑制作用 2003
• 血管を守るために－食後高血糖と動脈硬化:第３版 2003
• β遮断薬（血管の観点から） 2003
• 食後高血糖/IGTと大血管障害食後高血糖と大血管障害－ＩＧＴの段階からすでに動脈硬化は発症している－ 2003
• 食後高血糖／ＩＧＴと大血管障害－ＩＧＴ・糖尿病患者の動脈硬化を診る－炎症マーカー 2003
• 心血管病とエストロゲン－特集：性差医学の最前線 2003
• 血小板制御－特集：生体諸システムの制御臓器としての血管内皮細胞． 2003
• アトルパスタチンの長期使用効果ＧＲＥＡＣＥ試験を中心に 2003
• 大規模臨床試験が示唆する冠動脈疾患の新しい治療ツール：血管学・最新情報館１ 2003
• 降圧薬のPleiotropic Effects－その現状と臨床的意義－ 2003
• 冠循環の生理学：冠循環と心機能－冠循環の基礎．冠動脈の臨床(上)　 2003
• 対談　米国の臨床現場における栄養素の位置づけ―大規模試験の結果をどのように生かすか－． 2003
• 糖尿病合併症と血栓　１．糖代謝異常と血栓形成のメカニズム：血管壁の異常から 2003
• なぜ食後高血糖の抑制は重要なのか－動脈硬化進展メカニズムからのアプローチ. 2003
• 糖尿病における動脈硬化―予備軍だって安心できない糖尿病予備軍(IGT) 2003
• 冠動脈の臨床(下)－21世紀の診断治療体系 ADMA(asymmetric dimethyl arginine)と虚血性心疾患． 2003
• ＨＭＧ-ＣｏＡ還元酵素阻害薬の慢性心不全抑制作用 2003
• 平均ないしそれ以下のコレステロール値を示す高血圧患者におけるアトルバスタチンの冠動脈および脳卒中イベントの予防効果 2003
• 心血管系の老化と女性ホルモン－心不全とエストロゲン－． 2003
• 座談会　心血管リスクの総合的な治療を考える－糖尿病，高血圧をもつ患者さんの脂質管理－． 2003
• 循環器医から見た食後過血糖と血管不全 2003
• 対談　微小循環を良くすることで脂質や糖の代謝を改善. 2003
• 座談会 ASCOT Study－その意義と臨床に与える影響－. 2003
• 座談会　高血圧患者におけるコレステロール低下治療－ＡＳＣＯＴ脂質低下試験の意義－． 2003
• 急性冠症候群におけるスタチン系薬剤の役割 2003
• 教室訪問　佐賀大学医学部循環器・腎臓内科 2003
• 座談会　動脈硬化の発症・進展とニフェジピンの血管保護作用－直接作用と間接作用 2003
• スタチンの心筋炎症抑制作用 2003
• 血管拡張因子のインスリン抵抗性への影響－一酸化窒素（ＮＯ）・内皮由来過分極因子（EDHF）の検討－ 2003
• 対談　ホモシステインと心臓病―血中ホモシステイン濃度を低下させる葉酸 2003
• 生活習慣病実地診療のポイント－期待されるスタチンの多面的作用－． 2003
• 内皮由来過分極因子（ＥＤＨＦ） 2003
• 軽症糖尿病の治療意義－食後高血糖は心血管イベントの危険因子－. 2003
• 特別企画　エピデンスに基づいた糖尿病の治療戦略－糖尿病専門医と循環器専門医の連携－ 2003
• 単行本　ファーマナピゲーター　Ca桔抗薬編「スタチン」 2003
• 特別企画ＣＨＡＲＭに学ぶ「心保護」を意識した降圧療法 2003
• 座談会　各種愁訴を有する中高年女性の高血圧症に対する至週降圧療法を考える. 2003
• 座談会　心血管リスクの総合的な治療を考える－糖尿病，高血圧をもつ患者さんの脂質管理－ 2003
• ＡＮＰの心筋炎症抑制作用 2003
• 冠動脈の臨床　21世紀の診断治療体系　冠循環の病理，病態　虚血心筋　再灌漑流障害の機序に関する研究の動向 2003
• 抗高脂血症薬　スタチンと高血圧 2003
• The role of estrogen and estrogen-related drugs in cardiovasucular diseases. 2003
• スタチンの心筋炎症抑制作用 2003
• 特別企画　血管を守るために 食後高血糖と動脈硬化 2003
• β遮断薬（血管の観点から） 2003
• 急性冠症候群におけるスタチン系薬剤の役割 2003
• 食後高血糖/IGTと大血管障害 IGT・糖尿病患者の動脈硬化を診るー血管内皮機能ー 2003
• 食後高血糖/IGTと大血管障害 IGT・糖尿病患者の動脈硬化を診るー炎症マーカー 2003
• 特集　生体諸システムの制御臓器としての血管内皮細胞　―血小板制御 2003
• アトルバスタチンの長期使用効果GREACE試験を中心に 2003
• 大規模臨床試験が示唆する冠動脈疾患の新しい治療ツール/血管学・最新情報館1 2003
• 降圧薬のPleiotropic Effects-その現状と臨床的意義- 2003
• 冠循環の生理学：冠循環と心機能―冠循環の基礎 2003
• 虚血心筋：再灌流の機序に関する研究の動向―冠循環の病理、病態 2003
• 糖尿病合併症と血栓　１．糖代謝異常と血栓形成のメカニズム :血管壁の異常から 2003
• スタチンの心筋保護作用－シンバスタチンは慢性心不全にも有効－ 2003
• なぜ食後高血糖の抑制は重要なのか－動脈硬化進展メカニズムからのアプローチ 2003
• 糖尿病における動脈硬化－予備軍だって安心できない糖尿病予備軍（ＩＧＴ） 2003
• ADMA(asymmetric dimethyl arginine)と虚血性心疾患 2003
• ANPの心筋炎症抑制作用 2003
• 冠動脈の臨床　21世紀の診断治療体系　冠循環の病理,病態　虚血心筋　再灌流障害の機序に関する研究の動向 2003
• HMG-CoA還元酵素阻害薬の慢性心不全抑制作用 2003
• 循環器を理解するうえで重要な分子・現象　血管の形成と障害　血管拡張因子のインスリン抵抗性への影響　一酸化窒素(NO)・内皮由来過分極因子(EDHF)の検討 2003
• 抗高脂血症薬　スタチンと高血圧 2003
• 洞不全症候群、部分的心房停止、心房頻拍を呈した孤立性左室心筋緻密化障害の１例 2003
• Ｃａ２+感受性Ｋ+チャネル開口薬（ＮＳ1619）の心筋虚血・再灌流障害抑制効果 2003
• 特別講演「生活習慣病はどこまで治療できるか。」 2002/12
• 特別講演「血管内皮機能における炎症の役割」 2002/11
• 指定講演「食後高血糖と血管不全」 2002/11
• 指定講演「エストロゲンと心臓病」 2002/10
• 特別講演「高脂血症の診断と治療」 2002/10
• 特別講演「女性と心血管疾患‐エストロゲンと加齢の関与」 2002/10
• 特別講演「食後高血糖と血管不全」 2002/09
• 指定講演「ＡＮＰの心筋炎症抑制作用」 2002/08
• 特別講演　「血管不全の病態と治療」 2002/07
• 指定講演「Estrogen and Cardiac Hypertrophy」 2002/07
• ランチョンセミナー「血管不全の病態と治療」 2002/07
• 特別講演「虚血性心臓病の最近の知見－動脈硬化を治療するー」 2002/05
• 特別講演　「虚血性心臓病の病態と治療」 2002/05
• 特別講演　「ハートリスク管理の新知見」 2002/05
• 特別講演「冠危険因子管理のニューパラダイム」 2002/05
• 特別講演「血管内皮と心臓病」 2002/03
• 座談会「臓器合併症と高血圧の治療戦略」 2002/03
• 特別講演「虚血性心臓病診療の新知見」 2002/02
• 特別講演「虚血性心臓病の病態と治療」 2002/02
• 特別講演「ハートリスクマネジメントの最新知見」 2002/01
• Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF:metalloproteinase inhibitors as a new therapy. 2002
• Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation. 2002
• Adenosine-induced cardiac gene expression of inchemic murine hearts revealed by cDNA array hybridization. 2002
• Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. 2002
• Opening of the adenosine triphophate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide　synthesis :role of 70-kDa S6 kinase and extracellular signal-regulated kinase. 2002
• Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers synergistically increase coronary blood flow in canine ischemic myocardium: Role of bradykinin. 2002
• Association of (-)786T-C mutation of endothelial nitric oxide synthase gene with insulin resistance. 2002
• 選択的エストロゲン受容体調節薬ラロキシフェンは心筋虚血再灌流障害を抑制する 2002
• プリン代謝性内因物質アデノシンの産生代謝系変異による心血管保護作用の究明及びその新治療法への応用 2002
• 内科ケースカンファレンス５０ 2002
• Effects of HMG-CoA Reductase Inhibitors on Cells of the Vascular Wall 2002
• 特集　循環器疾患治療薬の最新知識―スタチン系薬剤 Vascular　Statin vs. Hepatic statins 2002
• 循環器治療最前線 内皮由来過分極因子　（EDHF） 2002
• 特集　高脂血症 心疾患を合併する高脂血症 2002
• 臓器繊維症‐発症機序の解明と対策　心筋リモデリングと機能不全 2002
• 血管内皮細胞におけるチトクロームP450と酸化ストレス　–動脈硬化における抗酸化作用 2002
• 冠動脈疾患の二次予防におけるNCEP目標値を目指したアトルバスタチン治療と「通常」治療 2002
• 治す　不整脈死をどう予防するか　β遮断薬 2002
• 循環器の生物学　内皮由来過分極因子(EDHF) 2002
• 特別講演「急性冠症候群の病態と治療」 2001/12
• 特別講演「虚血性心疾患の病態と治療戦略」 2001/11
• 特別講演「循環器疾患におけるレニンアンジオテンシン系の役割」 2001/10
• 特別講演　「急性冠症候群の病態と治療戦略」 2001/09
• 指定講演　「酸化ストレスと血管内皮機能」 2001/09
• 指定講演「内皮由来過分極因子（EDHF）と血管機能」 2001/08
• 特別講演　「急性冠症候群の病態と治療」 2001/07
• 特別講演　「HMG-CoA還元酵素阻害剤の心不全抑制作用」　 2001/07
• 特別講演　「ハートリスクマネジメントの最新の動向」　 2001/06
• 特別講演　「内皮由来過分極因子　（EDHF）」 2001/06
• 特別講演　　「血管内皮由来過分極因子（EDHF）」 2001/05
• 特別講演　「ハートリスクマネジメントの最近の動向」　 2001/05
• 「ハートリスク管理の最近の知見」 2001/03
• 「内皮由来過分極因子（EDHF）」　 2001/03
• 指定講演　“EDHF and Vascular Protection” 2001/02
• 基調講演「心血管イベント抑制の治療戦略」 2001/02
• 指定講演　“EDHF and Vascular Signaling” 2001/01
• Role of mitochondrial and sarcolemmal K　(ATP) channels in ischemic preconditioning of the canine heart. 2001
• Activation of Gαlpha s mediates and induction of tissue-type plasminoger activator gene transcription by epoxyeicosatrienoic acids. 2001
• Effects of bezafibrate and simvastatin on plasma lipoproteins in hypercholesterolemia resistant to hormone replacement therapy. 2001
• Differential subcellular actions of ACE inhibitors and AT(1) receptor antagonists on cardiac remodeling induced by chronic inhibition of NO synthesis in rats. 2001
• Role of cellular acidosis in production of nitric oxide in canine ischemic myocardium. 2001
• Nifedipine limits infarct size via NO-dependent mechanisms in dogs. 2001
• Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. 2001
• Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart. 2001
• Statins as antioxidant therapy for preventing cardiac myocytes hyperetrophy. 2001
• Benidipine, a long-acting Ca channel blocker, limits infarct size via bradykinin- and NO-dependent mechanisms in canine hearts. 2001
• K+チャネル開口薬ニコランジルのNo-reflow現象抑制効果及び心筋梗塞縮小効果の検討 2001
• 内皮由来過分極因子（EDHF）の血管保護作用 2001
• エストロゲンの心血管機能調節機構　　―NOとの連関― 2001
• 酸化ストレスーフリーラジカル医学生物学の最前線　　血管平滑筋制御と酸化ストレス 2001
• Endothelium-Derived Hyperpolarizing Factor Ameliolates Ischemic Heart Failure 2001
• Role of adenosine in Cardioprotection 2001
• エビデンスが集積するスタチンのPleiotropic effects 2001
• 内皮由来過分極因子（EDHF）と動脈硬化 2001
• State of the Arts　　血管内皮由来過分極因子（EDHF） 2001
• HMG-CoA 還元酵素阻害剤の心不全抑制作用―Cardiostatinの意義 2001
• 脂質低下療法のエビデンスとイベント抑制のメカニズム 2001
• 不整脈死をどう予防するか- β遮断薬 2001
• 内皮由来過分極因子 (EDHF) の動脈硬化抑制分子メカニズムの解明とその臨床応用 2001
• 心筋細胞に対するエストロゲンの作用とその分子機構 2001
• エストロゲンの心血管機能調節機構　NOとの連関 2001
• 虚血・再灌流障害における心筋保護 2001
• アデノシンと心筋保護-プレコンディショニングとの関わり 2001
• 循環器疾患における酸化ストレスの役割　心筋虚血再灌流障害と酸化ストレス 2001
• Vascular Biology研究と臨床への応用　内皮由来過分極因子(EDHF)の血管保護作用 2001
• 酸化ストレスと老化・疾患　血管平滑筋弛緩の制御と酸化ストレス 2001
• 特別講演　「女性と心疾患」 2000/09
• Pleiotropic Effects of Statins on Atherosclerosis 特別講演「HMG-CoA還元酵素阻害薬の心不全抑制効果」 2000/09
• 「内皮由来過分極因子」 2000/09
• 特別講演　“Endothelium dependent hyperpolarizing factor and vascular signaling” 2000/09
• 特別講演　「HMG-CoA 還元酵素阻害薬の心血管保護作用　Cardiostatinの意義」 2000/09
• Cellular mechanisms of cardioprotection afforded by inhibitors of angiotensin converting enzyme in ischemic hearts: role of bradykinin and nitric oxide. 2000/05
• Inflammation におけるNOの役割　「エストロゲンの心血管機能調節機構」 2000/05
• 21世紀のHRTの展望　「女性ホルモンと心不全」 2000/04
• Increased cardiac levels of nitric oxide in patients with chronic heart failure. 2000
• Protein tyrosine kinase is not involved in the infarct size-limiting effect of ischemic preconditioning in canine hearts. 2000
• Cellular mechanisums of cardiopotenction afforded by inhibitors of angiotentsin converting enzyme in ischemic hearts: role of brandykinin and nitrico oxide. 2000
• 虚血プレコンディショニングの分子メカニズムの解明-細胞膜・ミトコンドリアATP感受性K+チャネル開口による相加的心筋梗塞サイズ縮小効果 　 2000
• ATPと自律神経疾患　プレコンディショニングの分子メカニズム　細胞膜・ミトコンドリアATP感受性K+チャネル開口による虚血プレコンディショニングの心筋保護作用 2000
• マグネシウムと心疾患治療薬 2000
• 女性と心疾患 女性における心疾患の特徴ー心不全ー 2000
• 心血管疾患と性差　「心筋細胞に対するエストロゲンの作用とその分子機構」 2000
• 生体防御の場としての血管内皮　内皮由来過分極因子(EDHF)　新たな抗動脈硬化分子 2000
• 女性と心疾患　　女性における心疾患の特徴ー心不全ー 2000
• 臓器保護薬としてのACE阻害薬,ATII受容体拮抗薬の新しい流れ心血管保護薬としてのACE阻害薬とATII受容体拮抗薬　心不全の予後を改善する　ACE阻害薬のメリット 2000
• A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs. 1999
• Improvement by 5-amino-4-imidazole carboxamide riboside of the contractile dysfunction that follows brief periods of ischemia through increases in ecto-5-nucleotidase activity and adenosine release in canine hearts. 1999
• 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down regulation of p27(Kip1). 1999
• Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. 1999
• Intracoronary administration of adenosine triphosphate increases coronary blood flow and attenuates the severity of myocardial ischemic injury in dogs. 1999
• Adenosine and cardioprotection in the diseased heart. 1999
• ATP感受性K+チャネル開口による心筋梗塞縮小効果：分子メカニズムの検討 1999
• Role of Ca2+-activated K+ channels in the protective effect of ACE inhibition against ischemic myocardial injury. 1998
• Increased release of nitric oxide in ischemic hearts after exercise in patients with effort angina. 1998
• Elevation of plasma adenosine levels may attenuate the severity of hronic heart failure. 1998
• Inhibition of angiotensin-converting enzyme increases the nitric oxide levels in canine ischemic myocardium. 1998
• Nisoldipine selectively induces coronary vasodilation and improves mild myocardial ischemia in dogs: a potential role of cellular acidosis. 1998
• 血管内皮依存性過分極因子(EDHF) 1998
• Effect of acute dynamic exercise on circulating plasma nitric oxide level and correlation to norepinephrine release in normal subjects. 1997
• Activation of ecto-5'-nucleotidase by protein kinase C and its role ischemic tolerance in the canine heart. 1997
• Bradykinin mediation of Ca2+-activated K+ channels regulates coronary blood flow in ischemic myocardium. 1997
• Role of intracellular Ca2+ in activation of protein kinase C during ischemic preconditioning. 1997
• Amelioration of ischemia- and reperfusion-induced myocardial injury by 17beta-estradiol: role of nitric oxide and calcium-activated potassium channels. 1997
• Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. 1997
• eversible reduction in plasma concentrations of nitrogen oxide in induced by cirarette smorking in young adults. 1997
• Inhibition of nitric oxide synthesis increases adenosine production via an extracellular pathway through activation of protein kinase C. 1997
• Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart. 1997
• Temporary acidosis during early reperfusion limits infarct size in dogs. 1997
• Roles of NO and Ca2+－activated K + channels in coronary vasodilition induced by 17beta-estradiol in ischemic heart failure. 1997
• Vesnarinone inhibits adenosine uptake in endothelial cells, smooth muscle cells and myocytes, and mediates cytoprotection. 1997
• Ecto-5'-nucleotidase mediates infarct size-limiting effect by ischemic preconditioning in the rabbit heart. 1997
• Role of protein kinase C-alpha in activation of ecto-5'-nucleotidase in the preconditioned canine myocardium. 1997
• Reversible reduction in plasma concentrations of nitrogen oxide in induced by cirarette smorking in young adults. 1997
• 心臓におけるATP感受性K+チャネル開口によるアデノシン・NO遊出増加作用 1997
• 虚血心筋におけるNO産生と冠血流調節メカニズム 1997
• 内因性心保護メカニズムとアデノシン 1997
• Role of activation of ectosolic 5'-nucleotidase in the coardioprotection mediated by opening of K+c channels. 1996
• Role of activation of protein kinase C the infarct size-limiting effect of ischemic preconditioning througth activation of ecto-5-nucleotidase. 1996
• Cardioprotection due to preconditioning correlates with increased ecto-5-nucleotidase activity. 1996
• Role of nitric oxide in regulation of coronary blood flow during myocardium ischemia in dogs. 1996
• Activation of ecto-5'-nucleotidase by protein kinase C attenuates irreversible cellular injury due to hypoxia and reoxygenation in rat cardiomyocytes. 1996
• Activated polymorphonuclear leukocytes induce constriction of canine coronary artery via Mac-1,but not LFA-1,and ICAM-1. 1996
• Increased release of NO during ischemia reduces myocardial contractility and improves metabolic dysfunction. 1996
• Adenosine inhibits leukocyte-induced vasoconstriction. 1996
• Activation of ecto-5'-nucleotidase and cardioprotection by ischemic preconditioning (Brief Review). 1996
• ATP感受性K+チャネル開口薬の心筋梗塞縮小効果とprotein kinase C活性化の役割 1996
• 心臓カテーテル検査 1996
• 循環研究プロトコロール　動脈硬化、高血圧、心臓病研究の最前線 1996
• 心筋虚血におけるNOと冠循環調節 1996
• ACE阻害薬の心筋保護作用におけるNO産生増強効果の意義 1996
• ACE阻害剤の心筋保護作用におけるブラディキニンーNO産生系の役割 1996
• アデノシン受容体 1996
• NOの虚血心筋保護作用とそのメカニズム 1996
• 虚血性心疾患とACE阻害薬 1996
• 冠循環とアデノシン 1996
• Alpha 1-adrenoceptor activation increases ecto-5'-nucleotidase activity and adenosine release in rat cardiomyocytes by activating protein kinase C. 1995
• Evidence for nitric oxide generation in the cardiomyocytes: its augmentation by hypoxia. 1995
• Beneficial effects of inhibition of angiotensin converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. 1995
• Bidirectional effects of aminophylline on myocardial ischemia. 1995
• Downward shift of coronary pressure –flow relationship following a brief period of ichemia in dogs. 1995
• Activation of protein kinase C increases adenosine production in the hypoxic canine coronary artery through the extracellular pathway. 1995
• Plasma nitric oxide end products are increased in the ischemic canine heart. 1995
• Roles of alpha 1-adrenoceptor activity in release of nitric oxide during ischemia of canine heart. 1995
• Effect of coronary perfusion on myocardial contractility in the heart. 1995
• Beneficial role of interaction between -adrenoceptor activity and adenosine in myocardial ischemc and reperfusion injury. 1995
• Role of activation of ecto-5'-nucleotidase for cardioprotection in ischemic preconditioning. In: Berardinelli L, Pelleg A, eds. 1995
• Role of activation of ecto-5'-nucleotidase for cardioprotection in ischemic and reperfusion injury: Role of purine and adenosine metabolism 1995
• β受容体遮断薬Na＋/H＋交換阻害薬の短期投与による心筋症自然発症ハムスターの心筋組織線維化抑制作用 1995
• ATP感受性K＋チャネル開口の心筋壊死縮小効果0とそのメカニズムに関する検討 1995
• 虚血性心疾患患者における運動負荷によるNitric Oxide（NO）産生の増加 1995
• Lippolysaccaride投与によるアデノシン産生酵素活性化と心筋虚血耐性効果 1995
• 心筋虚血とNO 1995
• アデノシンの虚血・再灌流障害に対する心筋保護作用 1995
• AICA riboside myocardial ischemia in coronary microembolization in dogs. 1994/10
• Evidence for deactivation of both ectosolic and cytosolic 5'-nucleotidase by adenosine A1 receptor activation in the rat cardiomyocyte. 1994
• Roles of α-adrenoceptor activity and adenosine linkage in myocardial ischemic and reperfusion injury. In; Nimi H, Oda M, Sawada T, Xiu RJ, eds. 1994
• 堀　正二、北風政史、森岡敏一、岡崎康司、南野哲男、野出孝一 1994
• 冠血管アデノシン産生におけるアデノシン産生酵素活性の役割 1994
• Becker型筋ジストロフィーの心不全を合併した一例 1994
• 心筋梗塞とischemic preconditioning 1994
• Ischemic Preconditioningの心筋壊死縮小効果におけるアデノシン産生増加の意義 1993
• Nucleotide sequence of the hag gene encoding flagellin of Escherichia coli. 1986/12

Books

• Ⅳ特殊な冠動脈病変に対するPCI治療の考え方 病変部位 左冠動脈主幹部遠位部病変;　2015
  ANNOUNCEMENT INFO.;　, 198-207
  AUTHOR;　
  
• Chapter 5 Practice ～種々の疾患リスクとしての高尿酸血症 １.循環器疾患と尿酸代謝の関わり ②動脈硬化（尿酸と血管リモデリング）の形成と進展 1)血管内皮機能;　2015
  ANNOUNCEMENT INFO.;　, 68-73
  AUTHOR;　
  
• 5章 拡張不全の治療 50●拡張不全診療における米国のガイドラインに関して解説してください;　2015
  ANNOUNCEMENT INFO.;　, 172-174
  AUTHOR;　
  
• II.心不全診療Q&A 1.心不全の疫学 2.日本人の心不全の原因疾患について教えてください;　2015
  ANNOUNCEMENT INFO.;　, 84-86
  AUTHOR;　
  
• IV.高血圧・肺高血圧・脂質異常症 A.高血圧 5.高血圧診療における最適な血管障害指標は何か？;　2015
  ANNOUNCEMENT INFO.;　, 366-374
  AUTHOR;　
  
• 文献792-496;　2015
  ANNOUNCEMENT INFO.;　, 78
  AUTHOR;　
  
• Ⅴ.治療 F.降圧薬の特徴と薬理・副作用　5.β遮断薬（含αβ遮断薬）、α遮断薬;　2014
  ANNOUNCEMENT INFO.;　, 114-115
  AUTHOR;　
  
• Lecture 8　専門医はこう考える　一問一答　Q14.観血的治療（外科・歯科など）をおこなう際の血圧管理はどうしていますか？;　2014
  ANNOUNCEMENT INFO.;　, 196-197
  AUTHOR;　
  
• Ⅴ.バルーンのピンチも乗り越える！ バルーン通過困難時 041分岐部病変の側枝にバルーンが通過せず、KBTもできないとき;　2014
  ANNOUNCEMENT INFO.;　, 179-184　
  AUTHOR;　
  
• PART6 2型糖尿病治療におけるSGLT2阻害薬の位置づけを探る 3.SGLT2阻害薬のベネフィットを展望する;　2014
  ANNOUNCEMENT INFO.;　, 97-106
  AUTHOR;　
  
• 高血圧治療薬　α遮断薬;　2014
  ANNOUNCEMENT INFO.;　, 53
  AUTHOR;　
  
• 高血圧治療薬　β遮断薬（含αβ遮断薬）;　2014
  ANNOUNCEMENT INFO.;　, 52-53
  AUTHOR;　
  
• Ⅲ循環器診療における医療安全;　2014
  ANNOUNCEMENT INFO.;　, 65-67
  AUTHOR;　
  
• 末梢動脈疾患(PAD)患者の下肢病変　治療(①薬物療法)　;　2014
  ANNOUNCEMENT INFO.;　, 72-75
  AUTHOR;　
  
• 末梢動脈疾患(PAD)患者の下肢病変　治療(②血管内治療)　　;　2014
  ANNOUNCEMENT INFO.;　, 76-81
  AUTHOR;　
  
• IV薬物療法関連のエビデンス 29.Alogliptin;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 7.β遮断薬はなぜ冠動脈疾患に有効か？;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 17 スタチン;　2013
  ANNOUNCEMENT INFO.;　, 212-225
  AUTHOR;　
  
• 第7章 虚血性心疾患 急性冠症候群とその治療;　2013
  ANNOUNCEMENT INFO.;　, 395-399
  AUTHOR;　
  
• 第4章 治療薬総論 その他の抗動脈硬化薬;　2013
  ANNOUNCEMENT INFO.;　, 183-184
  AUTHOR;　
  
• IV.ひと工夫した降圧薬の使い方 1)時間降圧療法～夜間投与への有用性～;　2013
  ANNOUNCEMENT INFO.;　, 4, 132-137
  AUTHOR;　
  
• 血流依存性血管拡張反応(FMD);　2013
  ANNOUNCEMENT INFO.;　, 412, 特別号1, S161-S162
  AUTHOR;　
  
• 時計遺伝子;　2012
  ANNOUNCEMENT INFO.;　, 149-156
  AUTHOR;　
  
• 日本人では心不全の発症予防になにを指導すればよいですか？;　2012
  ANNOUNCEMENT INFO.;　, 90-92
  AUTHOR;　
  
• 日本人の心不全は欧米人と差がありますか;　2012
  ANNOUNCEMENT INFO.;　, 87-89
  AUTHOR;　
  
• 日本人の心不全の原因疾患について教えてください;　2012
  ANNOUNCEMENT INFO.;　, 84-86
  AUTHOR;　
  
• 糖尿病患者では心不全のリスクが高くなるのですか？;　2012
  ANNOUNCEMENT INFO.;　, 120-121
  AUTHOR;　
  
• 拡張不全の治療はどのようにしたらよいでしょうか？　;　2011
  ANNOUNCEMENT INFO.;　, 216-217
  AUTHOR;　
  
• 糖尿病と抗血栓療法;　2011
  ANNOUNCEMENT INFO.;　, 218-225
  AUTHOR;　
  
• 心不全診断で重要な心電図変化を教えてください;　2011
  ANNOUNCEMENT INFO.;　, 99-102
  AUTHOR;　
  
• ジギタリスの使い方のポイントを教えてください;　2011
  ANNOUNCEMENT INFO.;　, 197-199
  AUTHOR;　
  
• 心不全のくすり;　2011
  ANNOUNCEMENT INFO.;　, 119-131
  AUTHOR;　
  
• 序;　2011
  ANNOUNCEMENT INFO.;　, 1
  AUTHOR;　
  
• 検査・診断;　2011
  ANNOUNCEMENT INFO.;　, 55
  AUTHOR;　
  
• Glucose Lowering: Is it Safe for the Heart?;　2011
  ANNOUNCEMENT INFO.;　, 74-75
  AUTHOR;　
  
• 高血圧における血管不全の診断と降圧薬の選び方;　2011
  ANNOUNCEMENT INFO.;　, 115-120
  AUTHOR;　
  
• 心房性不整脈合併例の治療方法について教えてください.;　2011
  ANNOUNCEMENT INFO.;　, 233-236
  AUTHOR;　
  
• 心室性不整脈合併例の治療方法について教えてください;　2011
  ANNOUNCEMENT INFO.;　, 237-239
  AUTHOR;　
  
• 負荷心電図;　2011
  ANNOUNCEMENT INFO.;　, S74-S76
  AUTHOR;　
  
• プラバスタチン;　2010/03
  ANNOUNCEMENT INFO.;　, 815-818
  AUTHOR;　
  
• 心血管CT、MRI、冠動脈CT;　2009/09
  ANNOUNCEMENT INFO.;　, 100-103
  AUTHOR;　
  
• Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease;　2009/05
  ANNOUNCEMENT INFO.;　, 156-157
  AUTHOR;　
  
• Reversal of Atherosclerosis with Aggressive Lipid Lowering;　2009/05
  ANNOUNCEMENT INFO.;　, 156-157
  AUTHOR;　
  
• 脂質異常症・動脈硬化を伴った高血圧とβ遮断薬;　2009/04
  ANNOUNCEMENT INFO.;　, 231-236
  AUTHOR;　
  
• 狭心症をいかに予防するか;　2009/03
  ANNOUNCEMENT INFO.;　, 25-31
  AUTHOR;　
  
• Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease;　2009
  ANNOUNCEMENT INFO.;　, 156-157
  AUTHOR;　
  
• Reversal of Atherosclerosis with Aggressive Lipid Lowering;　2009
  ANNOUNCEMENT INFO.;　, 222-223
  AUTHOR;　
  
• 心血管CT,MRI,冠動脈CT;　2009
  ANNOUNCEMENT INFO.;　, 101-103
  AUTHOR;　
  
• 高血圧管理のための薬物療法　長時間作用型カルシウム拮抗薬;　2008/05
  ANNOUNCEMENT INFO.;　, 123-128
  AUTHOR;　
  
• 先天性心膜欠損症[完全，不完全];　2008/03
  ANNOUNCEMENT INFO.;　, 142-144
  AUTHOR;　
  
• ARBとスタチン;　2008/01
  ANNOUNCEMENT INFO.;　, 280-281
  AUTHOR;　
  
• 先天性左側心膜欠損症;　2008
  ANNOUNCEMENT INFO.;　, 138-141
  AUTHOR;　
  
• 膠原病に伴う心疾患;　2007/10
  ANNOUNCEMENT INFO.;　, 256-262
  AUTHOR;　
  
• 腎疾患に伴う心疾患;　2007/10
  ANNOUNCEMENT INFO.;　, 264-272
  AUTHOR;　
  
• 心房細動アップストリーム治療の考え方と実際／糖尿病を有する心房細動;　2007/08
  ANNOUNCEMENT INFO.;　, 157-164
  AUTHOR;　
  
• 病態生理　食後高血糖;　2007/06
  ANNOUNCEMENT INFO.;　, 624-627
  AUTHOR;　
  
• 高感度CRP;　2007/06
  ANNOUNCEMENT INFO.;　, 175-178
  AUTHOR;　
  
• 慢性心不全の管理、どうしよう？;　2007/04
  ANNOUNCEMENT INFO.;　, 260-263
  AUTHOR;　
  
• レニン・アンジオテンシン系の病態生理　血管;　2006/12
  ANNOUNCEMENT INFO.;　, 170-177
  AUTHOR;　
  
• 喫煙　冠危険因子を知る(2)：ライフスタイルと虚血性心疾患;　2006/11
  ANNOUNCEMENT INFO.;　, 124-130
  AUTHOR;　
  
• 高脂血症のコントロール目標と治療　冠危険因子への介入;　2006/11
  ANNOUNCEMENT INFO.;　, 181-188
  AUTHOR;　
  
• 高トリグリセライド血症の注意すべき合併症;　2006/09
  ANNOUNCEMENT INFO.;　, 127-129
  AUTHOR;　
  
• 酸化ストレスと老化・疾患　循環器疾患　酸化ストレスによる血管内皮機能障害;　2006/04
  ANNOUNCEMENT INFO.;　, 262-264
  AUTHOR;　
  
• 高血糖、高インスリン血症と動脈硬化;　2006/03
  ANNOUNCEMENT INFO.;　, 173-179
  AUTHOR;　
  
• ラロキシフェンと心血管系疾患;　2006/03
  ANNOUNCEMENT INFO.;　, 280-283
  AUTHOR;　
  
• HMG-CoA還元酵素阻害薬の使い方;　2006/01
  ANNOUNCEMENT INFO.;　, 342-348
  AUTHOR;　
  
• 診断と治療　最近の進歩　心筋症　拡張型心筋症のスタチン療法;　2006/01
  ANNOUNCEMENT INFO.;　, 245-250
  AUTHOR;　
  
• Q41高血圧で脳卒中の家系～脳卒中を予防したいが、よい薬がある？;　2006/01
  ANNOUNCEMENT INFO.;　, 116-117
  AUTHOR;　
  
• Q42動脈硬化を予防する効果の高い降圧薬がある？;　2006/01
  ANNOUNCEMENT INFO.;　, 118-119
  AUTHOR;　
  
• Q43心疾患を合併した高血圧患者によい降圧薬は？;　2006/01
  ANNOUNCEMENT INFO.;　, 120-122
  AUTHOR;　
  
• 高血圧の生化学検査第12回　ADMA;　2005/12
  ANNOUNCEMENT INFO.;　, 12, 12, 93-96
  AUTHOR;　
  
• メタボリックシンドロームの分子メカニズムから予防まで;　2005/11
  ANNOUNCEMENT INFO.;　, 10, 2, 96-97
  AUTHOR;　
  
• 脂溶性スタチンのpleiotropic effect;　2005/11
  ANNOUNCEMENT INFO.;　, 4257, 102-102
  AUTHOR;　
  
• 抗血小板療法の意義とEBM;　2005/10
  ANNOUNCEMENT INFO.;　, 180-185
  AUTHOR;　
  
• 抗血小板療法の実際;　2005/10
  ANNOUNCEMENT INFO.;　, 186-190
  AUTHOR;　
  
• 抗血小板療法で注意することは;　2005/10
  ANNOUNCEMENT INFO.;　, 220-221
  AUTHOR;　
  
• HMG-CoA還元酵素阻害薬による血管リモデリング治療と臨床的意義-Beyond lipid control-;　2005/10
  ANNOUNCEMENT INFO.;　, 58, 4, 388-396
  AUTHOR;　
  
• 虚血・再灌流傷害におけるＲＡＳの関与-交感神経亢進、酸化ストレス-;　2005/10
  ANNOUNCEMENT INFO.;　, 2, 4, 289-293
  AUTHOR;　
  
• 血管障害への影響;　2005/09
  ANNOUNCEMENT INFO.;　, 165-167
  AUTHOR;　
  
• 労作時に胸が痛い　ふらつきも感じる！？;　2005/06
  ANNOUNCEMENT INFO.;　, 83-86
  AUTHOR;　
  
• メタボリックシンドローム包括的治療薬としてのアンジオテンシン受容体阻害薬とスタチン系薬剤;　2005/05
  ANNOUNCEMENT INFO.;　, 156-160
  AUTHOR;　
  
• 骨粗鬆症を伴う高血圧;　2005/04
  ANNOUNCEMENT INFO.;　, 108-110
  AUTHOR;　
  
• 感染症の関与はどこまで明らかになったか;　2005/03
  ANNOUNCEMENT INFO.;　, 24-29
  AUTHOR;　
  
• 血管内皮細胞機能異常;　2005/03
  ANNOUNCEMENT INFO.;　, 60-63
  AUTHOR;　
  
• 遺伝子調節＜ＰＰＡＲ＞;　2005/03
  ANNOUNCEMENT INFO.;　, 130-131
  AUTHOR;　
  
• 食後高血糖と糖尿病合併症;　2005
  ANNOUNCEMENT INFO.;　, 212-219
  AUTHOR;　
  
• 食後高血糖による血管内皮機能の障害とその制御;　2005
  ANNOUNCEMENT INFO.;　, 925, 3-3
  AUTHOR;　
  
• 『高血圧治療の新展開』～ＡＲＢの心保護作用～;　2005
  ANNOUNCEMENT INFO.;　, 147, 15-15
  AUTHOR;　
  
• 急性冠症候群の病態と治療;　2005
  ANNOUNCEMENT INFO.;　, 15, 58-60
  AUTHOR;　
  
• エストロゲンの心筋保護作用;　2005
  ANNOUNCEMENT INFO.;　, 42, 6, 630-632
  AUTHOR;　
  
• ＳＥＲＭ;　2005
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 心不全をやっつけろ！-その鼓動をいつまでも;　2005
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 動脈硬化の性差の分子基盤とエストロゲン治療;　2004/12
  ANNOUNCEMENT INFO.;　, 36, 12, 88-92
  AUTHOR;　
  
• 血管不全の概念;　2004/12
  ANNOUNCEMENT INFO.;　, 21-24
  AUTHOR;　
  
• 血管内皮前駆細胞による血管内皮再生とスクチン;　2004/12
  ANNOUNCEMENT INFO.;　, 75-79
  AUTHOR;　
  
• 腎不全;　2004/12
  ANNOUNCEMENT INFO.;　, 143-150
  AUTHOR;　
  
• 虚血性心疾患と性差　一酸化窒素;　2004/10
  ANNOUNCEMENT INFO.;　, 21, 11, 31-35
  AUTHOR;　
  
• 心肥大と性差;　2004/10
  ANNOUNCEMENT INFO.;　, 21, 11, 41-49
  AUTHOR;　
  
• ＮＯの心保護作用：臨床分子内分泌学(1)－心血管内分泌代謝系（上）;　2004/09
  ANNOUNCEMENT INFO.;　, 854, 510-512
  AUTHOR;　
  
• 成因／糖尿病と動脈硬化;　2004/09
  ANNOUNCEMENT INFO.;　, 174-179
  AUTHOR;　
  
• 心不全：臨床;　2004/09
  ANNOUNCEMENT INFO.;　, 54-58
  AUTHOR;　
  
• 腎障害;　2004/09
  ANNOUNCEMENT INFO.;　, 64-68
  AUTHOR;　
  
• 心不全;　2004/09
  ANNOUNCEMENT INFO.;　, 218-221
  AUTHOR;　
  
• 血管炎症と心不全;　2004/07
  ANNOUNCEMENT INFO.;　, 1, 3, 54-59
  AUTHOR;　
  
• 高血圧,心血管病の合併　病態に応じた高脂血症の薬物治療;　2004/06
  ANNOUNCEMENT INFO.;　, 81, 6, 987-991
  AUTHOR;　
  
• 積極的な脂質管理が必要な患者とは？－メタポリックシンドロームのメカニズムについて;　2004/06
  ANNOUNCEMENT INFO.;　, 8, 2, 22-29
  AUTHOR;　
  
• COPERNICUS;　2004/04
  ANNOUNCEMENT INFO.;　, 164-165
  AUTHOR;　
  
• pleiotropic effect;　2004/04
  ANNOUNCEMENT INFO.;　, 15, 2, 191-194
  AUTHOR;　
  
• ホルモン補充療法の臨床：動脈硬化と心血管系;　2004/04
  ANNOUNCEMENT INFO.;　, 22, 4, 51-54
  AUTHOR;　
  
• 高脂血症におけるA II受容体拮抗薬の治療戦略の根拠は何か;　2004/03
  ANNOUNCEMENT INFO.;　, 272-276
  AUTHOR;　
  
• 心血管イベントとスタチン;　2004/02
  ANNOUNCEMENT INFO.;　, 36-41
  AUTHOR;　
  
• 高脂血症治療－最近の現況;　2004/02
  ANNOUNCEMENT INFO.;　, 41, 2, 111-112
  AUTHOR;　
  
• 代謝疾患治療薬　ＨＭＧ-ＣｏＡ還元酵素阻害薬;　2004/01
  ANNOUNCEMENT INFO.;　, 92, 1, 116-122
  AUTHOR;　
  
• Behcet disease with exacerbation in summer and late coronary stent occlusion.;　2004
  ANNOUNCEMENT INFO.;　Nippon Naika Gakkai Zasshi., 93, 5, 1003-1005
  AUTHOR;　Nakajima A,Yoshida K,Utsunomiya T,Node K
  
• 食後高血糖と大血管症;　2004
  ANNOUNCEMENT INFO.;　, 152-157
  AUTHOR;　
  
• 食後高血糖と血管不全;　2004
  ANNOUNCEMENT INFO.;　, 129-129
  AUTHOR;　
  
• プライマリーケアの実際　臨床研修マニュアル;　2004
  ANNOUNCEMENT INFO.;　, 964-969
  AUTHOR;　
  
• ホルモン補充療法の功罪　パイオクリニカ編集委員会;　2004
  ANNOUNCEMENT INFO.;　, 19, 11, 88-91
  AUTHOR;　
  
• ＦＭＤによる血管内皮機能検査法糖尿病と代謝;　2004
  ANNOUNCEMENT INFO.;　, 32, 1, 16-19
  AUTHOR;　
  
• 心不全を伴う高血圧症;　2004
  ANNOUNCEMENT INFO.;　, 673, 11-16
  AUTHOR;　
  
• 高脂血症治療の最新の動向;　2004
  ANNOUNCEMENT INFO.;　, 81, 5, 125-130
  AUTHOR;　
  
• 治療への展開　抗動脈硬化薬としてのスタチンの多目的作用：実験医学増刊　血管研究の最先端と治療への展開;　2004
  ANNOUNCEMENT INFO.;　, 22, 8, 172-175
  AUTHOR;　
  
• ステント内遅発性閉塞を起こした夏期増悪型Behcet病の１例;　2004
  ANNOUNCEMENT INFO.;　, 93
  AUTHOR;　
  
• 食後高血糖と動脈硬化;　2004
  ANNOUNCEMENT INFO.;　, 674, 17-23
  AUTHOR;　
  
• 急性冠症候群における血管炎症の意義;　2004
  ANNOUNCEMENT INFO.;　, 44, 8, 311-317
  AUTHOR;　
  
• 循環器医が治療する糖尿病と大血管障害;　2004
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 血管不全フロンティア;　2004
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 心血管イベントとスタチン;　2004
  ANNOUNCEMENT INFO.;　, 36-41
  AUTHOR;　
  
• COPERNICUS;　2004
  ANNOUNCEMENT INFO.;　, 164-165
  AUTHOR;　
  
• VII心血管病変の治療の実際　４．心不全;　2004
  ANNOUNCEMENT INFO.;　, 218-221
  AUTHOR;　
  
• 血管不全の概念;　2004
  ANNOUNCEMENT INFO.;　, 21-24
  AUTHOR;　
  
• 連載：日本人に適した高指血症治療を考える－フィブラートという選択－第５回　フィプラートのPleiotropic effect.;　2003/08
  ANNOUNCEMENT INFO.;　, 4, 4, 445　-449
  AUTHOR;　
  
• 女性と心血管疾患－エストロゲンと加齢の関与－　２．心臓に対する作用;　2003/08
  ANNOUNCEMENT INFO.;　, 5, 4　-4
  AUTHOR;　
  
• 高血圧合併症患者には積極的なスタチン投与を－ＡＳＣＯＴ脂質低下療法試験の結果を受けて－.;　2003/08
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 座談会ASCOT(Anglo-Scandiavian Cardiac outcomes Trial-Lipid Lowering Arm)Study－その意義と臨床に与える影響－;　2003/06
  ANNOUNCEMENT INFO.;　, 36, 25, 28-30
  AUTHOR;　
  
• 座談会　21世紀の心血管疾患予防および管理(2).;　2003/05
  ANNOUNCEMENT INFO.;　, 53-54
  AUTHOR;　
  
• β遮断薬;　2003/02
  ANNOUNCEMENT INFO.;　, 188　-193
  AUTHOR;　
  
• β遮断薬;　2003/02
  ANNOUNCEMENT INFO.;　, 188-193
  AUTHOR;　
  
• 抗血小板治療の最前線－循環器疾患領域における低容量アスピリンの使い方と可能性:第２版;　2003
  ANNOUNCEMENT INFO.;　, 155-157
  AUTHOR;　
  
• 生活習慣病と血管内皮障害－スタチンとACE阻害薬の多目的効果が意味するもの:第３版;　2003
  ANNOUNCEMENT INFO.;　, 164　-167
  AUTHOR;　
  
• ＡＮＰの心筋炎症抑制作用;　2003
  ANNOUNCEMENT INFO.;　, 51-54
  AUTHOR;　
  
• 血管を守るために－食後高血糖と動脈硬化:第３版;　2003
  ANNOUNCEMENT INFO.;　, 105-108
  AUTHOR;　
  
• β遮断薬（血管の観点から）;　2003
  ANNOUNCEMENT INFO.;　, 14, 14-15
  AUTHOR;　
  
• 食後高血糖/IGTと大血管障害食後高血糖と大血管障害－ＩＧＴの段階からすでに動脈硬化は発症している－;　2003
  ANNOUNCEMENT INFO.;　, 4-23
  AUTHOR;　
  
• 食後高血糖／ＩＧＴと大血管障害－IGT・糖尿病患者の動脈硬化を診る－血管内皮機能.;　2003
  ANNOUNCEMENT INFO.;　, 65-69
  AUTHOR;　
  
• 食後高血糖／ＩＧＴと大血管障害－ＩＧＴ・糖尿病患者の動脈硬化を診る－炎症マーカー;　2003
  ANNOUNCEMENT INFO.;　, 70-75
  AUTHOR;　
  
• 心血管病とエストロゲン－特集：性差医学の最前線;　2003
  ANNOUNCEMENT INFO.;　, 109　-120
  AUTHOR;　
  
• 血小板制御－特集：生体諸システムの制御臓器としての血管内皮細胞．;　2003
  ANNOUNCEMENT INFO.;　, 145-149
  AUTHOR;　
  
• アトルパスタチンの長期使用効果ＧＲＥＡＣＥ試験を中心に;　2003
  ANNOUNCEMENT INFO.;　, 3, 12-14
  AUTHOR;　
  
• 大規模臨床試験が示唆する冠動脈疾患の新しい治療ツール：血管学・最新情報館１;　2003
  ANNOUNCEMENT INFO.;　, 32, 40-42
  AUTHOR;　
  
• 降圧薬のPleiotropic Effects－その現状と臨床的意義－;　2003
  ANNOUNCEMENT INFO.;　, 641-647
  AUTHOR;　
  
• 冠循環の生理学：冠循環と心機能－冠循環の基礎．冠動脈の臨床(上)　;　2003
  ANNOUNCEMENT INFO.;　, 61, 50-60
  AUTHOR;　
  
• 虚血心筋：再潅流障害の機序に関する研究の動向－冠循環の病理，病態．冠動脈の臨床(上)．;　2003
  ANNOUNCEMENT INFO.;　, 61, 135-141
  AUTHOR;　
  
• 対談　米国の臨床現場における栄養素の位置づけ―大規模試験の結果をどのように生かすか－．;　2003
  ANNOUNCEMENT INFO.;　, 32, 64-66
  AUTHOR;　
  
• 糖尿病合併症と血栓　１．糖代謝異常と血栓形成のメカニズム：血管壁の異常から;　2003
  ANNOUNCEMENT INFO.;　, 12-16
  AUTHOR;　
  
• スタチンの心筋保護作用－シンバスタチンは慢性心不全にも有効－;　2003
  ANNOUNCEMENT INFO.;　, 26-27
  AUTHOR;　
  
• なぜ食後高血糖の抑制は重要なのか－動脈硬化進展メカニズムからのアプローチ.;　2003
  ANNOUNCEMENT INFO.;　, 16, 1-12
  AUTHOR;　
  
• 糖尿病における動脈硬化―予備軍だって安心できない糖尿病予備軍(IGT);　2003
  ANNOUNCEMENT INFO.;　, 1-2
  AUTHOR;　
  
• 冠動脈の臨床(下)－21世紀の診断治療体系 ADMA(asymmetric dimethyl arginine)と虚血性心疾患．;　2003
  ANNOUNCEMENT INFO.;　, 61, 867　-873
  AUTHOR;　
  
• ＨＭＧ-ＣｏＡ還元酵素阻害薬の慢性心不全抑制作用;　2003
  ANNOUNCEMENT INFO.;　, 24, 108　　-112
  AUTHOR;　
  
• 平均ないしそれ以下のコレステロール値を示す高血圧患者におけるアトルバスタチンの冠動脈および脳卒中イベントの予防効果;　2003
  ANNOUNCEMENT INFO.;　, 1149-1158
  AUTHOR;　
  
• 座談会　高血圧患者におけるコレステロール低下治療－ＡＳＣＯＴ指貫低下試験の意義－．;　2003
  ANNOUNCEMENT INFO.;　, 52-57
  AUTHOR;　
  
• 心血管系の老化と女性ホルモン－心不全とエストロゲン－．;　2003
  ANNOUNCEMENT INFO.;　, 40, 332　-335
  AUTHOR;　
  
• 座談会　心血管リスクの総合的な治療を考える－糖尿病，高血圧をもつ患者さんの脂質管理－．;　2003
  ANNOUNCEMENT INFO.;　, 8, 1-8
  AUTHOR;　
  
• 循環器医から見た食後過血糖と血管不全;　2003
  ANNOUNCEMENT INFO.;　, 6-7
  AUTHOR;　
  
• 対談　微小循環を良くすることで脂質や糖の代謝を改善.;　2003
  ANNOUNCEMENT INFO.;　, 48　-50
  AUTHOR;　
  
• 座談会 ASCOT Study－その意義と臨床に与える影響－.;　2003
  ANNOUNCEMENT INFO.;　, 28-30
  AUTHOR;　
  
• 座談会　高血圧患者におけるコレステロール低下治療－ＡＳＣＯＴ脂質低下試験の意義－．;　2003
  ANNOUNCEMENT INFO.;　, 52-57
  AUTHOR;　
  
• 急性冠症候群におけるスタチン系薬剤の役割;　2003
  ANNOUNCEMENT INFO.;　, 32-36
  AUTHOR;　
  
• 教室訪問　佐賀大学医学部循環器・腎臓内科;　2003
  ANNOUNCEMENT INFO.;　, 27-29
  AUTHOR;　
  
• 座談会　動脈硬化の発症・進展とニフェジピンの血管保護作用－直接作用と間接作用;　2003
  ANNOUNCEMENT INFO.;　, 3, 6-10
  AUTHOR;　
  
• スタチンの心筋炎症抑制作用;　2003
  ANNOUNCEMENT INFO.;　, 33-40
  AUTHOR;　
  
• 血管拡張因子のインスリン抵抗性への影響－一酸化窒素（ＮＯ）・内皮由来過分極因子（EDHF）の検討－;　2003
  ANNOUNCEMENT INFO.;　, 230-233
  AUTHOR;　
  
• 対談　ホモシステインと心臓病―血中ホモシステイン濃度を低下させる葉酸;　2003
  ANNOUNCEMENT INFO.;　, 70-72
  AUTHOR;　
  
• 生活習慣病実地診療のポイント－期待されるスタチンの多面的作用－．;　2003
  ANNOUNCEMENT INFO.;　, 500, 91-92
  AUTHOR;　
  
• 内皮由来過分極因子（ＥＤＨＦ）;　2003
  ANNOUNCEMENT INFO.;　, 58, 11, 2725-2729
  AUTHOR;　
  
• 軽症糖尿病の治療意義－食後高血糖は心血管イベントの危険因子－.;　2003
  ANNOUNCEMENT INFO.;　, 1-4
  AUTHOR;　
  
• 特別企画　エピデンスに基づいた糖尿病の治療戦略－糖尿病専門医と循環器専門医の連携－;　2003
  ANNOUNCEMENT INFO.;　, 24-25
  AUTHOR;　
  
• 単行本　ファーマナピゲーター　Ca桔抗薬編「スタチン」;　2003
  ANNOUNCEMENT INFO.;　, 182-188
  AUTHOR;　
  
• 特別企画ＣＨＡＲＭに学ぶ「心保護」を意識した降圧療法;　2003
  ANNOUNCEMENT INFO.;　, 16-17
  AUTHOR;　
  
• 座談会　各種愁訴を有する中高年女性の高血圧症に対する至週降圧療法を考える.;　2003
  ANNOUNCEMENT INFO.;　, 14-15
  AUTHOR;　
  
• 座談会　心血管リスクの総合的な治療を考える－糖尿病，高血圧をもつ患者さんの脂質管理－;　2003
  ANNOUNCEMENT INFO.;　, 8-8
  AUTHOR;　
  
• ＡＮＰの心筋炎症抑制作用;　2003
  ANNOUNCEMENT INFO.;　, 35, 51-54
  AUTHOR;　
  
• 冠動脈の臨床　21世紀の診断治療体系　冠循環の病理，病態　虚血心筋　再灌漑流障害の機序に関する研究の動向;　2003
  ANNOUNCEMENT INFO.;　, 61, 135-141
  AUTHOR;　
  
• 抗高脂血症薬　スタチンと高血圧;　2003
  ANNOUNCEMENT INFO.;　, 10, 1007-1011
  AUTHOR;　
  
• 血管不全と炎症の関わり;　2003
  ANNOUNCEMENT INFO.;　, 50, 449-469
  AUTHOR;　
  
• 内科ケースカンファレンス５０;　2002
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Effects of HMG-CoA Reductase Inhibitors on Cells of the Vascular Wall;　2002
  ANNOUNCEMENT INFO.;　Milestone in Drug Therapy
  AUTHOR;　Koichi Node, James K Liao. Birkhauser Verlag. Editor Michel J Parnhm.
  
• 酸化ストレスーフリーラジカル医学生物学の最前線　　血管平滑筋制御と酸化ストレス;　2001
  ANNOUNCEMENT INFO.;　, 203-207
  AUTHOR;　
  
• Endothelium-Derived Hyperpolarizing Factor Ameliolates Ischemic Heart Failure;　2001
  ANNOUNCEMENT INFO.;　Microcirculation annual, 17, 27-28
  AUTHOR;　Koichi Node, Masafumi Kitakaze, Masatsugu Hori　 Nihon-Igakukan.　Editor M Tsuchiya, M Asano, F Kajiya
  
• Role of adenosine in Cardioprotection;　2001
  ANNOUNCEMENT INFO.;　Heart Failure-Frontier Cardiology. Sprigler
  AUTHOR;　Masafumi Kitakaze, Tetsuo Minamino, Koichi Node, Seiji Takashima, Hiroharu Funaya, Tsunehiko Kuzuya, Masatsugu Hori.
  
• 心臓カテーテル検査;　1996
  ANNOUNCEMENT INFO.;　, 2, 456-461
  AUTHOR;　
  
• 循環研究プロトコロール　動脈硬化、高血圧、心臓病研究の最前線;　1996
  ANNOUNCEMENT INFO.;　, 180-184
  AUTHOR;　
  
• 心筋虚血とNO;　1995
  ANNOUNCEMENT INFO.;　, 75-82
  AUTHOR;　
  

Original Articles

• Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients With Cancer ;　2023/02
  ANNOUNCEMENT INFO.;　J Clin Oncol, 41, 5, 980-990
  AUTHOR;　*Hidehiro Kaneko, Yuichiro Yano, Hokyou Lee, Hyeok-Hee Lee, Akira Okada, Yuta Suzuki, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Akira Nishiyama, Koichi Node, Hyeon Chang Kim, Hideo Yasunaga, Issei Komuro
  
• Body fluid regulation via chronic inhibition of sodium-glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial ;　2023/01
  ANNOUNCEMENT INFO.;　Clin Res Cardiol, 112, 1, 87-97
  AUTHOR;　*Shinya Fujiki, Atsushi Tanaka, Takumi Imai, Michio Shimabukuro, Hiroki Uehara, Ikuko Nakamura, Kazuo Matsunaga, Makoto Suzuki, Takeshi Kashimura, Tohru Minamino, Takayuki Inomata, Koichi Node, CANDLE Trial Investigators
  
• Glycemic status and the association of change in blood pressure with incident cardiovascular disease ;　2022/12
  ANNOUNCEMENT INFO.;　Am Heart J, 254, 48-56
  AUTHOR;　*Yuta Suzuki, Hidehiro Kaneko, Yuichiro Yano, Akira Okada, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Kentaro Kamiya, Atsuhiko Matsunaga, Junya Ako, Koichi Node, Hideo Yasunaga, Issei Komuro
  
• Association of Life's Simple 7 with incident cardiovascular disease in 52,956 patients with cancer ;　2022/12
  ANNOUNCEMENT INFO.;　Eur J Prev Cardiol, 29, 18, 2324-2332
  AUTHOR;　*Hidehiro Kaneko, Yuta Suzuki, Kensuke Ueno, Akira Okada, Katsuhito Fujiu, Satoshi Matsuoka, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Kentaro Kamiya, Koichi Node, Hideo Yasunaga, Issei Komuro
  
• Dose-dependent relationship of blood pressure and glycemic status with risk of aortic dissection and aneurysm ;　2022/12
  ANNOUNCEMENT INFO.;　Eur J Prev Cardiol, 29, 18, 2338-2346
  AUTHOR;　*Yuta Suzuki, Hidehiro Kaneko, Yuichiro Yano, Akira Okada, Hidetaka Itoh, Kensuke Ueno, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Isao Yokota, Koichi Node, Hideo Yasunaga, Issei Komuro
  
• Threshold of Body Mass Index for the Development of Hypertension Among Japanese Adults;　2022/11
  ANNOUNCEMENT INFO.;　J Nutr, 152, 11, 2565-2571
  AUTHOR;　*Yuta Suzuki, Hidehiro Kaneko, Yuichiro Yano, Akira Okada, Yohei Hashimoto, Hidetaka Itoh, Satoshi Matsuoka, Isao Yokota, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Kentaro Kamiya, Atsuhiko Matsunaga, Junya Ako, Koichi Node, Hideo Yasunaga, Issei Komuro
  
• Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors;　2022/11
  ANNOUNCEMENT INFO.;　Kidney Int, 102, 5, 1147-1153
  AUTHOR;　*Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Koichi Node, Masaomi Nangaku, Hideo Yasunaga, Issei Komuro
  
• Sex Difference in the Association between Lipid Profile and Incident Cardiovascular Disease among Young Adults;　2022/10
  ANNOUNCEMENT INFO.;　J Atheroscler Thromb, 29, 10, 1475-1486
  AUTHOR;　*Tatsuya Kamon, Hidehiro Kaneko, Hidetaka Itoh, Akira Okada, Satoshi Matsuoka, Hiroyuki Kiriyama, Katsuhito Fujiu, Kojiro Morita, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Sunao Nakamura, Koichi Node, Hideo Yasunaga, Issei Komuro
  
• Association of Cardiovascular Health Metrics with Risk of Transition to Hypertension in Non-Hypertensive Young Adults ;　2022/10
  ANNOUNCEMENT INFO.;　Am J Hypertens, 35, 10, 858-866
  AUTHOR;　*Yuta Suzuki, Hidehiro Kaneko, Yuichiro Yano, Akira Okada, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Atsuhiko Matsunaga, Koichi Node, John W McEvoy, Carolyn S P Lam, Suzanne Oparil, Hideo Yasunaga, Issei Komuro
  
• So-far overlooked HFpEF patients with normal natriuretic peptide level need more evidence ;　2022/10
  ANNOUNCEMENT INFO.;　ESC Heart Fail, 9, 5, 3659-3660
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Potential negative effect of total parenteral nutrition on the human circadian clock ;　2022/10
  ANNOUNCEMENT INFO.;　Genes Cells, 27, 10, 613-620
  AUTHOR;　*Muneto Tatsumoto, Ritsuko Matsumura, Takuyuki Endo, Isao T Tokuda, Koichi Node, Makoto Akashi
  
• Multimodality Imaging Approach for a Left Ventricular Aneurysm in a Patient With Myocardial Infarction and Non-Obstructive Coronary Arteries ;　2022/09
  ANNOUNCEMENT INFO.;　Circ J, 86, 10, 1586
  AUTHOR;　Goro Yoshioka, Shinjo Sonoda, Shinichi Aishima, Koichi Node
  
• Antihypertensive drugs and cancer risk ;　2022/09
  ANNOUNCEMENT INFO.;　Am J Hypertens, 35, 9, 767-783
  AUTHOR;　*Satoshi Kidoguchi, Naoki Sugano, Takashi Yokoo, Hidehiro Kaneko, Hiroshi Akazawa, Mikio Mukai, Koichi Node, Yuichiro Yano, Akira Nishiyama, Japanese Society of Hypertension (JSH) working group “Onco-Hypertension”
  
• Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists ;　2022/09
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol, 21, 1, 176
  AUTHOR;　*Kosuke Sawami, Atsushi Tanaka, Koichi Node
  
• Medication Naïve Blood Pressure and Incident Cancers: Analysis of Two Nationwide Population-Based Databases;　2022/08
  ANNOUNCEMENT INFO.;　Am J Hypertens, 35, 8, 731-739
  AUTHOR;　*Hidehiro Kaneko, Yuichiro Yano, Hyeok-Hee Lee, Hokyou Lee, Akira Okada, Hidetaka Itoh, Kojiro Morita, Akira Fukui, Katsuhito Fujiu, Yuta Suzuki, Satoshi Matsuoka, Sunao Nakamura, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Akira Nishiyama, Koichi Node, Anthony J Viera, Paul Muntner, Suzanne Oparil, Hyeon Chang Kim, Hideo Yasunaga, Issei Komuro
  
• Need for more evidence of safety in the pharmacological therapy of anemia in chronic kidney disease: a cardiovascular perspective ;　2022/08
  ANNOUNCEMENT INFO.;　Eur Heart J Cardiovasc Pharmacother, 8, 5, e27-e28
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Age-Specific Relation of Cardiovascular Health Metrics With Incident Cardiovascular Disease;　2022/08
  ANNOUNCEMENT INFO.;　Am J Cardiol, 177, 34-39
  AUTHOR;　*Hidetaka Itoh, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Katsuhito Fujiu, Satoshi Matsuoka, Nobuaki Michihata, Taisuke Jo, Koki Nakanishi, Norifumi Takeda, Hiroyuki Morita, Koichi Node, Marco R Di Tullio, Shunichi Homma, Hideo Yasunaga, Issei Komuro
  
• Assessment of thromboembolism risk in COVID-19 patients with cardiovascular disease risk factors: Analysis of a Japanese Nationwide Registry;　2022/08
  ANNOUNCEMENT INFO.;　Thromb Res, 216, 90-96
  AUTHOR;　*Eiji Shibahashi, Kentaro Jujo, Shunsuke Kuroda, Shingo Matsumoto, Takahide Sano, Takeshi Kitai, Taishi Yonetsu, Shun Kohsaka, Sho Torii, Tetsuo Yamaguchi, Takuya Kishi, Issei Komuro, Kenichi Hirata, Koichi Node, Yuya Matsue
  
• Semiquantitative assessed proteinuria and risk of heart failure: analysis of a nationwide epidemiological database ;　2022/08
  ANNOUNCEMENT INFO.;　Nephrol Dial Transplant, 37, 9, 1691-1699
  AUTHOR;　*Akira Fukui, Hidehiro Kaneko, Akira Okada, Yuichiro Yano, Hidetaka Itoh, Satoshi Matsuoka, Kojiro Morita, Hiroyuki Kiriyama, Tatsuya Kamon, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Sunao Nakamura, Akira Nishiyama, Koichi Node, Takashi Yokoo, Masaomi Nangaku, Hideo Yasunaga, Issei Komuro
  
• Prevalence of hypertensive diseases and treated hypertensive patients in Japan: A nationwide administrative claims database study;　2022/07
  ANNOUNCEMENT INFO.;　Hypertens Res, 45, 7, 1123-1133
  AUTHOR;　*Takashi Waki, Katsuyuki Miura, Sachiko Tanaka-Mizuno, Yusuke Ohya, Koichi Node, Hiroshi Itoh, Hiromi Rakugi, Jumpei Sato, Kazuo Goda, Masaru Kitsuregawa, Tomoki Ishikawa, Naohiro Mitsutake
  
• New-Onset Atrial Fibrillation in Patients With Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease - Insights From the CLAVIS-COVID Registry ;　2022/07
  ANNOUNCEMENT INFO.;　Circ J, 86, 8, 1237-1244
  AUTHOR;　*Takahide Sano, Shingo Matsumoto, Takanori Ikeda, Shunsuke Kuroda, Takeshi Kitai, Taishi Yonetsu, Shun Kohsaka, Sho Torii, Koichi Node, Yuya Matsue
  
• Hospitalizations for Cardiovascular Diseases During the Early Stage of the COVID-19 Pandemic in Japan;　2022/07
  ANNOUNCEMENT INFO.;　Circ Rep, 4, 8, 353-362
  AUTHOR;　*Tadafumi Sugimoto, Atsushi Mizuno, Daisuke Yoneoka, Shingo Matsumoto, Chisa Matsumoto, Yuya Matsue, Mari Ishida, Michikazu Nakai, Yoshitaka Iwanaga, Yoshihiro Miyamoto, Koichi Node
  
• Prediabetes in Young Adults and Its Association with Cardiovascular Health Metrics in the Progression to Diabetes ;　2022/06
  ANNOUNCEMENT INFO.;　J Clin Endocrinol Metab, 107, 7, 1843-1853
  AUTHOR;　*Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Satoshi Matsuoka, Hidetaka Itoh, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Satoko Yamaguchi, Koichi Node, Toshimasa Yamauchi, Hideo Yasunaga, Issei Komuro
  
• Development of a Laboratory Risk-Score Model to Predict One-Year Mortality in Acute Myocardial Infarction Survivors ;　2022/06
  ANNOUNCEMENT INFO.;　J Clin Med, 11, 12, 3497
  AUTHOR;　Yuhei Goriki, Atsushi Tanaka, Goro Yoshioka, Kensaku Nishihira, Nehiro Kuriyama, Yoshisato Shibata, Koichi Node
  
• Healthcare resource utilization in patients treated with empagliflozin in East Asia ;　2022/05
  ANNOUNCEMENT INFO.;　J Diabetes Investig, 13, 5, 810-821
  AUTHOR;　*Wayne H-H Sheu, Yutaka Seino, Elise Chia-Hui Tan, Daisuke Yabe, Kyoung Hwa Ha, Masaomi Nangaku, Wook-Jin Chung, Koichi Node, Atsutaka Yasui, Wei-Yu Lei, Sunwoo Lee, Anastasia Ustyugova, Riho Klement, Anouk Deruaz-Luyet, Moe H Kyaw, Dae Jung Kim, EMPRISE East Asia study group
  
• Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus ;　2022/05
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol, 21, 1, 67
  AUTHOR;　*Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Kentaro Kamiya, Atsuhiko Matsunaga, Junya Ako, Koichi Node, Hideo Yasunaga, Issei Komuro
  
• Collective Knowledge Used to Unveil Cardiovascular Injury Emerged during COVID-19 ;　2022/05
  ANNOUNCEMENT INFO.;　Int J Mol Sci, 23, 9, 5178
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Revisited Metformin Therapy in Heart Failure With Preserved Ejection Fraction;　2022/05
  ANNOUNCEMENT INFO.;　JACC Heart Fail, 10, 5, 365-366
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Age-Dependent Relationship of Hypertension Subtypes With Incident Heart Failure;　2022/05
  ANNOUNCEMENT INFO.;　J Am Heart Assoc, 11, 9, e025406
  AUTHOR;　*Yuta Suzuki, Hidehiro Kaneko, Yuichiro Yano, Akira Okada, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Satoko Yamaguchi, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Koichi Node, Hyeon-Chang Kim, Anthony J Viera, Suzanne Oparil, Hideo Yasunaga, Issei Komuro
  
• Author Correction: A novel soluble epoxide hydrolase vaccine protects murine cardiac muscle against myocardial infarction ;　2022/05
  ANNOUNCEMENT INFO.;　Sci Rep, 12, 1, 7737
  AUTHOR;　*Takahiro Kitsuka, Aya Shiraki, Jun-Ichi Oyama, Hironori Nakagami, Atsushi Tanaka, Koichi Node
  
• Mediators of the effects of canagliflozin on N-terminal pro-brain natriuretic peptide concentration: An exploratory mediation analysis of the randomized CANDLE trial ;　2022/05
  ANNOUNCEMENT INFO.;　Diabetes Obes Metab, 24, 5, 962-965
  AUTHOR;　Atsushi Tanaka, Takumi Imai, Makoto Suzuki, Shinya Hiramitsu, Naohiko Takahashi, Toshiaki Kadokami, Arihiro Kiyosue, Masami Nishino, Yasushi Sakata, Koichi Node, CANDLE trial investigators
  
• Association of retinal atherosclerosis assessed using Keith-Wagener-Barker system with incident heart failure and other atherosclerotic cardiovascular disease: Analysis of 319,501 individuals from the general population;　2022/05
  ANNOUNCEMENT INFO.;　Atherosclerosis, 348, 68-74
  AUTHOR;　*Satoshi Matsuoka, Hidehiro Kaneko, Akira Okada, Hidetaka Itoh, Yuta Suzuki, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Sunao Nakamura, Koichi Node, Hideo Yasunaga, Issei Komuro
  
• Impact of body mass index on the outcome of Japanese patients with cardiovascular diseases and/or risk factors hospitalized with COVID-19 infection;　2022/04
  ANNOUNCEMENT INFO.;　J Cardiol, 79, 4, 476-481
  AUTHOR;　*Saito T, Yamaguchi T, Kuroda S, Kitai T, Yonetsu T, Kohsaka S, Torii S, Node K, Matsumoto S, Matsue Y, Kodama T
  
• Cardiac acoustic biomarkers as surrogate markers to diagnose the phenotypes of pulmonary hypertension: an exploratory study ;　2022/04
  ANNOUNCEMENT INFO.;　Heart Vessels, 37, 4, 593-600
  AUTHOR;　*Nobuhide Yamakawa, Norihiko Kotooka, Tomoyuki Kato, Tatsuhiko Kuroda, Koichi Node
  
• A novel soluble epoxide hydrolase vaccine protects murine cardiac muscle against myocardial infarction;　2022/04
  ANNOUNCEMENT INFO.;　Sci Rep, 12, 1, 6923
  AUTHOR;　*Takahiro Kitsuka, Aya Shiraki, Jun-Ichi Oyama, Hironori Nakagami, Atsushi Tanaka, Koichi Node
  
• The role of cell-autonomous circadian oscillation of Cry transcription in circadian rhythm generation ;　2022/04
  ANNOUNCEMENT INFO.;　Cell Rep, 39, 3, 110703
  AUTHOR;　*Ritsuko Matsumura, Kazuto Yoshimi, Yuka Sawai, Nanami Yasumune, Kohhei Kajihara, Tatsuya Maejima, Tsuyoshi Koide, Koichi Node, Makoto Akashi
  
• Association between proteinuria and incident colorectal cancer: analysis of a nationwide population-based database ;　2022/04
  ANNOUNCEMENT INFO.;　BMJ Open, 12, 4, e056250
  AUTHOR;　*Satoshi Matsuoka, Hidehiro Kaneko, Akira Okada, Akira Fukui, Yuichiro Yano, Hidetaka Itoh, Kojiro Morita, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Satoko Yamaguchi, Sunao Nakamura, Akira Nishiyama, Takashi Yokoo, Koichi Node, Toshimasa Yamauchi, Masaomi Nangaku, Hideo Yasunaga, Issei Komuro
  
• Impact of serum lactate dehydrogenase on the short-term prognosis of COVID-19 with pre-existing cardiovascular diseases ;　2022/04
  ANNOUNCEMENT INFO.;　J Cardiol, 79, 4, 501-508
  AUTHOR;　*Akiko Masumoto, Takeshi Kitai, Shingo Matsumoto, Shunsuke Kuroda, Shun Kohsaka, Ryo Tachikawa, Ryutaro Seo, Asako Doi, Keisuke Tomii, Taishi Yonetsu, Sho Torii, Issei Komuro, Ken-Ichi Hirata, Koichi Node, Yuya Matsue, Yutaka Furukawa
  
• Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study ;　2022/04
  ANNOUNCEMENT INFO.;　Front Cardiovasc Med, 9, 882821
  AUTHOR;　*Tatsuya Maruhashi, Yukihito Higashi, Hisako Yoshida, Atsushi Tanaka, Kazuo Eguchi, Hirofumi Tomiyama, Kazuomi Kario, Toru Kato, Nozomu Oda, Nobuhiro Tahara, Mitsutoshi Oguri, Hirotaka Watada, Koichi Node
  
• Differential effect of a xanthine oxidase inhibitor on arterial stiffness and carotid atherosclerosis: a subanalysis of the PRIZE study ;　2022/04
  ANNOUNCEMENT INFO.;　Hypertens Res, 45, 4, 602-611
  AUTHOR;　*Kazuki Shiina, Hirofumi Tomiyama, Atsushi Tanaka, Hisako Yoshida, Kazuo Eguchi, Kazuomi Kario, Toru Kato, Hiroki Teragawa, Shigeru Toyoda, Mitsuru Ohishi, Yoshihiro Fukumoto, Bonpei Takase, Tomoko Ishizu, Koichi Node, PRIZE Study Investigators
  
• Risk for Proteinuria in Newly Defined Hypertensive People Based on the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline;　2022/04
  ANNOUNCEMENT INFO.;　Am J Cardiol, 168, 83-89
  AUTHOR;　*Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Hidetaka Itoh, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Satoko Yamaguchi, Yuichiro Yano, Kentaro Kamiya, Atsuhiko Matsunaga, Junya Ako, Akira Fukui, Takashi Yokoo, Akira Nishiyama, Koichi Node, Toshimasa Yamauchi, Masaomi Nangaku, Hideo Yasunaga, Issei Komuro
  
• Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial ;　2022/04
  ANNOUNCEMENT INFO.;　RMD Open, 8, 1, e002226
  AUTHOR;　Atsushi Tanaka, Shigeru Toyoda, Toru Kato, Hisako Yoshida, Shuichi Hamasaki, Masato Watarai, Tomoko Ishizu, Shinichiro Ueda, Teruo Inoue, Koichi Node, PRIZE study investigators
  
• Women with type 2 diabetes and coronary artery disease have a higher risk of heart failure than men, with a significant gender interaction between heart failure risk and risk factor management: a retrospective registry study ;　2022/04
  ANNOUNCEMENT INFO.;　BMJ Open Diabetes Res Care, 10, 2, e002707
  AUTHOR;　*Yuko Fujita, Takeshi Morimoto, Akihiro Tokushige, Masayuki Ikeda, Michio Shimabukuro, Koichi Node, Shinichiro Ueda
  
• Atrial Structural Remodeling in Patients With Atrial Fibrillation Is a Diffuse Fibrotic Process: Evidence From High-Density Voltage Mapping and Atrial Biopsy ;　2022/03
  ANNOUNCEMENT INFO.;　J Am Heart Assoc, 11, 6, e024521
  AUTHOR;　○Takanori Yamaguchi, Toyokazu Otsubo, Yuya Takahashi, Kana Nakashima, Akira Fukui, Kei Hirota, Yumi Ishii, Kodai Shinzato, Ryosuke Osako, Mai Tahara, Yuki Kawano, Atsushi Kawaguchi, Shinichi Aishima, Naohiko Takahashi, Koichi Node
  
• Better vascular function tests in cardiovascular care: learning from evidence and providing improved diagnostics to the patient ;　2022/03
  ANNOUNCEMENT INFO.;　Hypertens Res, 45, 3, 538-540
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial;　2022/03
  ANNOUNCEMENT INFO.;　Diabetes Metab Syndr Obes, 15, 685-694
  AUTHOR;　*Hiroki Teragawa, Takeshi Morimoto, Yuichi Fujii, Tomohiro Ueda, Mio Sakuma, Michio Shimabukuro, Osamu Arasaki, Koichi Node, Takashi Nomiyama, Shinichiro Ueda
  
• Impact of Tweeting Summaries by the Japanese Circulation Society Official Account on Article Viewership - Pilot Trial;　2022/03
  ANNOUNCEMENT INFO.;　Circ J, 86, 4, 715-720
  AUTHOR;　*Atsushi Mizuno, Kenya Kusunose, Takuya Kishi, Jeffrey Rewley, Chisa Matsumoto, Yuki Sahashi, Mari Ishida, Shoji Sanada, Memori Fukuda, Tadafumi Sugimoto, Miki Hirano, Daisuke Yoneoka, Masataka Sata, Toshihisa Anzai, Koichi Node
  
• Clinical roles of vascular function assessment in cancer care ;　2022/02
  ANNOUNCEMENT INFO.;　Support Care Cancer, 30, 2, 985-987
  AUTHOR;　*Kosuke Sawami, Atsushi Tanaka, Koichi Node
  
• Serum Albumin and Bleeding Events After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction (from the HAGAKURE-ACS Registry) ;　2022/02
  ANNOUNCEMENT INFO.;　Am J Cardiol, 165, 19-26
  AUTHOR;　Goro Yoshioka, Masahiro Natsuaki, Yuhei Goriki, Kodai Shinzato, Kensaku Nishihira, Nehiro Kuriyama, Mitsuhiro Shimomura, Yohei Inoue, Toshiyuki Nishikido, Hiroshi Hongo, Tetsuya Kaneko, Kohei Kamishita, Kensuke Yokoi, Ayumu Yajima, Yoshiko Sakamoto, Motoko Tago, Atsushi Kawaguchi, Takanori Yamaguchi, Machiko Asaka, Norihiko Kotooka, Shinjo Sonoda, Yutaka Hikichi, Yoshisato Shibata, Koichi Node
  
• Simple risk-score model for in-hospital major bleeding based on multiple blood variables in patients with acute myocardial infarction ;　2022/01
  ANNOUNCEMENT INFO.;　Int J Cardiol, 346, 1-7
  AUTHOR;　Yuhei Goriki, Goro Yoshioka, Masahiro Natsuaki, Kodai Shinzato, Kensaku Nishihira, Nehiro Kuriyama, Mitsuhiro Shimomura, Yohei Inoue, Toshiyuki Nishikido, Tetsuya Kaneko, Kensuke Yokoi, Ayumu Yajima, Yoshiko Sakamoto, Motoko Tago, Atsushi Kawaguchi, Fumi Yamamoto, Atsushi Tanaka, Takanori Yamaguchi, Aya Shiraki, Machiko Asaka, Norihiko Kotooka, Shinjo Sonoda, Yutaka Hikichi, Yoshisato Shibata, Koichi Node
  
• Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study ;　2022/01
  ANNOUNCEMENT INFO.;　Hypertens Res, 45, 1, 106-115
  AUTHOR;　*Kenya Kusunose, Hisako Yoshida, Atsushi Tanaka, Hiroki Teragawa, Yuichi Akasaki, Yoshihiro Fukumoto, Kazuo Eguchi, Haruo Kamiya, Kazuomi Kario, Hirotsugu Yamada, Masataka Sata, Koichi Node, PRIZE Study Investigators(Machiko Asaka, Ayumu Yajima and others et al.)
  
• Statement of the Asian Hypertension Society Network: the Okinawa Declaration on the unity of hypertension societies in Asian countries and regions to overcome hypertension and hypertension-related diseases ;　2022/01
  ANNOUNCEMENT INFO.;　Hypertens Res, 45, 1, 1-2
  AUTHOR;　*Yusuke Ohya, Kazuomi Kario, Hiroshi Itoh, Akira Nishiyama, Toshihiko Ishimitsu, Atsuhiro Ichihara, Hisashi Kai, Naoki Kashihara, Tomohiro Katsuya, Katsuyuki Miura, Masashi Mukoyama, Satoko Nakamura, Koichi Node, Mitsuru Ohishi, Shigeyuki Saito, Hirotaka Shibata, Tatsuo Shimosawa, Kouichi Tamura, Kazunori Toyoda, Mohd Arifin Mohd Ali, Yook-Chin Chia, Godwin Constantine, Erwinanto Erwinanto, Sang Hyun Ihm, Hsien-Li Kao, Huynh Van Minh, S N Narasingan, Deborah Ignacia D Ona, Saulat Siddique, Apichard Sukonthasarn, Boon Wee Teo, Tsolmon Unurjargal, Ji-Guang Wang, Tzung-Dau Wang, Hiromi Raukgi
  
• Age Modified Relationship Between Modifiable Risk Factors and the Risk of Atrial Fibrillation ;　2022/01
  ANNOUNCEMENT INFO.;　Circ Arrhythm Electrophysiol, 15, 1, e010409
  AUTHOR;　*Satoshi Matsuoka, Hidehiro Kaneko, Akira Okada, Kojiro Morita, Hidetaka Itoh, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Katsuhito Fujiu, Sunao Nakamura, Koichi Node, Hideo Yasunaga, Issei Komuro
  
• Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy ;　2022/01
  ANNOUNCEMENT INFO.;　J Atheroscler Thromb, 29, 1, 24-37
  AUTHOR;　*Masato Furuhashi, Ichiro Sakuma, Takeshi Morimoto, Yukimura Higashiura, Akiko Sakai, Megumi Matsumoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Koichi Node, Shinichiro Ueda
  
• Impact of Glucose Tolerance and Its Change on Incident Proteinuria: Analysis of a Nationwide Population-Based Dataset;　2022
  ANNOUNCEMENT INFO.;　Am J Nephrol, 53, 4, 307-315
  AUTHOR;　*Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Hidetaka Itoh, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Satoko Yamaguchi, Kentaro Kamiya, Atsuhiko Matsunaga, Junya Ako, Koichi Node, Toshimasa Yamauchi, Masaomi Nangaku, Hideo Yasunaga, Issei Komuro
  
• Change in Cardiovascular Health Metrics and Risk for Proteinuria Development: Analysis of a Nationwide Population-Based Database ;　2022
  ANNOUNCEMENT INFO.;　Am J Nephrol, 53, 2-3, 240-248
  AUTHOR;　*Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Hidetaka Itoh, Kojiro Morita, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Satoko Yamaguchi, Kentaro Kamiya, Atsuhiko Matsunaga, Junya Ako, Akira Fukui, Akira Nishiyama, Takashi Yokoo, Koichi Node, Toshimasa Yamauchi, Masaomi Nangaku, Hideo Yasunaga, Issei Komuro
  
• Spatiotemporal dynamics of SETD5-containing NCoR-HDAC3 complex determines enhancer activation for adipogenesis ;　2021/12
  ANNOUNCEMENT INFO.;　Nat Commun, 12, 1, 7045
  AUTHOR;　*Yoshihiro Matsumura, Ryo Ito, Ayumu Yajima, Rei Yamaguchi, Toshiya Tanaka, Takeshi Kawamura, Kenta Magoori, Yohei Abe, Aoi Uchida, Takeshi Yoneshiro, Hiroyuki Hirakawa, Ji Zhang, Makoto Arai, Chaoran Yang, Ge Yang, Hiroki Takahashi, Hitomi Fujihashi, Ryo Nakaki, Shogo Yamamoto, Satoshi Ota, Shuichi Tsutsumi, Shin-Ichi Inoue, Hiroshi Kimura, Youichiro Wada, Tatsuhiko Kodama, Takeshi Inagaki, Timothy F Osborne, Hiroyuki Aburatani, Koichi Node, Juro Sakai
  
• Natriuretic Peptide-Based Risk Prediction and Assessment of Treatment Effect: Revisited in This Era ;　2021/12
  ANNOUNCEMENT INFO.;　JACC Heart Fail, 9, 12, 941-942
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Prognostic impact of follow-up serum albumin after acute myocardial infarction ;　2021/12
  ANNOUNCEMENT INFO.;　ESC Heart Fail, 8, 6, 5456-5465
  AUTHOR;　Goro Yoshioka, Atsushi Tanaka, Kensaku Nishihira, Masahiro Natsuaki, Atsushi Kawaguchi, Nozomi Watanabe, Yoshisato Shibata, Koichi Node
  
• Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline ;　2021/12
  ANNOUNCEMENT INFO.;　J Atheroscler Thromb
  AUTHOR;　*Matsuoka S, Kaneko H, Kamon T, Suzuki Y, Yano Y, Okada A, Itoh H, Morita K, Fukui A, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Nakamura S, Yokoo T, Nishiyama A, Node K, Yasunaga H, Komuro I
  
• JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure;　2021/12
  ANNOUNCEMENT INFO.;　J Card Fail, 27, 12, 1404-1444
  AUTHOR;　*Tsutsui H, Ide T, Ito H, Kihara Y, Kinugawa K, Kinugawa S, Makaya M, Murohara T, Node K, Saito Y, Sakata Y, Shimizu W, Yamamoto K, Bando Y, Iwasaki YK, Kinugasa Y, Mizote I, Nakagawa H, Oishi S, Okada A, Tanaka A, Akasaka T, Ono M, Kimura T, Kosaka S, Kosuge M, Momomura SI
  
• A novel prediction model of acute kidney injury based on combined blood variables in STEMI;　2021/12
  ANNOUNCEMENT INFO.;　JACC Asia, 1, 3, 372-381
  AUTHOR;　Goriki Y, Tanaka A, Nishihira K, Kuriyama N, Shibata Y, Node K
  
• Relation of the Metabolic Syndrome to Incident Colorectal Cancer in Young Adults Aged 20 to 49 Years ;　2021/11
  ANNOUNCEMENT INFO.;　Am J Cardiol, 158, 132-138
  AUTHOR;　*Takahiro Jimba, Hidehiro Kaneko, Yuichiro Yano, Hidetaka Itoh, Haruki Yotsumoto, Hikari Seki, Kojiro Morita, Hiroyuki Kiriyama, Tatsuya Kamon, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Akira Nishiyama, Koichi Node, Hideo Yasunaga, Issei Komuro
  
• New Vision, Mission, and Values of the Japanese Circulation Society ;　2021/11
  ANNOUNCEMENT INFO.;　Circ J, 85, 12, 2248-2251
  AUTHOR;　*Mari Ishida, Chisa Matsumoto, Keisuke Kida, Memori Fukuda, Nobuyuki Kagiyama, Kenya Kusunose, Shingo Matsumoto, Seitaro Nomura, Takahiro Okumura, Yasutsugu Shiono, Tatsunori Taniguchi, Atsushi Mizuno, Takuya Kishi, Koichi Node, Issei Komuro, Ken-Ichi Hirata, Directors of the Japanese Circulation Society
  
• JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure ;　2021/11
  ANNOUNCEMENT INFO.;　Circ J, 85, 12, 2252-2291
  AUTHOR;　*Hiroyuki Tsutsui, Tomomi Ide, Hiroshi Ito, Yasuki Kihara, Koichiro Kinugawa, Shintaro Kinugawa, Miyuki Makaya, Toyoaki Murohara, Koichi Node, Yoshihiko Saito, Yasushi Sakata, Wataru Shimizu, Kazuhiro Yamamoto, Yasuko Bando, Yu-Ki Iwasaki, Yoshiharu Kinugasa, Isamu Mizote, Hitoshi Nakagawa, Shogo Oishi, Akiko Okada, Atsushi Tanaka, Takashi Akasaka, Minoru Ono, Takeshi Kimura, Shun Kosaka, Masami Kosuge, Shin-Ichi Momomura, Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group
  
• Untreated Hypertension and Subsequent Incidence of Colorectal Cancer: Analysis of a Nationwide Epidemiological Database ;　2021/11
  ANNOUNCEMENT INFO.;　J Am Heart Assoc, 10, 22, e022479
  AUTHOR;　*Hidehiro Kaneko, Yuichiro Yano, Hidetaka Itoh, Kojiro Morita, Hiroyuki Kiriyama, Tatsuya Kamon, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Akira Nishiyama, Koichi Node, George Bakris, Katsuyuki Miura, Paul Muntner, Anthony J Viera, Suzanne Oparil, Donald M Lloyd-Jones, Hideo Yasunaga, Issei Komuro
  
• Lifestyle- and comorbidity-related factors for the prescription of proton pump inhibitors after Helicobacter pylori eradication in Japan;　2021/11
  ANNOUNCEMENT INFO.;　JGH Open, 5, 11, 1284-1288
  AUTHOR;　Shimada F, Endo H, Takamori A, Matsunaga T, Fujimoto S, Shirai S, Kakiuchi T, Akutagawa T, Sakata Y, Node K, Yamanouchi K, Nakamura S, Fujimoto K, Esaki M
  
• Association Between Blood Pressure Classification Using the 2017 ACC/AHA Blood Pressure Guideline and Retinal Atherosclerosis ;　2021/10
  ANNOUNCEMENT INFO.;　Am J Hypertens, 34, 10, 1049-1056
  AUTHOR;　*Satoshi Matsuoka, Hidehiro Kaneko, Yuichiro Yano, Hidetaka Itoh, Akira Fukui, Kojiro Morita, Hiroyuki Kiriyama, Tatsuya Kamon, Katsuhito Fujiu, Hikari Seki, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Sunao Nakamura, Takashi Yokoo, Akira Nishiyama, Koichi Node, Hideo Yasunaga, Issei Komuro
  
• WBC count predicts heart failure in diabetes and coronary artery disease patients: a retrospective cohort study ;　2021/10
  ANNOUNCEMENT INFO.;　ESC Heart Fail, 8, 5, 3748-3759
  AUTHOR;　*Atsuhiko Kawabe, Takanori Yasu, Takeshi Morimoto, Akihiro Tokushige, Shin-Ichi Momomura, Kenichi Sakakura, Koichi Node, Taku Inoue, Shinichiro Ueda, CHD Collaborative Investigators
  
• What Is Behind the HbA1c Value?;　2021/10
  ANNOUNCEMENT INFO.;　J Am Coll Cardiol, 78, 15, e117
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Multiple Cardiovascular Diseases or Risk Factors Increase the Severity of Coronavirus Disease 2019 ;　2021/10
  ANNOUNCEMENT INFO.;　Circ J, 85, 11, 2111-2115
  AUTHOR;　*Tomoyuki Yamada, Taku Ogawa, Kenta Minami, Yusuke Kusaka, Masaaki Hoshiga, Akira Ukimura, Takahide Sano, Takeshi Kitai, Taishi Yonetsu, Sho Torii, Shun Kohsaka, Shunsuke Kuroda, Koichi Node, Yuya Matsue, Shingo Matsumoto
  
• Advance care planning from the penultimate hospitalization in patients with end-stage heart failure: a single-center, 10-year experience ;　2021/09
  ANNOUNCEMENT INFO.;　Heart Vessels, 36, 9, 1290-1297
  AUTHOR;　Machiko Asaka, Norihiko Kotooka, Ayumu Yajima, Koichi Node
  
• Proximal Optimization Technique Facilitates Wire Entry Into Stumpless Chronic Total Occlusion of Side Branch ;　2021/09
  ANNOUNCEMENT INFO.;　JACC Cardiovasc Interv, 14, 17, e231-e233
  AUTHOR;　○Kensuke Yokoi, Shinjo Sonoda, Goro Yoshioka, Kota Jojima, Masahiro Natsuaki, Koichi Node
  
• Semiquantitative assessed proteinuria and risk of heart failure: Analysis of a nationwide epidemiological database ;　2021/09
  ANNOUNCEMENT INFO.;　Nephrol Dial Transplant
  AUTHOR;　*Akira Fukui, Hidehiro Kaneko, Akira Okada, Yuichiro Yano, Hidetaka Itoh, Satoshi Matsuoka, Kojiro Morita, Hiroyuki Kiriyama, Tatsuya Kamon, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Sunao Nakamura, Akira Nishiyama, Koichi Node, Takashi Yokoo, Masaomi Nangaku, Hideo Yasunaga, Issei Komuro
  
• Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents ;　2021/09
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol, 20, 1, 175
  AUTHOR;　Atsushi Tanaka, Shigeru Toyoda, Takumi Imai, Kazuki Shiina, Hirofumi Tomiyama, Yasushi Matsuzawa, Takahiro Okumura, Yumiko Kanzaki, Katsuya Onishi, Arihiro Kiyosue, Masami Nishino, Yasushi Sakata, Koichi Node, CANDLE trial investigators
  
• Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial ;　2021/09
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol, 20, 1, 186
  AUTHOR;　*Kusunose K, Imai T, Tanaka A, Dohi K, Shiina K, Yamada T, Kida K, Eguchi K, Teragawa H, Takeishi Y, Ohte N, Yamada H, Sata M, Node K; CANDLE Trial Investigators
  
• External validation of the 4C Mortality Score for patients with COVID-19 and pre-existing cardiovascular diseases/risk factors;　2021/09
  ANNOUNCEMENT INFO.;　BMJ Open, 11, 9, e052708
  AUTHOR;　*Kuroda S, Matsumoto S, Sano T, Kitai T, Yonetsu T, Kohsaka S, Torii S, Kishi T, Komuro I, Hirata KI, Node K, Matsue Y
  
• Relation of Serum Uric Acid and Cardiovascular Events in Adults Aged 20-49 Years ;　2021/08
  ANNOUNCEMENT INFO.;　Am J Cardiol, 152, 150-157
  AUTHOR;　*Hikari Seki, Hidehiro Kaneko, Hiroyuki Morita, Hidetaka Itoh, Kojiro Morita, Satoshi Matsuoka, Hiroyuki Kiriyama, Tatsuya Kamon, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Yuichiro Yano, Sunao Nakamura, Koichi Node, Hideo Yasunaga, Issei Komuro
  
• Association of Body Mass Index with Ischemic and Hemorrhagic Stroke ;　2021/07
  ANNOUNCEMENT INFO.;　Nutrients, 13, 7, 2343
  AUTHOR;　*Masahiro Shiozawa, Hidehiro Kaneko, Hidetaka Itoh, Kojiro Morita, Akira Okada, Satoshi Matsuoka, Hiroyuki Kiriyama, Tatsuya Kamon, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Sunao Nakamura, Koichi Node, Hideo Yasunaga, Issei Komuro
  
• Call for Fine Remote Monitoring of Prognostic Signs and Symptoms in Heart Failure ;　2021/07
  ANNOUNCEMENT INFO.;　JACC Heart Fail, 9, 7, 530
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin ;　2021/07
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol, 20, 1, 160
  AUTHOR;　Atsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, Yosuke Okada, Toshinari Takamura, Isao Taguchi, Shigeru Toyoda, Hirofumi Tomiyama, Shinichiro Ueda, Yukihito Higashi, Koichi Node, EMBLEM Investigators
  
• Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation ;　2021/06
  ANNOUNCEMENT INFO.;　Circulation, 143, 23, 2244-2253
  AUTHOR;　*Hidehiro Kaneko, Yuichiro Yano, Hidetaka Itoh, Kojiro Morita, Hiroyuki Kiriyama, Tatsuya Kamon, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Koichi Node, Robert M Carey, Joao A C Lima, Suzanne Oparil, Hideo Yasunaga, Issei Komuro
  
• Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial ;　2021/06
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol, 20, 1, 105
  AUTHOR;　Atsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, Yosuke Okada, Toshinari Takamura, Isao Taguchi, Shigeru Toyoda, Hirofumi Tomiyama, Shinichiro Ueda, Yukihito Higashi, Koichi Node, EMBLEM Investigators
  
• In-hospital therapy for worsening heart failure: black box or sweet spot? ;　2021/06
  ANNOUNCEMENT INFO.;　ESC Heart Fail, 8, 3, 2357-2358
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Relationship Between Official Twitter Ambassadors and the Number of Retweets in the Annual Congress - "Tweet the Meeting";　2021/06
  ANNOUNCEMENT INFO.;　Circ Rep, 3, 7, 414-418
  AUTHOR;　*Atsushi Mizuno, Jeffrey Rewley, Takuya Kishi, Chisa Matsumoto, Yuki Sahashi, Mari Ishida, Shoji Sanada, Memori Fukuda, Tadafumi Sugimoto, Miki Hirano, Koichi Node
  
• Intensive Care Unit Admission for Moderate-to-Severe COVID-19 Patients With Known Cardiovascular Diseases or Their Risk Factors - Insights From a Nationwide Japanese Cohort Study ;　2021/06
  ANNOUNCEMENT INFO.;　Circ Rep, 3, 7, 375-380
  AUTHOR;　*Naofumi Yoshida, Sachiyo Iwata, Masato Ogawa, Kazuhiro P Izawa, Shunsuke Kuroda, Shun Kohsaka, Taishi Yonetsu, Takeshi Kitai, Sho Torii, Takahide Sano, Yoshitada Sakai, Tomoya Yamashita, Ken-Ichi Hirata, Yuya Matsue, Shingo Matsumoto, Koichi Node
  
• Fasting Plasma Glucose and Incident Colorectal Cancer: Analysis of a Nationwide Epidemiological Database;　2021/06
  ANNOUNCEMENT INFO.;　J Clin Endocrinol Metab
  AUTHOR;　*Hidetaka Itoh, Hidehiro Kaneko, Akira Okada, Yuichiro Yano, Kojiro Morita, Hikari Seki, Hiroyuki Kiriyama, Tatsuya Kamon, Katsuhito Fujiu, Satoshi Matsuoka, Sunao Nakamura, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Akira Nishiyama, Koichi Node, Hideo Yasunaga, Issei Komuro
  
• Fluid volume regulation in patients with heart failure ;　2021/05
  ANNOUNCEMENT INFO.;　Lancet Diabetes Endocrinol, 9, 5, 256-257
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Clinical and Biomarker Profiles and Prognosis of Elderly Patients With Coronavirus Disease 2019 (COVID-19) With Cardiovascular Diseases and/or Risk Factors ;　2021/05
  ANNOUNCEMENT INFO.;　Circ J, 85, 6, 921-928
  AUTHOR;　*Shingo Matsumoto, Shunsuke Kuroda, Takahide Sano, Takeshi Kitai, Taishi Yonetsu, Shun Kohsaka, Sho Torii, Takuya Kishi, Issei Komuro, Ken-Ichi Hirata, Koichi Node, Yuya Matsue
  
• Outcomes of Drug-Eluting Stent Thrombosis After Treatment for Acute Versus Chronic Coronary Syndrome ;　2021/05
  ANNOUNCEMENT INFO.;　JACC Cardiovasc Interv, 14, 10, 1082-1090
  AUTHOR;　*Fumi Yamamoto, Masahiro Natsuaki, Shoichi Kuramitsu, Masanobu Ohya, Hiromasa Otake, Kazunori Horie, Futoshi Yamanaka, Hiroki Shiomi, Gaku Nakazawa, Kenji Ando, Kazushige Kadota, Shigeru Saito, Takeshi Kimura, Koichi Node, REAL-ST Registry Investigators
  
• Nationwide Survey of Japanese Cardiac Rehabilitation Training Facilities During the Coronavirus Disease 2019 Outbreak ;　2021/05
  ANNOUNCEMENT INFO.;　Circ Rep, 3, 6, 311-315
  AUTHOR;　*Keisuke Kida, Miho Nishitani-Yokoyama, Shogo Oishi, Yuji Kono, Kentaro Kamiya, Takuya Kishi, Koichi Node, Shigeru Makita, Yutaka Kimura, Japanese Association of Cardiac Rehabilitation (JACR) Public Relations Committee
  
• The lncRNA Caren antagonizes heart failure by inactivating DNA damage response and activating mitochondrial biogenesis ;　2021/05
  ANNOUNCEMENT INFO.;　Nat Commun, 12, 1, 2529
  AUTHOR;　*Michio Sato, Tsuyoshi Kadomatsu, Keishi Miyata, Junco S Warren, Zhe Tian, Shunshun Zhu, Haruki Horiguchi, Aman Makaju, Anna Bakhtina, Jun Morinaga, Taichi Sugizaki, Kaname Hirashima, Kumiko Yoshinobu, Mai Imasaka, Masatake Araki, Yoshihiro Komohara, Tomohiko Wakayama, Shinichi Nakagawa, Sarah Franklin, Koichi Node, Kimi Araki, Yuichi Oike
  
• Is It Time to Shift the Monotherapy After Percutaneous Coronary Intervention From Aspirin to P2Y 12 Inhibitors? - New Normal in the New-Generation Era ;　2021/05
  ANNOUNCEMENT INFO.;　Circ J, 85, 6, 794-796
  AUTHOR;　Masahiro Natsuaki, Koichi Node
  
• Low HbA(1c) Level and High Mortality: A Reversal of Cause and Effect?;　2021/05
  ANNOUNCEMENT INFO.;　JACC Cardiovasc Interv, 14, 10, 1158-1159
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Association Between Statin Use Prior to Admission and Lower Coronavirus Disease 2019 (COVID-19) Severity in Patients With Cardiovascular Disease or Risk Factors ;　2021/05
  ANNOUNCEMENT INFO.;　Circ J, 85, 6, 939-943
  AUTHOR;　*Yuji Ikari, Yuya Matsue, Sho Torii, Misaki Hasegawa, Kazuki Aihara, Shunsuke Kuroda, Takahide Sano, Takeshi Kitai, Taishi Yonetsu, Shun Kohsaka, Takuya Kishi, Issei Komuro, Ken-Ichi Hirata, Koichi Node, Shingo Matsumoto
  
• The Japanese Medical Science Federation COVID-19 Expert Opinion English Version ;　2021/04
  ANNOUNCEMENT INFO.;　JMA J, 4, 2, 148-162
  AUTHOR;　*Masaomi Nangaku, Takashi Kadowaki, Hiroshi Yotsuyanagi, Norio Ohmagari, Moritoki Egi, Junichi Sasaki, Tetsuya Sakamoto, Yoshinori Hasegawa, Takashi Ogura, Shigeru Chiba, Koichi Node, Ryo Suzuki, Yasuhiro Yamaguchi, Atsuko Murashima, Norihiko Ikeda, Eriko Morishita, Kenji Yuzawa, Hiroyuki Moriuchi, Satoshi Hayakawa, Daisuke Nishi, Atsushi Irisawa, Toshiaki Miyamoto, Hidetaka Suzuki, Hirohito Sone, Yuuji Fujino
  
• JCS 2018 Guideline on Diagnosis of Chronic Coronary Heart Diseases ;　2021/03
  ANNOUNCEMENT INFO.;　Circ J, 85, 4, 402-572
  AUTHOR;　*Masakazu Yamagishi, Nagara Tamaki, Takashi Akasaka, Takanori Ikeda, Kenji Ueshima, Shiro Uemura, Yutaka Otsuji, Yasuki Kihara, Kazuo Kimura, Takeshi Kimura, Yoshiki Kusama, Shinichiro Kumita, Hajime Sakuma, Masahiro Jinzaki, Hiroyuki Daida, Yasuchika Takeishi, Hiroshi Tada, Taishiro Chikamori, Kenichi Tsujita, Kunihiko Teraoka, Kenichi Nakajima, Tomoaki Nakata, Satoshi Nakatani, Akihiko Nogami, Koichi Node, Atsushi Nohara, Atsushi Hirayama, Nobusada Funabashi, Masaru Miura, Teruhito Mochizuki, Hiroyoshi Yokoi, Kunihiro Yoshioka, Masafumi Watanabe, Toshihiko Asanuma, Yuichi Ishikawa, Takahiro Ohara, Koichi Kaikita, Tokuo Kasai, Eri Kato, Hiroshi Kamiyama, Masaaki Kawashiri, Keisuke Kiso, Kakuya Kitagawa, Teruhito Kido, Toshio Kinoshita, Tomonari Kiriyama, Teruyoshi Kume, Akira Kurata, Satoshi Kurisu, Masami Kosuge, Eitaro Kodani, Akira Sato, Yasutsugu Shiono, Hiroki Shiomi, Junichi Taki, Masaaki Takeuchi, Atsushi Tanaka, Nobuhiro Tanaka, Ryoichi Tanaka, Takuya Nakahashi, Takehiro Nakahara, Akihiro Nomura, Akiyoshi Hashimoto, Kenshi Hayashi, Masahiro Higashi, Takafumi Hiro, Daisuke Fukamachi, Hitoshi Matsuo, Naoya Matsumoto, Katsumi Miyauchi, Masao Miyagawa, Yoshitake Yamada, Keiichiro Yoshinaga, Hideki Wada, Tetsu Watanabe, Yukio Ozaki, Shun Kohsaka, Wataru Shimizu, Satoshi Yasuda, Hideaki Yoshino, Japanese Circulation Society Working Group
  
• Cardiology Department Practices in the First Wave of the Coronavirus Disease Pandemic - A Nationwide Survey in Japan by the Japanese Circulation Society ;　2021/02
  ANNOUNCEMENT INFO.;　Circ Rep, 3, 3, 137-141
  AUTHOR;　*Atsushi Mizuno, Chisa Matsumoto, Daisuke Yoneoka, Takuya Kishi, Mari Ishida, Shoji Sanada, Memori Fukuda, Yoshihiko Saito, Keiko Yamauchi-Takihara, Hiroyuki Tsutsui, Keiichi Fukuda, Issei Komuro, Koichi Node
  
• Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors ;　2021/02
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol, 20, 1, 41
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Vascular functional tests and preemptive medicine ;　2021/01
  ANNOUNCEMENT INFO.;　Hypertens Res, 44, 1, 117-119
  AUTHOR;　Atsushi Tanaka, Shigeru Toyoda, Koichi Node
  
• Decline incidence in upper gastrointestinal bleeding in several recent years: data of the Japan claims database of 13 million accumulated patients;　2021/01
  ANNOUNCEMENT INFO.;　J Clin Biochem Nutr, 68, 1, 95-100
  AUTHOR;　Fujimoto S, Tsuruoka N, Esaki M, Takamori A, Sakata Y, Shimoda R, Akutagawa T, Node K, Anzai K, Sugisaki N, Iwakiri R, Takagi K, Yamanouchi K, Fujimoto K
  
• Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure ;　2021/01
  ANNOUNCEMENT INFO.;　N Engl J Med, 384, 2, 105-116
  AUTHOR;　*Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE; GALACTIC-HF Investigators( Node Koichi et al.)
  
• Letter by Tanaka and Node Regarding Article, "Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases: A Nationwide Study" ;　2021/01
  ANNOUNCEMENT INFO.;　Circ Cardiovasc Qual Outcomes, 14, 1, e007186
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Cardiology Department Policy in Japan After Coronavirus Disease-2019 (COVID-19) - Descriptive Summary of 2nd Nationwide Survey by the Japanese Circulation Society ;　2021/01
  ANNOUNCEMENT INFO.;　Circ Rep, 3, 2, 100-104
  AUTHOR;　*Atsushi Mizuno, Chisa Matsumoto, Takuya Kishi, Mari Ishida, Shoji Sanada, Memori Fukuda, Issei Komuro, Kenichi Hirata, Koichi Node
  
• Lifestyle- and Comorbidity-Related Risk Factors Associated with Prescription of Gastric Acid Secretion Inhibitors to Japanese Patients Who Were Helicobacter pylori Negative and Had No Upper Gastrointestinal Lesions ;　2021
  ANNOUNCEMENT INFO.;　Digestion, 102, 3, 437-445
  AUTHOR;　Takuya Matsunaga, Hiroyoshi Endo, Ayako Takamori, Furitsu Shimada, Hironobu Takedomi, Shimpei Shirai, Nanae Tsuruoka, Yasuhisa Sakata, Ryo Shimoda, Keizo Anzai, Koichi Node, Kohei Yamanouchi, Kazuma Fujimoto
  
• A detection method for latent circadian rhythm sleep-wake disorder;　2020/12
  ANNOUNCEMENT INFO.;　EBioMedicine , 62, 103080
  AUTHOR;　*Makoto Akashi, Reimi Sogawa, Ritsuko Matsumura, Atsuhiro Nishida, Rino Nakamura, Isao T Tokuda, Koichi Node
  
• Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes - A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society ;　2020/12
  ANNOUNCEMENT INFO.;　Circ J, 85, 1, 82-125
  AUTHOR;　*Eiichi Araki, Atsushi Tanaka, Nobuya Inagaki, Hiroshi Ito, Kohjiro Ueki, Toyoaki Murohara, Kenjiro Imai, Masataka Sata, Takehiro Sugiyama, Hideki Ishii, Shunsuke Yamane, Takashi Kadowaki, Issei Komuro, Koichi Node, Directors of the JCS and JDS
  
• When and for Whom Should We Use SGLT2 Inhibitors in HFrEF? ;　2020/12
  ANNOUNCEMENT INFO.;　JACC Heart Fail , 8, 12, 1056
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• How should we monitor the cardiovascular benefit of sodium-glucose cotransporter 2 inhibition?;　2020/12
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol, 19, 1, 206
  AUTHOR;　Tanaka A, Node K
  
• Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial;　2020/12
  ANNOUNCEMENT INFO.;　Diabetes Metab Syndr Obes, 13, 4993-5001
  AUTHOR;　＊Teragawa H, Morimoto T, Fujii Y, Ueda T, Sakuma M, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Ueda S
  
• The effect of switching from statin-monotherapy to statin/ezetimibe combination therapy on lipid profiles in patients with type 2 diabetes and dyslipidemia: a multicenter open-label study (EUCLID);　2020/12
  ANNOUNCEMENT INFO.;　Vasc Fail, 4, 1, 22-31
  AUTHOR;　Takeshita M, Tanaka A, Kawaguchi A, Sato K, Toyoda S, Inoue T, Node K
  
• Usefulness of the SAGE score to predict elevated values of brachial-ankle pulse wave velocity in Japanese subjects with hypertension ;　2020/11
  ANNOUNCEMENT INFO.;　Hypertens Res. , 43, 11, 1284-1292
  AUTHOR;　*Hirofumi Tomiyama, Charalambos Vlachopoulos, Panagiotis Xaplanteris, Hiroki Nakano, Kazuki Shiina, Tomoko Ishizu, Takahide Kohro, Yukihito Higashi, Bonpei Takase, Toru Suzuki, Tsutomu Yamazaki, Tomoo Furumoto, Kazuomi Kario, Teruo Inoue, Shinji Koba, Yasuhiko Takemoto, Takuzo Hano, Masataka Sata, Yutaka Ishibashi, Koichi Node, Atsushi Tanaka, Koji Maemura, Yusuke Ohya, Taiji Furukawa, Hiroshi Ito, Toshiaki Ohkuma, Toshiharu Ninomiya, Taishiro Chikamori, Akira Yamashina, Shin-Ichiro Ueda
  
• Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design ;　2020/11
  ANNOUNCEMENT INFO.;　Diabetes Ther . , 11, 11, 2739-2755
  AUTHOR;　*Shinya Fujiki, Kenichi Iijima, Masaaki Okabe, Shinichi Niwano, Kenichi Tsujita, Shigeto Naito, Kenji Ando, Kengo Kusano, Ritsushi Kato, Junichi Nitta, Tetsuji Miura, Takeshi Mitsuhashi, Kazuomi Kario, Yusuke Kondo, Masaki Ieda, Nobuhisa Hagiwara, Toyoaki Murohara, Kazuyoshi Takahashi, Hirofumi Tomita, Yasuchika Takeishi, Toshihisa Anzai, Wataru Shimizu, Masafumi Watanabe, Yoshihiro Morino, Takeshi Kato, Hiroshi Tada, Yoshihisa Nakagawa, Masafumi Yano, Koji Maemura, Takeshi Kimura, Hisako Yoshida, Keiko Ota, Takahiro Tanaka, Nobutaka Kitamura, Koichi Node, Yoshifusa Aizawa, Ippei Shimizu, Daisuke Izumi, Kazuyuki Ozaki, Tohru Minamino, EMPA-ICD investigators
  
• Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society;　2020/11
  ANNOUNCEMENT INFO.;　Diabetol Int, 12, 1, 1-51
  AUTHOR;　＊Araki E, Tanaka A, Inagaki N, Ito H, Ueki K, Murohara T, Imai K, Sata M, Sugiyama T, Ishii H, Yamane S, Kadowaki T, Komuro I, Node K; directors of the JCS, JDS
  
• Crosstalk between the liver and heart: revisited for prevention and treatment ;　2020/10
  ANNOUNCEMENT INFO.;　ESC Heart Fail . , 7, 6, 4489-4490
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Recommendations for Maintaining the Cardiovascular Care System Under the Conditions of the COVID-19 Pandemic - 1st Edition, April 2020 ;　2020/10
  ANNOUNCEMENT INFO.;　Circ J. , 84, 11, 2023-2026
  AUTHOR;　*Takuya Kishi, Atsushi Mizuno, Mari Ishida, Chisa Matsumoto, Memori Fukuda, Shoji Sanada, Naoya Itoh, Hideaki Oka, Koichi Node, Issei Komuro, Collaborators and Advisors of the COVID-19 Task Force Mission Team of the Japanese Circulation Society, and Directors of the Japanese Circulation Societies
  
• Reduction in hsCRP levels is associated with decreased incidence of cardiovascular events in Japanese hypertensive women but not in men ;　2020/10
  ANNOUNCEMENT INFO.;　Sci Rep . , 10, 1, 17040
  AUTHOR;　*Shokei Kim-Mitsuyama, Hirofumi Soejima, Osamu Yasuda, Koichi Node, Hideaki Jinnouchi, Eiichiro Yamamoto, Taiji Sekigami, Hisao Ogawa, Kunihiko Matsui
  
• Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care ;　2020/09
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol. , 19, 1, 132
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus;　2020/09
  ANNOUNCEMENT INFO.;　Front Endocrinol (Lausanne) , 11, 575557
  AUTHOR;　*Masato Furuhashi, Ichiro Sakuma, Takeshi Morimoto, Yukimura Higashiura, Akiko Sakai, Megumi Matsumoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Koichi Node, Shinichiro Ueda
  
• Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study;　2020/09
  ANNOUNCEMENT INFO.;　Endocrinol Diabetes Metab, 4, 1, e00183
  AUTHOR;　＊Seino Y, Kim DJ, Yabe D, Tan EC, Chung WJ, Ha KH, Nangaku M, Node K, Klement R, Yasui A, Lei WY, Lee S, Kyaw MH, Deruaz-Luyet A, Brodovicz KG, H-H Sheu W; EMPRISE East Asia study group
  
• Two-Year Experience in "Tweeting the Meeting" During the Scientific Sessions - Rapid Report From the Japanese Circulation Society;　2020/09
  ANNOUNCEMENT INFO.;　Circ Rep, 2, 11, 691-694
  AUTHOR;　＊Mizuno A, Kishi T, Matsumoto C, Ishida M, Sanada S, Fukuda M, Sahashi Y, Sugimoto T, Hirano M, Yoshikawa Y, Yamamoto E, Kimura T, Node K
  
• Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE) ;　2020/08
  ANNOUNCEMENT INFO.;　ESC Heart Fail, 7, 4, 1585-1594
  AUTHOR;　Atsushi Tanaka, Itaru Hisauchi, Isao Taguchi, Akira Sezai, Shigeru Toyoda, Hirofumi Tomiyama, Masataka Sata, Shinichiro Ueda, Jun-Ichi Oyama, Masafumi Kitakaze, Toyoaki Murohara, Koichi Node, CANDLE Trial Investigators
  
• Increased arterial stiffness and cardiovascular risk prediction in controlled hypertensive patients with coronary artery disease: post hoc analysis of FMD-J (Flow-mediated Dilation Japan) Study A ;　2020/08
  ANNOUNCEMENT INFO.;　Hypertens Res. , 43, 8, 781-790
  AUTHOR;　*Tatsuya Maruhashi, Junko Soga, Noritaka Fujimura, Naomi Idei, Shinsuke Mikami, Yumiko Iwamoto, Akimichi Iwamoto, Masato Kajikawa, Takeshi Matsumoto, Nozomu Oda, Shinji Kishimoto, Shogo Matsui, Haruki Hashimoto, Yuji Takaeko, Takayuki Yamaji, Takahiro Harada, Yiming Han, Yoshiki Aibara, Farina Mohamad Yusoff, Takayuki Hidaka, Yasuki Kihara, Kazuaki Chayama, Kensuke Noma, Ayumu Nakashima, Chikara Goto, Hirofumi Tomiyama, Bonpei Takase, Takahide Kohro, Toru Suzuki, Tomoko Ishizu, Shinichiro Ueda, Tsutomu Yamazaki, Tomoo Furumoto, Kazuomi Kario, Teruo Inoue, Shinji Koba, Kentaro Watanabe, Yasuhiko Takemoto, Takuzo Hano, Masataka Sata, Yutaka Ishibashi, Koichi Node, Koji Maemura, Yusuke Ohya, Taiji Furukawa, Hiroshi Ito, Hisao Ikeda, Akira Yamashina, Yukihito Higashi
  
• Suspected Borderline Aldosteronism in Hypertension: The Next Target? ;　2020/08
  ANNOUNCEMENT INFO.;　J Am Coll Cardiol. , 76, 6, 759-760
  AUTHOR;　Atsushi Tanaka, Hirotaka Shibata, Koichi Node
  
• Prognostic Impact of Serum Albumin for Developing Heart Failure Remotely after Acute Myocardial Infarction ;　2020/08
  ANNOUNCEMENT INFO.;　Nutrients. , 12, 9, E2637
  AUTHOR;　Goro Yoshioka, Atsushi Tanaka, Kensaku Nishihira, Yoshisato Shibata, Koichi Node
  
• Does cilnidipine, a dual L- and N-type Ca 2+ blocker, shows promise in drug repositioning approaches? ;　2020/07
  ANNOUNCEMENT INFO.;　Hypertens Res. , 43, 7, 726-728
  AUTHOR;　○Aya Shiraki, Kana Nakashima, Koichi Node
  
• NT-proBNP in Heart Failure With Preserved Ejection Fraction: Quest for a Marker Reflecting the Truth ;　2020/07
  ANNOUNCEMENT INFO.;　JACC Heart Fail. , 8, 7, 596-597
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Impact of Renal Dysfunction on Left Atrial Structural Remodeling and Recurrence After Catheter Ablation for Atrial Fibrillation - A Propensity Score Matching Analysis ;　2020/07
  ANNOUNCEMENT INFO.;　Circ J. , 84, 8, 1254-1260
  AUTHOR;　*Yuya Takahashi, Takanori Yamaguchi, Akira Fukui, Toyokazu Otsubo, Kei Hirota, Yuki Kawano, Kana Nakashima, Mai Tahara, Takayuki Kitai, Atsushi Kawaguchi, Naohiko Takahashi, Koichi Node
  
• Management of anticoagulant therapy using a portable point-of-care international normalized ratio device and social networking service in a patient with a left ventricular assist device ;　2020/07
  ANNOUNCEMENT INFO.;　J Cardiol Cases . , 22, 4, 156-158
  AUTHOR;　Machiko Asaka, Daisuke Nagatomo, Norihiko Kotooka, Tetsuya Kaneko, Ayumu Yajima, Toshifumi Morooka, Koichi Node
  
• Effect of rivaroxaban on urinary albumin excretion in patients with atrial fibrillation and chronic kidney disease: a randomized trial (X-NOAC) ;　2020/06
  ANNOUNCEMENT INFO.;　Hypertens Res. , 43, 6, 571-574
  AUTHOR;　Atsushi Tanaka, Makoto Suzuki, Kazuo Matsunaga, Isao Taguchi, Shiro Nakahara, Atsuko Chihara, Jun-Ichi Oyama, Koichi Node
  
• Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized trial ;　2020/06
  ANNOUNCEMENT INFO.;　J Diabetes Investig. , 11, 6, 1551-1563
  AUTHOR;　Atsushi Tanaka, Michio Shimabukuro, Noritaka Machii, Hiroki Teragawa, Yosuke Okada, Kosuke R Shima, Toshinari Takamura, Isao Taguchi, Itaru Hisauchi, Shigeru Toyoda, Yasushi Matsuzawa, Hirofumi Tomiyama, Minako Yamaoka-Tojo, Shinichiro Ueda, Yukihito Higashi, Koichi Node
  
• Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy ;　2020/06
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol. , 19, 1, 89
  AUTHOR;　*Masato Furuhashi, Ichiro Sakuma, Takeshi Morimoto, Yukimura Higashiura, Akiko Sakai, Megumi Matsumoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Koichi Node, Shinichiro Ueda
  
• Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial ;　2020/06
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol. , 19, 1, 85
  AUTHOR;　Atsushi Tanaka, Michio Shimabukuro, Yosuke Okada, Kazuhiro Sugimoto, Akira Kurozumi, Keiichi Torimoto, Hiroyuki Hirai, Koichi Node, PROCEED trial investigators
  
• Promising roles of sodium-glucose cotransporter 2 inhibitors in heart failure prevention and treatment;　2020/06
  ANNOUNCEMENT INFO.;　Diabetol Int. , 11, 3, 252-260
  AUTHOR;　Atsushi Tanaka, Koichi Node
  
• Ex vivo Culture Assay Using Human Hair Follicles to Study Circadian Characteristics;　2020/06
  ANNOUNCEMENT INFO.;　Bio Protoc, 10, 11, e3638
  AUTHOR;　＊Nishida A, Miyawaki Y, Node K, Akashi M
  
• Coronavirus Disease 2019 (COVID-19) Information for Cardiologists - Systematic Literature Review and Additional Analysis ;　2020/05
  ANNOUNCEMENT INFO.;　Circ J. , 84, 6, 1039-1043
  AUTHOR;　*Tadafumi Sugimoto, Atsushi Mizuno, Takuya Kishi, Naoya Ito, Chisa Matsumoto, Memori Fukuda, Nobuyuki Kagiyama, Tatsuhiro Shibata, Takashi Ohmori, Shogo Oishi, Jun Fuse, Keisuke Kida, Fujimi Kawai, Mari Ishida, Shoji Sanada, Issei Komuro, Koichi Node
  
• Bright light improves sleep in patients with Parkinson's disease: possible role of circadian restoration ;　2020/05
  ANNOUNCEMENT INFO.;　Sci Rep. , 10, 1, 7982
  AUTHOR;　*Takuyuki Endo, Ritsuko Matsumura, Isao T Tokuda, Tomoko Yoshikawa, Yasufumi Shigeyoshi, Koichi Node, Saburo Sakoda, Makoto Akashi
  
• Joint Declaration on COVID-19 by the Japan Stroke and Japanese Circulation Societies;　2020/05
  ANNOUNCEMENT INFO.;　Circ Rep, 2, 6, 343-344
  AUTHOR;　＊Kishi T, Hirano T, Mizuno A, Hashimoto Y, Matsumoto C, Fukuda M, Sanada S, Ishida M, Node K, Miyamoto S, Komuro I; Directors of the Japan Stroke and Japanese Circulation Societies
  
• Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial ;　2020/04
  ANNOUNCEMENT INFO.;　PLoS Med. , 17, 4, e1003095
  AUTHOR;　Atsushi Tanaka, Isao Taguchi, Hiroki Teragawa, Nobukazu Ishizaka, Yumiko Kanzaki, Hirofumi Tomiyama, Masataka Sata, Akira Sezai, Kazuo Eguchi, Toru Kato, Shigeru Toyoda, Ryoichi Ishibashi, Kazuomi Kario, Tomoko Ishizu, Shinichiro Ueda, Koji Maemura, Yukihito Higashi, Hirotsugu Yamada, Mitsuru Ohishi, Kotaro Yokote, Toyoaki Murohara, Jun-Ichi Oyama, Koichi Node, PRIZE study investigators
  
• A Novel Predictive Model for In-Hospital Mortality Based on a Combination of Multiple Blood Variables in Patients with ST-Segment-Elevation Myocardial Infarction ;　2020/03
  ANNOUNCEMENT INFO.;　J Clin Med. , 9, 3, 852
  AUTHOR;　Yuhei Goriki, Atsushi Tanaka, Kensaku Nishihira, Atsushi Kawaguchi, Masahiro Natsuaki, Nozomi Watanabe, Keiichi Ashikaga, Nehiro Kuriyama, Yoshisato Shibata, Koichi Node
  
• Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure ;　2020/02
  ANNOUNCEMENT INFO.;　J Cardiol. , 75, 2, 140-147
  AUTHOR;　*Shigeru Toyoda, Akiko Haruyama, Shu Inami, Takuo Arikawa, Fumiya Saito, Ryo Watanabe, Masashi Sakuma, Shichiro Abe, Toshiaki Nakajima, Atsushi Tanaka, Koichi Node, Teruo Inoue
  
• Current status of long-term prognosis among all subtypes of pulmonary hypertension in Japan ;　2020/02
  ANNOUNCEMENT INFO.;　Int J Cardiol. , 300, 228-235
  AUTHOR;　*Katsuya Kozu, Koichiro Sugimura, Masaaki Ito, Ken-Ichi Hirata, Koichi Node, Takuya Miyamoto, Shuichi Ueno, Hiroshi Watanabe, Hiroaki Shimokawa, Japanese Pulmonary Circulation Study Group
  
• Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial ;　2020/02
  ANNOUNCEMENT INFO.;　Sci Rep. , 10, 1, 3548
  AUTHOR;　*Takeshi Morimoto, Ichiro Sakuma, Mio Sakuma, Akihiro Tokushige, Masahiro Natsuaki, Tomohiro Asahi, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Koichi Node, Shinichiro Ueda
  
• Diagnostic Criteria of Flow-Mediated Vasodilation for Normal Endothelial Function and Nitroglycerin-Induced Vasodilation for Normal Vascular Smooth Muscle Function of the Brachial Artery ;　2020/01
  ANNOUNCEMENT INFO.;　J Am Heart Assoc. , 9, 2, e013915
  AUTHOR;　*Tatsuya Maruhashi, Masato Kajikawa, Shinji Kishimoto, Haruki Hashimoto, Yuji Takaeko, Takayuki Yamaji, Takahiro Harada, Yiming Han, Yoshiki Aibara, Farina Mohamad Yusoff, Takayuki Hidaka, Yasuki Kihara, Kazuaki Chayama, Ayumu Nakashima, Chikara Goto, Hirofumi Tomiyama, Bonpei Takase, Takahide Kohro, Toru Suzuki, Tomoko Ishizu, Shinichiro Ueda, Tsutomu Yamazaki, Tomoo Furumoto, Kazuomi Kario, Teruo Inoue, Shinji Koba, Kentaro Watanabe, Yasuhiko Takemoto, Takuzo Hano, Masataka Sata, Yutaka Ishibashi, Koichi Node, Koji Maemura, Yusuke Ohya, Taiji Furukawa, Hiroshi Ito, Hisao Ikeda, Akira Yamashina, Yukihito Higashi
  
• Risk Factors for Post-Endoscopic Retrograde Pancreatography Pancreatitis: A Retrospective Chart Review in a Regional Hospital in Japan ;　2020/01
  ANNOUNCEMENT INFO.;　Digestion , 101, 5, 557-562
  AUTHOR;　Takuya Shimamura, Koichi Miyahara, Ayako Takamori, Hidenori Hidaka, Yoichiro Ito, Shun Fujimoto, Hironobu Takedomi, Nanae Tsuruoka, Yasuhisa Sakata, Yuichiro Eguchi, Koichi Node, Takahiro Noda, Kazuma Fujimoto
  
• Systemic hemodynamic atherothrombotic syndrome (SHATS) - Coupling vascular disease and blood pressure variability: Proposed concept from pulse of Asia ;　2020
  ANNOUNCEMENT INFO.;　Prog Cardiovasc Dis. , 63, 1, 22-32
  AUTHOR;　*Kazuomi Kario, Julio A Chirinos, Raymond R Townsend, Michael A Weber, Angelo Scuteri, Alberto Avolio, Satoshi Hoshide, Tomoyuki Kabutoya, Hirofumi Tomiyama, Koichi Node, Mitsuru Ohishi, Sadayoshi Ito, Takuya Kishi, Hiromi Rakugi, Yan Li, Chen-Huan Chen, Jeong Bae Park, Ji-Guang Wang
  
• Brachial-Ankle Pulse Wave Velocity Versus Its Stiffness Index β-Transformed Value as Risk Marker for Cardiovascular Disease. ;　2019/12
  ANNOUNCEMENT INFO.;　J Am Heart Assoc. , 8, 24, e013004
  AUTHOR;　*Tomiyama H, Ohkuma T, Ninomiya T, Nakano H, Matsumoto C, Avolio A, Kohro T,　Higashi Y, Maruhashi T, Takase B, Suzuki T, Ishizu T, Ueda S, Yamazaki T,　Furumoto T, Kario K, Inoue T, Koba S, Takemoto Y, Hano T, Sata M, Ishibashi Y,　Node K, Maemura K, Ohya Y, Furukawa T, Ito H,　Chikamori T, Yamashina A
  
• Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial. ;　2019/12
  ANNOUNCEMENT INFO.;　J Clin Med. , 9, 1, E93
  AUTHOR;　*Hirai H, Higa M, Morimoto T, Sakuma M, Arasaki O, Nomiyama T, Node K, Ueda S, Shimabukuro M.
  
• Systemic hemodynamic atherothrombotic syndrome (SHATS) - Coupling vascular disease and blood pressure variability: Proposed concept from pulse of Asia. ;　2019/12
  ANNOUNCEMENT INFO.;　Prog Cardiovasc
  AUTHOR;　*Kario K, Chirinos JA, Townsend RR, Weber MA, Scuteri A, Avolio A, Hoshide S,　Kabutoya T, Tomiyama H, Node K, Ohishi M, Ito S, Kishi T, Rakugi H, Li Y, Chen CH, Park JB, Wang JG.
  
• GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy. ;　2019/11
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol. , 18, 1, 164
  AUTHOR;　Shiraki A, Oyama JI, Nishikido T, Node K.
  
• Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.;　2019/11
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol. , 18, 1, 158
  AUTHOR;　Chihara A, Tanaka A, Morimoto T, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Ueda S, Node K.
  
• Effect of Lubiprostone on Urinary Protein Excretion: A Report of Two IgA Nephropathy Patients with Chronic Constipation.;　2019/11
  ANNOUNCEMENT INFO.;　Intern Med. , 58, 22, 3255-3259
  AUTHOR;　Takeshita M, Tanaka A, Nakamura T, Sato E, Node K.
  
• Total adiponectin is associated with incident cardiovascular and renal events in treated hypertensive patients: subanalysis of the ATTEMPT-CVD randomized trial.;　2019/11
  ANNOUNCEMENT INFO.;　Sci Rep. , 9, 1, 16589
  AUTHOR;　*Kim-Mitsuyama S, Soejima H, Yasuda O, Node K, Jinnouchi H, Yamamoto E,　Sekigami T, Ogawa H, Matsui K.
  
• Full-metal jacket technique using second-generation drug-eluting stent: clinical and angiographic follow-up in 2 years. ;　2019/10
  ANNOUNCEMENT INFO.;　Cardiovasc Interv Ther. , 34, 4, 305-311
  AUTHOR;　Yoshioka G, Kuriyama N, Watanabe N, Ashikaga K, Shibata Y, Node K.
  
• Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial. ;　2019/10
  ANNOUNCEMENT INFO.;　Diabetes Care. , 42, 10, e159-e161
  AUTHOR;　Tanaka A, Shimabukuro M, Machii N, Teragawa H, Okada Y, Shima KR, Takamura T, Taguchi I, Hisauchi I, Toyoda S, Matsuzawa Y, Tomiyama H, Yamaoka-Tojo M, Yoshida　H, Sato Y, Ikehara Y, Ueda S, Higashi Y, Node K; EMBLEM Investigators.
  
• JSH Statement: Asahikawa declaration in promotion of diversity by the Japanese society of hypertension-the JSH Asahikawa declaration. ;　2019/10
  ANNOUNCEMENT INFO.;　Hypertens Res. , 42, 10, 1483-1484
  AUTHOR;　*Nakamura S, Hasebe N, Yatabe M, Kishi T, Ishida M, Ichihara A, Node K,　Ishimitsu T, Itoh H, Ito M, Ohishi M, Ohkubo T, Kai H, Kashihara N, Kario K, Saitoh S, Tsuchihashi T, Nishiyama A, Higaki J, Miura K, Rakugi H, Kawano Y,　Tamura K, Yatabe T, Ohya Y, Ito S.
  
• JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure　- Digest Version. ;　2019/09
  ANNOUNCEMENT INFO.;　Circ J. , 83, 10, 2084-2184
  AUTHOR;　*Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, Kitakaze M, Kinugawa K,　Kihara Y, Goto Y, Komuro I, Saiki Y, Saito Y, Sakata Y, Sato N, Sawa Y, Shiose A,　Shimizu W, Shimokawa H, Seino Y, Node K, Higo T, Hirayama A, Makaya M, Masuyama　T, Murohara T, Momomura SI, Yano M, Yamazaki K, Yamamoto K, Yoshikawa T,　Yoshimura M, Akiyama M, Anzai T, Ishihara S, Inomata T, Imamura T, Iwasaki YK,　Ohtani T, Onishi K, Kasai T, Kato M, Kawai M, Kinugasa Y, Kinugawa S, Kuratani T,　Kobayashi S, Sakata Y, Tanaka A, Toda K, Noda T, Nochioka K, Hatano M, Hidaka T, Fujino T, Makita S, Yamaguchi O, Ikeda U, Kimura T, Kohsaka S, Kosuge M,　Yamagishi M, Yamashina A; Japanese Circulation Society and the Japanese Heart　Failure Society Joint Working Group.
  
• The effect of continuous positive airway pressure (CPAP) treatment on serum levels of proBDNF and mature BDNF in patients with obstructive sleep apnea. ;　2019/09
  ANNOUNCEMENT INFO.;　Sleep Breath. , 23, 3, 889-892
  AUTHOR;　○Mizoguchi Y, Oyama JI, Imamura Y, Node K, Monji A.
  
• Influence of preoperative serum creatinine level and intraoperative volume of contrast medium on the risk of acute kidney injury after transfemoral transcatheter aortic valve implantation: a retrospective observational study.;　2019/08
  ANNOUNCEMENT INFO.;　BMC Res Notes. , 12, 1, 484
  AUTHOR;　○Miura D, Yamada Y, Kusaba S, Nogami E, Yunoki J, Sakamoto Y, Hikichi Y, Node K, Sakaguchi Y.
  
• 2-Cl-C.OXT-A stimulates contraction through the suppression of phosphodiesterase activity in human induced pluripotent stem cell-derived cardiac organoids. ;　2019/07
  ANNOUNCEMENT INFO.;　PLoS One. , 14, 7, e0213114
  AUTHOR;　○Kitsuka T, Itoh M, Amamoto S, Arai KI, Oyama J, Node K, Toda S, Morita S, Nishida T, Nakayama K.
  
• In vivo evaluation of the effect of lithium on peripheral circadian clocks by real-time monitoring of clock gene expression in near-freely moving mice.;　2019/07
  ANNOUNCEMENT INFO.;　Sci Rep. , 9, 1, 10909
  AUTHOR;　*Sawai Y, Okamoto T, Muranaka Y, Nakamura R, Matsumura R, Node K, Akashi M.
  
• JSH Statement: Kyoto declaration on hypertension research in Asia. ;　2019/06
  ANNOUNCEMENT INFO.;　Hypertens Res. , 42, 6, 759-760
  AUTHOR;　*Ito M, Ishimitsu T, Ichihara A, Itoh H, Ohishi M, Ohkubo T, Kai H, Kashihara N, Kario K, Saitoh S, Tsuchihashi T, Nakamura S, Nishiyama A, Node K, Hasebe N,　Higaki J, Miura K, Rakugi H, Tamura K, Kawano Y, Yatabe T, Ohya Y, Ito S.
  
• Anemia is an independent risk factor for cardiovascular and renal events in hypertensive outpatients with well-controlled blood pressure: a subgroup analysis of the ATTEMPT-CVD randomized trial.;　2019/06
  ANNOUNCEMENT INFO.;　Hypertens Res. , 42, 6, 883-891
  AUTHOR;　*Kim-Mitsuyama S, Soejima H, Yasuda O, Node K, Jinnouchi H, Yamamoto E, Sekigami T, Ogawa H, Matsui K.
  
• Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial.;　2019/06
  ANNOUNCEMENT INFO.;　Sci Rep. , 9, 1, 8537
  AUTHOR;　*Morimoto T, Sakuma I, Sakuma M, Tokushige A, Natsuaki M, Asahi T, Shimabukuro　M, Nomiyama T, Arasaki O, Node K, Ueda S.
  
• Microvascular and macrovascular endothelial function in two different types of primary aldosteronism. ;　2019/05
  ANNOUNCEMENT INFO.;　Hypertens Res. , 42, 5, 739-740
  AUTHOR;　*Kato T, Node K.
  
• Rheumatoid Arthritis and Vascular Failure - Rheumatoid Arthritis Is a Risk Factor for Cardiovascular Disease. ;　2019/05
  ANNOUNCEMENT INFO.;　Intern Med. , 58, 10, 1373-1374
  AUTHOR;　○Oyama JI, Node K.
  
• Development of an immunodeficient pig model allowing long-term accommodation of artificial human vascular tubes. ;　2019/05
  ANNOUNCEMENT INFO.;　Nat Commun. , 10, 1, 2244
  AUTHOR;　○Itoh M, Mukae Y, Kitsuka T, Arai K, Nakamura A, Uchihashi K, Toda S,　Matsubayashi K, Oyama JI, Node K, Kami D, Gojo S, Morita S, Nishida T, Nakayama　K, Kobayashi E.
  
• Target of Triglycerides as Residual Risk for Cardiovascular Events in Patients With Coronary Artery Disease　- Post Hoc Analysis of the FMD-J Study A. ;　2019/04
  ANNOUNCEMENT INFO.;　Circ J. , 83, 5, 1064-1071
  AUTHOR;　*Kajikawa M, Maruhashi T, Kishimoto S, Matsui S, Hashimoto H, Takaeko Y,　Yusoff FM, Kihara Y, Chayama K, Goto C, Noma K, Nakashima A, Tomiyama H, Takase　B, Kohro T, Suzuki T, Ishizu T, Ueda S, Yamazaki T, Furumoto T, Kario K, Inoue T,　Koba S, Watanabe K, Takemoto Y, Hano T, Sata M, Ishibashi Y, Node K, Maemura K,　Ohya Y, Furukawa T, Ito H, Ikeda H, Yamashina A, Higashi Y.
  
• Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials.;　2019/02
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol. , 18, 1, 19
  AUTHOR;　Tanaka A, Node K.
  
• Differential effect of concomitant antidiabetic agents on carotid atherosclerosis: a subgroup analysis of the PROLOGUE study. ;　2019/02
  ANNOUNCEMENT INFO.;　Heart Vessels. , 34, 2, 375-384
  AUTHOR;　Tanaka A, Kawaguchi A, Oyama JI, Ishizu T, Ito H, Fukui J, Kondo T, Kuroki S, Nanasato M, Higashi Y, Kaku K, Inoue T, Murohara T, Node K.
  
• A reduction of BMI predicts the risk of rehospitalization and cardiac death in non-obese patients with heart failure.;　2019/02
  ANNOUNCEMENT INFO.;　Int J Cardiol. , 276, 166-170
  AUTHOR;　Nishikido T, Oyama JI, Nagatomo D, Node K.
  
• Bipolar Voltage Mapping for the Evaluation of Atrial Substrate: Can We Overcome the Challenge of Directionality? ;　2019/02
  ANNOUNCEMENT INFO.;　J Atr Fibrillation. , 11, 5, 2116
  AUTHOR;　Yamaguchi T, Fukui A, Node K.
  
• COA-Cl (2-Cl-C.OXT-A) can promote coronary collateral development following acute myocardial infarction in mice. ;　2019/02
  ANNOUNCEMENT INFO.;　Sci Rep. , 9, 1, 2533
  AUTHOR;　Nishikido T, Oyama JI, Shiraki A, Tsukamoto I, Igarashi J, Node K.
  
• Loss of Endogenous HMGB2 Promotes Cardiac Dysfunction and Pressure Overload-Induced Heart Failure in Mice.;　2019/01
  ANNOUNCEMENT INFO.;　Circ J. , 83, 2, 368-378
  AUTHOR;　*Sato M, Miyata K, Tian Z, Kadomatsu T, Ujihara Y, Morinaga J, Horiguchi H,　Endo M, Zhao J, Zhu S, Sugizaki T, Igata K, Muramatsu M, Minami T, Ito T, Bianchi　ME, Mohri S, Araki K, Node K, Oike Y.
  
• Gut microbiota and hypertension. ;　2019/01
  ANNOUNCEMENT INFO.;　Hypertens Res. , 42, 5, 741-743
  AUTHOR;　○Oyama JI, Node K.
  
• Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. ;　2019/01
  ANNOUNCEMENT INFO.;　N Engl J Med. , 380, 4, 347-357
  AUTHOR;　*Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG,　Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH,　Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE?TIMI 58 Investigators., Collaborators (Node K etc.)
  
• Inflammation in pulmonary artery hypertension. ;　2019
  ANNOUNCEMENT INFO.;　Vascul Pharmacol. , 118-119, 106562
  AUTHOR;　*Sakuma M, Toyoda S, Inoue T, Node K.
  
• Brachial artery diameter as a marker for cardiovascular risk assessment: FMD-J study. ;　2018
  ANNOUNCEMENT INFO.;　Atherosclerosis. , 268, 92-98
  AUTHOR;　*Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Iwamoto A, Kajikawa M, Matsumoto T, Oda N, Kishimoto S, Matsui S, Hashimoto H, Aibara Y, Yusoff FM, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Tomiyama H, Takase B, Kohro T, Suzuki T, Ishizu T, Ueda S, Yamazaki T, Furumoto T, Kario K, Inoue T, Koba S, Watanabe K, Takemoto Y, Hano T, Sata M, Ishibashi Y, Node K, Maemura K, Ohya Y, Furukawa T, Ito H, Ikeda H, Yamashina A, Higashi Y.
  
• The non-biphenyl-tetrazole angiotensin AT1 receptor antagonist eprosartan is a unique and robust inverse agonist of the active state of the AT1 receptor.;　2018
  ANNOUNCEMENT INFO.;　Br J Pharmacol. , 175, 12, 2454-2469
  AUTHOR;　*Takezako T, Unal H, Karnik SS, Node K.
  
• Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure. ;　2018
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol. , 17, 1, 74
  AUTHOR;　Tanaka A, Node K.
  
• Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.;　2018
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol. , 17, 1, 85
  AUTHOR;　Tanaka A, Node K.
  
• Effect of anagliptin and sitagliptin on low-density lipoprotein cholesterol in type 2 diabetic patients with dyslipidemia and cardiovascular risk: rationale and study design of the REASON trial. ;　2018
  ANNOUNCEMENT INFO.;　Cardiovasc Drugs Ther. , 32, 1, 73-80
  AUTHOR;　*Ueda S, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Morimoto T.
  
• Role of tissue factor in vascular failure.;　2018
  ANNOUNCEMENT INFO.;　Circ J. , 82, 5, 1255-1257
  AUTHOR;　*Inoue T, Sakuma M, Toyoda S, Node K.
  
• N-Terminal Pro-B-Type natriuretic peptide is not a significant predictor of stroke incidence after 5 years　- The Ohasama Study. ;　2018
  ANNOUNCEMENT INFO.;　Circ J. , 82, 8, 2055-2062
  AUTHOR;　*Satoh M, Murakami T, Asayama K, Hirose T, Kikuya M, Inoue R, Tsubota-Utsugi M, Murakami K, Matsuda A, Hara A, Obara T, Kawasaki R, Nomura K, Metoki H, Node K, Imai Y, Ohkubo T.
  
• Intensive treat-to-target statin therapy in high-risk Japanese patients with hypercholesterolemia and diabetic retinopathy: report of a randomized study. ;　2018
  ANNOUNCEMENT INFO.;　Diabetes Care. , 41, 6, 1275-1284
  AUTHOR;　*Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M, Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S, Saito Y, Seino Y, Shigeeda T, Shindo S, Sugawara M, Sugiyama S, Terauchi Y, Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R; EMPATHY Investigators.
  
• Potential role of the pancreatic hormone insulin in resetting human peripheral clocks.;　2018
  ANNOUNCEMENT INFO.;　Genes Cells. , 23, 5, 393-399
  AUTHOR;　*Kajimoto J, Matsumura R, Node K, Akashi M.
  
• Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus.;　2018
  ANNOUNCEMENT INFO.;　Geriatr Gerontol Int. , 18, 4, 631-639
  AUTHOR;　Tago M, Oyama JI, Sakamoto Y, Shiraki A, Uchida F, Chihara A, Ikeda H, Kuroki S, Gondo S, Iwamoto T, Uchida Y, Node K.
  
• The first multicenter, randomized, controlled trial of home telemonitoring for Japanese patients with heart failure: home telemonitoring study for patients with heart failure (HOMES-HF);　2018
  ANNOUNCEMENT INFO.;　Heart Vessels. , 33, 8, 866-876
  AUTHOR;　〇Kotooka N, Kitakaze M, Nagashima K, Asaka M, Kinugasa Y, Nochioka K, Mizuno A, Nagatomo D, Mine D, Yamada Y, Kuratomi A, Okada N, Fujimatsu D, Kuwahata S, Toyoda S, Hirotani SI, Komori T, Eguchi K, Kario K, Inomata T, Sugi K, Yamamoto K, Tsutsui H, Masuyama T, Shimokawa H, Momomura SI, Seino Y, Sato Y, Inoue T, Node K; HOMES-HF study investigators.
  
• Comparison of the effects of linagliptin and voglibose on endothelial function in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, pilot study (EFFORT).;　2018
  ANNOUNCEMENT INFO.;　Heart Vessels. , 33, 8, 958-964
  AUTHOR;　*Koyama T, Tanaka A, Yoshida H, Oyama JI, Toyoda S, Sakuma M, Inoue T, Otsuka Y, Node K.
  
• Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial.;　2018
  ANNOUNCEMENT INFO.;　Heart Vessels. , 33, 9, 965-977
  AUTHOR;　Tanaka A, Komukai S, Shibata Y, Yokoi H, Iwasaki Y, Kawasaki T, Horiuchi K, Nakao K, Ueno T, Nakashima H, Tamashiro M, Hikichi Y, Shimomura M, Tago M, Toyoda S, Inoue T, Kawaguchi A, Node K; Pioglitazone Reduce Inflammation and Restenosis with and without Drug Eluting Stent (PRIDE) Study Investigators.
  
• Effects of uric acid on vascular endothelial function from bedside to bench.;　2018
  ANNOUNCEMENT INFO.;　Hypertens Res. , 41, 11, 923-931
  AUTHOR;　*Otani N, Toyoda S, Sakuma M, Hayashi K, Ouchi M, Fujita T, Anzai N, Tanaka A, Node K, Uemura N, Inoue T.
  
• The Japanese Society of Hypertension-Digest of plan for the future.;　2018
  ANNOUNCEMENT INFO.;　Hypertens Res. , 41, 12, 989-990
  AUTHOR;　Node K, Kishi T, Tanaka A, Itoh H, Rakugi H, Ohya Y, Miura K, Okamura T, Ishimitsu T, Ichihara A, Ito M, Ohishi M, Ohkubo T, Kai H, Kashihara N, Kario K, Saitoh S, Tsuchihashi T, Nakamura S, Nishiyama A, Hasebe N, Higaki J, Tamura K, Kawano Y, Yatabe T, Ito S; JSH Future Plan Working Group and Executive Board Members.
  
• Pleiotropic effects of calcium channel blockers.;　2018
  ANNOUNCEMENT INFO.;　Hypertens Res. , 41, 4, 230-233
  AUTHOR;　*Toyoda S, Sakuma M, Node K, Inoue T.
  
• Is GRK2 a new target for cardiovascular disease?;　2018
  ANNOUNCEMENT INFO.;　Hypertens Res. , 41, 8, 575-577
  AUTHOR;　○Oyama JI, Node K.
  
• Physiological diagnostic criteria for vascular failure.;　2018
  ANNOUNCEMENT INFO.;　Hypertension. , 72, 5, 1060-1071
  AUTHOR;　Tanaka A, Tomiyama H, Maruhashi T, Matsuzawa Y, Miyoshi T, Kabutoya T, Kario K, Sugiyama S, Munakata M, Ito H, Ueda S, Vlachopoulos C, Higashi Y, Inoue T, Node K; Physiological Diagnosis Criteria for Vascular Failure Committee.
  
• Mobilization of progenitor cells and assessment of vessel healing after second generation drug-eluting stenting by optical coherence tomography.;　2018
  ANNOUNCEMENT INFO.;　Int J Cardiol Heart Vasc. , 18, 17-24
  AUTHOR;　*Sakuma M, Nasuno T, Abe S, Obi S, Toyoda S, Taguchi I, Sohma R, Inoue KI, Nishino S, Node K, Attizzani G, Bezerra H, Costa M, Simon D, Inoue T.
  
• Longitudinal association among endothelial function, arterial stiffness and subclinical organ damage in hypertension.;　2018
  ANNOUNCEMENT INFO.;　Int J Cardiol. , 253, 161-166
  AUTHOR;　*Tomiyama H, Ishizu T, Kohro T, Matsumoto C, Higashi Y, Takase B, Suzuki T, Ueda S, Yamazaki T, Furumoto T, Kario K, Inoue T, Koba S, Takemoto Y, Hano T, Sata M, Ishibashi Y, Node K, Maemura K, Ohya Y, Furukawa T, Ito H, Yamashina A.
  
• Sitagliptin on carotid intima-media thickness in type 2 diabetes patients receiving primary or secondary prevention of cardiovascular disease: A subgroup analysis of the PROLOGUE study.;　2018
  ANNOUNCEMENT INFO.;　Int J Cardiol. , 271, 331-335
  AUTHOR;　Tanaka A, Yoshida H, Nanasato M, Oyama JI, Ishizu T, Ajioka M, Ishiki R, Saito M, Shibata Y, Kaku K, Maemura K, Higashi Y, Inoue T, Murohara T, Node K.
  
• Cross-sectional and longitudinal associations between serum uric acid and endothelial function in subjects with treated hypertension. ;　2018
  ANNOUNCEMENT INFO.;　Int J Cardiol. , 272, 308-313
  AUTHOR;　Tanaka A, Kawaguchi A, Tomiyama H, Ishizu T, Matsumoto C, Higashi Y, Takase B, Suzuki T, Ueda S, Yamazaki T, Furumoto T, Kario K, Inoue T, Koba S, Takemoto Y, Hano T, Sata M, Ishibashi Y, Maemura K, Ohya Y, Furukawa T, Ito H, Yamashina A, Node K.
  
• Endothelial dysfunction, increased arterial stiffness, and cardiovascular risk prediction in patients with coronary artery disease: FMD-J (Flow-Mediated Dilation Japan) study A.;　2018
  ANNOUNCEMENT INFO.;　J Am Heart Assoc. , 7, 14, e008588
  AUTHOR;　*Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Iwamoto A, Kajikawa M, Matsumoto T, Oda N, Kishimoto S, Matsui S, Hashimoto H, Aibara Y, Mohamad Yusoff F, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Tomiyama H, Takase B, Kohro T, Suzuki T, Ishizu T, Ueda S, Yamazaki T, Furumoto T, Kario K, Inoue T, Koba S, Watanabe K, Takemoto Y, Hano T, Sata M, Ishibashi Y, Node K, Maemura K, Ohya Y, Furukawa T, Ito H, Ikeda H, Yamashina A, Higashi Y.
  
• Prediction of stroke after cardiac catheterization: no reason, no stroke.;　2018
  ANNOUNCEMENT INFO.;　J Atheroscler Thromb. , 25, 3, 221-223
  AUTHOR;　Tanaka A, Node K.
  
• Azelnidipine Inhibits the Differentiation and Activation of THP-1 Macrophages through the L-Type Calcium Channel.;　2018
  ANNOUNCEMENT INFO.;　J Atheroscler Thromb. , 25, 8, 690-697
  AUTHOR;　*Komoda H, Shiraki A, Oyama JI, Nishikido T, Node K.
  
• Incidence of aspiration pneumonia during hospitalization in Japanese hospitalized cases did not increase whereas concern factors were exacerbated in a time-dependent manner: analysis of Diagnosis Procedure Combination (DPC) data.;　2018
  ANNOUNCEMENT INFO.;　J Clin Biochem Nutr. , 63, 1, 66-69
  AUTHOR;　Nonaka S, Fujii S, Hara M, Morita S, Sueoka E, Node K, Fujimoto K.
  
• Obesity Is a Culprit in Heart Failure: Do NOT Miss HFpEF, Especially in Obese Women.;　2018
  ANNOUNCEMENT INFO.;　JACC Heart Fail. , 6, 11, 971-972
  AUTHOR;　Tanaka A, Node K.
  
• Cardiovascular and renal protective role of angiotensin blockade in hypertension with advanced CKD: a subgroup analysis of ATTEMPT-CVD randomized trial. ;　2018
  ANNOUNCEMENT INFO.;　Sci Rep. , 8, 1, 3150
  AUTHOR;　*Kim-Mitsuyama S, Soejima H, Yasuda O, Node K, Jinnouchi H, Yamamoto E, Sekigami T, Ogawa H, Matsui K.
  
• The addition of human iPS cell-derived neural progenitors changes the contraction of human iPS cell-derived cardiac spheroids. ;　2018
  ANNOUNCEMENT INFO.;　Tissue Cell. , 53, 61-67
  AUTHOR;　*Mukae Y, Itoh M, Noguchi R, Furukawa K, Arai KI, Oyama JI, Toda S, Nakayama K, Node K, Morita S.
  
• Increased amputation risk with canagliflozin treatment:behind the large cardiovascular benefit? ;　2017
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol. , 16, 1, 129
  AUTHOR;　Tanaka A, Node K.
  
• Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.;　2017
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol. , 16, 1, 48
  AUTHOR;　Tanaka A, Shimabukuro M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H, Teragawa H, Sugiyama S, Yoshida H, Sato Y, Kawaguchi A, Ikehara Y, Machii N,　Maruhashi T, Shima KR, Takamura T, Matsuzawa Y, Kimura K, Sakuma M, Oyama JI,　Inoue T, Higashi Y, Ueda S, Node K; EMBLEM Trial Investigators.
  
• Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.;　2017
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol. , 16, 1, 63
  AUTHOR;　Yamada H, Tanaka A, Kusunose K, Amano R, Matsuhisa M, Daida H, Ito M, Tsutsui H, Nanasato M, Kamiya H, Bando YK, Odawara M, Yoshida H, Murohara T, Sata M, Node K; PROLOGUE Study Investigators.
  
• α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study.;　2017
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol. , 16, 1, 86
  AUTHOR;　Shimabukuro M, Tanaka A, Sata M, Dai K, Shibata Y, Inoue Y, Ikenaga H, Kishimoto S, Ogasawara K, Takashima A, Niki T, Arasaki O, Oshiro K, Mori Y, Ishihara M, Node K; Collaborators on the Effect of Miglitol on Glucose Metabolism in Acute Coronary Syndrome (MACS) Study.
  
• Reduction in incomplete stent apposition area caused by jailed struts after single stenting at left main bifurcation lesions: micro-CT analysis using a three-dimensional elastic bifurcated coronary artery model.;　2017
  ANNOUNCEMENT INFO.;　Cardiovasc Interv Ther. , 32, 1, 12-17.
  AUTHOR;　Hikichi Y, Umezu M, Node K, Iwasaki K.
  
• Association Between Waist-to-Height Ratio and Endothelial Dysfunction in Patients With Morbidity　- A Report From the FMD-J Study. ;　2017
  ANNOUNCEMENT INFO.;　Circ J. , 81, 12, 1911-1918
  AUTHOR;　Tokushige A, Ueda S, Tomiyama H, Ohishi M, Kohro T, Higashi Y, Takase B, Suzuki T, Ishizu T, Yamazaki T, Furumoto T, Kario K, Inoue T, Koba S, Takemoto Y, Hano T, Sata M, Ishibashi Y, Node K, Maemura K, Ohya Y, Furukawa T, Ito H, Yamashina A.
  
• Hypercholesterolemia Causes Circadian Dysfunction: A Potential Risk Factor for Cardiovascular Disease. ;　2017
  ANNOUNCEMENT INFO.;　EBioMedicine. , 20, 127-136
  AUTHOR;　Akashi M, Matsumura R, Matsuo T, Kubo Y, Komoda H, Node K.
  
• Effect of different light-dark schedules on estrous cycle in mice, and implications for mitigating the adverse impact of night work. ;　2017
  ANNOUNCEMENT INFO.;　Genes Cells. , 22, 10, 876-884
  AUTHOR;　Yoshinaka K, Yamaguchi A, Matsumura R, Node K, Tokuda I, Akashi M.
  
• Prevalence of prehypertension and left ventricular hypertrophy. Hypertens Res. ;　2017
  ANNOUNCEMENT INFO.;　Hypertens Res. , 40, 6, 544-545
  AUTHOR;　Oyama JI, Node K
  
• Amelioration of arterial pressure lability: an unmissable target for diabetes management.;　2017
  ANNOUNCEMENT INFO.;　Hypertens Res. , 40, 7, 629-631
  AUTHOR;　Tanaka A, Node K.
  
• Endothelial Function Is Impaired in Patients Receiving Antihypertensive Drug Treatment Regardless of Blood Pressure Level: FMD-J Study (Flow-Mediated Dilation Japan).;　2017
  ANNOUNCEMENT INFO.;　Hypertension. , 70, 4, 790-797
  AUTHOR;　Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, Iwamoto A, Kajikawa M, Matsumoto T, Oda N, Kishimoto S, Matsui S, Hashimoto H, Aibara Y, Yusoff FBM, Hidaka T, Kihara Y, Chayama K, Noma K, Nakashima A, Goto C, Tomiyama H, Takase B, Kohro T, Suzuki T, Ishizu T, Ueda S, Yamazaki T, Furumoto T, Kario K, Inoue T, Koba S, Watanabe K, Takemoto Y, Hano T, Sata M, Ishibashi Y, Node K, Maemura K, Ohya Y, Furukawa T, Ito H, Ikeda H, Yamashina A, Higashi Y.
  
• APEQ Study Investigators. Association Between Blood Pressure Lowering and Quality of Life by reatment of Azilsartan. ;　2017
  ANNOUNCEMENT INFO.;　Int Heart J. , 58, 5, 752-761
  AUTHOR;　Fujiwara N, Tanaka A, Kawaguchi A, Tago M, Oyama JI, Uchida Y, Matsunaga K, Moroe K, Toyoda S, Inoue T, Ikeda H, Node K; APEQ Study Investigators.
  
• Protective effects of bisoprolol against myocardial injury and pulmonary dysfunction in patients with chronic heart failure. ;　2017
  ANNOUNCEMENT INFO.;　Int J Cardiol. , 226, 71-76
  AUTHOR;　Toyoda S, Haruyama A, Inami S, Amano H, Arikawa T, Sakuma M, Abe S, Tanaka A, Node K, Inoue T.
  
• Myeloid-related protein-8/14 in acute coronary syndrome.;　2017
  ANNOUNCEMENT INFO.;　Int J Cardiol., 249, 25-31
  AUTHOR;　Sakuma M, Tanaka A, Kotooka N, Hikichi Y, Toyoda S, Abe S, Taguchi I, Node K, Simon DI, Inoue T.
  
• EGCG, a green tea catechin, attenuates the progression of heart failure induced by the heart/muscle-specific deletion of MnSOD in mice. ;　2017
  ANNOUNCEMENT INFO.;　J Cardiol. , 69, 2, 417-427
  AUTHOR;　Oyama JI, Shiraki A, Nishikido T, Maeda T, Komoda H, Shimizu T, Makino N, Node K.
  
• Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology. ;　2017
  ANNOUNCEMENT INFO.;　J Cardiol. , 69, 3, 501-507
  AUTHOR;　Tanaka A, Node K.
  
• Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial.;　2017
  ANNOUNCEMENT INFO.;　J Cardiol. , 69, 3, 511-517
  AUTHOR;　Kajiwara M, Tanaka A, Kawasaki T, Nakao K, Sakamoto T, Toyoda S, Inoue T, Koga N, Node K.
  
• Who Will Be Rehospitalized Next?: Targeting Heart Failure Patients With Brittle?Dimensions. ;　2017
  ANNOUNCEMENT INFO.;　JACC Heart Fail. , 5, 10, 760-761
  AUTHOR;　Tanaka A, Node K.
  
• Validity and Reliability of Three-chamber-View Three-directional Encoded Phase-contrast Magnetic Resonance Velocity-Vector Mapping for Transmitral Velocity Measurements: Comparison with Doppler Echocardiography and Intra- and Inter-observer Variability. ;　2017
  ANNOUNCEMENT INFO.;　Magn Reson Med Sci. , 16, 2, 152-158
  AUTHOR;　Suzuki M, Kotooka N, Sakuma M, Nakazono T, Node K, Irie H.
  
• Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased　agonism.;　2017
  ANNOUNCEMENT INFO.;　Pharmacol Res. , 23, 40-50
  AUTHOR;　Takezako T, Unal H, Karnik SS, Node K.
  
• N-terminal pro-brain natriuretic peptide and associated factors in the general working population: a baseline survey of the Uranosaki cohort study.;　2017
  ANNOUNCEMENT INFO.;　Sci Rep. , 7, 1, 5810
  AUTHOR;　Tanaka A, Yoshida H, Kawaguchi A, Oyama JI, Kotooka N, Toyoda S, Inoue T, Natsuaki M, Node K.
  
• A simple method using ex vivo culture of hair follicle tissue to investigate intrinsic circadian characteristics in humans. ;　2017
  ANNOUNCEMENT INFO.;　Sci Rep. , 7, 1, 6824
  AUTHOR;　Yamaguchi A, Matsumura R, Matsuzaki T, Nakamura W, Node K, Akashi M.
  
• Effect of particulate matters on cardiovascular disease;　2017
  ANNOUNCEMENT INFO.;　J. Balneol. Climatol. Phys. Med. , 80, 2, 61?65
  AUTHOR;　Oyama JI, Node K
  
• High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial. ;　2016
  ANNOUNCEMENT INFO.;　J Cardiol., 67, 4, 340-6
  AUTHOR;　Nishikido T, Oyama JI, Keida T, Ohira H, Node K.
  
• The relationship between neutrophil to lymphocyte　ratio, endothelial function, and severity in patients with obstructive sleep　apnea.;　2016
  ANNOUNCEMENT INFO.;　J Cardiol., 67, 3, 295-302
  AUTHOR;　Oyama JI, Nagatomo D, Yoshioka G, Yamasaki A, Kodama K, Sato M, Komoda H,　Nishikido T, Shiraki A, Node K.
  
• Impact of Obstructive Sleep Apnoea on Heart Failure　with Preserved Ejection Fraction.;　2016
  ANNOUNCEMENT INFO.;　Heart Lung Circ., 25, 5, 435-41
  AUTHOR;　*Arikawa T, Toyoda S, Haruyama A, Amano H, Inami S, Otani N, Sakuma M, Taguchi I, Abe S, Node K, Inoue T.
  
• Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study.;　2016
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol., 15, 1, 150
  AUTHOR;　Tomiyama H, Miwa T, Kan K, Matsuhisa M, Kamiya H, Nanasato M, Kitano T, Sano H, Ohno J, Iida M, Sata M, Yamada H, Maemura K, Tanaka A, Murohara T, Node K.
  
• Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study.;　2016
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol., 15, 1, 134
  AUTHOR;　Maruhashi T, Higashi Y, Kihara Y, Yamada H, Sata M, Ueda S, Odawara M, Terauchi Y, Dai K, Ohno J, Iida M, Sano H, Tomiyama H, Inoue T, Tanaka A, Murohara T, Node K; PROLOGUE Study Investigators
  
• Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.;　2016
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol., 15, 1, 133
  AUTHOR;　Tanaka A, Murohara T, Taguchi I, Eguchi K, Suzuki M, Kitakaze M, Sato Y, Ishizu T, Higashi Y, Yamada H, Nanasato M, Shimabukuro M, Teragawa H, Ueda S, Kodera S, Matsuhisa M, Kadokami T, Kario K, Nishio Y, Inoue T, Maemura K, Oyama J, Ohishi M, Sata M, Tomiyama H, Node K; PROTECT Study Investigators.
  
• Novel insights into renovascular hypertension and cardio-renal protection by iron restriction.;　2016
  ANNOUNCEMENT INFO.;　Hypertens Res., 39, 12, 829-831
  AUTHOR;　Tanaka A, Node K.
  
• The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial.;　2016
  ANNOUNCEMENT INFO.;　PLoS Med., 13, 6, e1002051
  AUTHOR;　Oyama J, Murohara T, Kitakaze M, Ishizu T, Sato Y, Kitagawa K, Kamiya H, Ajioka M, Ishihara M, Dai K, Nanasato M, Sata M, Maemura K, Tomiyama H, Higashi Y, Kaku K, Yamada H, Matsuhisa M, Yamashita K, Bando YK, Kashihara N, Ueda S, Inoue T, Tanaka A, Node K; PROLOGUE Study Investigators
  
• Estimation methods for human circadian phase by use of peripheral tissues.;　2016
  ANNOUNCEMENT INFO.;　Hypertens Res., 39, 9, 623-7
  AUTHOR;　Matsumura R, Node K, Akashi M.
  
• Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.;　2016
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol., 15, 87
  AUTHOR;　Oyama J, Tanaka A, Sato Y, Tomiyama H, Sata M, Ishizu T, Taguchi I, Kuroyanagi T, Teragawa H, Ishizaka N, Kanzaki Y, Ohishi M, Eguchi K, Higashi Y, Yamada H, Maemura K, Ako J, Bando YK, Ueda S, Inoue T, Murohara T, Node K; PRIZE Study Investigators
  
• Deletion of Apoptosis Inhibitor of Macrophage (AIM)/CD5L Attenuates the Inflammatory Response and Infarct Size in Acute Myocardial Infarction.;　2016
  ANNOUNCEMENT INFO.;　J Am Heart Assoc., 5, 4, e002863
  AUTHOR;　Nishikido T, Oyama J, Shiraki A, Komoda H, Node K.
  
• Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.;　2016
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol., 15, 57
  AUTHOR;　Tanaka A, Inoue T, Kitakaze M, Oyama J, Sata M, Taguchi I, Shimizu W, Watada H, Tomiyama H, Ako J, Sakata Y, Anzai T, Uematsu M, Suzuki M, Eguchi K, Yamashina A, Saito Y, Sato Y, Ueda S, Murohara T, Node K.
  
• Aquaporin-2 is a potential biomarker for tolvaptan efficacy in decompensated heart failure complicated by diabetic nephrotic syndrome.;　2016
  ANNOUNCEMENT INFO.;　Int J Cardiol., 210, 1-3
  AUTHOR;　Tanaka A, Nakamura T, Sato E, Node K.
  
• Long-term effects of AST-120 on the progression and prognosis of pre-dialysis chronic kidney disease: a 5-year retrospective study.;　2016
  ANNOUNCEMENT INFO.;　Heart Vessels., 31, 10, 1625-32
  AUTHOR;　Sato E, Tanaka A, Oyama J, Yamasaki A, Shimomura M, Hiwatashi A, Ueda Y, Amaha M, Nomura M, Matsumura D, Nakamura T, Node K.
  
• Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial).;　2016
  ANNOUNCEMENT INFO.;　Heart Vessels., 31, 10, 1583-9
  AUTHOR;　Shimomura M, Oyama J, Takeuchi M, Shibata Y, Yamamoto Y, Kawasaki T, Komoda H, Kodama K, Sakuma M, Toyoda S, Inoue Y, Mine D, Natsuaki M, Komatsu A, Hikichi Y, Yamagishi S, Inoue T, Node K.
  
• Development of a three-dimensional pre-vascularized scaffold-free contractile cardiac patch for treating heart disease.;　2016
  ANNOUNCEMENT INFO.;　J Heart Lung Transplant., 35, 1, 137-45
  AUTHOR;　Noguchi R, Nakayama K, Itoh M, Kamohara K, Furukawa K, Oyama J, Node K, Morita S.
  
• A trial of telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD): Biomarker study.;　2016
  ANNOUNCEMENT INFO.;　Eur J Prev Cardiol., 23, 9, 913-21
  AUTHOR;　Ogawa H, Soejima H, Matsui K, Kim-Mitsuyama S, Yasuda O, Node K, Yamamuro M, Yamamoto E, Kataoka K, Jinnouchi H, Sekigami T; ATTEMPT-CVD investigators.
  
• A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients. ;　2016
  ANNOUNCEMENT INFO.;　Drug Metab Pharmacokinet. , 31, 6, 467-470
  AUTHOR;　Sai K, Kajinami K, Akao H, Iwadare M, Sato-Ishida R, Kawai Y, Takeda K, Tanimoto T, Yamano T, Akasaka T, Ishida T, Hirata KI, Saku K, Yagi S, Soeki T, Sata M, Ueno M, Miyazaki S, Shiraki A, Oyama JI, Node K, Sugamura K, Ogawa H, Kurose K, Maekawa K, Matsuzawa Y, Imatoh T, Hasegawa R; Japanese Pharmacogenomics Data Science Consortium., Saito Y.
  
• Correction: Scaffold-Free Tubular Tissues Created by a Bio-3D Printer Undergo Remodeling and Endothelialization when Implanted in Rat Aortae.;　2015
  ANNOUNCEMENT INFO.;　PLoS One., 10, 12, e0145971
  AUTHOR;　○Itoh M, Nakayama K, Noguchi R, Kamohara K, Furukawa K, Uchihashi K, Toda S,　Oyama J, Node K, Morita S.
  
• Reliability of measurement of endothelial function across multiple institutions and establishment of reference values in Japanese. ;　2015
  ANNOUNCEMENT INFO.;　Atherosclerosis., 242, 2, 433-42
  AUTHOR;　*Tomiyama H, Kohro T, Higashi Y, Takase B, Suzuki T, Ishizu T, Ueda S, Yamazaki　T, Furumoto T, Kario K, Inoue T, Koba S, Watanabe K, Takemoto Y, Hano T, Sata M, Ishibashi Y, Node K, Maemura K, Ohya Y, Furukawa T, Ito H, Ikeda H, Yamashina A.
  
• Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells. ;　2015
  ANNOUNCEMENT INFO.;　Int J Mol Sci., 16, 8, 18894-922
  AUTHOR;　Tanaka A, Yuasa S, Node K, Fukuda K.
  
• Choice of Antihypertensive Combination Therapy Based on Daily Salt Intake. ;　2015
  ANNOUNCEMENT INFO.;　Am J Med Sci., 350, 3, 160-6
  AUTHOR;　*Toyoda S, Inami S, Kato T, Tsukada K, Nakamoto A, Kikegawa Y, Suzuki A, Anraku Y, Node K, Inoue T.
  
• Rationale and design of the efficacy of rivaroxaban on renal function in patients with non-valvular atrial fibrillation and chronic kidney disease: The X-NOAC study. ;　2015
  ANNOUNCEMENT INFO.;　Int J Cardiol., 188, 52-3
  AUTHOR;　*Suzuki M, Fukamizu S, Oyama J, Mizukami A, Matsumura A, Hashimoto Y, Node K.
  
• A novel cardioprotective mechanism of exogenous nitric oxide: inhibition of Rho-associated kinase activity. ;　2015
  ANNOUNCEMENT INFO.;　Hypertens Res., 38, 7, 461-2
  AUTHOR;　Tanaka A, Node K.
  
• Structure-Function Basis of Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for Active-State Angiotensin II Type 1 Receptor. ;　2015
  ANNOUNCEMENT INFO.;　Mol Pharmacol., 88, 3, 488-501
  AUTHOR;　*Takezako T, Unal H, Karnik SS, Node K.
  
• The effects and safety of vildagliptin on cardiac function after acute myocardial infarction.;　2015
  ANNOUNCEMENT INFO.;　Int J Cardiol., 188, 13-5
  AUTHOR;　Nishikido T, Oyama J, Ohira H, Node K.
  
• Glycemic variability and cardiac remodeling in patients with acute myocardial infarction. ;　2015
  ANNOUNCEMENT INFO.;　Circ J., 79, 5, 972-3
  AUTHOR;　*Natsuaki M, Node K.
  
• Docosahexaenoic Acid with a statin and endothelial function in patients with coronary artery disease. ;　2015
  ANNOUNCEMENT INFO.;　J Atheroscler Thromb., 22, 5, 440-1
  AUTHOR;　*Kato T, Node K.
  
• Association between N-terminal pro B-type natriuretic peptide and day-to-day blood pressure and heart rate variability in a general population: the Ohasama study.;　2015
  ANNOUNCEMENT INFO.;　J Hypertens., 33, 8, 1536-41
  AUTHOR;　*Satoh M, Hosaka M, Asayama K, Kikuya M, Inoue R, Metoki H, Tsubota-Utsugi M, Hara A, Hirose T, Obara T, Totsune K, Hoshi H, Mano N, Node K, Imai Y, Ohkubo T.
  
• A trial of telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD): Biomarker study. ;　2015
  ANNOUNCEMENT INFO.;　Eur J Prev Cardiol., http://cpr.sagepub.com/content/early/2015/08/21/2047487315603221.abstract
  AUTHOR;　*Ogawa H, Soejima H, Matsui K, Kim-Mitsuyama S, Yasuda O, Node K, Yamamuro M, Yamamoto E, Kataoka K, Jinnouchi H, Sekigami T; ATTEMPT-CVD investigators.
  
• Development of a three-dimensional pre-vascularized scaffold-free　contractile cardiac patch for treating heart disease.;　2015
  ANNOUNCEMENT INFO.;　J Heart Lung Transplant., 35, 1, 137-145
  AUTHOR;　○Noguchi R, Nakayama K, Itoh M, Kamohara K, Furukawa K, Oyama JI, Node K, Morita S.
  
• Molecular analysis of ATP-sensitive K(+) channel subunits expressed in mouse portal vein.;　2015
  ANNOUNCEMENT INFO.;　Vascul Pharmacol., 75, 29-39
  AUTHOR;　○Yamamoto T, Takahara K, Inai T, Node K, Teramoto N.
  
• Long-term effects of AST-120 on the progression and prognosis of pre-dialysis chronic kidney disease: a 5-year retrospective study. ;　2015
  ANNOUNCEMENT INFO.;　Heart Vessels.
  AUTHOR;　*Sato E, Tanaka A, Oyama JI, Yamasaki A, Shimomura M, Hiwatashi A, Ueda Y, Amaha M, Nomura M, Matsumura D, Nakamura T, Node K.
  
• Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial).;　2015
  ANNOUNCEMENT INFO.;　Heart Vessels.
  AUTHOR;　Shimomura M, Oyama JI, Takeuchi M, Shibata Y, Yamamoto Y, Kawasaki T, Komoda H, Kodama K, Sakuma M, Toyoda S, Inoue Y, Mine D, Natsuaki M, Komatsu A, Hikichi Y, Yamagishi SI, Inoue T, Node K.
  
• Effect of a Low-Intensity Pulsed Ultrasound Device, SX-1001, on Clinical Symptoms in Buerger Disease With Limb Ischemia.;　2015
  ANNOUNCEMENT INFO.;　Int Heart J., 56, 6, 632-8
  AUTHOR;　*Higashi Y, Azuma N, Takeishi Y, Minamino T, Kihara Y, Node K, Sata M, Fukumoto Y, Origasa H, Matsuo H, Naritomi H, Fujita M, Shimizu W.
  
• Takotsubo cardiomyopathy in the presence of right ventricular apical pacing: A case report.;　2014
  ANNOUNCEMENT INFO.;　J of Arrhythmia., 30, 6, 506-508
  AUTHOR;　*Matsumoto M, Ohga M, Uemura S, Node K.　
  
• Successful treatment of primary cardiac lymphoma causing ST-elevation myocardial infarction by percutaneous coronary intervention combined with chemotherapy. ;　2014
  ANNOUNCEMENT INFO.;　BMJ Case Rep. pii: bcr2014207267.
  AUTHOR;　Nagatomo D, Oyama J, Yoshihara M, Node K.
  
• Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes.;　2014
  ANNOUNCEMENT INFO.;　J Am Heart Assoc. , 3, 6, e001263
  AUTHOR;　*Tanaka A, Yuasa S, Mearini G, Egashira T, Seki T, Kodaira M, Kusumoto D, Kuroda Y, Okata S, Suzuki T, Inohara T, Arimura T, Makino S, Kimura K, Kimura A, Furukawa T, Carrier L, Node K, Fukuda K.
  
• Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013).;　2014
  ANNOUNCEMENT INFO.;　Circ J. , 78, 11, 2779-801
  AUTHOR;　*Ogawa H, Akasaka T, Hattori R, Inoue T, Kawashima S, Kawasuji M, Kimura K, Miwa K, Mizuno K, Mohri M, Murohara T, Node K.
  
• The mammalian circadian clock protein period counteracts cryptochrome in phosphorylation dynamics of circadian locomotor output cycles kaput (CLOCK). ;　2014
  ANNOUNCEMENT INFO.;　J Biol Chem. , 289, 46, 32064-72
  AUTHOR;　*Matsumura R, Tsuchiya Y, Tokuda I, Matsuo T, Sato M, Node K, Nishida E, Akashi M.
  
• Sympathetic nerve activity and endothelial function.;　2014
  ANNOUNCEMENT INFO.;　Hypertens Res. , 37, 12, 1035-6
  AUTHOR;　Oyama J, Node K.
  
• Therapeutic potential of α-glucosidase inhibitors to prevent postprandial endothelial dysfunction. ;　2014
  ANNOUNCEMENT INFO.;　Int Heart J. , 55, 5, 386-90
  AUTHOR;　*Kato T, Node K.
  
• The role of the endocrine system in feeding-induced tissue-specific circadian entrainment. ;　2014
  ANNOUNCEMENT INFO.;　Cell Rep. , 8, 2, 393-401
  AUTHOR;　*Sato M, Murakami M, Node K, Matsumura R, Akashi M.
  
• A positive role for PERIOD in mammalian circadian gene expression. ;　2014
  ANNOUNCEMENT INFO.;　Cell Rep. , 7, 4, 1056-64
  AUTHOR;　*Akashi M, Okamoto A, Tsuchiya Y, Todo T, Nishida E, Node K.
  
• Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study. ;　2014
  ANNOUNCEMENT INFO.;　Int J Cardiol. , 174, 2, 383-4
  AUTHOR;　Oyama J, Ishizu T, Sato Y, Kodama K, Bando YK, Murohara T, Node K.
  
• The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014).;　2014
  ANNOUNCEMENT INFO.;　Hypertens Res. , 37, 4, 253-390
  AUTHOR;　*Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura　H, Miura K, Morishita R, Naruse M, Node K.
  
• Risk markers for coronary plaque progression and destabilization beyond LDL-cholesterol in acute coronary syndrome. ;　2014
  ANNOUNCEMENT INFO.;　Int J Cardiol. , 173, 2, 329-31
  AUTHOR;　Taguchi I, Koizumi S, Kageyama M, Nasuno T, Toyoda S, Abe S, Node K, Inoue T.
  
• Varenicline-assisted smoking cessation decreases oxidative stress and restores endothelial function.;　2014
  ANNOUNCEMENT INFO.;　Hypertens Res. , 37, 7, 655-8
  AUTHOR;　*Kato T, Umeda A, Miyagawa K, Takeda H, Adachi T, Toyoda S, Taguchi I, Inoue T, Node K.
  
• Incretin therapy and heart failure.;　2014
  ANNOUNCEMENT INFO.;　Circ J. , 78, 4, 819-24
  AUTHOR;　Oyama J, Node K.
  
• Compensation for intracellular environment in expression levels of mammalian circadian clock genes.;　2014
  ANNOUNCEMENT INFO.;　Sci Rep. 4:4032. doi:10.1038/srep04032
  AUTHOR;　*Matsumura R, Okamoto A, Node K, Akashi M.
  
• Do incretins improve endothelial function? ;　2014
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol. doi: 10.1186/1475-2840-13-21., 13, 1, 21
  AUTHOR;　Oyama JI, Higashi Y, Node K.
  
• Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report. ;　2014
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol. doi: 10.1186/1475-2840-13-15., 13, 1, 15
  AUTHOR;　*Nakamura I, Oyama JI, Komoda H, Shiraki A, Sakamoto Y, Taguchi I, Hiwatashi A, Komatsu A, Takeuchi M, Yamagishi SI, Inoue T, Node K.
  
• High-intensity signals in coronary plaques on noncontrast T1-weighted magnetic resonance imaging as a novel determinant of coronary events. ;　2014
  ANNOUNCEMENT INFO.;　J Am Coll Cardiol. , 63, 10, 989-99
  AUTHOR;　*Noguchi T, Kawasaki T, Tanaka A, Yasuda S, Goto Y, Ishihara M, Nishimura K, Miyamoto Y, Node K, Koga N.
  
• Clinical significance of non-slip element balloon angioplasty for patients of coronary artery disease: a preliminary report.;　2014
  ANNOUNCEMENT INFO.;　 J Cardiol. , 63, 1, 19-23
  AUTHOR;　*Taguchi I, Kageyama M, Kanaya T, Abe S, Node K, Inoue T.
  
• Guidelines for Diagnosis and Treatment of Patients With Vasospastic Angina (Coronary Spastic Angina) (JCS 2013): Digest Version;　2014
  ANNOUNCEMENT INFO.;　Circulation Journal. , 78, 11, 2779-2801
  AUTHOR;　Ogawa H, Akasaka T, Hattori R, Kawashima S, Kawasuji M, Kimura K, Miwa K, Mizuno K, Mohri M, Murohara T, Node K.
  
• The late-phase inflammatory response after drug-eluting stent implantation. ;　2014
  ANNOUNCEMENT INFO.;　Heart Vessels. , 29, 2, 213-9
  AUTHOR;　*Taguchi I, Yoneda S, Abe S, Toyoda S, Nasuno T, Nishino S, Kageyama M, Tokura M, Ogawa M, Node K, Inoue T.
  
• Endothelium-derived hyperpolarizing factor and hypertension.;　2013
  ANNOUNCEMENT INFO.;　Hypertens Res., 36, 10, 852-853
  AUTHOR;　Oyama J, Node K.
  
• Interleukin 27 inhibits atherosclerosis via immunoregulation of macrophages in mice.;　2013
  ANNOUNCEMENT INFO.;　Am J Physiol Heart Circ Physiol., 305, 3, H420-H429
  AUTHOR;　*Hirase T, Hara H, Miyazaki Y, Ide N, Nishimoto-Hazuku A, Fujimoto H, Saris CJ, Yoshida H, Node K
  
• Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version: JSN, JRS, and JCS Joint Working Group.;　2013
  ANNOUNCEMENT INFO.;　Circ J., 77, 7, 1883-1914
  AUTHOR;　Ohno I, Hayashi H, Aonuma K, Horio M, Kashihara N, Okada H, Komatsu Y, Tamura S, Awai K, Yamashita Y, Kuwatsuru R, Hirayama A, Saito Y, Murohara T, Tamaki N, Sato A, Takayama T, Imai E, Yasuda Y, Koya D, Tsubakihara Y, Horie S, Korogi Y, Narumi Y, Hayakawa K, Daida H, Node K, Kubota I.
  
• A molecular clock regulates angiopoietin-like 1 protein 2 expression.;　2013
  ANNOUNCEMENT INFO.;　Plos One., 8, 2, e57921
  AUTHOR;　*Kadomatsu T, Uragami S, Akashi M, Tsuchiya Y , Nakajima H, Nakashima Y, Endo M, Miyata K, Terada K, Takeshi T, Node K, Oike Y.
  
• Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.;　2013
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol., 12, 1, 131
  AUTHOR;　*Kawamori R, Node K, Hanafusa T, Atsumi Y, Naito Y, Oka Y.
  
• Home telemonitoring study for Japanese patients with heart failure (HOMES-HF): protocol for a multicentre randomised controlled trial.;　2013
  ANNOUNCEMENT INFO.;　BMJ Open. pii:e002972, 3, 6, e002972
  AUTHOR;　Kotooka N, Asaka M, Sato Y, Kinugasa Y, Nochioka K, Mizuno A, Nagatomo D, Mine D, Yamada Y, Eguchi K, Hanaoka H, Inomata T, Fukumoto Y, Yamamoto K, Tsutsui H, Masuyama T, Kitakaze M, Inoue T, Shimokawa H, Momomura S, Seino Y, Node K; HOMES-HF study investigators.
  
• Predictive value of high-molecular weight adiponectin in subjects with a higher risk of the development of metabolic syndrome: From a population based 5-year follow-up data.;　2013
  ANNOUNCEMENT INFO.;　Int J Cardiol., 167, 3, 1068-1070
  AUTHOR;　Kotooka N, Komatsu A, Takahashi H, Nonaka M, Kawaguchi C, Komoda H, Asaka M, Abe S, Taguchi I, Toyoda S, Nishiyama M, Inoue T, Node K.
  
• Nuclear receptor-mediated cell-autonomous oscillatory expression of the circadian transcription factor, neuronal PAS domain protein 2 (NPAS2).;　2013
  ANNOUNCEMENT INFO.;　J Biol Chem., 288, 51, 36548-36553
  AUTHOR;　*Matsumura R, Matsubara C, Node K, Takumi T, Akashi M.
  
• 併用療法からエックスフォージ切り替えにおける費用対効果とアドヒアランスに関する検討;　2013
  ANNOUNCEMENT INFO.;　, 20, 1, 106-115
  AUTHOR;　
  
• Detection of early stage atherosclerotic plaques using PET and CT fusion imaging targeting P-selectin in low density lipoprotein receptor-deficient mice.;　2013
  ANNOUNCEMENT INFO.;　Biochem Biophys Res Commun., 433, 1, 47-51
  AUTHOR;　*Nakamura I, Hasegawa K, WadaY, Hirase T, Node K, Watanabe Y.
  
• High-intensity signals in coronary plaques on non-contrast T1-weighted magnetic resonance imaging as a novel determinant of coronary events.;　2013
  ANNOUNCEMENT INFO.;　J Am Coll Cardiol., 63, 10, 989-999
  AUTHOR;　○Noguchi T, Kawasaki T, Tanaka A, Yasuda S, Goto Y, Ishihara M, Nishimura K, Miyamoto Y, Node K, Koga N.
  
• Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version : JSN, JRS, and JCS Joint Working Group.;　2013
  ANNOUNCEMENT INFO.;　Clin Exp Nephrol., 17, 4, 441-479
  AUTHOR;　*Ohno I, *Hayashi H, Aonuma K, Horio M, Kashihara N, Okada H, Komatsu Y, Tamura S, Awai K, Yamashita Y, Kuwatsuru R, Hirayama A, Saito Y, Murohara T, Tamaki N, Sato A, Takayama T, Imai E, Yasuda Y, Koya D, Tsubakihara Y, Horie S, Korogi Y, Narumi Y, Hayakawa K, Daida H, Node K, Kubota I.
  
• An out-of-lab trial: a case example for the effect of intensive exercise on rhythms of human clock gene expression.;　2013
  ANNOUNCEMENT INFO.;　J Circadian Rhythms., 11, 1, 10
  AUTHOR;　*Okamoto A, Yamamoto T, Matsumura R, Node K, *Akashi M.
  
• Effects of sitagliptin beyond glycemic contol: Focus on quality of life.;　2013
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol., 12, 1, 35
  AUTHOR;　Sakamoto Y, Oyama JI, Ikeda H, Kuroki S, Gondoh S, Iwamoto T, Uchida Y, Kodama K, Hiwatashi A, Shimomura M, Taguchi I, Inoue T, Node K and S-DOG investigators.
  
• シルニジピンとアムロジピンの降圧および腎保護効果に関する比較研究;　2013
  ANNOUNCEMENT INFO.;　Progress in Medicine., 33, 5, 1147-1153
  AUTHOR;　
  
• Is direct renin inhibition superior to angiotensin receptor blocade in the effects beyond blood pressure lowering?;　2013
  ANNOUNCEMENT INFO.;　Japanese Journal of Clinical Physiology., 6, 42, 89-95
  AUTHOR;　*Taguchi I, Toyoda S, Arikawa T, Ogino Y, Koizumi S,Kikuchi M, Abe S, Node K, Inoue T.
  
• Evaluation of serial changes in tissue characteristics during statin-induced plaque regression by virtual histology intravascular ultrasound.;　2013
  ANNOUNCEMENT INFO.;　Am J Cardiol., 111, 9, 1246-1252
  AUTHOR;　*Taguchi I, Oda K, Yoneda S, Kageyama M, Kanaya T, Toyoda S, Abe S, Node K, Inoue T.
  
• Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension.;　2013
  ANNOUNCEMENT INFO.;　Hypertens Res., 36, 7, 608-613
  AUTHOR;　*Taguchi I, Toyoda S, Takano K, Arikawa T, Kikuchi M, Ogawa M, Abe S, Node K, Inoue T.
  
• Prognostic stratification of patients with vasospastic angina: a comprehensive clinical risk score developed by the Japanese coronary spasm association.;　2013
  ANNOUNCEMENT INFO.;　J Am Coll Cardiol., 62, 13, 1144-1153
  AUTHOR;　*Takagi Y, Takahashi J, Yasuda S, Miyata S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Goto T, Tanabe Y, Sueda S, Sato T, Ogawa S, Kubo N, Momomura S, Ogawa H, *Shimokawa H; Japanese Coronary Spasm Association.
  
• Effects of pitavastatin in Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study).;　2013
  ANNOUNCEMENT INFO.;　Circ J., 77, 4, 917-925
  AUTHOR;　*Takano H, Mizuma H, Kuwabara Y, Sato Y, Shindo S, Kotooka N, Fujimatsu D, Kobayashi Y, Inoue T, Node K, *Komuro I; PEARL Study Investigators.
  
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes.;　2013
  ANNOUNCEMENT INFO.;　N Engl J Med., 369, 14, 1327-1335
  AUTHOR;　*White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; EXAMINE Investigators.
  
• Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF);　2013
  ANNOUNCEMENT INFO.;　Eur J Heart Fail., 15, 1, 110-118
  AUTHOR;　*Yamamoto K, Origasa H, Hori M; J-DHF Investigators.
  
• Increased oxidative stress impairs adipose tissue function in sphingomyelin synthase 1 null mice.;　2013
  ANNOUNCEMENT INFO.;　PLoS One., 8, 4, e61380
  AUTHOR;　*Yano M, Yamamoto T, Nishimura N, Gotoh T, Watanabe K, Ikeda K, Garan Y, Taguchi R, Node K, Okazaki T, Oike Y.
  
• Repetitive hyperthermia attenuates progression of left ventricular hypertrophy and increases telomerase activity in hypertensive rats.;　2012/05
  ANNOUNCEMENT INFO.;　, 302, 10, H2092-101
  AUTHOR;　Oyama J, Maeda T, Sasaki M, Higuchi Y, Node K, Makino N.
  
• The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells.;　2012/04
  ANNOUNCEMENT INFO.;　Atherosclerosis. 2012 Apr;221(2):375-82., 221, 2, 375-82
  AUTHOR;　Shiraki A, Oyama J, Komoda H, Asaka M, Komatsu A, Sakuma M, Kodama K, Sakamoto Y, Kotooka N, Hirase T, Node K.
  
• Continuous positive airway pressure therapy improves vascular dysfunction and decreases oxidative stress in patients with the metabolic syndrome and obstructive sleep apnea syndrome.;　2012/04
  ANNOUNCEMENT INFO.;　Clin Cardiol. 2012 Apr;35(4):231-6., 35, 4, 231-6
  AUTHOR;　Oyama J, Yamamoto H, Maeda T, Ito A, Node K, Makino N.
  
• Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure: the pitavastatin heart failure study (PEARL study).;　2012/04
  ANNOUNCEMENT INFO.;　Int J Cardiol. 2012 Apr 19;156(2):144-7., 156, 2, 144-7
  AUTHOR;　Mizuma H, Inoue T, Takano H, Shindo S, Oka T, Fujimatsu D, Kuwabara Y, Node K, Komuro I; PEARL Study Investigators.
  
• Endothelial dysfunction as a cellular mechanism for vascular failure.;　2012/02
  ANNOUNCEMENT INFO.;　Am J Physiol Heart Circ Physiol. 2012 Feb 1;302(3):H499-505., 302, 3, H499-500
  AUTHOR;　Hirase T, Node K.
  
• Hyperthermia by bathing in a hot spring improves cardiovascular functions and reduces the production of inflammatory cytokines in patients with chronic heart failure.;　2012/01
  ANNOUNCEMENT INFO.;　Heart Vessels. 2012 Jan 11 [Epub ahead of print]
  AUTHOR;　Oyama JI, Kudo Y, Maeda T, Node K, Makino N.
  
• Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model.;　2012/01
  ANNOUNCEMENT INFO.;　J Cardiol. 2012 Jan;59(1):91-6.
  AUTHOR;　Sohma R, Inoue T, Abe S, Taguchi I, Kikuchi M, Toyoda S, Arikawa T, Hikichi Y, Sanada S, Asanuma H, Kitakaze M, Node K.
  
• 積極的降圧治療の有効性と安全性およびQOLに関する研究 -ロサルタンサブ解析-;　2012
  ANNOUNCEMENT INFO.;　Progress in Medicine., 32, 6, 163-169
  AUTHOR;　
  
• A multicenter study design to assess the clinical usefulness of semi-automatic measurement of flow-mediated vasodilatation of the brachial artery.;　2012
  ANNOUNCEMENT INFO.;　Int Heart J., 53, 3, 170-175
  AUTHOR;　*Tomiyama H, Kohro T, Higashi Y, Takase B, Suzuki T, Ishizu T, Ueda S, Yamazaki T, Furumoto T, Kario K, Inoue T, Koba S, Watanabe K, Takemoto Y, Hano T, Sata M, Ishibashi Y, Node K, Maemura K, Ohya Y, Furukawa T, Ito H, Yamashina A.
  
• Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.;　2012
  ANNOUNCEMENT INFO.;　Lancet Neurol., 11, 6, 503-511
  AUTHOR;　*Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC; ARISTOTLE Committees and Investigators.
  
• Prospective cohort study of　gastrointestinal complications and vascular diseases in patients taking aspirin: 　rationale and design of the MAGIC Study.;　2011/12
  ANNOUNCEMENT INFO.;　Cardiovasc Drugs Ther. 2011 Dec;　, 25, 6, 551-560
  AUTHOR;　Origasa H, Goto S, Shimada K, Uchiyama S, Okada Y, Sugano K, Hiraishi H,　Uemura N, Ikeda Y; MAGIC Investigators.
  
• Antihypertensive treatment using an angiotensin receptor blocker　and a thiazide diuretic improves patients' quality of life: the Saga Challenge　Antihypertensive Study (S-CATS).;　2011/12
  ANNOUNCEMENT INFO.;　Hypertens Res. 2011 Dec;　, 34, 12, 1288-1294
  AUTHOR;　Kamura A, Inoue T, Kuroki S, Ishida S, Iimori K, Kato T, Naitoh H, Tamesue S, Ikeda H, Node K.
  
• IL-27 inhibits hyperglycemia and pancreatic islet inflammation induced by streptozotocin in mice.;　2011/11
  ANNOUNCEMENT INFO.;　Am J Pathol. 2011 Nov;　, 179, 5, 2327-2336
  AUTHOR;　Fujimoto H, Hirase T, Miyazaki Y, Hara H, Ide-Iwata N, Nishimoto-Hazuku A, Saris CJ, Yoshida H, Node K.
  
• Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis.;　2011/10
  ANNOUNCEMENT INFO.;　JACC Cardiovasc Interv. 2011 Oct;　Review.　, 4, 10, 1057-1066
  AUTHOR;　Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI.
  
• Renovascular protective effects of erythropoietin in patients with chronic kidney disease.;　2011/09
  ANNOUNCEMENT INFO.;　Intern Med. 2011;　, 50, 18, 1929-1934
  AUTHOR;　Fujiwara N, Nakamura T, Sato E, Kawagoe Y, Hikichi Y, Ueda Y, Node K.
  
• Apixaban versus warfarin in patients with atrial fibrillation.;　2011/09
  ANNOUNCEMENT INFO.;　N Engl J Med. 2011 Sep 15;　, 365, 11, 981-992
  AUTHOR;　Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker　G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser　SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko　A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators.
  
• Prediction of Acute Coronary Syndrome by Using Multislice Computed Tomography.;　2011/07
  ANNOUNCEMENT INFO.;　Circ J. [Epub ahead of print]　discussion 2026　, 75, 8, 2013-2018
  AUTHOR;　Kawasaki T, Koga N, Node K.
  
• Relationships among hyperuricemia, metabolic syndrome, and endothelial function.;　2011/07
  ANNOUNCEMENT INFO.;　Am J Hypertens., 24, 7, 770-774
  AUTHOR;　Tomiyama H, Higashi Y, Takase B, Node K, Sata M, Inoue T, Ishibashi Y, Ueda S, Shimada K, Yamashina A.
  
• Angiotensin II induces microtubule reorganization mediated by a deacetylase SIRT2 in endothelial cells.;　2011/06
  ANNOUNCEMENT INFO.;　Hypertens Res. doi: 10.1038/hr.2011.64. [Epub ahead of print], 34, 8, 949-956
  AUTHOR;　Hashimoto-Komatsu A, Hirase T, Asaka M, Node K.
  
• Design and Rationale of Japanese Evaluation Between Formula of Azelnidipine and Amlodipine Add on Olmesartan to Get Antialbuminuric Effect Study (J-FLAG) : Evaluation of the Antialbuminuric Effects between Calcium Channel Blocker with Sympatholytic Action in Hypertensive Patients with Diabetes and Albuminuria.;　2011/06
  ANNOUNCEMENT INFO.;　Cardiovasc Drugs Ther. [Epub ahead of print]　, 25, 4, 341-347
  AUTHOR;　Ando K, Haneda M, Ito S, Kashihara N, Node K, Nangaku M, Shimosawa T, Kishimoto J, Fujita T.
  
• Clinical characteristics and long-term prognosis of vasospastic angina patients who survived out-of-hospital cardiac arrest: multicenter registry study of the Japanese Coronary Spasm Association.;　2011/06
  ANNOUNCEMENT INFO.;　Circ Arrhythm Electrophysiol. 2011 Jun;　, 4, 3, 295-302
  AUTHOR;　Takagi Y, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Goto T, Tanabe Y, Sueda S, Sato T, Ogawa S, Kubo N, Momomura S, Ogawa H, Shimokawa H; Japanese Coronary Spasm Association.
  
• A promising culture model for analyzing the interaction between adipose tissue and cardiomyocytes.;　2011/04
  ANNOUNCEMENT INFO.;　Endocrinology., 152, 4, 1599-1605
  AUTHOR;　Anan M, Uchihashi K, Aoki S, Matsunobu A, Ootani A, Node K, Toda S.
  
• Pleiotropic effects of ARB on dyslipidemia.;　2011/03
  ANNOUNCEMENT INFO.;　Curr Vasc Pharmacol.Review., 9, 2, 129-135
  AUTHOR;　Taguchi I, Inoue T, Kikuchi M, Toyoda S, Arikawa T, Abe S, Node K.
  
• Inhibition of intestinal cholesterol absorption might explain cholesterol-lowering effect of telmisartan.;　2011/02
  ANNOUNCEMENT INFO.;　J Clin Pharm Ther., 36, 1, 103-110
  AUTHOR;　Inoue T, Taguchi I, Abe S, Toyoda S, Sakuma M, Node K.
  
• Mitochondrial dysfunction and increased reactive oxygen species impair insulin secretion in sphingomyelin synthase 1-null mice.;　2011/02
  ANNOUNCEMENT INFO.;　J Biol Chem., 286, 5, 3992-4002
  AUTHOR;　Yano M, Watanabe K, Yamamoto T, Ikeda K, Senokuchi T, Lu M, Kadomatsu T, Tsukano H, Ikawa M, Okabe M, Yamaoka S, Okazaki T, Umehara H, Gotoh T, Song WJ, Node K, Taguchi R, Yamagata K, Oike Y.
  
• The role of vascular failure in coronary artery spasm.;　2011/01
  ANNOUNCEMENT INFO.;　J Cardiol., 57, 1, 2-7
  AUTHOR;　Kawano H, Node K.
  
• Rab5a-mediated localization of claudin-1 is regulated by proteasomes in endothelial cells.;　2011/01
  ANNOUNCEMENT INFO.;　Am J Physiol Cell Physiol., 300, 1, C87-C96
  AUTHOR;　Asaka M, Hirase T, Hashimoto-Komatsu A, Node K.
  
• [Anti-atherosclerotic effect of fibrates and eicosapentaenoic acid].;　2011/01
  ANNOUNCEMENT INFO.;　Nippon Rinsho. Review. Japanese., 69, 1, 87-91
  AUTHOR;　Sakamoto Y, Node K.
  
• Potential Benefit of Statin Therapy for Dyslipidemia with Chronic Kidney Disease: Fluvastatin Renal Evaluation Trial (FRET).;　2011
  ANNOUNCEMENT INFO.;　Intern Med.　, 50, 12, 1273-1278
  AUTHOR;　Inoue T, Ikeda H, Nakamura T, Abe S, Taguchi I, Kikuchi M, Toyoda S, Miyazono M, Kishi T, Sanai T, Node K.
  
• Effects of aerobic exercise on lipid profiles and high molecular weight adiponectin in Japanese workers.;　2011
  ANNOUNCEMENT INFO.;　Intern Med., 50, 5, 389-395
  AUTHOR;　Guo W, Kawano H, Piao L, Itoh N, Node K, Sato T.
  
• Prediction of acute coronary syndrome by using　multislice computed tomography. -Can we predict the onset of acute coronary　syndrome? (Pro)-.;　2011
  ANNOUNCEMENT INFO.;　Circ J. 2011;　discussion 2026., 75, 8, 2013-2018
  AUTHOR;　Kawasaki T, Koga N, Node K.
  
• Risk stratification based on metabolic syndrome as well as non- metabolic risk factors in the assessment of carotid atherosclerosis.;　2011
  ANNOUNCEMENT INFO.;　J Atheroscler Thromb. 2011;　, 18, 6, 504-512
  AUTHOR;　Noda H, Iso H, Yamashita S, Ueno H, Yokode M, Yamada N, Ouchi Y; Defining Vascular Disease (DVD) Research Group.
  
• DESの可能性と限界について　ベンチテストからの考察;　2011
  ANNOUNCEMENT INFO.;　, 6, 3, 299-304
  AUTHOR;　
  
• 運動負荷試験による血圧変化と心・血管病との関連;　2011
  ANNOUNCEMENT INFO.;　, 41, 2, 47-53
  AUTHOR;　
  
• Marked cerebral atrophy is correlated with kidney dysfunction in nondisabled adults.;　2010/12
  ANNOUNCEMENT INFO.;　Hypertens Res., 33, 12, 1232-1237
  AUTHOR;　Yakushiji Y, Nanri Y, Hirotsu T, Nishihara M, Hara M, Nakajima J, Eriguchi M, Nishiyama M, Hara H, Node K.
  
• PCI using a 4-Fr "child" guide catheter in a "mother" guide catheter: Kyushu KIWAMI� ST registry.;　2010/12
  ANNOUNCEMENT INFO.;　Catheter Cardiovasc Interv. doi: 10.1002/ccd.22741., 76, 7, 919-923
  AUTHOR;　Hiwatashi A, Iwabuchi M, Yokoi H, Tayama S, Sakamoto T, Noda K, Shibata Y, Hikichi Y, Node K, Ueno T, Nobuyoshi M.
  
• On behalf of the PEARL Study Investigators. Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure The pitavastatin heart failure study (PEARL study).;　2010/11
  ANNOUNCEMENT INFO.;　Int J Cardiol.[Epub ahead of print]
  AUTHOR;　Mizuma H, Inoue T, Takano H, Shindo S, Oka T, Fujimatsu D, Kuwabara Y, Node K, Komuro I
  
• Low serum albumin level is risk factor for patients with percutaneous endoscopic gastrostomy.;　2010/11
  ANNOUNCEMENT INFO.;　Intern Med. 2010;49(21):2283-8., 49, 21, 2283-2288
  AUTHOR;　Tominaga N, Shimoda R, Iwakiri R, Tsuruoka N, Sakata Y, Hara H, Hayashi S, Morita S, Hamasaki Y, Matsushima T, Miyazaki K, Node K, Fujimoto K.
  
• Japan Arteriosclerosis Longitudinal Study (JALS) group. Body mass index and risk of stroke and myocardial infarction in a relatively lean population: meta-analysis of 16 Japanese cohorts using individual data.;　2010/09
  ANNOUNCEMENT INFO.;　Circ Cardiovasc Qual Outcomes., 3, 5, 498-505
  AUTHOR;　Yatsuya H, Toyoshima H, Yamagishi K, Tamakoshi K, Taguri M, Harada A, Ohashi Y, Kita Y, Naito Y, Yamada M, Tanabe N, Iso H, Ueshima H;
  
• Guidelines for Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease (JCS 2008);　2010/09
  ANNOUNCEMENT INFO.;　Circ J. 2010 Sep;74(9):1989-2020. Epub 2010 Aug 18., 74, 9, 1989-2020
  AUTHOR;　JCS Joint Working Group.
  
• Activation of matrix metalloproteinase-9 is associated with mobilization of bone marrow-derived cells after coronary stent implantation.;　2010/08
  ANNOUNCEMENT INFO.;　Int J Cardiol. [Epub ahead of print]
  AUTHOR;　Inoue T, Taguchi I, Abe S, Toyoda S, Nakajima K, Sakuma M, Node K.
  
• Noninvasive method for assessing the human circadian clock using hair follicle cells.;　2010/08
  ANNOUNCEMENT INFO.;　Proc Natl Acad Sci U S A., 107, 35, 15643-15648
  AUTHOR;　Akashi M, Soma H, Yamamoto T, Tsugitomi A, Yamashita S, Yamamoto T, Nishida E, Yasuda A, Liao JK, Node K.
  
• Guidelines for diagnosis and treatment of patients with vasospastic angina(coronary spastic angina) (JCS 2008): digest version.;　2010/08
  ANNOUNCEMENT INFO.;　Circ J., 74, 8, 1745-1762
  AUTHOR;　JCS Joint Working Group.
  
• Sulfatides are associated with neointimal thickening after vascular injury.;　2010/07
  ANNOUNCEMENT INFO.;　Atherosclerosis., 211, 1, 291-296
  AUTHOR;　Inoue T, Taguchi I, Abe S, Li G, Hu R, Nakajima T, Hara A, Aoyama T, Kannagi R, Kyogashima M, Node K.
  
• Ultrasonographic detection of thyroid nodules in hemodialysis patients in Japan.;　2010/06
  ANNOUNCEMENT INFO.;　 Ther Apher Dial., 14, 3, 323-327
  AUTHOR;　Sanai T, Okamura K, Inoue T, Abe T, Tsuruya K, Node K..
  
• Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study.;　2010/03
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol., 24, 9, 12
  AUTHOR;　Kato T, Inoue T, Node K.
  
• Medical agents acting on the renin-angiotensin-aldosterone axis for the treatment of heart failure.;　2010/03
  ANNOUNCEMENT INFO.;　Hypertens Res., 33, 3, 192-193
  AUTHOR;　Kawano H, Node K.
  
• Effect of exercise therapy on monocyte and neutrophil counts in overweight women.;　2010/02
  ANNOUNCEMENT INFO.;　Am J Med Sci., 339, 2, 152-156
  AUTHOR;　Michishita R, Shono N, Inoue T, Tsuruta T, Node K.
  
• Effects of PPARgamma agonist on dyslipidemia and atherosclerosis.;　2010/02
  ANNOUNCEMENT INFO.;　Nippon Rinsho. Review. Japanese., 68, 2, 294-298
  AUTHOR;　Komatsu A, Node K.
  
• Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker.;　2010/01
  ANNOUNCEMENT INFO.;　Clin Exp Hypertens., 32, 2, 121-128
  AUTHOR;　Komoda H, Inoue T, Node K.
  
• 透析導入後に初めて診断され、酵素補充療法が著効したFabry病の1例;　2010
  ANNOUNCEMENT INFO.;　, 43, 1, 99-103
  AUTHOR;　
  
• Body mass index and risk of stroke and myocardial infarction in a relatively lean population: meta-analysis of 16 Japanese cohorts using individual data.;　2010
  ANNOUNCEMENT INFO.;　Circ Cardiovasc Qual Outcomes. 3(5):498-505, 2010, 3, 5, 498-505
  AUTHOR;　Yatsuya H, Toyoshima H, Yamagishi K, Tamakoshi K, Taguri M, Harada A, Ohashi Y, Kita Y, Naito Y, Yamada M, Tanabe N, Iso H, Ueshima H; Japan Arteriosclerosis Longitudinal Study (JALS) group.
  
• Involvement of the protein kinase CK2 in the regulation of mammalian circadian rhythms.;　2009/06
  ANNOUNCEMENT INFO.;　Sci Signal., 2, 73, ra26-ra26
  AUTHOR;　Tsuchiya Y, Akashi M, Matsuda M, Goto K, Miyata Y, Node K, Nishida E.
  
• 不安定プラークの診断は可能だったか;　2009/05
  ANNOUNCEMENT INFO.;　, 3, 3, 230-230
  AUTHOR;　
  
• 虚血性心疾患;　2009/04
  ANNOUNCEMENT INFO.;　, 27, 4, 346-350
  AUTHOR;　
  
• Molecular basis of restenosis and novel issues of drug-eluting stents.;　2009/04
  ANNOUNCEMENT INFO.;　Circ J. 2009 Apr;73(4):615-21. Epub 2009 Mar 13. Review., 73, 4, 615-21
  AUTHOR;　Inoue T, Node K.
  
• Increased interleukin-13 levels in patients with chronic heart failure.;　2009/01
  ANNOUNCEMENT INFO.;　Int J Cardiol., 131, 421-423
  AUTHOR;　Nishimura Y, Inoue T, Nitto T, Morooka T, Node K.
  
• The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009).;　2009/01
  ANNOUNCEMENT INFO.;　Hypertens Res., 32, 1, 3-107
  AUTHOR;　Ogihara T, Kikuchi K, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuoka H, Matsuura H, Naruse M, Rakugi H, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Hisatome I, Katayama S, Kita T, Matsumoto M, Nakao K, Nishikawa T, Ouchi Y, Teramoto T, Ueda S, Yamasaki M, Yokoyama H, Abe I, Ando K, Arita M, Doi Y, Gejyo F, Goto A, Hasebe N, Hirata Y, Hirata Y, Hirawa N, Hirooka Y, Iseki K, Iso H, Ito M, Ito T, Itoh H, Kai H, Kamide K, Kashihara N, Kashiwagi A, Katsuya T, Kikuchi T, Kimura K, Kitamura K, Kiyohara Y, Kobayashi S, Kohara K, Kohno M, Komuro I, Kumagai H, Kushiro T, Kuwajima I, Makino H, Matsuzaki M, Minami J, Miyamori I, Morimoto S, Murohara T, Node K, Ogawa H, Ohya , Saito Y, Takahashi H, Takahashi S, Takazawa K, Tamura K, Tochikubo O, Tomino Y, Tomita K, Tsubakihara Y, Tsutsui H, Uchiyama S, Uehara Y, Ura N, Urata H, Watanabe T, Yamada H, Yamashina A, Yasujima M, Yoshimura M, Arakawa K, Kaneko Y, Omae T, Yoshinaga K, Abe K, Eto T, Fukiyama K, Hasegawa T, Hiwada K, Iimura O, Iinuma M, Ishii M, Saruta T, Takeshita A, Tsujimoto Y, Yazaki Y, Ishimitsu T, Rakugi H.
  
• Eicosapentaenoic acid increases cytochrome P-450 2J2 gene expression and epoxyeicosatrienoic acid production via peroxisome proliferator-activated receptor gamma in endothelial cells.;　2009
  ANNOUNCEMENT INFO.;　J Cardiol., 54, 3, 368-374
  AUTHOR;　＊Wang D, Hirase T, Nitto T, Soma M, Node K.
  
• Association between high molecular weight adiponectin levels and metabolic parameters.;　2009
  ANNOUNCEMENT INFO.;　J Atheroscler　Thromb., 16, 5, 553-559
  AUTHOR;　Fujimatsu D, Kotooka N, Inoue T, Nishiyama M, Node K
  
• Benefits and risks of combination therapy in hypertension.;　2009
  ANNOUNCEMENT INFO.;　Hypertens Res., 32, 9, 727-728
  AUTHOR;　Node K.
  
• Postprandial hyperglycemia as an etiological factor in vascular failure.;　2009
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol., 8, 23-23
  AUTHOR;　Node K, Inoue T.
  
• Ebstein anomaly by cardiac magnetic resonance imaging.;　2009
  ANNOUNCEMENT INFO.;　J Am Coll Cardiol., 53, 17, 1568-1568
  AUTHOR;　Nakamura I, Kotooka N, Komori Y, Node K.
  
• Benefits and limitations of cypher stent-based bifurcation approaches: in vitro evaluation using micro-focus CT scan.;　2009
  ANNOUNCEMENT INFO.;　Journal of Interventional Cardiology, 22, 2, 128-134
  AUTHOR;　Hikichi Y, Inoue T, Node K.
  
• Estimated glomerular filtration rate as a predictor of secondary outcomes in Japanese patients with coronary artery disease.;　2009
  ANNOUNCEMENT INFO.;　J Cardiol., 53, 2, 232-239
  AUTHOR;　＊Matsuo K, Inoue T, Node K.
  
• Molecular basis of restenosis and novel issues of drug-eluting stents.;　2009
  ANNOUNCEMENT INFO.;　Circ J., 73, 4, 615-621
  AUTHOR;　Inoue T, Node K.
  
• Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment.;　2009
  ANNOUNCEMENT INFO.;　Cardiovasc Diabetol., 28, 8, 5-5
  AUTHOR;　Node K, Inoue T, Boyko V, Goldberg I, Fisman EZ, Adler Y, Schwammenthal E, Matas Z, Behar S, Tenenbaum A.
  
• Identification of four novel mutations in F5 associated with congenital factor V deficiency.;　2009
  ANNOUNCEMENT INFO.;　Int J Hematol., 89, 1, 71-75
  AUTHOR;　Kanaji S, Kanaji T, Honda M, Nakazato S, Wakayama K, Tabata Y, Shibata S, Gondo H, Nakamura I, Node K, Miura M, Miyahara M, Okamura T, Nagumo F, Ohta S, Izuhara K.
  
• Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance.;　2009
  ANNOUNCEMENT INFO.;　Diabetes Res Clin Pract., 83, 1, 77-82
  AUTHOR;　Yokoyama H, Inoue T, Node K.
  
• Ebastein Anomaly by Cardiac Magnetic Resonance Imaging.;　2009
  ANNOUNCEMENT INFO.;　Journal of the American College of Cardiology, 53, 17, 1568-1568
  AUTHOR;　Nakamura I, Kotooka N, Komori Y, Node K.
  
• 慢性心不全の診断と治療;　2009
  ANNOUNCEMENT INFO.;　, 23, 5, 559-564
  AUTHOR;　
  
• Eicosapentaenoic acid increases cytochrome P-450 2J2 gene expression and epoxyeicosatrienoic acid production via peroxisome proliferator-activated receptor γ in endothelial cells.;　2009
  ANNOUNCEMENT INFO.;　J Cardiol. 54(3):368-74, 2009, 54, 3, 368-74
  AUTHOR;　Wang D, Hirase T, Nitto T, Soma M, Node K.
  
• Flow-mediated vasodilation as a diagnostic modality for vascular failure. Hypertens;　2009
  ANNOUNCEMENT INFO.;　Hypertens Res. 31(12):2105-13, 2009 Review., 31, 12, 2105-13
  AUTHOR;　Inoue T, Matsuoka H, Higashi Y, Ueda S, Sata M, Shimada KE, Ishibashi Y, Node K; Vascular Failure Workshop Group.
  
• Vascular Failure Workshop Group. Flow-mediated vasodilation as a diagnostic modality for vascular failure.;　2008/12
  ANNOUNCEMENT INFO.;　Hypertens Res., 31, 2105-2113
  AUTHOR;　Inoue T, Matsuoka H, Higashi Y, Ueda S, Sata M, Shimada KE, Ishibashi Y, Node K;
  
• Associations of monocytes, neutrophil count, and C-reactive protein with maximal oxygen uptake in overweight women.;　2008/12
  ANNOUNCEMENT INFO.;　J Cardiol., 52, 247-253
  AUTHOR;　Michishita R, Shono N, Inoue T, Tsuruta T, Node K.
  
• A polymorphism regulates CYP4A11 transcriptional activity and is associated with hypertension in a Japanese population.;　2008/12
  ANNOUNCEMENT INFO.;　Hypertension., 52, 1142-1148
  AUTHOR;　Sugimoto K, Akasaka H, Katsuya T, Node K, Fujisawa T, Shimaoka I, Yasuda O, Ohishi M, Ogihara T, Shimamoto K, Rakugi H.
  
• Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease.;　2008/12
  ANNOUNCEMENT INFO.;　Atherosclerosis. 2008 Dec;201(2):385-91., 201, 385-391
  AUTHOR;　Inoue T, Eguchi Y, Matsumoto T, Kijima Y, Kato Y, Ozaki Y, Waseda K, Oda H, Seiki K, Node K, Urade Y.
  
• Flow-mediated vasodilation as a diagnostic modality for vascular failure.;　2008/12
  ANNOUNCEMENT INFO.;　Hypertens Res. 2008 Dec;31(12):2105-13. Review., 31, 12, 2105-13
  AUTHOR;　Inoue T, Matsuoka H, Higashi Y, Ueda S, Sata M, Shimada KE, Ishibashi Y, Node K; Vascular Failure Workshop Group.
  
• Fracture of a sirolimus-eluting stent with migration.;　2008/11
  ANNOUNCEMENT INFO.;　Int J Cardiol., 130, 86-88
  AUTHOR;　Kamura A, Kawasaki T, Koga N, Inoue T, Node K.
  
• Prognostic value of pentraxin 3 in patients with chronic heart failure.;　2008/10
  ANNOUNCEMENT INFO.;　Int J Cardiol., 130, 19-22
  AUTHOR;　Kotooka N, Inoue T, Aoki S, Anan M, Komoda H, Node K.
  
• Renoprotective effect of telmisartan in patients with chronic kidney disease.;　2008/10
  ANNOUNCEMENT INFO.;　Clin Exp Hypertens., 30, 662-672
  AUTHOR;　Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Node K.
  
• [Prevention of CVD in patients with CKD].;　2008/09
  ANNOUNCEMENT INFO.;　Nippon Rinsho.Review. Japanese., 66, 9, 1741-1745
  AUTHOR;　Nishimoto-Hazuku A, Node K.
  
• Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome.;　2008/09
  ANNOUNCEMENT INFO.;　 Metabolism., 57, 1278-1285
  AUTHOR;　Uchida T, Shimizu M, Sakai Y, Nakano T, Hara K, Takebayashi K, Inoue T, Node K, Inukai T, Takayanagi K, Aso Y.
  
• A case report of nephrotic syndrome due to collapsing focal segmental glomerulosclerosis treated with low-density lipoprotein apheresis.;　2008/08
  ANNOUNCEMENT INFO.;　Ther Apher Dial., 12, 333-336
  AUTHOR;　Miyazono M, Tomiyoshi Y, Kishi T, Ikeda Y, Sakemi T, Sanai T, Node K.
  
• Endoscopic thoracic sympathectomy as a novel strategy for vasospastic angina refractory to medical treatments.;　2008/08
  ANNOUNCEMENT INFO.;　J Cardiol., 52, 49-52
  AUTHOR;　Yoshida K, Inoue T, Hirakawa N, Node K.
  
• Angiotensin II increases expression of IP-10 and the renin-angiotensin system in endothelial cells.;　2008/06
  ANNOUNCEMENT INFO.;　Hypertens Res., 31, 1257-1267
  AUTHOR;　Ide N, Hirase T, Nishimoto-Hazuku A, Ikeda Y, Node K.
  
• Telmisartan as a metabolic sartan for targeting vascular failure.;　2008/06
  ANNOUNCEMENT INFO.;　Expert Opin Pharmacother. 2008 Jun;9(8):1397-406., 9, 1397-1406
  AUTHOR;　Inoue T, Node K.
  
• Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor-1alpha upregulation in endothelial cells.;　2008/05
  ANNOUNCEMENT INFO.;　J Cardiovasc Pharmacol., 51, 267-273
  AUTHOR;　Nishimoto-Hazuku A, Hirase T, Ide N, Ikeda Y, Node K.
  
• Molecular defects associated with antithrombin deficiency and dilated cardiomyopathy in a Japanese patient.;　2008/05
  ANNOUNCEMENT INFO.;　Intern Med., 47, 925-931
  AUTHOR;　Fujimori Y, Okimatsu H, Kashiwagi T, Sanda N, Okumura K, Takagi A, Nagata K, Murate T, Uchida A, Node K, Saito H, Kojima T.
  
• Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency.;　2008/05
  ANNOUNCEMENT INFO.;　 Hypertens Res., 31, 841-850
  AUTHOR;　Nakamura T, Inoue T, Suzuki T, Kawagoe Y, Ueda Y, Koide H, Node K.
  
• Mechanical stretch and angiotensin II increase interleukin-13 production and interleukin-13 receptor alpha2 expression in rat neonatal cardiomyocytes.;　2008/04
  ANNOUNCEMENT INFO.;　Circ J., 72, 647-653
  AUTHOR;　Nishimura Y, Inoue T, Morooka T, Node K.
  
• Mitogen-activated protein kinase is a functional component of the autonomous circadian system in the suprachiasmatic nucleus.;　2008/04
  ANNOUNCEMENT INFO.;　J Neurosci., 28, 18, 4619-4623
  AUTHOR;　Akashi M, Hayasaka N, Yamazaki S, Node K.
  
• Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease.;　2008/03
  ANNOUNCEMENT INFO.;　Int J Cardiol., 124, 319-325
  AUTHOR;　Inoue T, Komoda H, Nonaka M, Kameda M, Uchida T, Node K.
  
• STAT6 mediates apoptosis of human coronary arterial endothelial cells by interleukin-13.;　2008/03
  ANNOUNCEMENT INFO.;　Hypertens Res., 31, 3, 535-541
  AUTHOR;　Nishimura Y, Nitto T, Inoue T, Node K.
  
• Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.;　2008/02
  ANNOUNCEMENT INFO.;　 Clin Nephrol., 70, 385-392
  AUTHOR;　Nakamura T, Inoue T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H, Node K.
  
• Reversible primary hypothyroidism in Japanese patients undergoing maintenance hemodialysis.;　2008/02
  ANNOUNCEMENT INFO.;　Clin Nephrol., 69, 107-113
  AUTHOR;　Sanai T, Inoue T, Okamura K, Sato K, Yamamoto K, Abe T, Node K, Tsuruya K, Iida M.
  
• Partial blood recirculation: a new trial for prolonging filter life during continuous hemodiafiltration.;　2008/02
  ANNOUNCEMENT INFO.;　 Ther Apher Dial., 12, 96-99
  AUTHOR;　Ikeda Y, Kishi T, Kishi C, Miyazono M, Okazaki Y, Nakashima M, Sakemi T, Sanai T, Node K.
  
• Increased circulating platelet-derived microparticles are associated with stent-induced vascular inflammation.;　2008
  ANNOUNCEMENT INFO.;　Atherosclerosis., 196, 469-476
  AUTHOR;　Inoue T, Komoda H, Kotooka N, Morooka T, Fujimatsu D, Hikichi Y, Soma R, Uchida T, Node K.
  
• Alternative spliced variants in the pantetheinase family of genes expressed in human neutrophils.;　2008
  ANNOUNCEMENT INFO.;　Gene., 426, 57-64
  AUTHOR;　Nitto T, Inoue T, Node K.
  
• IL-13 attenuates vascular tube formation via JAK2-STAT6 pathway.;　2008
  ANNOUNCEMENT INFO.;　Circ J., 72, 469-475
  AUTHOR;　Nishimura Y, Nitto T, Inoue T, Node K.
  
• Expression of the cytochrome P450 epoxygenase CYP2J2 in human monocytic leukocytes.;　2008
  ANNOUNCEMENT INFO.;　Life Sci., 83, 339-345
  AUTHOR;　Nakayama K, Nitto T, Inoue T, Node K.
  
• IL-13 Attenuates Vascular Tube Formation Via JAK2-STAT6 Pathway.;　2008
  ANNOUNCEMENT INFO.;　Circ J., 72, 3, 469-475
  AUTHOR;　Nishimura Y, Nitto T, Inoue T, Node K.
  
• Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening.;　2008
  ANNOUNCEMENT INFO.;　Atherosclerosis., 197, 1, 368-374
  AUTHOR;　Kotooka N, Inoue T, Fujimatsu D, Morooka T, Hashimoto S, Hikichi Y, Uchida T, Sugiyama A, Node K.
  
• Mechanical Stretch and Angiotensin II Increase Interleukin-13 Production and interleukin-13 Receptor alpha2 Expression in Rat Neonatal Cardiomyocytes.;　2008
  ANNOUNCEMENT INFO.;　Circ J., 72, 4, 647-653
  AUTHOR;　Nishimura Y, Inoue T, Morooka T, Node K.
  
• STAT6 mediates apoptosis of fuman coronary arterial endothelial cells by Interleukin-13.;　2008
  ANNOUNCEMENT INFO.;　Hypertens Res., 31, 535-541
  AUTHOR;　Nishimura Y, Nitto T, Inoue T, Node K.
  
• Simvastatin Stimulates Vascular Endothelial Growth Factor Production by Hypoxia-inducible Factor-1alpha Upregulation in Endothelial Cells.;　2008
  ANNOUNCEMENT INFO.;　J Cardiovasc Pharmacol., 51, 3, 267-273
  AUTHOR;　Nishimoto-Hazuku A, Hirase T, Ide N, Ikeda Y, Node K.
  
• Tropical fruit camu-camu(Myrciaria dubia) has anti-oxidative and anti-inflammatory properties.;　2008
  ANNOUNCEMENT INFO.;　J Cardiol., 52, 127-132
  AUTHOR;　Inoue T, Komoda H, Uchida T, Node K.
  
• 急性咽喉頭炎で入院した左房粘液腫の１例;　2008
  ANNOUNCEMENT INFO.;　, 57, 6, 933-937
  AUTHOR;　
  
• Alternative spliced variants in the pantetheinase family of genes expressed in human neutrophils.;　2008
  ANNOUNCEMENT INFO.;　Gene. 426(1-2):57-64, 2008, 426, 1-2, 57-64
  AUTHOR;　Nitto T, Inoue T, Node K.
  
• Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.;　2007/06
  ANNOUNCEMENT INFO.;　Am J Med Sci., 333, 6, 321-326
  AUTHOR;　Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K.
  
• Impaired glucose tolerance: A possible contributor to left ventricular hypertrophy and diastolic dysfunction.;　2007/05
  ANNOUNCEMENT INFO.;　Int J Cardiol., 118, 1, 76-80
  AUTHOR;　Fujita M, Asanuma H, Kim J, Liao Y, Hirata A, Tsukamoto O, Minamino T, Hori M, Goto M, Node K, Kitakaze M.
  
• Effect of Telmisartan on Cholesterol Levels in Patients with Hypertension - Saga Telmisartan Aggressive Research (STAR).;　2007/05
  ANNOUNCEMENT INFO.;　Horm Metab Res., 39, 5, 372-376
  AUTHOR;　Inoue T, Morooka T, Moroe K, Ikeda H, Node K.
  
• Association between silent ST segment depression in exercise electrocardiography and insulin resistance in obese subjects.;　2007/05
  ANNOUNCEMENT INFO.;　J Cardiol., 49, 5, 231-239
  AUTHOR;　Michishita R, Shono N, Kiyonaga A, Tanaka H, Shindo M, Kasahara T, Tsuruta T, Inoue T, Node K.
  
• Establishment of a quantitative, qualitative, and high-throughput analysis of sulfatides from small amounts of sera by matrix-assisted laser desorption ionization-time of flight mass spectrometry.;　2007/03
  ANNOUNCEMENT INFO.;　Anal Biochem., 362, 1, 1-7
  AUTHOR;　Li G, Hu R, Kamijo Y, Nakajima T, Aoyama T, Inoue T, Node K, Kannagi R, Kyogashima M, Hara A.
  
• Mobilization of CD34-Positive Bone Marrow-Derived Cells After Coronary Stent Implantation.;　2007/02
  ANNOUNCEMENT INFO.;　Circulation., 115, 5, 553-561
  AUTHOR;　Inoue T, Sata M, Hikichi Y, Sohma R, Fukuda D, Uchida T, Shimizu M, Komoda H, Node K.
  
• Effects of statins on restenosis after coronary stent implantation.;　2007/02
  ANNOUNCEMENT INFO.;　Angiology., 58, 1, 55-60
  AUTHOR;　Kamishirado H, Inoue T, Sakuma M, Tsuda T, Hayashi T, Takayanagi K, Node K.
  
• Remnant-like lipoprotein particle level and insulin resistance are associated with in-stent restenosis in patients with stable angina.;　2007/01
  ANNOUNCEMENT INFO.;　Coron Artery Dis., 18, 4, 319-322
  AUTHOR;　Kato T, Inoue T, Inagaki H, Hashimoto S, Hikichi Y, Tanaka A, Isobe M, Node K.
  
• Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study.;　2007/01
  ANNOUNCEMENT INFO.;　Am Heart J., 153, 6, 1055.e1-8
  AUTHOR;　Yamada T, Node K, Mine T, Morita T, Kioka H, Tsukamoto Y, Tamaki S, Masuda M, Okuda K, Fukunami M.
  
• Serum sulfatides as a novel biomarker for cardiovascular disease in patients with end-stage renal failure.;　2007
  ANNOUNCEMENT INFO.;　Glycoconj J., 24, 565-571
  AUTHOR;　Hu R, Li G, Kamijo Y, Aoyama T, Nakajima T, Inoue T, Node K, Kannagi R, Kyogashima M, Hara A.
  
• Statin therapy for vascular failure.;　2007
  ANNOUNCEMENT INFO.;　Cardiovasc Drugs Ther., 21, 281-295
  AUTHOR;　Inoue T, Node K.
  
• High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease.;　2007
  ANNOUNCEMENT INFO.;　Am J Cardiol., 100, 4, 569-574
  AUTHOR;　Inoue T, Kotooka N, Morooka T, Komoda H, Uchida T, Aso Y, Inukai T, Okuno T, Node K.
  
• Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus.;　2007
  ANNOUNCEMENT INFO.;　Metabolism., 56, 1458-1463
  AUTHOR;　Yokoyama H, Kannno S, Ishimura I, Node K.
  
• Clinical diagnosis of metabolic syndrome 4. Therapy for metabolic syndrome.;　2007
  ANNOUNCEMENT INFO.;　Intern Med., 46, 1289-1289
  AUTHOR;　Node K.
  
• Beneficial effects of olmesartan and temocapril on urinary liver-type Fatty Acid-binding protein levels in normotensive patients with immunoglobin a nephropathy.;　2007
  ANNOUNCEMENT INFO.;　Am J Hypertens., 20, 1195-1201
  AUTHOR;　Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K.
  
• Statin Therapy for Vascular Failure.;　2007
  ANNOUNCEMENT INFO.;　Cardiovascular Drugs & Therapy, 21, 281-295
  AUTHOR;　Inoue T, Node K.
  
• Anti-inflammatory Effects of Simvastatin on Human Oral Cells.;　2007
  ANNOUNCEMENT INFO.;　Inflammation and Regeneration.Mini Review, 27, 2, 107-111
  AUTHOR;　Sakoda K, Yamamoto M, Negishi Y, JK Liao, Node K, Izumi Y.
  
• 小山論文に対するEditorial Comment;　2007
  ANNOUNCEMENT INFO.;　, 39, 1, 32-32
  AUTHOR;　
  
• Effects of candesartan for middle-aged and elderly women with hypertension and menopausal-like symptoms.;　2006/12
  ANNOUNCEMENT INFO.;　Hypertens Res., 29, 12, 1007-1012
  AUTHOR;　Ikeda H, Inoue T, Uemura S, Kaibara R, Tanaka H, Node K.
  
• A new clinical entity for vascular disease.;　2006/12
  ANNOUNCEMENT INFO.;　J Hypertens., 24, 11, 2121-2130
  AUTHOR;　Inoue T, Node K.
  
• Atorvastatin therapy associated with improvement in left ventricular remodeling in a case of idiopathic dilated cardiomyopathy.;　2006/12
  ANNOUNCEMENT INFO.;　Am J Med Sci., 332, 6, 361-363
  AUTHOR;　Yamada T, Node K, Mine T, Morita T, Kioka H, Tamaki S, Tsukamoto Y, Masuda M, Okuda K, Fukunami M.
  
• Postprandial hyperglycemia is a possible contributor to paroxysmal atrial fibrillation: a case report.;　2006/11
  ANNOUNCEMENT INFO.;　J Cardiol., 48, 269-272
  AUTHOR;　Kato T, Ishida S, Morooka T, Inoue T, Node K.
  
• Simvastatin decreases IL-6 and IL-8 production in epithelial cells.;　2006/06
  ANNOUNCEMENT INFO.;　J Dent Res., 85
  AUTHOR;　Sakoda K, Yamamoto M, Negishi Y, Liao JK, Node K, Izumi Y.
  
• An appropriate indication for the initiation of beta-blocker therapy in dilated cardiomyopathy.;　2006/01
  ANNOUNCEMENT INFO.;　, 105, 1, 61-66
  AUTHOR;　Morooka T, Inoue T, Kotooka N, Fujimatsu D, Komatsu A, Uchida F, Yoshida K, Hashimoto S, Hikichi Y, Kato T, Node K.
  
• Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.;　2006
  ANNOUNCEMENT INFO.;　Am J Nephrol., 26, 1, 82-86
  AUTHOR;　Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Inoue T, Node K.
  
• Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.;　2006
  ANNOUNCEMENT INFO.;　Am J Kidney Dis., 47, 3, 439-444
  AUTHOR;　Nakamura T, Sugaya T, Node K, Ueda Y, Koide H.
  
• Stent-induced neutrophil activation is associated with an oxidative burst in the inflammatory process, leading to neointimal thickening.;　2006
  ANNOUNCEMENT INFO.;　Thromb Haemost., 95, 1, 43-48
  AUTHOR;　 Inoue T, Kato T, Hikichi Y, Hashimoto S, Hirase T, Morooka T, Imoto Y, Takeda Y, Sendo F, Node K.
  
• Low-density lipoprotein subfractions and the prevalence of silent lacunar infarction in subjects with essential hypertension.;　2006
  ANNOUNCEMENT INFO.;　Hypertens Res., 29, 5, 303-307
  AUTHOR;　Kato T, Inoue T, Yamagishi S, Morooka T, Okimoto T, Node K
  
• Atorvastatin inhibits angiotensin II-induced T-type Ca2+ channel expression in endothelial cells.;　2006
  ANNOUNCEMENT INFO.;　Biochem Biophys Res Commun., 347, 2, 394-400
  AUTHOR;　Wang D, Hirase T, Inoue T, Node K.
  
• Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin.;　2006
  ANNOUNCEMENT INFO.;　Diabetes., 55, 7, 1954-1960
  AUTHOR;　Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, Okuno T, Inoue T, Node K, Tobe T, Inukai T, Nakano Y.
  
• Short-term passive smoking causes endothelial dysfunction via oxidative stress in nonsmokers;　2006
  ANNOUNCEMENT INFO.;　Can J Physiol Pharmacol., 84, 5, 523-529
  AUTHOR;　Kato T, Inoue T, Morooka T, Yoshimoto N, Node K.
  
• Marked increase of insulin gene transcription by suppression of the Rho/Rho-kinase pathway.;　2006
  ANNOUNCEMENT INFO.;　Biochem Biophys Res Commun., 350, 1, 68-73
  AUTHOR;　Nakamura Y, Kaneto H, Miyatsuka T, Matsuoka TA, Matsuhisa M, Node K, Hori M, Yamasaki Y.
  
• Comparison of changes in circulating platelet-derived microparticles and platelet surface P-selectin expression after coronary stent implantation.;　2006
  ANNOUNCEMENT INFO.;　Platelets., 17, 6, 416-420
  AUTHOR;　Inoue T, Hikichi Y, Morooka T, Yoshida K, Fujimatsu D, Komoda H, Kameda M, Nonaka M, Sohma R, Hashimoto S, Node K.
  
• α-Glucosidease Inhibitors:New Therapeutic Agents for Chronic Heart Failure.;　2006
  ANNOUNCEMENT INFO.;　Hypertension Research, 29, 10, 741-742
  AUTHOR;　Node K
  
• A 71-Year-Old Man With Chest Pain;　2005/05
  ANNOUNCEMENT INFO.;　, 45, 5, 225-227
  AUTHOR;　
  
• Difference in the Influence of the Lipid Profile as a Coronary Risk Factor in Patients with and Without Diabetes Mellitus.;　2005
  ANNOUNCEMENT INFO.;　Vascular Disease Prevention, 2, 11-16
  AUTHOR;　Inoue T, Hayashi M, Uchida T, Sakuma M, Hayashi T, Nakajima K, Node K.
  
• Long-term benefits of monteplase before coronary angioplasty in acute myocardial infarction;　2005
  ANNOUNCEMENT INFO.;　AMERICAN JOURNAL OF CARDIOLOGY, 95, 4, 506-508
  AUTHOR;　Inoue, T / Nishiki, R / Kageyama, M / Chida, R / Hayashi, T / Takayanagi, K / Hikichi, Y / Node, K
  
• 肥満女性における高感度ＣＲＰと食後糖脂質代謝との関連;　2005
  ANNOUNCEMENT INFO.;　, 11, 1, 52-57
  AUTHOR;　
  
• Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients;　2005
  ANNOUNCEMENT INFO.;　BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 331, 1, 347-350
  AUTHOR;　Ohtoshi, K / Kaneto, H / Node, K / Nakamura, Y / Shiraiwa, T / Matsuhisa, M / Yamasaki, Y
  
• Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting.;　2005
  ANNOUNCEMENT INFO.;　J Am Coll Cardiol., 46, 2, 239-245
  AUTHOR;　Inoue T, Kato T, Uchida T, Sakuma M, Nakajima A, Shibazaki M, Imoto Y, Saito M, Hashimoto S, Hikichi Y, Node K.
  
• Therapeutic Potential of Monteplase in Acute Myocardiol Infarction.;　2005
  ANNOUNCEMENT INFO.;　AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 5, 4, 225-231
  AUTHOR;　Inoue, T / Nishiki, R / Kageyama, M / Node, K
  
• A calcium channel blocker amlodipine increases coronary blood flow via both adenosine- and NO-dependent mechanisms in ischemic hearts.;　2005
  ANNOUNCEMENT INFO.;　J Mol Cell Cardiol., 39, 4, 605-614
  AUTHOR;　Asanuma H, Minamino T, Sanada S, Ogita H, Kim J, Fujita M, Hirata A, Tsukamoto O, Ogai A, Node K, Hori M, Tomoike H, Kitakaze M.
  
• 感染症の関与はどこまであきらかになったか;　2005
  ANNOUNCEMENT INFO.;　, 24-29
  AUTHOR;　
  
• Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice.;　2004
  ANNOUNCEMENT INFO.;　Hypertension., 43, 2, 237-242
  AUTHOR;　Ogita H,Node K,Liao Y,Ishikura F,Beppu S,Asanuma H,Sanada S,Takashima S,Minamino T,Hori M,Kitakaze M
  
• Oestrogen increases myocardial blood now in men: assessment by 13N-ammonia positron emission tomography.;　2004
  ANNOUNCEMENT INFO.;　Nucleare Medicine Communications., 25, 557-562
  AUTHOR;　Yoshioka J,Hasegawa S,Node K,Nakatani D,Kitakaze M,Hori M,Nishimura T
  
• Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C.;　2004
  ANNOUNCEMENT INFO.;　Circulation., 110, 1, 51-57
  AUTHOR;　Sanada S,Asanuma H,Tsukamoto O,Minamino T,Node K,Takashima S,Fukushima T,Ogai A,Shinozaki Y,Fujita M,Hirata A,Okuda H,Shimokawa H,Tomoike H,Hori M,Kitakaze M
  
• Raloxifene improves coronary perfusion, cardiac contractility, and myocardial metabolism in the ischemic heart: role of phosphatidylinositol 3-kinase/ Akt pathway.;　2004
  ANNOUNCEMENT INFO.;　J Cardiovasc Pharmacol., 43, 6, 821-829
  AUTHOR;　Ogita H,Node K,Asanuma H,Sanada S,Kim J,Takashima S,Minamino T,Hori M,Kitakaze M.
  
• Beta-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts.;　2004
  ANNOUNCEMENT INFO.;　Circulation., 109, 22, 2773-2779
  AUTHOR;　Asanuma H,Minamino T,Sanada S,Takashima S,Ogita H,Ogai A,Asakura M,Liao Y,Asano Y,Shintani Y,Kim J,Shinozaki Y,Mori H,Node K,Kitamura S,Tomoike H,Hori M,Kitakaze M
  
• Methotrexate and MX-68, a new derivative of methotrexate, limit infarct size via adenosine-dependent mechanisms in canine hearts.;　2004
  ANNOUNCEMENT INFO.;　J Cardiovasc Pharmacol., 43, 4, 574-579
  AUTHOR;　Asanuma H,Sanada S,Ogai A,Minamino T,Takashima S,Asakura M,Ogita H,Shinozaki Y,Mori H,Node K,Tomoike H,Hori M,Kitakaze M
  
• Therapeutic potential of monteplase in acute myocardial infarction as a powerful thromolytic agent for pretreatment of coronary intervention.;　2004
  ANNOUNCEMENT INFO.;　Cardiovasc Drug Rev., 22, 4, 320-333
  AUTHOR;　Inoue T,Nishiki R,Kageyama M,Node K
  
• Selective blockade of serotonin 5-HT2A receptor increases coronary blood now via augmented cardiac nitric oxide release through 5-HTIB receptor in hypoperfused canine hearts.;　2004
  ANNOUNCEMENT INFO.;　J Mol Cell Cardiol., 37, 6, 1219-1223
  AUTHOR;　Fujita M,Minamino T,Sanada S,Asanuma H,Hirata A,Ogita H,Okada K,Tsukamoto O,Takashima S,Tomoike H,Node K,Hori M,Kitakaze M
  
• Opening of Ca2+-activated K+ channels is involved in ischemic preconditioning in canine hearts.;　2004
  ANNOUNCEMENT INFO.;　J Mol Cell Cardiol., 37, 6, 1213-1218
  AUTHOR;　Shintani Y,Node K,Asanuma H,Sanada S,Takashima S,Asano Y,Liao Y,Fujita M, Hirata A,Shinozaki Y,Fukushima T,Nagamachi Y,Okuda H,Kim J,Tomoike H,HoriM,Kitakaze M
  
• Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2.;　2004
  ANNOUNCEMENT INFO.;　Circulation., 110, 15, 2132-2136
  AUTHOR;　Spiecker M,Darius H,Hankeln T,Soufi M,Sattler AM,Schaefer JR,Node K,Borgel J,Mugge A,Lindpaintner K,Huesing A,Maisch B,Zeldin DC,Liao JK.
  
• Cilostazol Inhibits Leukocyte Integrin Mac-1, Leading to a Potential Reduction in Restenosis After Coronary Stent Implantation;　2004
  ANNOUNCEMENT INFO.;　JOURNAL- AMERICAN COLLEGE OF CARDIOLOGY, 44, 7, 1408-1414
  AUTHOR;　Inoue, T / Uchida, T / Sakuma, M / Imoto, Y / Ozeki, Y / Ozaki, Y / Hikichi, Y / Node, K
  
• Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase.;　2004
  ANNOUNCEMENT INFO.;　Circulation., 110, 15, 2143-2149
  AUTHOR;　Sanada S,Asanuma H,Minamino T,Node K,Takashima S,Okuda H,Shinozaki Y,Ogai A,Fujita M,Hirata A,Kim J,Asano Y,Mori H,Tomoike H,Kitamura S, Hori M,Kitakaze M
  
• 洞不全症候群,部分的心房停止,心房頻拍を呈した孤立性左室心筋緻密化障害の1例;　2003/08
  ANNOUNCEMENT INFO.;　, 19, 3, 372-376
  AUTHOR;　
  
• Aging of cardiovascular system and female hormone : Heart failure and estrogen;　2003/07
  ANNOUNCEMENT INFO.;　, 40, 4, 332-335
  AUTHOR;　
  
• Canine DNA array as a potential tool for combining physiology and molecular biology.;　2003
  ANNOUNCEMENT INFO.;　Circ J., 67, 788-792
  AUTHOR;　Asakura M,Takashima S,Asano Y,Honma T,Asanuma H,Sanada S,Shintani Y,Liao Y,Kim J,Ogita H,Node K,Minamino T,Yorikane R,Agai A,Kitamura S,Tomoike H,Hori M,Kitakaze M
  
• Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy.;　2003
  ANNOUNCEMENT INFO.;　Circulation., 108, 839-843
  AUTHOR;　Node K,Fujita M,Kitakaze M,Hori M,Liao JK
  
• Eicosapentaenoic acid reduces myocardial injury induced by ischemia and reperfusion in rabbit hearts.;　2003
  ANNOUNCEMENT INFO.;　J Cardiovasc Pharmacol., 41, 964-969
  AUTHOR;　Ogita H,Node K,Asanuma H,Sanada S,Takashima S,Minamino T,Soma M,Kim J,Hori M,Kitakaze M
  
• Impaired cardiac response to exercise in post-menopausal women:relationship with peripheral vascular function.;　2003
  ANNOUNCEMENT INFO.;　Nucl Med Commun., 24, 383-389
  AUTHOR;　Yoshioka J,Node K,Hasegawa S,Paul AK,Mu X,Maruyama K,Nakatani D,Kitakaze M,Hori M,Nishimura T
  
• Celiprolol increases coronary blood flow and reduces severity of myocardial ischemia via nitric oxide release.;　2003
  ANNOUNCEMENT INFO.;　J Cardiovasc Pharmacol., 41, 499-505
  AUTHOR;　Asanuma H,Node K,Minamino T,Sanada S,Takashima S,Ueda Y,Sakata Y,Asakura M,Kim J,Ogita H,Tada M,Hori M,Kitakaze M
  
• Long-acting Ca2+ blockers prevent myocardial remodeling induced by chronic NO inhibition in rats.;　2003
  ANNOUNCEMENT INFO.;　Hypertension., 41, 963-967
  AUTHOR;　Sanada S,Node K,Minamino T,Takashima S,Ogai A,Asanuma H,Ogita H,Liao Y,Asakura M,Kim J,Hori M,Kitakaze M
  
• プリン代謝性内因物質アデノシンの産生代謝系変異による心血管保護作用の究明及びその新治療法への応用．;　2003
  ANNOUNCEMENT INFO.;　, 30, 93-97
  AUTHOR;　
  
• The role of estrogen and estrogen-related drugs in cardiovasucular diseases.;　2003
  ANNOUNCEMENT INFO.;　Current Drug Metabolism.Review., 4, 497-504
  AUTHOR;　Ogita H, Node K, Kitakaze M.
  
• スタチンの心筋炎症抑制作用;　2003
  ANNOUNCEMENT INFO.;　, 24, 8, 1457-1464
  AUTHOR;　
  
• Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF:metalloproteinase inhibitors as a new therapy.;　2002
  ANNOUNCEMENT INFO.;　Nat Med., 8, 35-40
  AUTHOR;　Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Beppu S, Tada M, Hori M, Higashiyama S.
  
• Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation.;　2002
  ANNOUNCEMENT INFO.;　Am J Physiol., 282, 1703-1708
  AUTHOR;　Liao Y, Isikura F, Beppu S, Asakura M, Takashima S, Asanuma H, Sanada S, Kim J, Ogita H, Kuzuya T, Node K, Kitakaze M, Hori M.
  
• Adenosine-induced cardiac gene expression of inchemic murine hearts revealed by cDNA array hybridization.;　2002
  ANNOUNCEMENT INFO.;　Circulation Journal., 66, 93-96
  AUTHOR;　Asakura M, Kitakaze M, Sakata Y, Asanuma H, Sanada S, Kim J, Ogita H, Liao Y, Node K, Takashima S, Tada M, Hori M.
  
• Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart.;　2002
  ANNOUNCEMENT INFO.;　J Am Coll Cardiol., 40, 998-1005
  AUTHOR;　Ogita H, Node K, Asanuma H, Sanada, S, Liao Y, Takashima S, MD, Asakura M, Mori H, Shinozaki Y, Hori M, Kiatakaze M.
  
• Opening of the adenosine triphophate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide　synthesis :role of 70-kDa S6 kinase and extracellular signal-regulated kinase.;　2002
  ANNOUNCEMENT INFO.;　J Am Coll Cardiol., 40, 991-997
  AUTHOR;　Sanada S, Node K, Asanuma H, Ogita H, Takashima S, Minamino T, Asakura M, Liao Y, Ogai A, Kim J, Hori M, Kitakaze M.
  
• Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers synergistically increase coronary blood flow in canine ischemic myocardium: Role of bradykinin.;　2002
  ANNOUNCEMENT INFO.;　J Am Coll Cardiol., 40, 162-166
  AUTHOR;　Kitakaze M, Asanuma H, Funaya H, Node K, Takashima S, Sanada S, Asakura M, Ogai H, Kim J, Hori M.
  
• Association of (-)786T-C mutation of endothelial nitric oxide synthase gene with insulin resistance.;　2002
  ANNOUNCEMENT INFO.;　Diabetologia., 45, 1594-1601
  AUTHOR;　Ohtoshi K, Yamasaki Y, Gorogawa S, Hayaishi-Okano R, Node K, Matsuhisa M, Kajimoto Y, Hori M.
  
• 選択的エストロゲン受容体調節薬ラロキシフェンは心筋虚血再灌流障害を抑制する;　2002
  ANNOUNCEMENT INFO.;　, 39, 1, 55-56
  AUTHOR;　
  
• プリン代謝性内因物質アデノシンの産生代謝系変異による心血管保護作用の究明及びその新治療法への応用;　2002
  ANNOUNCEMENT INFO.;　, 29, 129-133
  AUTHOR;　
  
• Role of mitochondrial and sarcolemmal K　(ATP) channels in ischemic preconditioning of the canine heart.;　2001
  ANNOUNCEMENT INFO.;　Am J Physiol Heart Circ Physiol., 280, 256-263
  AUTHOR;　Sanada S, Kitakaze M, Asanuma H, Harada K, Ogita H, Node K, Takashima S, Sakata Y, Asakura M, Shinozaki Y, Mori H, Kuzuya T, Hori M.
  
• Activation of Gαlpha s mediates and induction of tissue-type plasminoger activator gene transcription by epoxyeicosatrienoic acids.;　2001
  ANNOUNCEMENT INFO.;　J Biol Chem., 276, 15983-15989
  AUTHOR;　Node K, Ruan X, Dai J, Yang SX, Graham L, Zeldin DC, Liao JK.
  
• Effects of bezafibrate and simvastatin on plasma lipoproteins in hypercholesterolemia resistant to hormone replacement therapy.;　2001
  ANNOUNCEMENT INFO.;　Maturitas., 38, 279-286
  AUTHOR;　Ohmichi M, Ikegami H, Kurachi H, Node K, Morishige K, Nishio Y, Adachi K, Matumoto K, Hayakawa J, Tasaka K, Azuma C, Murata Y.
  
• Differential subcellular actions of ACE inhibitors and AT(1) receptor antagonists on cardiac remodeling induced by chronic inhibition of NO synthesis in rats.;　2001
  ANNOUNCEMENT INFO.;　Hypertension., 38, 404-411
  AUTHOR;　Sanada S, Kitakaze M, Node K, Takashima S, Ogai A, Asanuma H, Sakata Y, Asakura M, Ogita H, Liao Y, Fukushima T, Yamada J, Minamino T, Kuzuya T, Hori M.
  
• Role of cellular acidosis in production of nitric oxide in canine ischemic myocardium.;　2001
  ANNOUNCEMENT INFO.;　J Mol Cell Cardiol., 33, 9, 1727-1737
  AUTHOR;　Kitakaze M, Node K, Takashima S, Asanuma H, Asakura M, Sanada S, Shinozaki Y, Mori H, Sato H, Kuzuya T, Hori M.
  
• Nifedipine limits infarct size via NO-dependent mechanisms in dogs.;　2001
  ANNOUNCEMENT INFO.;　Basic Res Cardiol., 96, 497-505
  AUTHOR;　Asanuma H, Kitakaze M, Node K, Takashima S, Sakata Y, Asakura M, Sanada S, Shinozaki Y, Mori H, Tada m, Kuzuya T, Hori M.
  
• Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase.;　2001
  ANNOUNCEMENT INFO.;　Circulation., 104, 705-710
  AUTHOR;　Sanada S, Kitakaze M, Papst PJ, Asanuma H, Node K, Takashima S, Asakura M, Ogita H, Liao Y, Sakata Y, Ogai A, Fukushima T, Yamada J, Shinozaki Y, Kuzuya T, Mori H, Terada N, Hori M.
  
• Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart.;　2001
  ANNOUNCEMENT INFO.;　Circ Res., 88, 175-180
  AUTHOR;　Sanada S, Kitakaze M, Papst PJ, Hatanaka K, Asanuma H, Aki T, Shinozaki Y, Ogita H, Node K, Takashima S, Asakura M, Yamada J, Fukushima T, Ogai A, Kuzuya T, Mori H, Terada N, Yoshida K, Hori M.
  
• Statins as antioxidant therapy for preventing cardiac myocytes hyperetrophy.;　2001
  ANNOUNCEMENT INFO.;　 J Clin Invest., 108, 1429-1437
  AUTHOR;　Takemoto M, Node K, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK.
  
• Benidipine, a long-acting Ca channel blocker, limits infarct size via bradykinin- and NO-dependent mechanisms in canine hearts.;　2001
  ANNOUNCEMENT INFO.;　Cardiovasc Drugs Ther., 15, 225-231
  AUTHOR;　Asanuma H, Kitakaze M, Node K, Takashima S, Sakata Y, Asakura M, Sanada S, Shinozaki Y, Mori H, Tada M, Kuzuya T, Hori M.
  
• K+チャネル開口薬ニコランジルのNo-reflow現象抑制効果及び心筋梗塞縮小効果の検討;　2001
  ANNOUNCEMENT INFO.;　, 22, 4, 698-700
  AUTHOR;　
  
• ニコランジル長期投与により,NO欠乏による慢性心肥大が血圧非依存性に抑制される　KATPチャネル開口がP70S6KとERKに及ぼす影響;　2001
  ANNOUNCEMENT INFO.;　, 22, 4, 708-711
  AUTHOR;　
  
• 内皮由来過分極因子（EDHF）の血管保護作用;　2001
  ANNOUNCEMENT INFO.;　, 41, 8, 445-451
  AUTHOR;　
  
• エストロゲンの心血管機能調節機構　　―NOとの連関―;　2001
  ANNOUNCEMENT INFO.;　, 24, 2, 59-62
  AUTHOR;　
  
• Cellular mechanisms of cardioprotection afforded by inhibitors of angiotensin converting enzyme in ischemic hearts: role of bradykinin and nitric oxide.;　2000/05
  ANNOUNCEMENT INFO.;　Hypertens Res.Review., 23, 3, 253-259
  AUTHOR;　Kitakaze M, Node K, Takashima S, Minamino T, Kuzuya T, Hori M.
  
• Increased cardiac levels of nitric oxide in patients with chronic heart failure.;　2000
  ANNOUNCEMENT INFO.;　Am J Cardiol., 86, 474-477
  AUTHOR;　Node K, Kitakaze M, Yoshihara F, Sasaki T, Kuzuya T, Hori M.
  
• Protein tyrosine kinase is not involved in the infarct size-limiting effect of ischemic preconditioning in canine hearts.;　2000
  ANNOUNCEMENT INFO.;　Circ Res., 87, 303-308
  AUTHOR;　Kitakaze M, Node K, Asanuma H, Takashima S, Sakata Y, Asakura M, Sanada S, Shinozaki Y, Mori H, Kuzuya T, Hori M.
  
• Cellular mechanisums of cardiopotenction afforded by inhibitors of angiotentsin converting enzyme in ischemic hearts: role of brandykinin and nitrico oxide.;　2000
  ANNOUNCEMENT INFO.;　 Hypertents Res.Review., 23, 253-259
  AUTHOR;　Kitakaze M, Node K, Takashima S, Minamino T, Kuzuya T, Hori M.
  
• 虚血プレコンディショニングの分子メカニズムの解明-細胞膜・ミトコンドリアATP感受性K+チャネル開口による相加的心筋梗塞サイズ縮小効果 　;　2000
  ANNOUNCEMENT INFO.;　, 20, 2, 103-111
  AUTHOR;　
  
• ATPと自律神経疾患　プレコンディショニングの分子メカニズム　細胞膜・ミトコンドリアATP感受性K+チャネル開口による虚血プレコンディショニングの心筋保護作用;　2000
  ANNOUNCEMENT INFO.;　, 37, 3, 349-356
  AUTHOR;　
  
• A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs.;　1999
  ANNOUNCEMENT INFO.;　J Am Coll Cardiol., 33, 242-249
  AUTHOR;　Kitakaze M, Node K, Minamino T, Asanuma H, Kuzuya T, Hori M.
  
• Improvement by 5-amino-4-imidazole carboxamide riboside of the contractile dysfunction that follows brief periods of ischemia through increases in ecto-5-nucleotidase activity and adenosine release in canine hearts.;　1999
  ANNOUNCEMENT INFO.;　Jpn Circ J., 63, 542-553
  AUTHOR;　Kitakaze M, Takashima S, Minamino T, Node K, Shinozaki Y, Mori H, Kuzuya T, Hori M.
  
• 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down regulation of p27(Kip1).;　1999
  ANNOUNCEMENT INFO.;　J Biol Chem., 274, 21926-21931
  AUTHOR;　Laufs U, Marra D, Node K, Liao JK.
  
• Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.;　1999
  ANNOUNCEMENT INFO.;　Science., 285, 1276-1279
  AUTHOR;　Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK.
  
• Intracoronary administration of adenosine triphosphate increases coronary blood flow and attenuates the severity of myocardial ischemic injury in dogs.;　1999
  ANNOUNCEMENT INFO.;　Cardiovasc Drugs Ther., 13, 407-414
  AUTHOR;　Kitakaze M, Node K, Komamura K, Minamino T, Kosaka H, Kuzuya T, Hori M.
  
• Adenosine and cardioprotection in the diseased heart.;　1999
  ANNOUNCEMENT INFO.;　Jpn Circ J.Review., 63, 231-243
  AUTHOR;　Kitakaze M, Minamino T, Node K, Takashima S, Funaya H, Kuzuya T, Hori M.
  
• ATP感受性K+チャネル開口による心筋梗塞縮小効果：分子メカニズムの検討;　1999
  ANNOUNCEMENT INFO.;　, 19, 161-169
  AUTHOR;　
  
• Role of Ca2+-activated K+ channels in the protective effect of ACE inhibition against ischemic myocardial injury.;　1998
  ANNOUNCEMENT INFO.;　Hypertension., 31, 1290-1298
  AUTHOR;　Node K, Kitakaze M, Kosaka H, Minamino T, Mori H, Hori M.
  
• Increased release of nitric oxide in ischemic hearts after exercise in patients with effort angina.;　1998
  ANNOUNCEMENT INFO.;　J Am Coll Cardiol., 32, 63-68
  AUTHOR;　Node K, Kitakaze M, Kosaka H, Sato H, Koretsune Y, Hori M.
  
• Elevation of plasma adenosine levels may attenuate the severity of hronic heart failure.;　1998
  ANNOUNCEMENT INFO.;　 Cardiovasc Drugs Ther., 12, 307-309
  AUTHOR;　Kitakaze M, Minamino T, Node K, Koretsune Y, Komamura K, Funaya H, Kuzuya T, Hori M.
  
• Inhibition of angiotensin-converting enzyme increases the nitric oxide levels in canine ischemic myocardium.;　1998
  ANNOUNCEMENT INFO.;　J Mol Cell Cardiol., 30, 2461-2466
  AUTHOR;　Kitakaze M, Node K, Minamino T, Asanuma H, Ueda Y, Kosaka H, Kuzuya T, Hori M.
  
• Nisoldipine selectively induces coronary vasodilation and improves mild myocardial ischemia in dogs: a potential role of cellular acidosis.;　1998
  ANNOUNCEMENT INFO.;　Cardiovasc Drugs Ther., 12, 533-541
  AUTHOR;　Kitakaze M, Funaya H, Komamura K, Node K, Minamino T, Mori H, Takeda H, Kuzuya T, Hori M.
  
• Effect of acute dynamic exercise on circulating plasma nitric oxide level and correlation to norepinephrine release in normal subjects.;　1997
  ANNOUNCEMENT INFO.;　Am J Cardiol., 79, 526-528
  AUTHOR;　Node K, Kitakaze M, Sato H, Koretsune Y, Katsube Y, Karita M, Kosaka K, Hori M.
  
• Activation of ecto-5'-nucleotidase by protein kinase C and its role ischemic tolerance in the canine heart.;　1997
  ANNOUNCEMENT INFO.;　Brit J Pharmacol., 120, 273-281
  AUTHOR;　Node K, Kitakaze M, Minamino T, Tada M, Inoue M, Hori M, Kamada T.
  
• Bradykinin mediation of Ca2+-activated K+ channels regulates coronary blood flow in ischemic myocardium.;　1997
  ANNOUNCEMENT INFO.;　Circulation., 95, 1560-1567
  AUTHOR;　Node K, Kitakaze M, Kosaka H, Minamino T, Hori M.
  
• Role of intracellular Ca2+ in activation of protein kinase C during ischemic preconditioning.;　1997
  ANNOUNCEMENT INFO.;　Circulation., 96, 4, 1257-1265
  AUTHOR;　Node K, Kitakaze M, Sato H, Minamino T, Komamura K, Shinozaki Y, Mori H, Hori M.
  
• Amelioration of ischemia- and reperfusion-induced myocardial injury by 17beta-estradiol: role of nitric oxide and calcium-activated potassium channels.;　1997
  ANNOUNCEMENT INFO.;　Circulation., 96, 1953-1963
  AUTHOR;　Node K, Kitakaze M, Kosaka H, Minamino T, Funaya H, Hori M.
  
• Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension.;　1997
  ANNOUNCEMENT INFO.;　 Hypertension., 30, 405-408
  AUTHOR;　Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M.
  
• eversible reduction in plasma concentrations of nitrogen oxide in induced by cirarette smorking in young adults.;　1997
  ANNOUNCEMENT INFO.;　 Am J Cardiol., 79, 11, 1538-1541
  AUTHOR;　Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M.
  
• Inhibition of nitric oxide synthesis increases adenosine production via an extracellular pathway through activation of protein kinase C.;　1997
  ANNOUNCEMENT INFO.;　Circulation, 96, 5, 1586-1592
  AUTHOR;　Minamino T, Kitakaze M, Node K, Funaya H, Hori M.
  
• Plasma adenosine levels increase in patients with chronic heart failure.;　1997
  ANNOUNCEMENT INFO.;　Circulation., 95, 1363-1365
  AUTHOR;　Funaya H, Kitakaze M, Node K, Minamino T, Komamura K, Hori M.
  
• Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart.;　1997
  ANNOUNCEMENT INFO.;　Circulatiomn., 95, 2108-2114
  AUTHOR;　Kitakaze M, Minamino T, Funaya H, Node K, Shinozaki Y, Mori H, Hori M.
  
• Temporary acidosis during early reperfusion limits infarct size in dogs.;　1997
  ANNOUNCEMENT INFO.;　Am J Physiol., 272, 2071-2078
  AUTHOR;　Kitakaze M, Takashima S, Minamino T, Node K, Komamura K, Shinozaki Y, Mori H, Inoue M, Hori M, Kamada T.
  
• Roles of NO and Ca2+－activated K + channels in coronary vasodilition induced by 17beta-estradiol in ischemic heart failure.;　1997
  ANNOUNCEMENT INFO.;　FASEB J., 11, 793-799
  AUTHOR;　Node K, Kitakaze M, Kosaka H, Minamino T, Mori H, Hori M.
  
• Vesnarinone inhibits adenosine uptake in endothelial cells, smooth muscle cells and myocytes, and mediates cytoprotection.;　1997
  ANNOUNCEMENT INFO.;　J Mol Cell Cardiol., 29, 3413-3417
  AUTHOR;　Kitakaze M, Fong M, Yoshitake M, Minamino T, Node K, Okuyama Y, Terada N, Kambayashi T, Hori M.
  
• Ecto-5'-nucleotidase mediates infarct size-limiting effect by ischemic preconditioning in the rabbit heart.;　1997
  ANNOUNCEMENT INFO.;　J Cardiovasc Pharmacol., 30, 775-783
  AUTHOR;　Komamura K, Kitakaze M, Funaya H, Ueda Y, Node K, Minamino T, Kurihara T, Hori M.
  
• Role of protein kinase C-alpha in activation of ecto-5'-nucleotidase in the preconditioned canine myocardium.;　1997
  ANNOUNCEMENT INFO.;　Biochem Biophys Res Commun., 239, 171-175
  AUTHOR;　Kitakaze M, Funaya H, Minamino T, Node K, Sato H, Ueda Y, Okuyama Y, Kuzuya T, Hori M, Yoshida K.
  
• Reversible reduction in plasma concentrations of nitrogen oxide in induced by cirarette smorking in young adults.;　1997
  ANNOUNCEMENT INFO.;　Am J Cardiol., 79, 1538-1541
  AUTHOR;　Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M.
  
• 心臓におけるATP感受性K+チャネル開口によるアデノシン・NO遊出増加作用;　1997
  ANNOUNCEMENT INFO.;　, 18, 3, 181-185
  AUTHOR;　
  
• Role of activation of ectosolic 5'-nucleotidase in the coardioprotection mediated by opening of K+c channels.;　1996
  ANNOUNCEMENT INFO.;　Am J Physiol., 270, 1744-1756
  AUTHOR;　Kitakaze M, Minamino T, Node K, Komamura K, Morioka T, Kurihara T, Shinozaki Y, Chujo M, Mori H, Inoue M, Hori M, Kamada T.
  
• Role of activation of protein kinase C the infarct size-limiting effect of ischemic preconditioning througth activation of ecto-5-nucleotidase.;　1996
  ANNOUNCEMENT INFO.;　Circulation., 93, 781-791
  AUTHOR;　Kitakaze M, Node K, Minamino T, Komamura K, Funaya H, Shinozaki Y, Chujo M, Mori H, Inoue M, Hori M, Kamada T.
  
• Cardioprotection due to preconditioning correlates with increased ecto-5-nucleotidase activity.;　1996
  ANNOUNCEMENT INFO.;　Am J Physiol., 270, 238-244
  AUTHOR;　Minamino T, Kitakaze M, Morioka T, Node K, Komamura K, Takeda H, Inoue M, Hori M, Kamada T.
  
• Role of nitric oxide in regulation of coronary blood flow during myocardium ischemia in dogs.;　1996
  ANNOUNCEMENT INFO.;　J Am Coll Cardiol., 27, 1804-1812
  AUTHOR;　Kitakaze M, Node K, Takashima S, Minamino T, Komamura K, Kosaka H, Shinozaki Y, Chujo M, Mori H, Inoue M, Hori M, Kamada T.
  
• Activation of ecto-5'-nucleotidase by protein kinase C attenuates irreversible cellular injury due to hypoxia and reoxygenation in rat cardiomyocytes.;　1996
  ANNOUNCEMENT INFO.;　J Mol Cell Cardiol., 28, 1945-1955
  AUTHOR;　Kitakaze M, Minamino T, Node K, Komamura K, Inoue M, Hori H, Kamada T.
  
• Activated polymorphonuclear leukocytes induce constriction of canine coronary artery via Mac-1,but not LFA-1,and ICAM-1.;　1996
  ANNOUNCEMENT INFO.;　J Mol Cell Cardiol., 28, 1575-1581
  AUTHOR;　Minamino T, Kitakaze M, Node K, Funaya H, Inoue M, Hori M, Kamada T.
  
• Increased release of NO during ischemia reduces myocardial contractility and improves metabolic dysfunction.;　1996
  ANNOUNCEMENT INFO.;　Circulation., 93, 356-364
  AUTHOR;　Node K, Kitakaze M, Kosaka H, Komamura K, Minamino T, Tada M, Inoue M, Hori M, Kamada T.
  
• Adenosine inhibits leukocyte-induced vasoconstriction.;　1996
  ANNOUNCEMENT INFO.;　Am J physiol., 271, 2622-2628
  AUTHOR;　Minamino T, Kitakaze M, Node K, Funaya H, Inoue M, Hori M, Kamada T.
  
• Activation of ecto-5'-nucleotidase and cardioprotection by ischemic preconditioning (Brief Review).;　1996
  ANNOUNCEMENT INFO.;　Basic Res Cardiol., 91, 23-26
  AUTHOR;　Kitakaze M, Minamino T, Node K, Hori M, Kamada T.
  
• ATP感受性K+チャネル開口薬の心筋梗塞縮小効果とprotein kinase C活性化の役割;　1996
  ANNOUNCEMENT INFO.;　, 17, 109-113
  AUTHOR;　
  
• Alpha 1-adrenoceptor activation increases ecto-5'-nucleotidase activity and adenosine release in rat cardiomyocytes by activating protein kinase C.;　1995
  ANNOUNCEMENT INFO.;　Circulation., 91, 8, 2226-2234
  AUTHOR;　Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Okazaki Y, Node K, Komamura K, Iwakura K, Itoh T, Inoue M, Kamada T.
  
• Evidence for nitric oxide generation in the cardiomyocytes: its augmentation by hypoxia.;　1995
  ANNOUNCEMENT INFO.;　J Mol Cell Cardiol., 27, 2149-2154
  AUTHOR;　Kitakaze M, Node K, Komamura K, Minamino T, Inoue M, Hori M, Kamada T.
  
• Beneficial effects of inhibition of angiotensin converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs.;　1995
  ANNOUNCEMENT INFO.;　Circulation., 92, 4, 950-961
  AUTHOR;　Kitakaze M, Minamino T, Node K, Komamura K, Shinozaki Y, Mori H, Kosaka H, Inoue M, Hori M, Kamada T.
  
• Bidirectional effects of aminophylline on myocardial ischemia.;　1995
  ANNOUNCEMENT INFO.;　Circulation., 92, 1254-1260
  AUTHOR;　Minamino T, Kitakaze M, Hori M, Morioka T, Node K, Shinozaki Y, Chujo M, Mori, Takeda H, Inoue M, Kamada T.
  
• Downward shift of coronary pressure –flow relationship following a brief period of ichemia in dogs.;　1995
  ANNOUNCEMENT INFO.;　Am J Physiol., 269, 1237-1245
  AUTHOR;　Morioka T, Kitakaze M, Minamino T, Takashima S, Node K, Sato H, Shinozaki Y, Chujo M, Mori H, Inoue M, Hori M, Kamada T.
  
• Activation of protein kinase C increases adenosine production in the hypoxic canine coronary artery through the extracellular pathway.;　1995
  ANNOUNCEMENT INFO.;　Arterioscler Thromb Vasc Biol., 15, 2298-2304
  AUTHOR;　Minamino T, Kitakaze M, Komamura K, Node K, Takeda H, Inoue M, Hori M, Kamada T.
  
• Plasma nitric oxide end products are increased in the ischemic canine heart.;　1995
  ANNOUNCEMENT INFO.;　Biochem Biophys Res Commum., 211, 370-374
  AUTHOR;　Node K, Kitakaze M, Kosaka H, Komamura K, Minamino T, Tada M, Inoue M, Hori M, Kamada T.
  
• Roles of alpha 1-adrenoceptor activity in release of nitric oxide during ischemia of canine heart.;　1995
  ANNOUNCEMENT INFO.;　Biochem Biophys Res Commun., 212, 1133-1138
  AUTHOR;　Node K, Kitakaze M. Kosaka H, Komamura K, Minamino T, Tada M, Inoue M, Hori M, Kamada T.
  
• Effect of coronary perfusion on myocardial contractility in the heart.;　1995
  ANNOUNCEMENT INFO.;　In; Hori M, Maruyama Y, Reneman RS, eds. Cardiac adaptation and failure. Tokyo : Springer-Verlag., 21-35
  AUTHOR;　Kitakaze M, Minamino T, Morioka T, Node K, Inoue M, Hori M, Kamada T, Marban E.
  
• Beneficial role of interaction between -adrenoceptor activity and adenosine in myocardial ischemc and reperfusion injury.;　1995
  ANNOUNCEMENT INFO.;　In; Hori M, Maruyama Y, Reneman RS, eds. Cardiac adaptation and failure. Tokyo : Springer-Verlag., 48-52
  AUTHOR;　Hori M, Kitakaze M, Morioka T, Minamino T, Takashima S, Satoh H, Node K, Inoue M, Kamada T.
  
• Role of activation of ecto-5'-nucleotidase for cardioprotection in ischemic preconditioning. In: Berardinelli L, Pelleg A, eds.;　1995
  ANNOUNCEMENT INFO.;　Adenosine and adenine nucleotides: from molecular biology to integrative physiology. Boston: Kluwer Academic Publisher., 361-371
  AUTHOR;　Kitakaze M, Minamino T, Node K, Komamura K, Kurihara T, Inoue M, Hori M, Kamada T.
  
• Role of activation of ecto-5'-nucleotidase for cardioprotection in ischemic and reperfusion injury: Role of purine and adenosine metabolism;　1995
  ANNOUNCEMENT INFO.;　 In; A. Abd-Elfattah S, eds. Purine and myocardial protection. Boston: Kluwer Academic Publisher., 469-480
  AUTHOR;　Kitakaze M, Node K, Minamino T, Komamura K, Inoue M, Hori M, Kamada T.
  
• β受容体遮断薬Na＋/H＋交換阻害薬の短期投与による心筋症自然発症ハムスターの心筋組織線維化抑制作用;　1995
  ANNOUNCEMENT INFO.;　, 26, 263-264
  AUTHOR;　
  
• ATP感受性K＋チャネル開口の心筋壊死縮小効果0とそのメカニズムに関する検討;　1995
  ANNOUNCEMENT INFO.;　, 16, 79-85
  AUTHOR;　
  
• 虚血性心疾患患者における運動負荷によるNitric Oxide（NO）産生の増加;　1995
  ANNOUNCEMENT INFO.;　, 32, 148-149
  AUTHOR;　
  
• Lippolysaccaride投与によるアデノシン産生酵素活性化と心筋虚血耐性効果;　1995
  ANNOUNCEMENT INFO.;　, 31, 166-167
  AUTHOR;　
  
• AICA riboside myocardial ischemia in coronary microembolization in dogs.;　1994/10
  ANNOUNCEMENT INFO.;　Am J Physiol., 267, 4, 1483-1495
  AUTHOR;　Hori M, Kitakaze M, Takashima S, Morioka T, Sato H, Minamino T, Node K, Komamura K, Inoue M, Kamada T.
  
• Evidence for deactivation of both ectosolic and cytosolic 5'-nucleotidase by adenosine A1 receptor activation in the rat cardiomyocyte.;　1994
  ANNOUNCEMENT INFO.;　J Clin Invest., 94, 6, 2451-2456
  AUTHOR;　Kitakaze M, Hori M, Minamino T, Takashima S, Komamura K, Node K, Kurihara T,Morioka T, Sato H, Inoue M, Kamada T.
  
• Roles of α-adrenoceptor activity and adenosine linkage in myocardial ischemic and reperfusion injury. In; Nimi H, Oda M, Sawada T, Xiu RJ, eds.;　1994
  ANNOUNCEMENT INFO.;　Progress in microcirculation research. Tokyo: Pergamon., 371-374
  AUTHOR;　Kitakaze M, Hori M, Minamino T, Morioka T, Node K, Takashima S, Sato H, Komamura K, Inoue M, Kamada T.
  
• 堀　正二、北風政史、森岡敏一、岡崎康司、南野哲男、野出孝一;　1994
  ANNOUNCEMENT INFO.;　, 34, 905-909
  AUTHOR;　
  
• 冠血管アデノシン産生におけるアデノシン産生酵素活性の役割;　1994
  ANNOUNCEMENT INFO.;　, 84, 1005-1010
  AUTHOR;　
  
• Becker型筋ジストロフィーの心不全を合併した一例;　1994
  ANNOUNCEMENT INFO.;　, 23, 54-58
  AUTHOR;　
  
• Ischemic Preconditioningの心筋壊死縮小効果におけるアデノシン産生増加の意義;　1993
  ANNOUNCEMENT INFO.;　, 1330-1332
  AUTHOR;　
  
• Nucleotide sequence of the hag gene encoding flagellin of Escherichia coli.;　1986/12
  ANNOUNCEMENT INFO.;　J Bacteriol. 1986 Dec;168(3):1479-83., 168, 1479-1483
  AUTHOR;　Kuwajima G, Asaka J, Fujiwara T, Fujiwara T, Node K, Kondo E.
  

Material, Commentary, Editorials, Research Report, A Comprehensive Journal Articles

• Efficacy of Cardiac Computed Tomography for Diagnostic and Therapeutic Evaluation of Bioprosthetic Valve Thrombosis;　2022/05
  ANNOUNCEMENT INFO.;　Circ J, 86, 6, 1023
  AUTHOR;　Hikari Sakai, Kensuke Yokoi, Kohei Kaneta, Goro Yoshioka, Yoshiko Sakamoto, Koichi Node
  
• Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19) ;　2022/03
  ANNOUNCEMENT INFO.;　Circ J, 86, 4, 721
  AUTHOR;　Kohei Kaneta, Kensuke Yokoi, Kota Jojima, Norihiko Kotooka, Koichi Node
  
• First report of lotus root-like appearance at the site of coronary spasm in a patient with acute coronary syndrome ;　2020/07
  ANNOUNCEMENT INFO.;　Eur Heart J Case Rep . , 4, 4, 1-2
  AUTHOR;　Goro Yoshioka, Kensaku Nishihira, Yoshisato Shibata, Koichi Node
  
• In-stent restenosis following third-generation sirolimus-eluting stent implantation: first report analysed from imaging modalities and histopathological findings ;　2020/05
  ANNOUNCEMENT INFO.;　Eur Heart J. , 41, 17, 1707
  AUTHOR;　Goro Yoshioka, Kensaku Nishihira, Yujiro Asada, Koichi Node
  
• Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia ;　2020/05
  ANNOUNCEMENT INFO.;　CEN Case Rep. , 9, 2, 141-146
  AUTHOR;　Atsushi Tanaka, Tsukasa Nakamura, Eiichi Sato, Atsuko Chihara, Koichi Node
  
• Acute mitral regurgitation of unknown etiology associated with disseminated intravascular coagulation eventually diagnosed as enterococcus faecalis infective endocarditis by mitral valve surgery.;　2018
  ANNOUNCEMENT INFO.;　Am J Case Rep. , 19, 1467-1473
  AUTHOR;　〇Yamashita S, Tago M, Katsuki NE, Ajimi T, Nagatomo D, Kotooka N, Node K, Yamashita SI.
  
• Multiple potency of ezetimibe in a patient with macroproteinuric chronic kidney disease and statin-intolerant dyslipidemia. ;　2018
  ANNOUNCEMENT INFO.;　J Cardiol Cases. , 17, 6, 204-207
  AUTHOR;　Sawami K, Tanaka A, Nakamura T, Sato E, Ueda Y, Node K.
  
• Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome.;　2017
  ANNOUNCEMENT INFO.;　Intern Med. , 56, 2, 191-196
  AUTHOR;　Tanaka A, Nakamura T, Sato E, Ueda Y, Node K.
  
• Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report. ;　2017
  ANNOUNCEMENT INFO.;　Drugs R D. , 17, 1, 97-101
  AUTHOR;　Tanaka A, Nakamura T, Sato E, Node K.
  
• Therapeutic potential of tofogliflozin on nephrotic syndrome secondary to diabetic nephropathy;　2017
  ANNOUNCEMENT INFO.;　Journal of Cardiology Cases , 16, 1, 30-33
  AUTHOR;　Tanaka A, Nakamura T, Sato E, Node K
  
• Coexistence of atypical hemolytic uremic syndrome and crescentic IgA nephropathy treated with eculizumab: a case report;　2016
  ANNOUNCEMENT INFO.;　Clinical Nephrology_ Case Studies. , 4, 24-28
  AUTHOR;　D Matsumura, A Tanaka, T Nakamura, E Sato, K Node.
  
• Progressive idiopathic nodular glomerulosclerosis mimicking diabetic nephropathy without abnormal glycemic metabolism.;　2016
  ANNOUNCEMENT INFO.;　Nephrology (Carlton). , 21, 12, 1074-1075
  AUTHOR;　Tanaka A, Nakamura T, Sato E, Ueda Y, Node K.
  
• Impact of low-density lipoprotein apheresis for nephrotic syndrome in a patient with immunoglobulin M nephropathy. ;　2016
  ANNOUNCEMENT INFO.;　Nephrology (Carlton). , 21, 12, 1073-1074
  AUTHOR;　Tanaka A, Nakamura T, Sato E, Node K.
  
• Aquaporin-2 is a potential biomarker for tolvaptan efficacy in decompensated heart failure complicated by diabetic nephrotic syndrome. ;　2016
  ANNOUNCEMENT INFO.;　Int J Cardiol. , 210, 1-3
  AUTHOR;　Tanaka A, Nakamura T, Sato E, Node K.
  
• 洞不全症候群と心不全を発症した筋緊張性ジストロフィーの1例;　2009/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 済生会熊本病院での急性大動脈解離内科治療;　2009
  ANNOUNCEMENT INFO.;　, 33, 10, 769-774
  AUTHOR;　
  
• 連日透析後１回の心嚢穿刺で劇的な軽快を得た、尿毒症性心外膜炎による心タンポナーデの1例;　2009
  ANNOUNCEMENT INFO.;　, 42, 10, 791-796
  AUTHOR;　
  
• 防げ!！心血管疾患;　2007/03
  ANNOUNCEMENT INFO.;　, 14-14
  AUTHOR;　
  
• 日本心臓病学会雑感-鹿児島で感じたこと-;　2007
  ANNOUNCEMENT INFO.;　, 310-311
  AUTHOR;　
  
• ＜合併症発症予防と進展抑制の視点から＞循環器からの提言;　2006
  ANNOUNCEMENT INFO.;　, 197, 1, 113-117
  AUTHOR;　
  
• 各種薬剤の副作用とその予防効果　抗不整脈薬の副作用の予防対策;　2006
  ANNOUNCEMENT INFO.;　, 83, 9, 1306-1310
  AUTHOR;　
  
• プレイオトロピック効果からみたスタチンの特徴;　2006
  ANNOUNCEMENT INFO.;　, 42, 6, 733-737
  AUTHOR;　
  
• ＜酸化ストレスとRAS＞臨床知見　心血管系を中心とした新しいエビデンス;　2006
  ANNOUNCEMENT INFO.;　, 3, 4, 280-285
  AUTHOR;　
  
• ＜性差医学　性差の背景を探る　遺伝子・ホルモン・環境＞疾患と性差　各科における最新エビデンス　循環器疾患における性差;　2006
  ANNOUNCEMENT INFO.;　, 219, 5, 359-362
  AUTHOR;　
  
• 危険因子　高血圧　高感度CRP;　2006
  ANNOUNCEMENT INFO.;　, 5, 2, 74-75
  AUTHOR;　
  
• 血管内皮機能と未病　血管内皮機能と動脈硬化;　2006
  ANNOUNCEMENT INFO.;　, 12, 1, 38-39
  AUTHOR;　
  
• 冠動脈疾患とスタチン;　2006
  ANNOUNCEMENT INFO.;　, 54, 8, 887-891
  AUTHOR;　
  
• 酸化ストレス制御による予防・治療　スタチンの抗酸化作用;　2006
  ANNOUNCEMENT INFO.;　, 218, 1, 111-113
  AUTHOR;　
  
• 慢性心不全治療の最新の進歩;　2006
  ANNOUNCEMENT INFO.;　, 16, 90-91
  AUTHOR;　
  
• 糖尿病患者の予後決定に関する病態解析　糖尿病と血管内皮細胞機能異常;　2006
  ANNOUNCEMENT INFO.;　, 17, 1, 54-60
  AUTHOR;　
  
• ＜性差医療＞循環器疾患と性差　高血圧と性差;　2006
  ANNOUNCEMENT INFO.;　, 60, 6, 848-851
  AUTHOR;　
  
• 動脈硬化の病態基盤　酸化ストレスの意義;　2006
  ANNOUNCEMENT INFO.;　, 59, 114-120
  AUTHOR;　
  
• 動脈硬化の血管基盤　血管内皮細胞と動脈硬化;　2006
  ANNOUNCEMENT INFO.;　, 59, 21-24
  AUTHOR;　
  
• メタボリックシンドロームにおける動脈硬化予防をめざした薬物療法の可能性;　2006
  ANNOUNCEMENT INFO.;　, 217, 1, 23-26
  AUTHOR;　
  
• ＜糖尿病合併症マネージメント＞糖尿病と虚血性心疾患;　2006
  ANNOUNCEMENT INFO.;　, 94, 1, 91-96
  AUTHOR;　
  
• ＜高脂血症管理　今後の展望＞スタチンのプレイオトロピック効果をどう評価するか？;　2006
  ANNOUNCEMENT INFO.;　, 4, 3, 18-24
  AUTHOR;　
  
• メタボリックシンドロームからみた高血圧治療;　2006
  ANNOUNCEMENT INFO.;　, 6, 4, 2-6
  AUTHOR;　
  
• ＫATPチャネル開口薬による心筋虚血プレコンディショニング;　2006
  ANNOUNCEMENT INFO.;　, 26, 1, 47-55
  AUTHOR;　
  
• Ca拮抗薬によるプラークの安定化;　2006
  ANNOUNCEMENT INFO.;　, 273, 20-21
  AUTHOR;　
  
• 次々と動脈硬化症を発症したメタボリックシンドロームの１例;　2006
  ANNOUNCEMENT INFO.;　, 10, 1, 47-51
  AUTHOR;　
  
• 心不全と血管機能;　2006
  ANNOUNCEMENT INFO.;　, 59, 3, 223-238
  AUTHOR;　
  
• ＜プライマリ・ケア医のための高血圧診療のコツ＞降圧薬コンビネーションに関して　併用に注意が必要な組み合わせにはどのようなものがあるか;　2006
  ANNOUNCEMENT INFO.;　, 8, 4, 1303-1307
  AUTHOR;　
  
• 目で見る性差医学;　2006
  ANNOUNCEMENT INFO.;　, 13, 2, 2-5
  AUTHOR;　
  
• 食後高血糖がもたらす血管内皮機能不全;　2006
  ANNOUNCEMENT INFO.;　, 16, 84-85
  AUTHOR;　
  
• メタボリックシンドロームの臨床　メタボリックシンドロームの治療;　2006
  ANNOUNCEMENT INFO.;　, 95, 9, 1737-1741
  AUTHOR;　
  
• PROactiveの臨床的意義―サブグループ解説（心筋梗塞既往例）の観点から―;　2006
  ANNOUNCEMENT INFO.;　, 2, 71-79
  AUTHOR;　
  
• 糖尿病マクロアンギオパシーの検査・診断法の進歩　血管内皮機能評価法;　2006
  ANNOUNCEMENT INFO.;　, 64, 11, 2069-2073
  AUTHOR;　
  
• 急性冠症候群と炎症;　2006
  ANNOUNCEMENT INFO.;　, 38, 11, 1073-1073
  AUTHOR;　
  
• ＜急性冠症候群と炎症＞新規炎症マーカー;　2006
  ANNOUNCEMENT INFO.;　, 387, 11, 1078-1088
  AUTHOR;　
  
• 基礎研究と臨床研究から考えるRASの病態への関与;　2006
  ANNOUNCEMENT INFO.;　, 26, 12
  AUTHOR;　
  
• 循環器領域における糖尿病治療薬の位置づけはどう変わるか;　2006
  ANNOUNCEMENT INFO.;　, 39, 3, 38-39
  AUTHOR;　
  
• DEAL座談会　冠動脈疾患患者における積極的脂質低下療法の重要性に新たなエビデンス;　2006
  ANNOUNCEMENT INFO.;　, 39, 4, 24-25
  AUTHOR;　
  
• Ca拮抗薬のbeyond blood pressure lowering effects;　2006
  ANNOUNCEMENT INFO.;　, 39, 4, 32-33
  AUTHOR;　
  
• ASCOT-サブ解析の結果をどう捉えるか-循環器領域の専門家のコメント集;　2006
  ANNOUNCEMENT INFO.;　, 39, 5, 33
  AUTHOR;　
  
• 心血管イベントの多角的予防戦略を考える　食後高血糖による血管障害の機序とその予防;　2006
  ANNOUNCEMENT INFO.;　, 39, 5, 50-51
  AUTHOR;　
  
• MEGA Study-そのエビデンスをいかに日常臨床に活かすか-;　2006
  ANNOUNCEMENT INFO.;　, 39, 5, 54-55
  AUTHOR;　
  
• 座談会　高血圧症がもたらす血管病変を意識した降圧療法の重要性;　2006
  ANNOUNCEMENT INFO.;　, 39, 9, 14-15
  AUTHOR;　
  
• アムロジピンとアトルバスタチンのシナジー効果;　2006
  ANNOUNCEMENT INFO.;　, 39, 11, 30-31
  AUTHOR;　
  
• 日本の降圧療法の課題に挑む;　2006
  ANNOUNCEMENT INFO.;　, 39, 12, 16
  AUTHOR;　
  
• TRENDY試験から得られたエビデンス;　2006
  ANNOUNCEMENT INFO.;　, 39, 11, 42-43
  AUTHOR;　
  
• 対談　Ca拮抗薬の血管保護作用を考える;　2006
  ANNOUNCEMENT INFO.;　, 24, 3, 150-155
  AUTHOR;　
  
• インタビュー　CHARM試験を語る;　2006
  ANNOUNCEMENT INFO.;　, 3, 2, 55-64
  AUTHOR;　
  
• 血管不全(Vascular Failure)予防を考慮した食後高血糖管理;　2006
  ANNOUNCEMENT INFO.;　, 39, 21, 65-65
  AUTHOR;　
  
• 座談会　今こそβ遮断薬の魅力を考える;　2006
  ANNOUNCEMENT INFO.;　, 39, 25,26, 22-23
  AUTHOR;　
  
• インタビュー　TROPHY試験-ARBの新たな可能性を求めて;　2006
  ANNOUNCEMENT INFO.;　, 3, 3, 63-69
  AUTHOR;　
  
• 座談会　スタチンの多面的心血管保護作用;　2006
  ANNOUNCEMENT INFO.;　, 39, 31, 36-37
  AUTHOR;　
  
• 座談会　スタチンの心血管保護作用をめぐる新しい展開;　2006
  ANNOUNCEMENT INFO.;　, 39, 39, 32-33
  AUTHOR;　
  
• インタビュー　TROPHY試験-カンデサルタンの高血圧発症予防効果;　2006
  ANNOUNCEMENT INFO.;　, 13, 4, 53-59
  AUTHOR;　
  
• CASE－Jに期待する;　2006
  ANNOUNCEMENT INFO.;　, 39, 40, 63-63
  AUTHOR;　
  
• 座談会　日本人における高血圧性臓器障害の予防をめざして～脳卒中発症抑制の観点から～;　2006
  ANNOUNCEMENT INFO.;　, 24, 10, 141-147
  AUTHOR;　
  
• 日本人における２型糖尿病治療の動向;　2006
  ANNOUNCEMENT INFO.;　, 39, 43, 47-47
  AUTHOR;　
  
• 座談会　ARBによる血管保護を考慮した高血圧治療;　2006
  ANNOUNCEMENT INFO.;　, 39, 34, 14-15
  AUTHOR;　
  
• 座談会　エビデンス・ガイドラインを踏まえた降圧治療;　2006
  ANNOUNCEMENT INFO.;　, 1-8
  AUTHOR;　
  
• 循環器医科から見た糖尿病治療;　2006
  ANNOUNCEMENT INFO.;　, 39, 47, 44-45
  AUTHOR;　
  
• ランダム化臨床試験を読み解く―高血圧・冠動脈疾患領域―ASCOT;　2006
  ANNOUNCEMENT INFO.;　, 88-91
  AUTHOR;　
  
• ランダム化臨床試験を読み解く－高血圧・冠動脈疾患領域－HOPE;　2006
  ANNOUNCEMENT INFO.;　, 122-123
  AUTHOR;　
  
• ARBを軸とした２１世紀の降圧Strategy;　2006
  ANNOUNCEMENT INFO.;　, 39, 50, 44-45
  AUTHOR;　
  
• 座談会　糖尿病合併例における血圧・脂質の積極的低下療法の重要性;　2006
  ANNOUNCEMENT INFO.;　, 4315, C1-C6
  AUTHOR;　
  
• 座談会　REAL　VALUEの結果とメカニズムを検証する;　2006
  ANNOUNCEMENT INFO.;　, 39, 52, 10-11
  AUTHOR;　
  
• 食後の軽い高血糖を抑える意義は？;　2006
  ANNOUNCEMENT INFO.;　, 3-3
  AUTHOR;　
  

General Lectures

• A Novel Soluble Epoxide Hydrolase Peptide Vaccine Attenuates Cardiac Remodeling After Myocardial Infarction Through Angiogenesis;　2021/11
  ANNOUNCEMENT INFO.;　AHA Scientific Sessions 2021 (Virtual Event), 2021,11,13-15
  AUTHOR;　*Takahiro Kitsuka, Aya Shiraki, Jun-ichi Oyama, Hironori Nakagami, Atsushi Tanaka and Koichi Node
  
• The Long Non-Coding Rna Caren Improves Cardiac Dysfunction in Aged Mice;　2021/11
  ANNOUNCEMENT INFO.;　AHA Scientific Sessions 2021 (Virtual Event), 2021,11,13-15
  AUTHOR;　Michio Sato, Keishi Miyata, Tsuyoshi Kadomatsu, Koichi Node and Yuichi Oike
  
• Comparison Of The Clinical Effect Of Empagliflozin On Glycemic And Non-glycemic Parameters In Japanese Patients With Type 2 Diabetes And Cardiovascular Disease Treated With Or Without Baseline Metformin;　2021/09
  ANNOUNCEMENT INFO.;　Hypertension Scientific Sessions 2021(Virtual), 2021, 9,27-29
  AUTHOR;　Atsushi Tanaka and Koichi Node
  
• Clinical impact of CREDO-kyoto risk score on in-hospital bleeding in patients with acute coronary syndrome;　2021/08
  ANNOUNCEMENT INFO.;　ESC Congress 2021 -The Digital Experience (Online Meeting), 2021, 8,27-30
  AUTHOR;　*Y. Minematsu, M. Natsuaki, G. Yoshioka, K. Shinzato, Y. Nishimura, T. Nishikido, K. Node
  
• Empagliflozin improves prognosis and energetic properties through modulating mitochondrial function in failing murine hearts;　2021/08
  ANNOUNCEMENT INFO.;　ESC Congress 2021 -The Digital Experience (Online Meeting), 2021, 8,27-30
  AUTHOR;　○A, Shiraki, J, Oyama, T, Shimizu, T, Nakajima, T, Yokota, K, Node
  
• Prognostic impact of follow-up serum albumin after acute myocardial infarction;　2021/08
  ANNOUNCEMENT INFO.;　ESC Congress 2021 -The Digital Experience (Online Meeting), 2021, 8,27-30
  AUTHOR;　G Yoshioka, A Tanaka, Y Shibata, K Node
  
• Long-year follow-up of Acute Myocardial Infarction with Preserved Initial LVEF: Prognostic Impact of Progressively Reduced LVEF;　2021/08
  ANNOUNCEMENT INFO.;　ESC Congress 2021 -The Digital Experience (Online Meeting), 2021, 8,27-30
  AUTHOR;　G Yoshioka, N Watanabe, Y Shibata, K Node
  
• Prognostic impact of initial serum albumin for newly developing heart failure after acute myocardial infarction;　2021/08
  ANNOUNCEMENT INFO.;　ESC Congress 2021 -The Digital Experience (Online Meeting), 2021, 8,27-30
  AUTHOR;　K Shinzato, G Yoshioka, N Watanabe, Y Shibata, K Node
  
• Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE);　2021/08
  ANNOUNCEMENT INFO.;　ESC Congress 2021 -The Digital Experience (Online Meeting), 2021, 8,27-30
  AUTHOR;　A Tanaka, I Hisauchi, I Taguchi, A Sezai, S Toyoda, H Tomiyama, M Sata, S Ueda, J Oyama, M Kitakaze, T Murohara, K Node
  
• Incidence of progressively reduced LVEF during long-year follow-up after myocardial infarction : impact for mid-term outcomes;　2021/08
  ANNOUNCEMENT INFO.;　ESC Congress 2021 -The Digital Experience (Online Meeting), 2021, 8,27-30
  AUTHOR;　G. Yoshioka, Y. Shibata, K. Node, N. Watanabe, N. Kuriyama, H. Koiwaya, K. Ogata, Y. Goriki, K. Shinzato
  
• Gender difference in Low-BMI patients with acute myocardial infarction makes an impact on mid-term outcomes;　2021/08
  ANNOUNCEMENT INFO.;　ESC Congress 2021 -The Digital Experience (Online Meeting), 2021, 8,27-30
  AUTHOR;　G. Yoshioka, Y. Shibata, K. Node, N. Kuriyama, N. Watanabe, H. Koiwaya, K. Ogata, Y. Goriki, K. Shinzato
  
• Reduction of estimated fluid volume parameters following initiation of empagliflozin in patients with type 2 diabetes and established cardiovascular disease;　2021/06
  ANNOUNCEMENT INFO.;　ADA 81st Scientific Sessions (Virtual Meeting), 2021, 6,25-29
  AUTHOR;　Tanaka A, Node K, EMBLEM trial investigators
  
• A NOVEL RISK-SCORE MODEL OF IN-HOSPITAL ACUTE KIDNEY INJURY BASED ON COMBINED BLOOD VARIABLES IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION;　2021/05
  ANNOUNCEMENT INFO.;　ACC2021(Virtual Conference), 2021, 5,25-28
  AUTHOR;　Yuhei Goriki, Atsushi Tanaka, Kensaku Nishihira, Atsushi Kawaguchi, Masahiro Natsuaki, Nehiro Kuriyama, Yoshisato Shibata, and Koichi Node
  
• Effects of febuxostat on carotid intima-media thickness in asymptomatic hyperuricemia: a randomized clinical trial (PRIZE);　2021
  ANNOUNCEMENT INFO.;　Joint Meeting ESH-ISH 2021(Virtual Congress), 2021, 4,11-14(on-demand until July 15)
  AUTHOR;　Tanaka A, Tagushi I, Teragawa H, Ishizaka N, Murohara T, Node K
  
• Prognostic impact of follow-up serum albumin after acute myocardial infarction;　2021
  ANNOUNCEMENT INFO.;　Heart Failure 2021(Online Congress), 2021, 6,29- 7, 1
  AUTHOR;　Goro Yoshioka, Atsushi Tanaka, Kensaku Nishihira, Masahiro Natsuaki, Atsushi Kawaguchi, Nozomi Watanabe, Yoshisato Shibata, Koichi Node
  
• Low Serum Albumin and Bleeding Events After Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: From the HAGAKUREACS Registry;　2021
  ANNOUNCEMENT INFO.;　The 19th International Symposium on Atherosclerosis（ISA2021）(Hybrid format) , 2021,10,24-27(onsite and online), 2021,10,24-11,30(On-demand), Kyoto
  AUTHOR;　Goro Yoshioka, Masahiro Natsuaki, Shinjo Sonoda, Koichi Node
  
• Right Ventricular Branch Compromise after Percutaneous Coronary Intervention and Baseline Chronic Kidney Disease: A High-Risk Combination Associated with Long-Term Prognoses in Acute Inferior Myocardial Infarction;　2021
  ANNOUNCEMENT INFO.;　The 19th International Symposium on Atherosclerosis（ISA2021）(Hybrid format) , 2021,10,24-27(onsite and online), 2021,10,24-11,30(On-demand), Kyoto
  AUTHOR;　○Shinjo Sonoda, Koshi Setoyama, Goro Yoshioka, Kensuke Yokoi, Kuninobu Kashiyama, Masahiro Natsukaki, Masaharu Kataoka, Koichi Node
  
• Secondary Analyses to Assess the Profound Effect of Empagliflozin on Endothelial Function in Patients with Type 2 Diabetes and Established Cardiovascular Diseases: The Placebo-Controlled Double-Blind Randomized EMBLEM Trial;　2020/06
  ANNOUNCEMENT INFO.;　ADA 80th Scientific Sessions (virtual meeting), 2020, 6,12-16
  AUTHOR;　Tanaka A, Node K and EMBLEM Trial Investigators
  
• Long-year follow-up of Acute Myocardial Infarction with Preserved Initial LVEF: Prognostic Impact of Progressively Reduced LVEF;　2020
  ANNOUNCEMENT INFO.;　ESC Congress 2020 ? The Digital Experience, 2020, 8, 29- 9, 1
  AUTHOR;　Goro Yoshioka, Kodai Shinzato, Koichi Node
  
• Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized clinical trial (CANDLE) ;　2020
  ANNOUNCEMENT INFO.;　ESC Congress 2020 ? The Digital Experience, 2020, 8, 29- 9, 1
  AUTHOR;　Atsushi Tanaka, Itaru Hisauchi, Isao Taguchi, Akira Sezai, Shigeru Toyoda, Masataka Sata, Shinichiro Ueda, Jun-ichi Oyama, Masafumi Kitakaze, Toyoaki Murohara, Koichi Node
  
• Comparison of Left Atrial Voltage Maps ? Does Mapping Catheter Configuration Pattern Matter?;　2019
  ANNOUNCEMENT INFO.;　40th Annual Heart Rhythm Scientific Sessions, 2019, 5, 8-11
  AUTHOR;　○Takanori Yamaguchi, Kana Nakashima, Toyokazu Otsubo, Yuya Takahashi, and Koichi Node
  
• Short-term effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular diseases: a placebo-controlled randomized trial (EMBLEM) ;　2019
  ANNOUNCEMENT INFO.;　EASD 2019 - 55th Annual Meeting of the European Association for the Study of Diabetes, 2019, 9, 16-20
  AUTHOR;　Atsushi Tanaka, Michio Shimabukuro, Noritaka Machii, Hiroki Teragawa, Yosuke Okada, Kosuke R. Shima, Toshinari Takamura, Isao Taguchi, Itaru Hisauchi, Yasunori Sato, Shinichiro Ueda, Yukihito Higashi, Koichi Node
  
• Spontaneous Internal Mammalian Artery Graft Dissection Triggered by Emotional Stress;　2019
  ANNOUNCEMENT INFO.;　TCT2019, 2019, 9, 25-29
  AUTHOR;　Kosuke Sawami, Masahiro Natsuaki, Hiroshi Hongo, Masataka Kajiwara, Yutaka Hikichi, Koichi Node
  
• Does low voltage zone represent localized fibrosis? -an analysis using HD grid mapping catheter in atrial fibrillation patients ;　2019
  ANNOUNCEMENT INFO.;　APHRS 2019-12th Asia Pacific Heart Rhythm Society Scientific Session, 2019, 10, 24-27
  AUTHOR;　○Otsubo T, Yamaguchi T, Nakashima K, Tahara M, Fukui A, Hirota K, Takahashi Y, Kitai T, Takahashi N, Node K.
  
• Effects of Canagliflozin in Patients With Type 2 Diabetes and Chronic Heart Failure: A Randomized Clinical Trial (CANDLE);　2019
  ANNOUNCEMENT INFO.;　AHA Scientific Sessions 2019, 2019, 11, 16-18
  AUTHOR;　Atsushi Tanaka, Itaru Hisauchi, Isao Taguchi, Akira Sezai, Shigeru Toyoda, Masataka Sata, Shinichiro Ueda, Jun-ichi Oyama, Masafumi Kitakaze, Toyoaki Murohara, Koichi Node
  
• Gender Differences in Cardiovascular Outcomes and Their Association With Risk Factors in Type 2 Diabetic Patients With Established Coronary Artery Disease;　2019
  ANNOUNCEMENT INFO.;　AHA Scientific Sessions 2019, 2019, 11, 16-18
  AUTHOR;　＊Yuko Fujita, Akihiro Tokushige, Takeshi Morimoto, Koichi Node, Shinichiro Ueda
  
• Dk-Crush Stenting Increases the Risk of Incomplete Stent Apposition Compared With Culotte Stenting for the Treatment of Left Main Coronary Bifurcation Lesion: Analysis From Micro CT;　2019
  ANNOUNCEMENT INFO.;　AHA Scientific Sessions 2019, 2019, 11, 16-18
  AUTHOR;　Yutaka Hikichi, Kaito Matsubara, Kouta Sugiyama, Xiaodong Zhu, Yusuke Tsuboko, Yuki Matsuhashi, Yohei Inoue, Masahiro Natsuaki, Koichi Node, Kiyotaka Iwasaki
  
• Cardiac Dysfunction Induced by Incretin-Related Drugs Due to Energetic Starvation in Non-Diabetic Failing Heart;　2019
  ANNOUNCEMENT INFO.;　AHA Scientific Sessions 2019, 2019, 11, 16-18
  AUTHOR;　○Aya Shiraki, Junichi Oyama, Koichi Node
  
• Pathophysiological association between serum uric acid and vascular damages in subjects with hypertension;　2018
  ANNOUNCEMENT INFO.;　ISA 2018-XVIIIIth International Symposium on Atherosclerosis, 2018.6.9-12
  AUTHOR;　Tanaka A, Kawaguchi A, Tomiyama H, Node K, On Behalf of the FMD-J Study Collaboration.
  
• Losing body weight is a strong independent predictor of rehospitalization and prognosis in patients with heart failure.;　2018
  ANNOUNCEMENT INFO.;　ESC Congress 2018, 2018.8.25-29
  AUTHOR;　Nishikido T, Oyama JI, Nagatomo D, Shiraki A, Node K.
  
• Mid-term outcomes of second-generation drug-eluting-stent implantation for left main coronary artery disease compare with first-generationdrug-eluting-stent.;　2018
  ANNOUNCEMENT INFO.;　ESC Congress 2018, 2018.8.25-29
  AUTHOR;　Yoshioka G, Kuriyama S, Nishino S, Node K, Shibata Y.
  
• Switching from an angiotensin II receptor blocker to azilsartan improved health-related QOL scores beyond sufficient blood pressure-lowering in patients with uncontrolled hypertension ;　2018
  ANNOUNCEMENT INFO.;　ISH 2018 -The 27th Scientific Meeting of the International Society of Hypertension (Hypertension Beijing 2018), The 14th Congress of the Asian Pacific Society of Hypertension (APSH), The 20th International Symposium on Hypertension and Related Diseases, and the 2018 Chinese Hypertension Meeting (CHL), 2018.9.20-23
  AUTHOR;　Tanaka A, Node K.
  
• EGCG attenuate cardiac hypertrophy in the hypertensive Dahl rats.;　2018
  ANNOUNCEMENT INFO.;　ISH 2018 -The 27th Scientific Meeting of the International Society of Hypertension (Hypertension Beijing 2018), The 14th Congress of the Asian Pacific Society of Hypertension (APSH), The 20th International Symposium on Hypertension and Related Diseases, and the 2018 Chinese Hypertension Meeting (CHL), 2018.9.20-23
  AUTHOR;　Shiraki A, Oyama JI, Node K
  
• Gender differences in structural remodeling and clinical outcomes among patients undergoing atrial fibrillation ablation.;　2018
  ANNOUNCEMENT INFO.;　APHRS 2018-11th Asia Pacific Heart Rhythm Society Scientific Session, 2018.10.17-20
  AUTHOR;　Yamaguchi T, Node K, Tsuchiya T, Otsubo T, Takahashi Y, Fukui A, Hirota K, Takahashi N, Kwano Y, Eshima K.
  
• N-Termainal Pro-Brain Natriuretic Peptide and Associated Clincial Variables in the General Working Population: a Vaseline Survey of the Uranosaki Cohort Study. ;　2017
  ANNOUNCEMENT INFO.;　IGM Congress 2017: The 8th Congress of the International Soceity for Gender Medicine, 2017, 9, 14-16
  AUTHOR;　Tanaka A, Node K
  
• Clinical association between serum uric acid level and vascular endothelial function: a sub-analysis from multicenter prospective observational study, FMD-J ;　2017
  ANNOUNCEMENT INFO.;　IGM Congress 2017: The 8th Congress of the International Soceity for Gender Medicine, 2017, 9, 14-16
  AUTHOR;　Tanaka A, Tomiyama H, Higashi Y, Node K.
  
• Treatment with novels agents (SGLT2i);　2017
  ANNOUNCEMENT INFO.;　ESC Congress 2017, 2017, 8, 26-30
  AUTHOR;　Node K
  
• The coronary collateral development by angiogenesis of COA-Cl (2-Cl-C.OXT-A) in myocardial infarction ;　2017
  ANNOUNCEMENT INFO.;　ESC Congress 2017, 2017, 8, 26-30
  AUTHOR;　Nishikido T, Oyama JI, I Tsukamoto, J Igarashi, Node K
  
• Continuous positive airway pressure therapy improves endothelial function and neutrophil-lymphocyte ratio in patients with obstructive sleep apnea syndrome;　2016
  ANNOUNCEMENT INFO.;　American College of Cardiology (ACC.16), 2016, 4, 2-4
  AUTHOR;　Oyama JI, Nagatomo D, Yoshioka G, Yamasaki A, Komoda H, Node K.
  
• Lack of association between HbA1c and cardiovascular outcome in Japanese type 2 diabetic patients with coronary artery disease. ;　2016
  ANNOUNCEMENT INFO.;　ESC Congress 2016, 2016, 8, 27-31
  AUTHOR;　Ueda S, Morimoto T, Node K.
  
• 「The effects of the vildagliptin for cardiac dysfunction after the acute myocardial infarction」 「Apoptosis inhibitor of macrophage activates inflammatory response after acute myocardial infarction」 「EGCG, a green tea catechin, attenuates the progression of heart failure induced by the heart/muscle-specific deletion of MnSOD in mice」 ;　2016
  ANNOUNCEMENT INFO.;　Hypertension Seoul, the 26th Scientific Meeting of the International Society of Hypertension, 2016,9,28
  AUTHOR;　Nishikido T, Oyama J, Shiraki A, Komoda H, Node K
  
• The Ratio of the Bilateral-filling Pressure (RAP/PCWP) is an Important Prognostic Factor in Congestive Heart Fialure;　2016
  ANNOUNCEMENT INFO.;　The 80th Annual Scientific Meeting of the Japanese Circulation Society (JCS2016), 2016, 3, 18-20
  AUTHOR;　Nagatomo D, Kotooka N、Nishikido T、Hikichi H、Oyama JI、Node K
  
• 2-year Follow-up Angiograpy of Second-generation Drug-eluting Stent Implantationof Chronic Total Occlusion;　2016
  ANNOUNCEMENT INFO.;　The 80th Annual Scientific Meeting of the Japanese Circulation Society (JCS2016), 2016, 3, 18-20
  AUTHOR;　Yoshioka G, Kuriyama N, Nakamura K, Goriki Y, Kuwahara D, Takei, T Yanagita Y, Nishinom S, Asato T, Kadooka K, Ogata K, Hoshiyama T, Matsuura H, Nakama T, Furugen M, Koiwaya H, Watanabe N, Matsuyama A, Ashikaga K, Node K, Shibata Y
  
• ”Full-metal Jacket” Stenting of Drug Eluting Stent in 2-year-Follow-up;　2016
  ANNOUNCEMENT INFO.;　The 80th Annual Scientific Meeting of the Japanese Circulation Society (JCS2016), 2016, 3, 18-20
  AUTHOR;　Yoshioka G, Kuriyama N, Nakamura K, Goriki Y, Kuwahara D, Takei, T Yanagita Y, Nishinom S, Asato T, Kadooka K, Ogata K, Hoshiyama T, Matsuura H, Nakama T, Furugen M, Koiwaya H, Watanabe N, Matsuyama A, Ashikaga K, Node K, Shibata Y
  
• Home Telemonitoring Study for Japanese Patients with Heart Failure (HOMES-HF);　2016
  ANNOUNCEMENT INFO.;　The 80th Annual Scientific Meeting of the Japanese Circulation Society (JCS2016), 2016, 3, 18-20
  AUTHOR;　Kotooka N, Sato Y、Mizuno A、Eguchi K、Inomata T、Yamamoto K、Tsutsui H、Masuyama T、Kitakaze M、Inoue T、Shimokawa H、Momomura S、Seino Y、Node K
  
• Choice of Anti-hypertensive Combination Therapy Based on Daily Salt Intake;　2016
  ANNOUNCEMENT INFO.;　The 80th Annual Scientific Meeting of the Japanese Circulation Society (JCS2016), 2016, 3, 18-20
  AUTHOR;　Toyoda S, Inami S、Kato T、Tsukada K、Nakamoto A、Kikegawa Y、Suzuki A、Anraku Y、Node K、Inoue T
  
• Blocking the Adaptor Protein CARD9 for NF-κB Signaling Inhibits Dendritic Cell-mediated Atherosclerosis;　2016
  ANNOUNCEMENT INFO.;　The 80th Annual Scientific Meeting of the Japanese Circulation Society (JCS2016), 2016, 3, 18-20
  AUTHOR;　Hirase T, Nagao H、Node K
  
• Decreasing of Body Mass Indes is Associated wit Repeated Hospitalizations of Patients with Heart Failure;　2016
  ANNOUNCEMENT INFO.;　The 80th Annual Scientific Meeting of the Japanese Circulation Society (JCS2016), 2016, 3, 18-20
  AUTHOR;　Nishikido T, Nagatomo D、Kotooka N、Hikichi Y、Oyama JI、 Node K
  
• Sex Difference in 1-year Cardiac Events Following Acute Myocardial Infraction ;　2016
  ANNOUNCEMENT INFO.;　The 80th Annual Scientific Meeting of the Japanese Circulation Society (JCS2016), 2016, 3, 18-20
  AUTHOR;　Goriki Y, Furugen M、Nakamura K、Kuwahara D、Yanagita Y、Takei T、Nishino S、Yoshioka G、Asato T、Kadooka K、Ogata K、Hoshiyama T、Matsuura H、Nakama T、Koiwaya H、Matsuyama A、Watanabe N、Ashikaga K、Kuriyama N、Node K、Shibata Y
  
• Varenicline-assisted smoking cessation improves vascular endothelial function associated with a reduction in oxidative stress」 ;　2016
  ANNOUNCEMENT INFO.;　The 9th International Conference on the Biology, Chemistry, and Therapeutic Applications of Nitric Oxide / The 16th Annual Scientific Meeting of the Nitric Oxide Society of Japan, 2016, 5, 20-22
  AUTHOR;　Kato T, Nagatomo D, Node K
  
• A Case Elderly Heart Failure Patient with Cardiac Cachexia; How should We Improve Malnutrition?;　2016
  ANNOUNCEMENT INFO.;　The 20th Annual Scientific Meeting of the Japanese Heart Failure Society, 2016, 10, 7-9
  AUTHOR;　Kuwano A、 Nagatomo D、 Higashi Y、 Kotooka N、 Node K
  
• 2型糖尿病高齢者におけるシタグリプチンの有効性と安全性;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Continuous positive airway pressure therapy improves endothelial function and neutrophil-lymphocyte ratio in patients with obstructive sleep apnea syndrome.;　2015
  ANNOUNCEMENT INFO.;　American College of Cardiology (ACC) 2015 Scientific Sessions, 2015, 3, 14-16
  AUTHOR;　Oyama JI, Nagatomo D, Yoshioka G, Yamasaki A, Komoda H, Node K.
  
• Lack of association between HbA1c and cardiovascular outcome in Japanese type 2 diabetic patients with coronary artery disease.;　2015
  ANNOUNCEMENT INFO.;　ESC Congress 2015 - European Society of Cardiology, 2015, 8,29-9,2
  AUTHOR;　Ueda S, Morimoto T, Node K.
  
• Apoptosis Inhibitor of Macrophage Activates Inflammatory Response After Acute Myocardial Infarction;　2015
  ANNOUNCEMENT INFO.;　American Heart Association Scientific Sessions 2015, 2015,11,7-11
  AUTHOR;　Nishikido T, Oyama J, Shiraki A, Komoda H, Node K.
  
• 感染性大動脈瘤のステントグラフト術後に炎症性大動脈瘤を発症したと考えられる一例;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 重症大動脈弁狭窄症に対するTAVI前後における心エコー図の変化と合併症の検討について;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 巨大冠動脈瘤を合併した左冠動脈冠静脈洞瘻の診断に心エコーが有用であった１例;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 正常心に生ずる僧帽弁の加齢変化についての検討;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 僧帽弁逸脱症における経胸壁心エコー図所見と手術所見の比較検討;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Pentraxin3 regulates activity of macrophages.;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　Shiraki A, Kotooka N, Oyama JI, Node K.
  
• High-dose statin therapy by rosuvastatin reduced small-dense LDL and MDA-LDL:The high-dose Statin therApy with Rosuvastatin for lipiD- lowing (SARD) trial;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• The Study of Evaluate the Effets of DPP-4 hinhibitor on Atherosclerosis in Patients with Diabetes Mellitus: PROLOGUE Study ;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• PIT catheter　PITカテーテルによる選択的冠動脈血栓溶解療法の有効性について;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 子宮頚部腫瘍に伴う肺塞栓症に対して血栓吸引療法により腫瘍塞栓を診断しえた1例;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 冠動静脈瘻を伴う巨大冠動脈瘤2症例に対する治療の比較;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 救急夜勤中の研修医の心拍変動異常についての検討;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 巨細胞性心筋炎による重症心不全にHeart Mate Ⅱ植込み後、左室流出路にマイクロバブルを認めた一例;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• post capillary PH患者において両室充満圧の比（RAP/PCWP）は右室の仕事量と相関し、予後を予測する;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• GLP-1受容体アナログの非糖尿病性心不全における作用;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• SGLT阻害薬と血圧に関する考察;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 脂質低下療法における高用量スタチンと標準量スタチンの比較試験(SARD trial);　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 心筋梗塞後の心機能障害に対するビルダグリプチンの効果;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 高度頸動脈病変を有する重症AS患者に対し、頸動脈ステント留置術施行後にTAVIを行った一例;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 心臓３D-CTによる評価が有用であった巨大冠静脈洞憩室頸部副伝導路による房室回帰性頻拍の１例;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• F-FDG-PETが診断および病勢の評価に有用であった心サルコイドーシスの2例;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 深部静脈のみならず動脈内にも多量の血栓を認めたType1プロテインC欠病症の1例;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• インクレチン関連薬の不全心に与える作用;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 冠動脈CTによる血管壁の評価が有用であった左冠動脈主幹部狭窄を伴う労作性狭心症の1例;　2015
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Endothelin-1 induces contraction variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes;　2014
  ANNOUNCEMENT INFO.;　American College of Cardiology 2014, 2014, 3, 29-31
  AUTHOR;　*Tanaka A, Yuasa S, Node K, Fukuda K.
  
• The ratio of the bilateral-filling pressure is superior to the right atrial pressure alone for predicting right ventricular dysfunction in patiets with post-capillary pulmonary hypertension.;　2014
  ANNOUNCEMENT INFO.;　European Society of Cardiology Congress 2014, 2014, 8, 30-9, 3
  AUTHOR;　Nagatomo D, Sakuma M, Kotooka N, Hikichi Y, Oyama J, Node K.
  
• What are Key Factors to Achieve Better Stent Apposition at Left Main Bifurcation by Culottes Stenting Technique? Micro-CT Analysis Using Bifurcated Elastic Coronary Artery Models ;　2014
  ANNOUNCEMENT INFO.;　American Heart Association 2014 Scientific session, 2014.11.15-11.19
  AUTHOR;　○Yutaka Hikichi, Koichi Node, Saga Univ, Saga, Japan; Takafumi Ohba, Tsuyoshi Inukai, Sho Kishigami, Jun Arai, Mitsuo Umezu, Kiyotaka Iwasaki
  
• 細胞のみで立体的心臓血管臓器を構築し移植する技術の開発;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 経胸壁心エコーで緊急手術の適応を判断した左室内の有茎性可動性球状血栓の一例;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 睡眠時無呼吸症候群患者における血管内皮機能に対する持続陽圧呼吸療法の効果について;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 細胞のみで構築する3次元血管組織型パッチの開発;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 新規組織工学技術による次世代型小口径人工血管の開発;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 患者特異的iPS細胞を用いた肥大型心筋症の疾患モデリングと新規発症メカニズムの解明;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 心拍変動解析を用いた研修医の自律神経機能評価と蓄積的疲労(第1報)　夜間救急研修中の研修医の1例;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• デリバリーバルーン3回拡張で留置したバイオリムスエリューティングステント;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Mismatch of bilateral filling pressure is effective for evaluation of right vetricular dysfunction;　2014
  ANNOUNCEMENT INFO.;　The 18th Annual Scientific Meeting of the Japanese Heart Failure Society, 2014, 10, 10-12
  AUTHOR;　Nagatomo D, Kotooka N, Oyama JI, Node K.
  
• Physiological role of insulin in feeding-induced circadian entrainment;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Disease modeling of hypertroppic cardiomyopathy by using patient-specific iPS;　2014
  ANNOUNCEMENT INFO.;　The 31st Annual Meeting of the International Society for Heart Research Japanese Section, 2014, 11, 28-29
  AUTHOR;　*Tanaka A, Yuasa S, Node K, Fukuda K
  
• SETDYは脂肪細胞分化と骨芽細胞分化を制御する;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Endothelin-1 induces contraction variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes;　2014
  ANNOUNCEMENT INFO.;　The 2th Inflammation and Regeneration Meeting, 2014/1/17
  AUTHOR;　*Atsushi Tanaka, Shinsuke Yuasa, Koichi Node, Keiichi Fukuda.
  
• Endothelin-1 induces contraction variability in hypertrophic cardiomyopathy-iPS cell-derived cardiomyocytes;　2014
  ANNOUNCEMENT INFO.;　The 78th Annual Scientific Meeting of the Japanese Circulation Society, 2014, 3, 21-23
  AUTHOR;　Atsushi Tanaka, Shinsuke Yuasa, Toru Egashira, Tomohisa Seki, Masaki Kodaira, Dai Kusumoto, Kojiro Yae, Yusuke Kuroda, Shinichiro Okata, Tomoyuki Suzuki, Takuro Arimura, Kensuke Kimura, Tetsushi Furukawa, Akinori Kimura, Koichi Node, Keiichi Fukuda.
  
• Endothelin-1 induces contraction variability in hypertrophic cardiomyopathy-iPS cell-derived cardiomyocytes;　2014
  ANNOUNCEMENT INFO.;　The 1th iHF forum, 2014,8,9
  AUTHOR;　Atsushi Tanaka, Shinsuke Yuasa, Giulia Mearini, Lucie Carrier, Koichi Node, Keiichi Fukuda.
  
• 「Vascular statinの特徴とさらなる可能性;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• バーロキサバン内服中に間質性肺炎を発症した心房細動の３症例;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 冠静脈洞内からのペーシング時のみ順行性伝道が顕在化した間欠性WPW症候群の一例;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 感染性大動脈瘤のステントグラフト術後に炎症性大動脈瘤を発症したと考えられる一例;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• バルーン大動脈弁形成術を先行させ、経カテーテル大動脈弁留置術を行った1症例;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 佐賀大学におけるTAVIの初期成績;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 急速に増大する心室瘤の診断に心エコー図検査が有用であった一例;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 広範型急性肺血栓塞栓症に対してカテーテル治療を行い救命し得た一例;　2014
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• High-sensitivity assay of plasma cardiac troponin T predicts the effects of pitavastatin I patients with chronic heart failure: a sub-group analysis from the pitavastatin heart failure study (PEARL).;　2013
  ANNOUNCEMENT INFO.;　European Society of Cardiology 2013, 2013.8.31-9.4
  AUTHOR;　Asaka M, Kotooka N, Hizuma H, Sato Y, Fujimatsu D, Kuwabra Y, takano H, Inoue T, Komuro I, Node K.
  
• Effects of pitavastatin on Japanese patients with chronic heart failure: a subanalysis of the PEARL.;　2013
  ANNOUNCEMENT INFO.;　European Society of Cardiology 2013, 2013.8.31-9.4
  AUTHOR;　*Kubota A, Takano H, Mizuma H, Kuwabara Y, Sato Y, Kotooka N, Inoue T, Node K, Komuro I, Kobayashi Y.
  
• Effectiveness of therapy with pitavastatin is associated with plasma interleukin-8 levels and improved cardiovascular outcomes in patients with chronic heart failure.;　2013
  ANNOUNCEMENT INFO.;　European Society of Cardiology 2013, 2013.8.31-9.4
  AUTHOR;　Sakuma M, Kotooka N, Mizuma H, Kuwabara Y, Sato Y, Fujimatsu D, Takano H, Inoue T, Komuro I, Node K.
  
• 糖尿病患者の大血管症Update;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 悪性リンパ腫による心臓腫瘍のため、ST上昇型急性心筋梗塞を発症した1例;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 高分子アディポネクチンはハイリスク男性においてメタボリック症候群発症を予測する;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• The Supporting Project "SAGA JOY" in Saga Prefecture and Saga University Hospital - Challenge to Reduce the Risk of Quitting;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　○Yoshida K, Node K.
  
• Effect of Diabetic Agent on Cardiovasuclar Failure in Japanese Patients;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　Shiraki A, Kodama K, Jun-ichi Oyama, Node K.
  
• Effects of Pitavastatin on Japanese Patients With Chronic Heart Failure -The Pitavastatin Heart Failure Study (PEARL Study)-;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　*Komuro I, Takano H , Mizuma H , Kuwabara Y, Sato Y , Shindo S , Kotooka N , Fujimatsu D, Kobayashi Y, Inoue T, Node K.
  
• Stenting Technique for Left Main Coronary Artery Stenosis can be Improved. Suggestion Raised from Bench Test Evaluation;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　Hikichi Y, Yoshioka G , Kakimoto Y, Tago M , Nagatomo D , Uchino M, Hiwatashi A, Kodama K , Shimomura M, Sakuma M, Asaka M, Komatsu A, Oyama JI, Kotooka N, Node K
  
• Endothelin-1 Has a Pivotal Role in Contraction Variability in Hypertrophic Cardiomyopathy-Induced Pluripotent Stem Cell-Derived Cardiomyocytes;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　*Tanaka A, Yuasa S, Node K, Fukuda K.
  
• Spheroid Based Cardiovascular Regeneration Using Robotics Engineering;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　○Noguchi R, Nakayama K, Oyama JI, Kamohara K, Furukawa K, Node K, Morita S.
  
• Sulfatides are Associated with Neointimal Thickning After Vascular Injury;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　*Nasuno T, Taguchi I, Abe S, Node K, Inoue T.
  
• Clinical and Angiographic Progression of Non-target Lesion after Percutaneous Coronary Intervention: Retrospective Analysis;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　Sakuma M, Hikichi Y, Shimomura M, Kotooka N, Oyama JI, Node K.
  
• Assesment by SYNTAX Score and EURO Score of Left Main Trunk (LMT) Disease;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　*Inoue Y, Shibata Y, Matsuyama A, Kuriyama N, Ashikaga K, Segara S, Nakama T, Fukushima Y, Kimura T, Ishikawa T, Ogata K, Node K.
  
• Five Years Consecutive Complete Follow-up Result of Silorims Eluting Stent (SES) Implanted Lesion;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　*Inoue Y, Shibata Y, Matsuyama A, Kuriyama N, Ashikaga K, Sagara S, Nakama T, Fukushima Y, Kimura T, Ishikawa T, Ogata K. Node K.
  
• 新しい組織工学を用いた自己細胞のみで形成される3次元組織構築法の開発;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 心不全のICTを用いた遠隔モニタリング(HOMES-HF);　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 体内時計と生活習慣病治療;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 糖尿病における心腎連関;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• CETP阻害薬の開発の現状;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 血管年齢を正確に知ってアンチエイジング！酸化ストレスと血管機能;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Atherosclerosis and Diabetes;　2013
  ANNOUNCEMENT INFO.;　35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC),
  AUTHOR;　Node K.
  
• 糖尿病患者の心疾患治療のevidence糖尿病合併冠動脈疾患患者レジストリに基づいたコホート研究とランダム化比較試験　積極的脂質低下降圧と標準的治療の比較;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 高齢者の慢性心不全在宅管理における遠隔モニタリングの可能性(HOMES-HF);　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 冠動脈疾患の至適血糖管理;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 体内時計と循環器疾患;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 慢性心不全における血中多価不飽和脂肪酸分画に対するピタバスタチンの影響;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 左主幹部病変に対するステント留置術の抱える問題点とその改善策;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• アゼルニジピンにおけるマクロファージ活性化抑制の作用機序;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 外来での心房細動患者における抗凝固療法の実態について;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 慢性心不全の在宅管理における遠隔モニタリングデバイスの長期的有効性について;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 心血管不全予防の為の糖尿病治療戦略;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Scaffold Freeな機能的心臓・血管組織構築法の開発;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 血管機能を高血圧診療に活かす;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ワークライフバランスの実現に向けて、今を見つめなおす;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• フェブキソスタット錠の糸球体濾過量(eGFR)と血圧に及ぼす影響;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 睡眠と生活リズムで心臓病を予防する;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 心血管リスクを考慮した糖尿病の治療戦略;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Home Telemonitoring for Japanese Patients with Chronic Heart Fiilure.;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　Kotooka N, Asaka M, Nagatomo D, Node K.
  
• インクレチン関連薬と心血管病;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 心臓MRAによる冠動脈疾患のスクリーニングとその有用性;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 糖尿病性腎症を合併した閉塞性動脈硬化症の経皮的動脈形成術にCO2造影が有用であった一例;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 新規組織工学を用いた自己細胞由来小口径血管の開発;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 持続性心室頻拍を頻発し急激な経過をたどった心筋膿瘍の1例;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 消化管出血後のショックを伴う心筋梗塞患者の治療に苦慮した症例;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 心エコー検査で急速な左室肥大の進行を認めたクッシング症候群の一例;　2013
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Repetitive hyperthermia attenuates progression of left ventricular hypertrophy and increases telomerase activity in hypertensive rats.;　2012
  ANNOUNCEMENT INFO.;　European Society of Cardiology, 2012.8.25-29
  AUTHOR;　Oyama J, Maeda T, Komoda H, Node K, Makino N.
  
• Endothelin-1 Has a Pivotal Role in Contraction Variability in Hypertrophic Cardiomyopathy-Induced Pluripotent Stent Cell-Derived Cardiomyocytes.;　2012
  ANNOUNCEMENT INFO.;　The 29th Annual Meeting of the International Society for Heart Research, 2012.10.26-27
  AUTHOR;　*Tanaka A, Yuasa S, Node K, Fukuda K.
  
• Epigallocatechin gallate attenuates the progression of heart failure induced by heart/muscle-specific deletion of Mn-SOD in mice through scavenging free radicals and improving the cardiac chronic inflammation.;　2012
  ANNOUNCEMENT INFO.;　AHA, 2012.11.3-7
  AUTHOR;　Oyama J, Komoda H, Node K, Makino N
  
• The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells.;　2012
  ANNOUNCEMENT INFO.;　The 61st Annual Scientific Session of ACC, 2012.3.24-27
  AUTHOR;　Shiraki A, Oyama J, Komoda H, Node K.
  
• Recent Advances in Coronary Vessel Wall Imaging with Cardiac MRI.;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　*Tanaka A, Node K.
  
• MRP8/14 is a Novel Biomarker for Atherothrombosis.;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　Sakuma M, Inoue T, Komoda H, Hikichi Y, Kotooka N, Taguchi I, Abe S, Toyoda S, Simon D, Node K.
  
• Molecular Basis Where by Activated AT1 Receptor Conformation Attenuate Inverse Agonist Efficacy.;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　*Takezako T, Ishiguro M, Sadashiva K, Baba H, Node K.
  
• 4-Year Consecutive Complete Follow-up Result of Silorims Eluting Stent (SES) Implanted Lesion.;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　*Inoue Y, Shibata Y, Kimura T, Fukushima Y, Nakama T, Sagara S, Nishihira K, Kuriyama N, Matsuyama A, Ashikaga K, Node K.
  
• Comparison of CABG and PCI with Drug-eluting Stent (DES) for the Teatment of LMT Disease .;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　*Inoue Y, Shibata Y, Kimura T, Fukushima Y, Nakama T, Mine D, Sagara S, Nishihira K, Ashikaga K, Kuriyama N, Matsuyama A, Node K.
  
• Comparison of CABG and PCI with Drug-Eluting Stent (DES) for the Treatment of 3-Vessel Disease by SYNTAX Score.;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　*Inoue Y, Shibata Y, Kimura T, Fukushima Y, Nakama T, Mine D, Sagara S, Nishihira K, Ashikaga K, Kuriyama N, Matsuyama A, Node K.
  
• Matrix Metalloproteinase-9 Might Contribute to Mobilization of Bone Marrow-Derived Cells After Coronary Stent Implantation.;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　*Taguchi I, Abe S, Kikuchi M, Toyoda S, Arikawa T, Sakuma M, Node K, Inoue T.
  
• 2型糖尿病患者におけるGLP-1アナログ製剤の睡眠障害に及ぼす影響　アクチグラフによる検討;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• The Glucagon-like Peptide 1 Analog Liraglutide Reduces TNF-α- induced Oxidative Stress and Inflammation in Endothelial Cells.;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　Shiraki A, Oyama J, Komoda H, Node K.
  
• 治療経過中のLDL-Cレベルではなく、スタチンの使用が糖尿病合併安定肝動脈疾患患者のイベント発症に関連する;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Audience Response System (ARS)を用いた心電図教育法;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 積極的降圧治療の有効性とQOLに関する調査S-CATS: Saga Challenge Antihypertensive Study　ロサルタンサブ解析;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 慢性心不全における在宅モニタリングの試み;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 冠静脈洞の著明な拡大を認めた一例;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ステント留置時にステントのshorteningを認め、IVUSカテーテルが抜去困難となった症例　;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• MRP8/14は不安定プラークのバイオマーカーになりうるか?;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• たこつぼ心筋症を発症した2:1房室ブロックに対するペースメーカー植え込み術後の1例;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 中枢性無呼吸と洞停止を合併したPerry 症候群の1 例;　2012
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 経皮的冠動脈ステント留置術が下肢閉塞性動脈硬化症、糖尿病性壊疽の創治癒に好影響を及ぼした一例;　2011/12
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 大動脈弁に付着した巨大疣腫を3D経食道心エコーで観察し得た感染性心内膜炎の一例;　2011/12
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Matrix Metalloproteinase-9 Might Contribute to Mobilization of Bone Marrow-Derived Cells After Coronary Stent Implantation.;　2011/11
  ANNOUNCEMENT INFO.;　American Heart Association Scientific Sessions 2011　2011.11.12
  AUTHOR;　Taguchi I, Node K
  
• Molecular Mechanism Whereby Activated State of the Angiotensin II Type 1 Receptor Attenuate Inverse Agonist Efficacy.;　2011/11
  ANNOUNCEMENT INFO.;　American Heart Association Scientific Sessions 2011　2011.11.12
  AUTHOR;　Takezako T, Node K
  
• 新規発症2型糖尿病患者の食後血管内皮機能不全に対するアカルボースとナテグリニドの効果の比較検討;　2011/11
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 肥満と塩分摂取量に関する検討;　2011/11
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 新規糖尿病治療薬GLP-1アナログ・リラグルチドの血管内皮細胞における抗酸化作用と抗炎症作用;　2011/10
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 慢性腎臓病におけるスタチンの腎保護作用について;　2011/10
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ２型糖尿病患者におけるGLP-1アナログ製剤の睡眠障害に及ぼす影響：アクチグラフによる検討;　2011/10
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 心臓MRAによる冠動脈疾患のスクリーニングとその有用性;　2011/09
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Interleukin 27 Inhibits Hyperglycemia and Pancreatic Islet inflammation Induce d by Streptozotocin in Mice;　2011/07
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 非糖尿病性早期CKDにおけるスタチンのAGE/RAGE系への影響;　2011/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ステント留置後のLate luminal loss-シロリムス溶出性ステントとパクリタキセル溶出性ステントとの比較;　2011/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• インスリン使用中2型糖尿病患者の心血管系リスクに関する研究(CREDIT Study)からみたレジメン維持例とインスリン離脱例の特徴;　2011/05
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• インスリン使用中の2型糖尿病患者を対象とした心血管系リスクに関する研究(CREDIT Study)からみた日本のインスリン導入の実態;　2011/05
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 病態モデル動物のライブイメージング 64Cu標識P-セレクチン抗体を用いたLDLレセプター欠損マウスの動脈硬化病変の検出;　2011/05
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Febrication of tissue engineered pulsatile 3-Dimensional scaffold-free cardiac tissue from embryonic stem cells.;　2011/04
  ANNOUNCEMENT INFO.;　ISHLT: The International Society for Heart ＆ Lung Transplantation　2011.4.14
  AUTHOR;　Noguchi R, Nakayama K, Ishihara K, Murata Y, Node K, Morita S
  
• 新しい組織工学技術を用いた自己細胞由来人工血管の作成の可能性;　2011/04
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• バイオリズムと生活習慣病;　2011/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 新しい心筋細胞立体構造体形成技術による心筋再生療法;　2011/02
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 慢性心不全における在宅モニタリングの有用性（HOMES-HF1）;　2011
  ANNOUNCEMENT INFO.;　, 12-12
  AUTHOR;　
  
• 左室補助装置送血管内疣腫および送血側人工弁心内膜症により、LVAD不全を呈した重症心不全の一例;　2011
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 拡張型心筋症、僧帽弁閉鎖不全症の周術期に心臓再同期療法を併用し有効であった1 例;　2011
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 経皮的冠動脈ステント留置術が下肢閉塞性動脈硬化症、糖尿病性壊疽の創治癒に好影響を 及ぼした一例;　2011
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 左冠動脈主幹部におけるKBTステント留置後の一剖検症例 "micro focus CTによるKBT後のstent strut評価";　2011
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• CKD について;　2010/08
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• The stent delivery by mother and child method using 4Fr, KIWAMI straight guide catheter (KIWAMI ST01), Kyushu KIWAMI ST Registry;　2010/08
  ANNOUNCEMENT INFO.;　
  AUTHOR;　Sakamoto T, Iwabuchi M, Tayama S, Hiwatashi A, Noda K, Shibata Y, Hikichi Y, Ueno T, Nobuyoshi M
  
• 透析の病態における酸化ストレスの意義 ビタメンブレンと酸化ストレス;　2010/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 一過性高ALP血症が疑われた維持透析患者の1例;　2010/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ANCA関連腎炎への肺クリプトコッカス症及びクリプトコッカス髄膜炎合併を契機に血液透析濾過療法施行し離脱し得た一例;　2010/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• CKD患者におけるAST-120投与による5年間の長期予後成績;　2010/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 腎疾患治療におけるニューモシスティス肺炎予防の意義;　2010/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 当院における高齢発症の微小変化型ネフローゼ症候群の検討;　2010/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 慢性腎不全保存期における甲状腺機能;　2010/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 頸部リンパ節腫脹を伴ったIgG4関連間質性腎炎の一例;　2010/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• アルガトロバン持続点滴が著効を示した、多発血栓症を併発したヘパリン起因性血小板減少症の一例;　2010/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Resistant Hypertension in the Elderly;　2010/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　Uchida F, Harada K, Inoue T, Kumajima I, Node K
  
• 血管不全に着目したGLP-1:糖尿病と血管不全;　2010/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Noninvasive Imaging of Long Pentraxin PTX3 in Advanced Atherosclerotic Plaque Using Magnetic Resonance Imaging.;　2010/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　Kotooka N, Komoda H, Nakamura I, Sakuma M, Yoshiaki K, Azuma T, Hirase T, Kobayashi T, Node K.
  
• General and Basic Cardiology Training in the Early Stage of Clinical Training is Important to Support the Medical Service.;　2010/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　Yoshida K, Node K
  
• Hyperintense Coronary Plaque on Non-Contrast T1-Weighted Cardiac Magnetic Resonance is Associated with Carotid Artery Inflammation;　2010/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　Tanaka A, Kawasaki T, Noguchi T, Hiromatsu Y, Fukuyama T, Koga N, Inoue T, Node K
  
• Comparison of CABG and PCI with Drug-eluting stent (DES) for the Treatment of 3-vessel Disease in Diabetic Patients;　2010/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　Mine D, Inoue Y, Nakama T, Shimomura M, Nishihira K, Ashikaga K, Nomura K, Kuriyama N, Matsuyama A, Yoshisato S, Node K
  
• 遺伝子検査でCorynebacterium jeikeiumが起炎菌と判明した人工弁心内膜炎の1例;　2010/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Angintensin II Stimulates Endothelial Cell Migration via SIRT2-mediated Deacetylaion of a-tubulin;　2009/11
  ANNOUNCEMENT INFO.;　American Heart　Association　Scientific Session 2009
  AUTHOR;　komatsu A、Hirase T、Asaka M、Node K.
  
• Localization at Cell-cell Contacts of a Tight Junction Protein Claudin1 is Regulated by Proteosome in Endothelial Cells;　2009/11
  ANNOUNCEMENT INFO.;　American Heart　Association　Scientific Session 2009.(2009.11.14-18)
  AUTHOR;　Asaka M、Hirase T、Komatsu A、Node K.
  
• ランチョンセミナー:高血圧診療のNew Wave;　2009/11
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 劇症型心筋炎により多彩な刺激伝導系障害をきたした1例;　2009/11
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 血管内皮細胞においてアンジオテンシンIIにより誘導される微小管再構築と細胞遊走;　2009/10
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 血管炎症と内皮細胞;　2009/10
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ランチョンセミナーLS-32:虚血性心疾患の立場から;　2009/09
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Angintensin II Stimulates Endothelial Cell Migration via SIRT2-mediated Deacetylaion of a-tubulin;　2009/08
  ANNOUNCEMENT INFO.;　The 10th US-Japan-Asia Dialogue on Cardiovascular Disseases and Young Investigator Competition.
  AUTHOR;　小松　愛子、平瀬　徹明、浅香　真知子、野出　孝一
  
• エアロビクスによるメタボリックシンドロームの予防効果　血中の高分子量アディポネクチンを含む身体健康度と生活の質の変化;　2009/07
  ANNOUNCEMENT INFO.;　, 2, 104-104
  AUTHOR;　
  
• Vascular Failure and Vascular Endothelial Function;　2009/06
  ANNOUNCEMENT INFO.;　10th International Symposium on Mechanisms of Vasodilatation., 1-3
  AUTHOR;　Node K.
  
• Expression of the Cytochrome P450 Epoxygenase CYP2j2 in Human Monocytic Leukocytes;　2009/06
  ANNOUNCEMENT INFO.;　10th International Symposium on Mechanisms of Vasodilatation., 1-3
  AUTHOR;　Nakayama K, Nitto T, Inoue T, Node K.
  
• 高血圧と心腎連関;　2009/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 妊娠・手術を契機に臨床症状を呈した先天性ＡＴ3欠損症の一例;　2009/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 内皮細胞における細胞間接触部位でのタイトジャンクション蛋白質Claudin-1のRab5a介在性局在化はプロテアソームにより制御される(Rab5a-mediated Localization at Cell -cell Contact Sites of a Tight Junction Protein Claudin-1 Is Regulated by Proteasome in Endothelial Cells)(英語);　2009/05
  ANNOUNCEMENT INFO.;　, 61, 180-180
  AUTHOR;　
  
• 当院における膜性腎症24例のIgGサブクラスの検討;　2009/04
  ANNOUNCEMENT INFO.;　, 51, 3, 365-365
  AUTHOR;　
  
• 試験紙による尿比重を加味した尿蛋白定性による尿蛋白の重症度判定における、目視法と自動分析機との比較;　2009/04
  ANNOUNCEMENT INFO.;　, 51, 3, 334-334
  AUTHOR;　
  
• 血管炎を伴わないMPO-ANCA陽性例の検討;　2009/04
  ANNOUNCEMENT INFO.;　, 51, 3, 322-322
  AUTHOR;　
  
• 早期CKD患者に対するベニジピンおよびアムロジピンの腎・血管保護作用;　2009/04
  ANNOUNCEMENT INFO.;　, 51, 3, 256-256
  AUTHOR;　
  
• Angiotensin II Stimulates Endothelial Cell Migration via SIRT2-mediated Deacetylaion of α-tubulin;　2009/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ラウンドテーブルディスカッション3　心腎連関の治療: CKD and Ischemic Heart Disease;　2009/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Featured Reserrch Session 12 :New Approaches to Atherosclerosis Research;　2009/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ランチョンセミナー２１:心腎連関の治療;　2009/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• パンテテイナーゼ関連分子のヒト好中球における選択的スプライシング;　2009/03
  ANNOUNCEMENT INFO.;　, 3, 123-123
  AUTHOR;　
  
• シンポジウム5 循環器疾患の性差をもたらす要素は何か？血管内皮機能の観点から;　2009/02
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• シンポジウム「佐賀県における地域医療連携の現状と課題」;　2009/02
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 血管内皮細胞におけるRab5a によるタイトジャンクション蛋白Claudin-1 の局在制御機構;　2009/02
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Keynote Lecture: New Target of Atherosclerosis Treatment;　2009
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ラウンドテーブルディスカション3:CKD and Ischemic Heart Disease　;　2009
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Effect of Statin on Chronic Heart Failure;　2009
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 安定狭心症患者のステント再狭窄には血清レムナント様リポ蛋白とインスリン抵抗性が関係する;　2009
  ANNOUNCEMENT INFO.;　, 15, 4, 370-370
  AUTHOR;　
  
• 【生体膜関連シンポジウム「脂質低下療法時代の生体膜研究」】 心血管保護薬としてのスタチンの多面的作用;　2009
  ANNOUNCEMENT INFO.;　, 34, 5, 249-253
  AUTHOR;　
  
• ランチョンセミナー「内皮依存症血管拡張反応検査（ＦＭＤ）の今後」;　2007/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 「大血管障害を見据えた糖尿病治療」;　2007/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ランチョンセミナー「糖尿病患者の大血管障害リスクの抑制を考慮した糖尿病治療薬の選択」;　2007/01
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ランチョンセミナー「大血管障害から考えた糖尿病治療」;　2006/10
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ランチョセミナー「循環器医からみた糖尿病治療」;　2006/09
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 「Statins for treatment of Chronic Heart Failure」;　2006/09
  ANNOUNCEMENT INFO.;　The 11th La Jolla-Capri-Yamaguchi-Seoul Research Conference（2006.9.6-8　yamaguchi）
  AUTHOR;　Koichi Node
  
• イブニングセミナー「糖尿病患者の心血管イベントを抑制するには！」;　2006/05
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• シンポジウム　メタボリックシンドロームの臨床
  「メタボリックシンドロームの治療」;　2006/04
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ランチョンセミナー「動脈硬化の診断マーカー」;　2006/04
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ランチョンセミナー「血管不全と心不全の連関」;　2006/04
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 学術講演「急性冠症候群の今後の治療」;　2006/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• イブニングセミナー「スタチンのプレイオトロピック作用」;　2006/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• シンポジウム Parmacological Intervention for Coronary Artery Disease「Acute Effect of Statin in Patients with Acute Myocardial Infarction-SAMIT(Atorvastatin in Acute Myocardial Infarction Trial-」;　2006/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ランチョンセミナー「メタボリックシンドロームの脂質管理」;　2006/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ランチョンセミナー「循環器疾患における血糖管理」;　2006/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• シンポジウム「血管内皮機能と動脈硬化」;　2006/01
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• セッション「心血管系疾患のマーカーとしてのCRP」;　2005/09
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• シンポジウム「性差から見た老化と疾病～循環器疾患と性差」;　2005/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• イブニングセミナー「食後高血糖による血管障害のメカニズム」;　2005/05
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• シンポジウム「NOの新しい機能-血管不全に対するNOの作用-」;　2005/04
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• イブニングセミナー「糖尿病における循環器の管理」;　2005/02
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ランチョンセミナー「中高年女性における高血圧」;　2004/11
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• シンポジウム「糖尿病患者における心血管合併症の予防と治療」;　2004/10
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ランチョンセミナー「虚血性心疾患治療におけるＣａ拮抗薬の役割」;　2004/09
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 教育講演「血管内皮機能の基礎と臨床」;　2004/09
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ランチョンセミナー「外因性ＮＯ供与の臨床的意義　血管弛緩因子のＮＯとＥＥＴの関係」;　2004/09
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Plenary Session "Pathological processes　that link postprandial hyperglycaemia, endothelial dysfunction and CV risk";　2004/07
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• Plenary Session "Pathological processes　that link postprandial hyperglycaemia, endothelial dysfunction and CV risk";　2004/07
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 教育講演会「虚血性心臓病診療の今後の展望」;　2004/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• What statin evidence is needed in Japan?;　2004/06
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• イブニングセミナー「食後高血糖による血管内皮機能障害とその制御」;　2004/05
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ランチョンセミナー　"Novel actions of Statins -Cardiovascular protection-";　2004/05
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• シンポジウム「糖尿病における大血管障害の管理の進歩と新展開 成因 食後高血糖と動脈硬化」;　2004/02
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• シンポジウム「冠動脈疾患－病態、診断、治療をめぐって－」;　2003/11
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 教育講演会「虚血性心臓病の診断と治療-今後の展望-」;　2003/11
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 教育講演会「糖尿病合併症の最前線-大血管合併症」;　2003/10
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• モーニングレクチャー「糖尿病性心不全とBNP」;　2003/10
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• サテライトシンポジウム「慢性心不全患者に対するスタチンの有効性」;　2003/10
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• シンポジウム　　"EET and Cardiovascular Remodeling";　2003/10
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ランチョンセミナー「生活習慣病実地診療のポイント-期待されるスタチンの多面的作用」;　2003/10
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 心疾患に対する薬物療法：エビデンスはどこまで蓄積されたか？―スタチン―;　2003/09
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 「食後高血糖と血管不全」;　2003/05
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 血管からのアプローチ「食後高血糖と血管不全」;　2003/05
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ランチョンセミナー「ＮＯと血管内皮機能」;　2003/05
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• ＮＯと循環器疾患：最近の知見「ＮＯの心血管保護作用」;　2003/05
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 「ＮＯと心筋保護における最新の動向」;　2003/05
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• 「心血管イベント発症予防におけるスタチンの有用性」　－不安定プラークの安定化－;　2003/04
  ANNOUNCEMENT INFO.;　
  AUTHOR;　
  
• スタチンの循環器疾患予防効果　　―「スタチンの心筋保護作用」―;　2003/03
  ANNOUNCEMENT INFO.;　
  AUTHOR;